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Regulatory T cells (Tregs) are currently being clinically assessed as a means to treat 
various immune conditions including transplant rejection. Despite their clinical 
application, Treg suppression mechanisms remain to be fully elucidated. Recently, the 
host laboratory discovered a novel mechanism of suppression by mouse Tregs; the 
release of immunomodulatory extracellular vesicles (EVs). These vesicles are released 
by many cell types and their contents specifically packaged, with bioactive material, to 
mediate cell-to-cell communication. Transfer of their contents into target cells 
modulates their functions.                                                                                                    
The goals of my research was to test whether; 1) mouse Treg EVs modulate bone-
marrow derived dendritic cells (BM-DCs) function through the transfer of microRNAs 
(miRNAs); 2) human Tregs release EVs and investigate their miRNA contents; 3) human 
Treg EVs modulate T responder cell (Tresps) functions in vitro; 4) human Treg EVs can 
function in vivo to protect against transplant rejection.                 
My results have shown that mouse Treg EVs specifically contained miR-142-3p and miR-
150-5p; and when co-cultured with BM-DCs, the expression levels of these miRNAs 
were increased in BM-DCs. miR-142-3p and miR-150-5p have been reported to 
modulate DC cytokine profiles suggesting that Treg EVs can affect the aforementioned. 
Indeed, mouse Treg EVs reduced IL-6 whilst increased IL-10 production levels by BM-
DCs, perhaps to promote an anti-inflammatory milieu. Human Tregs, upon activation 
released ~120nm sized cup-shaped EVs. These human Treg EVs suppressed Tresps 
proliferation and modulated their cytokine production profiles by inhibiting pro-
inflammatory IFNγ, IL-2 and IL-6 cytokine production levels whilst promoting the release 
of IL-10 and IL-4 by Tresps. Exclusive miRNAs which were absent in human Tregs but 
enriched in human Treg EVs included; miR-369-3p, miR-376c-3p and miR-195-3p, which 
were predicted to target 3’-untranslated regions (3’-UTR) of IFNγ, IL-2 and IL-6 mRNA. 
Importantly, human Treg EVs functioned in vivo to protect against human skin 
transplant damage by reducing immune cell infiltration of alloreactive CD3+ T cells, 
CD45+ and Ki67+ cells within the transplanted allograft. The results generated herein 
demonstrated that human Treg EVs are functionally immunosuppressive and can 
protect against transplant rejection, suggesting that Treg EVs may in the future be a 
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Rab27DKO= Rab27αashen/ashen β-/- knock-out   
RAG-2= recombinant-activating gene 2  
RBCs= Red blood cells  
RNA= ribonucleic acid   
RNase= ribonuclease  
RPMI= Roswell Park Memorial Institute  
SD= standard deviation   
SEM= standard error of the mean  
SLE= systemic erythematosus  
SOC= super optimal broth with catabolite repression  
SP= single positive  
TAE= Tris-acetate-EDTA   
Tconv= Conventional T cell 
TCR= T Cell Receptor 
Teff= T effector cell  
TEMS= tetraspanin enriched microdomains   
TGF-β= Transforming growth factor beta 1  
Th= T helper   
TIM-3= T cell immunoglobulin and mucin-domian containing-3 
TNF= tumour necrosis factor  




Tr1= Type-1 regulatory T cell 
TRAIL= TNF-related apoptosis-inducing ligand   
Treg= Regulatory T cell 
Tresps= T responder cells   
tRNA= transfer RNA  
TSDR= Treg-specific demethylated region  
Tsg101= tumour susceptibility gene 101  
tTregs= thymus-derived regulatory T cell 














Chapter 1 - General Introduction 
1.1 Transplantation 
Transplantation is the medical and surgical process of removing organs or tissues from 
the donor body to be placed and retained inside a recipient body with the purpose of 
replacing damaged, missing or suboptimal organs and tissues of the recipient. Although 
transplantation is the gold standard treatment for patients with end-stage organ failure 
by providing them with a better quality of life, it is still hindered by transplant rejection 
(Pervinder Sagoo, Lombardi, and Lechler 2012; Safinia et al. 2013).  
Transplant or allograft rejection is a complex process that occurs when the recipient’s 
immune cells identifies the donor antigen as ‘foreign’ similar to them identifying 
bacteria or viruses as harmful and thus initiates an immune response to destroy the 
donor allograft, ultimately leading to allograft dysfunction and failure (Pervinder Sagoo, 
Lombardi, and Lechler 2012).     
Existing protocols to manage allograft rejection include a life-long immunosuppressive 
drug regimen which can mitigate acute rejection (Ali et al. 2013), but due to their non-
specific immune suppression the patient can suffer from severe side effects. 
Nephrotoxicity, neurotoxicity, increased risk of developing cancer and increased 
susceptibility to acquiring infections are examples of these severe side effects (Salvadori 
and Bertoni n.d.; D. Hsu and Katelaris 2009). Notwithstanding, patients have survival 
rates of above 90% one year post-transplantation, however, the long-term acceptance 
of the allograft is still challenging due to chronic rejection (Romano et al. 2017). Since 
immunosuppressive drugs have minimal effectiveness to impede chronic rejection, the 
half-life of allografts remain limited to approximately 10-15 years (Gruessner and 
Gruessner 2013; Burgos et al. 2012). Another caveat associated with transplantation is 
the inadequate supply of donor organs to meet demands (Testa and Siegler 2014) and 
thus many patients unfortunately die before receiving a potentially life-saving organ.   
Despite these multiple impediments, several treatments are under investigation as a 
prospective means of inducing a state of ‘transplant tolerance’, whereby transplanted 




immunosuppression or the heavy dependency of adequate, available and suitable 
donor organs. 
 
1.2  Brief History of Transplantation 
British biologist and Nobel laureate Sir Peter Medawar (whom received a shared Nobel 
Prize in 1960 for his work on acquired immunological tolerance (Starzl 1995)) 
researched extensively on graft rejection, initially in human studies together with 
Gibson in 1943 (Gibson and Medawar 1943) and later in 1944 with rabbit studies 
(Medawar 1944), which lead to the discovery that rejection of the skin was an 
immunological phenomenon. By 1953, Billingham, Brent and Medawar published an 
article in Nature describing the novel discovery of acquired immune tolerance which is 
an active suppression of the immune system activity towards antigens (Billingham, 
Brent, and Medawar 1953). Since Sir Peter Medawar’s discoveries, it opened the 
experimental arena for many researchers searching for various strategies to dampen 
the recipient immune system (Starzl 1995). Table 1.1 summaries the first successful 
major transplant surgeries performed in human.    
 
Table 1.1- The first major achievements in human transplantation 
The outcome of transplantation has undeniably improved in recent times compared to 
historical surgeries, most attributable to enhanced surgical techniques including 
improved vascular anastomoses skills, sterility procedures, better preservation 
chemicals to improve prolonged periods of ex vivo donor organ storage whilst still 
preserving their functions and enhanced post-surgery medical treatments including 
modern immunosuppressive regimens (Enderby and Keller 2015; Kellar 2015). However, 








Kidney Recipient patient's own identical twin








Recipient patient's arterial oxyegn saturation 
was enchanced from 87% to 98% 
Patient received prednisone, azathioprine and 










Transplanted heart was functionally 
contracting in the recipient 




suitable organs, the long-term use of immunosuppressive drugs causing toxicity and a 
large percentage of transplants are chronically rejected despite immunosuppression.  
 
1.3  Pathways of Allorecognition 
It is vital that immune cells can distinguish between ‘self’ and ‘non-self’ cells to ensure 
that invading foreign pathogens are destroyed whilst tolerance to self-antigens are 
continued to maintain normal immune function. In the context of transplantation, the 
presence of ‘non-self’ cells inside a recipient can elicit an immune response, known as 
‘immunogenicity’. This is initiated when the immunological identification of histo-
incompatible antigens derived from the same species although from genetically 
disparate individuals occurs via the molecular engagement of a receptor-ligand system 
(T cell receptor (TCR)/ B cell receptor (BCR) - major histocompatibility complex (MHC)), 
a process termed ‘allorecognition’. The ensuing immune cell activation and responses 
lead to allograft rejection, a process known as the ‘alloresponse’ (Afzali, Lombardi, and 
Lechler 2008; Game and Lechler 2002; Benichou and Thomson 2009).  
The surgical procedure of organ transplantation is invasive to the patient and the donor 
organ is susceptible to ischemia/reperfusion injury, inflammatory damage and tissue 
stress. As a result, innate immune responses such as the complement system initiate 
the early process of allograft rejection. Nonetheless, studies performed on neonatally 
thymectomised (Miller 1961) and irradiated adult murine models (Hall, de Saxe, and 
Dorsch 1983; Hall, Dorsch, and Roser 1978a, 1978b) have revealed that recipient T cells 
are one of the most deleterious cell types that drive allograft rejection, therefore 
understanding these mechanisms could provide novel targets for intervention in 
transplantation therapy. 
These recipient T cells can recognise alloantigens via three known and distinct but not 
mutually exclusive pathways of allorecognition; the direct, indirect and semi-direct 
pathways (Figure 1.1). The direct pathway of allorecognition is one that donor antigen 
presenting cells (APCs) present intact allogeneic MHC-allopeptide complexes to 
recipient T cells. On the other hand, the indirect pathway of allorecognition occurs 
when recipient APCs encounter, process and present allopeptides in the context of 




features of both ‘direct’ and ‘indirect’ pathways. This pathway is when the recipient 
APCs acquires and presents allogeneic MHC-allopeptide complexes to recipient T cells.  
 
 
Figure 1.1- Pathways of allorecognition 
Schematic diagram illustrating the three distinct pathways of allorecognition. The direct 
pathway of allorecognition is one that donor antigen presenting cells (APCs) present 
intact allogeneic MHC-allopeptide complexes to recipient T cells. On the other hand, the 
indirect pathway of allorecognition occurs when recipient APCs encounter, process and 
present allopeptides in the context of recipient-MHC class II molecules. The semi direct 
pathway of allorecognition combines features of both ‘direct’ and ‘indirect’ pathways. 
This pathway is when the recipient APCs acquires and presents allogeneic MHC-
allopeptide complexes to recipient T cells. 
 
1.3.1 Direct 
‘Passenger’ leukocytes which reside in the allograft are a major source of tissue 
immunogenicity (Snell 1957). In particular, the high presence of donor APCs inherent in 
the allograft initiates rejection via the direct pathway (G. Yu et al. 2006). Additionally, 




direct allorecognition is highlighted by the exceptionally high frequency of T cell 
reactivity against allopeptides presented by allogeneic-MHC molecules (approximately 
1-10%) (Lindahl and Wilson 1977; Whitelegg et al. 2005) compared to T cells which 
recognise allopeptides presented in the context of self-MHC molecules (approximately 
0.01%) (Veerapathran et al. 2011; Ford and Burger 1983). Key studies which indicated 
that dendritic cells (DCs) were the principal APCs mediating priming of naïve T cells 
against allograft antigens was published in 1982 by Lechler and Batchelor (Lechler and 
Batchelor 1982b, 1982a). They performed experiments on rat kidneys whereby the 
kidneys were temporarily ‘parked’ in intermediate recipients to eliminate passenger 
leukocytes before being transferred into another recipient. The result was an enhanced 
allograft survival rate which was reversed by the repletion of donor DCs, suggesting that 
the principal passenger leukocytes were donor DCs which activated recipient T cells 
(Lechler and Batchelor 1982b, 1982a).  
 
1.3.2 Indirect 
The experiments performed by Lechler and Batchelor showed that depletion of donor 
DCs extended the survival rate of the rat kidney allografts. However, rejection was not 
completely avoidable, although it was at a slower kinetic in comparison to allografts 
that retained allogeneic DCs, this suggested that alloreactive T cells ought to be 
activated via a different pathway of allorecognition which would not implicate donor 
APCs (Lechler and Batchelor 1982b, 1982a). The genetic codes associated with antigen 
presentation contained within a MHC are the most polymorphic in vertebrates 
(Sommer 2005). Thus, it was conceivable that graft rejection is primarily activated by 
the recognition of donor MHC molecules presented in the intact arrangement (direct 
allorecognition) or as allopeptides presented in the context of recipient MHC molecules 
(indirect allorecognition). The frequency of T cells with indirect allospecificity is 
approximately 100-fold less than T cells with direct allospecificity (Z. Liu et al. 1993). 
Due to this large difference in frequency, it is thought that the indirect alloimmune 
responses are not as intense as the direct alloimmune response, although due to the 
constant supply of donor antigens in the allograft it marked the indirect pathway 
enabled to continue in extended terms. Thus, the indirect pathway is anticipated to be 




and report that demonstrated the involvement of the indirect pathway to allograft 
rejection was performed by Auchincloss et al. (Auchincloss et al. 1993). The authors 
transplanted skin grafts derived from a MHC class II knockout mice onto recipient mice 
which had CD8+ T cells removed (thus these mice were dependent on CD4+ T cell 
function) or CD4+ T cells removed. The CD8+ T cells- depleted mice rapidly rejected the 
MHC class II-deficient skin graft compared to the CD4+ T cells- depleted mice. This 
demonstrated the important role of CD4+ T cells in driving the allograft rejection 
process. Given that the donor grafts lacked MHC class II molecules, the CD4+ T cells was 
thus primed by recipient APCs presenting allopeptides (Auchincloss et al. 1993). 
Subsequently, Lee et al. demonstrated that the CD4+ T cells then helps activate CD8+ T 
cells to further drive allograft rejection (Lee et al. 1994).  
 
1.3.3 Semi direct 
Cross-talk between CD4+ and CD8+ T cells during an immune response stipulates a 
‘three-cell’ or ‘linked’ model in which both CD4+ and CD8+ T cells are activated by the 
same APCs (Ridge, Di Rosa, and Matzinger 1998). In this model, the CD8+ T cells 
required help from CD4+ T cells activated by the same APC.  In the context of 
transplantation, cross-talk between the direct and indirect pathways of allorecognition 
would represent a conundrum to this model as it would require that direct pathway 
CD8+ T cell and indirect pathway CD4+ T cells are activated by donor APCs and recipient 
APCs, respectively, thus demanding a ‘four-cell’ or ‘unlinked’ model. This apparent 
paradox can be addressed by the semi-direct pathway of allorecognition (Herrera et al. 
2004), in which the recipient APCs can acquire and present intact donor MHC-
allopeptide complexes by MHC transfer mechanisms by direct cell to cell contact 
(Game, Rogers, and Lechler 2005) or via exosomes (Morelli et al. 2004), along with this 
is the presentation of allopeptides in the indirect manner (Herrera et al. 2004). 
Consequently, both CD4+ and CD8+ T cells can be activated by the same APC and thus 
linked help or linked suppression can be addressed by a ‘three- cell’ model.  
The passenger leukocyte theory states that post-transplantation, donor APCs that reside 
in the allograft present donor MHC molecules directly to alloreactive T cells in 




Liu et al. (Q. Liu et al. 2016) revisited this concept, these authors demonstrated that 
donor exosomes can transfer donor DC MHC molecules to recipient APCs, a 
phenomenon termed ‘cross-dressing’ via exosomes. These recipient APCs that acquired 
exosomes became activated and were able to activate alloreactive T cells (Marino et al. 
2016; Q. Liu et al. 2016) and the donor exosomes rather than the passenger leukocytes 
initiate the alloresponse post-transplantation (Marino et al. 2016). 
Recently, the host laboratory demonstrated in indirect pathway-deficient recipient mice 
(lacking cross priming/cross presentation) that acquired allo-MHC class I-peptide 
complexes on recipient DCs may be the main source of alloantigen that drives CD8+ 
cytotoxic T cell responses and promote allograft rejection that can persist for the life-
span on the transplant (L A Smyth, Lechler, and Lombardi 2017). 
 
1.4 Immunosuppressive drugs 
Undeniably, immunosuppressive drugs have improved allograft survival but disposes 
the patients more susceptible to other health complications such as increased risk of 
cancer and acquiring infections (Lizotti Cilião et al. 2016; Welzl et al. 2014). T cells are 
the main culprits in driving transplant rejection with B cells playing a role via the 
production of allo-antibodies (Ali et al. 2013). Transplant rejection can be hyper-acute, 
acute or chronic. Hyper-acute rejection can occur within minutes post-transplantation 
as a response to pre-formed antibodies against donor human leukocyte antigen (HLA) 
(human MHC) (Moreau et al. 2013). Acute rejection can occur from the first week to 
several months post-transplantation and mainly involves the direct pathway of 
allorecognition (Moreau et al. 2013). Chronic rejection can occur years post-
transplantation and mainly involves the indirect pathway of allorecognition (Moreau et 
al. 2013). When allorecognition is initiated, a concerted course of activation of T cells 
leads to generation of effector T cells and subsequent production of various cytokines, 
allo-antibody production by activated B cells and macrophage activation altogether 
amplifies the alloimmune response. Over time, chronic rejection forces the graft to 
remodel its extracellular matrix caused by fibrotic scarring of expanding collagen fibres, 
disorganisation of fibronectin and proteoglycans which leads to progressively 




Rienstra et al. 2010; McManus et al. 1994). Modern immunosuppressants used to 
prevent graft rejection consists of various types of drugs aimed at targeting multiple cell 
types and their signalling pathways and suppressing the production of certain 
antibodies and cytokines. While the drugs used may vary between institutions, the 
treatment course will generally consist of a combination of calcineurin inhibitors (CNI), 
corticosteroids, anti-proliferatives and mammalian target of rapamycin (mTOR) 
inhibitors. At Guy’s Hospital (London, UK), the standard set of drugs prescribed to 
kidney transplant patients consists of tacrolimus (a CNI inhibitor), prednisone (a 
corticosteroid) and mycophenolate mofetil (MMF; an anti-proliferative). 
CNIs such as cyclosporine A and tacrolimus function by inhibiting the signalling 
phosphatase calcineurin, resulting in a block of T cell proliferation (Hamawy 2003). Due 
to CNIs’ selective activity on T cells, use of these drugs permit the maintenance of other 
myeloid-derived cell types and reduces the doses of corticosteroid required (Haberal et 
al. 2004). Both of these CNIs inhibit the production of pro-inflammatory cytokines IL-2, 
IFNγ and TNFα despite having differential effects on IL-10 and TGFβ (Duncan and Wilkes 
2005).  
Prednisone is a common corticosteroid used in transplantation therapy, although they 
are not as selective in action compared to CNIs since they affect multiple leukocyte cell 
types including T cells, B cells, macrophages, granulocytes and monocytes. These 
steroid hormones function by inhibiting the activation of several pro-inflammatory 
genes in the abovementioned leukocytes (Duncan and Wilkes 2005). Corticosteroids are 
lipophilic and can permeate across cell membranes where they bind glucocorticoid 
receptors in the cytoplasm. In lymphocytes, glucocorticoids negatively regulate cytokine 
gene expression, inflammatory enzyme production and synthesis of inflammatory 
receptors by targeting and inhibiting pro-inflammatory transcription factors such as 
activator protein-1 (AP-1) and nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-kB) (Duncan and Wilkes 2005).   
Anti-proliferative drugs such as MMF function by preventing de novo synthesis of 
purine, specifically preventing the synthesis of guanine thus inhibiting DNA and RNA 
production, which ultimately leads to prevention of T cell and B cell metabolism and 
their clonal expansion (Duncan and Wilkes 2005). Also, MMF functions by inhibiting 




cytotoxic natural killer (NK) cells and delayed-type hypersensitivity (DTH) response 
(Duncan and Wilkes 2005).  
Rapamycin is an example of a mTOR inhibitor that is structurally related to tacrolimus 
and similar in that it binds the FK506-binding protein 12 (FKBP12), but instead of 
targeting the calcineurin pathway, the rapamycin-FKBP12 complex inhibit the mTOR 
pathway. This inhibition of mTOR results in prevention of the translation of messenger 
ribonucleic acid (mRNAs) that are associated with cell cycle progression from G1 to S 
phase, thus preventing T cell proliferation (Duncan and Wilkes 2005).  
Despite these approaches, the half-life of a transplant is less than 10 years and one of 
the main aims of transplantation research is to induce a state of tolerance towards 
allogeneic antigens, thus reducing or eliminating the need for immunosuppression. 
 
1.5 Mechanisms of tolerance 
Immunological tolerance is a state of unresponsiveness of the immune system to 
antigens. Tolerance towards self-antigens is important to abrogate the development of 
various autoimmune diseases. Central tolerance is the tolerance achieved by deleting 
autoreactive cells before they can develop into fully incompetent cells. Peripheral 
tolerance occurs after T and B cells have matured and this process ensures that 
autoreactive cells which have escaped central tolerance do not initiate the 
development of autoimmune disease (Mueller 2010; Xing and Hogquist 2012). 
 
1.5.1 Central tolerance 
Central tolerance mechanisms occur in the primary lymphoid organs of the thymus and 
bone marrow for T cells and B cells, respectively. TCR and BCR genes contain multiple 
gene segments which undergoes a rearrangement process called variable-diversity-
joining (V(D)J) recombination to generate a functional gene. V(D)J recombination occurs 
in common lymphoid progenitor (CLP) cells to generate TCR or BCR with a given 
specificity.  The random nature of the process will likely generate T cells and B cells with 




Thymocytes are originally CD4- and CD8- (double negative (DN)), after which T cell 
lineage commitment and development, TCR gene arrangement occurs and produces αβ 
or γδ progenitors. When αβ processes continue within the DN cells, this produces CD4+ 
and CD8+ (double positive (DP)) thymocytes with somatic recombination of TCR genes 
which provides various αβ TCR with a wide range of specificity. The TCR affinity for self-
peptide-MHC complexes governs the fate of the thymocytes at this point (Klein et al. 
2014). DP thymocytes that do not recognise self-peptide MHC complexes undergo 
programmed cell death; whereas, if they recognise and bind self-peptide MHC 
complexes with a high affinity, they will undergo negative selection, thus preventing 
autoimmune conditions. Hence, the remaining DP thymocytes would be cells that bind 
to self-peptide MHC complexes with a low affinity and these cells are positively selected 
to differentiate into CD4+ or CD8+ (single positive (SP)) thymocytes and released into the 
periphery as naïve T cells. Furthermore, of the CD4+ SP thymocytes compartment, the 
cells that binds self-peptide-MHC complexes with a higher than average affinity will 
undergo an induction process to preferentially express Forkhead box P3 (FoxP3) and 
commit to the Treg lineage.  
 
1.5.2 Peripheral tolerance  
Although the central tolerance mechanisms are thorough, there are some autoreactive 
cells that may still escape this processing and arrive into the periphery. The potentially 
harmful impacts of these cells are managed by peripheral tolerance mechanisms which 
occur mainly in the lymph nodes. These peripheral tolerance mechanisms are described 
as below.  
 
1.5.2.1 Peripheral deletion by apoptosis 
Following T cell activation and expansion due to the initiation of a target antigen and 
eliminating the threat, T cell numbers have to be declined to ensure a return to normal 
immune cell homeostasis. Activation-induced cell death (AICD) is a natural capability of 
T cells to regulate their frequencies (Waring and Müllbacher 1999). T cells express Fas 
(cluster of differentiation (CD)95) and post TCR engagement upregulate Fas Ligand 




autocrine manner via the Fas/FasL pathway (Dhein et al. 1995).  Watanabe-Fukunaga et 
al. (Watanabe-Fukunaga et al. 1992) and Takakasi et al. (T. Takahashi et al. 1994) 
showed that Fas and FasL deficient mice exhibit signs of defects in peripheral tolerance 
by abnormal inflammation and autoimmune disease development. Marrack and Kappler 
(Marrack and Kappler 2004) and Mueller (Mueller 2010) demonstrated that Bcl-2-like 
protein 11 (Bim) and B-cell lymphoma 2 (Bcl-2)/ B-cell lymphoma-extra large (Bcl-xL) 
deficient mice also are unable to clear autoreactive lymphocytes leading to 
autoimmune disease in these mouse models.  
 
1.5.2.2 Immunological ignorance 
‘Immunoprivileged organs’ are organs whereby the antigens are tolerated without 
mounting an inflammatory immune response. Such organs include the brain, eyes, 
placenta, foetus and testicles. Anatomical barriers can physically separate the 
autoreactive T cells from reaching the antigen, for example within the central nervous 
system of the blood brain barrier, and thus autoreactive T cells are not activated in 
these anatomical sites.  
 
1.5.2.3 T cell anergy and costimulatory signals 
T cell activation principally require TCR engagement, however, to prompt an immune 
response a secondary co-stimulatory signal is required. During the first signal, the TCR 
recognises and binds to a cognate MHC-peptide complex. During the second signal, the 
co-stimulation can be provided by several different co-stimulatory molecules. The main 
co-stimulation is provided by CD28 which interacts with CD80/CD86 co-stimulatory 
molecules expressed on APCs; thus, subsequently promoting T cell survival, activation 
and proliferation (Lieping Chen and Flies 2013). Activation of T cells without CD28 
results in an anergic or unresponsive state which may lead to their deletion. Other co-
stimulatory molecules include CD27, tumour necrosis factor receptor superfamily 
member 4 (OX40), tumour necrosis factor receptor superfamily member 9 (41BB), 
inducible T cell costimulatory (ICOS) and CD40 ligand (CD40L), which its relative ligands 




peripheral system, autoreactive T cells can also be controlled by regulatory immune 
cells. 
 
1.6 Regulatory T cells 
In 1969, Nishizuka and Sakakura were the first to experimentally demonstrate that 
thymocytes have regulatory properties and they suggested that this contributed to the 
prevention of autoimmune disease (Nishizuka and Sakakura 1969). In 1970, Gershon 
and Kondo made the important discovery that certain T cells that were distinct from 
helper T cells can inhibit the immune responses (Gershon and Kondo 1970). In 1972, 
their research gained considerable attention after the publication of their article which 
coined the term ‘suppressor T cells’ and how T cells can inhibit the immune response 
(Gershon et al. 1972). These findings spurred many immunologists to research 
‘suppressor T cells’ but their interest sharply collapsed in the mid-1980s when the 
molecular analysis of the mouse MHC gene revealed no existence of the I-J molecule 
which was supposedly a key suppressor molecule directly linked with their suppressive 
function (Kronenberg et al. 1983). This halt in ‘suppressor T cell’ research was further 
compounded by the failure to identify a molecular marker to distinguish these 
‘suppressor T cells’ compared to other T cells types along with the ambiguity in their 
mechanisms of suppressive action (Kronenberg et al. 1983). 
It was not until 25 years later, in 1995, that Sakaguchi et al. published a seminal article 
demonstrating these ‘suppressor T cells’ can be distinguished from other CD4+ T cells by 
the expression of interleukin (IL)-2 receptor alpha chain (CD25) molecules and coined 
the term ‘regulatory T cells (Tregs)’ (S Sakaguchi et al. 1995). Sakaguchi et al. showed 
that the depletion of these CD4+CD25+ T cells resulted in various autoimmune diseases 
whereas the adoptive transfer of these cells into day 3 thymectomised mice prevented 
the autoimmune diseases (S Sakaguchi et al. 1995). 
Following this discovery, many groups published concurrently in 2001 demonstrating 
the existence of human CD4+CD25+ Tregs and their properties (Ng et al. 2001; C 
Baecher-Allan et al. 2001; Taams et al. 2001; Stephens et al. 2001; H Jonuleit et al. 




1.6.1 Treg subtypes 
1.6.1.1 CD4+ regulatory T cell subtypes 
Even though the field of Treg research is ever expanding in knowledge, there are 
controversies as to what defines a Treg. Tregs are not a single homogenous cell type but 
consists of many subpopulations, which can be distinguished by their surface markers 
and/or their expression levels of these markers, their mechanisms of activation and 
what molecular tools they use to suppress the target cells. Furthermore, although 
mouse and human Tregs do have some fundamental similarities there are disparities 
that exist, which will be explained below. 
The consensus and at the most basic level there are two main categories of CD4+ Tregs: 
CD4+ Tregs that are derived from the thymus (tTregs) and CD4+ T cells which are 
induced either in the periphery (pTregs) or in vitro (iTregs) to become suppressive. 
Other types of regulatory T cells also exist which are CD4-CD8+ Tregs and CD4-CD8- 
Tregs, but these are less well-defined as the CD4+ Tregs.  
 
1.6.1.2 Thymus-derived CD4+ Tregs 
Thymus-derived Tregs were previously termed ‘naturally-occurring Tregs’ and are CD4+, 
CD25+ and FoxP3+ (Romano et al. 2017). These Tregs constitutes approximately 5-10% 
of total peripheral CD4+ T cells (H Jonuleit et al. 2001) and 1-2% of whole blood. They 
are positively selected in the cortex via TCR through high-affinity recognition with self-
peptides-MHC complexes presented by thymic stromal cells. Through this process, 
these cells become anergic and are resistant to negative selection (Maggi et al. 2005). 
Tregs require activation of their TCR to become suppressive, but once activated they 
can suppress in an antigen independent manner (A M Thornton and Shevach 2000). 
tTregs constitutively express the lineage-determining transcription factor FoxP3 
(Romano et al. 2017) and in the absence of functional FoxP3, CD4+CD25+ Treg cells do 
not develop (van der Vliet and Nieuwenhuis 2007). Many groups have demonstrated 
that FoxP3 is a key player in immune suppression (S. Sakaguchi et al. 2009; Bin Dhuban 
et al. 2017; Kim 2009; Mercer and Unutmaz 2009) and its loss of FoxP3 expression 
levels in cells are linked to their reduced ability to suppress (Romano et al. 2017). The 




displaying a “scurfy” phenotype which is characterised by a scaly/ruffled skin, red 
irritated eyes, enlargement of secondary lymphoid organs and an early onset of death 
(Ramsdell and Ziegler 2014). In humans, FoxP3 mutations results in 
immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome 
disorder which is characterised by a variety of inflammatory conditions such as 
dermatitis, cachexia, thyroiditis, autoimmune haemolytic anaemia and membranous 
nephropathy (Wildin, Smyk-Pearson, and Filipovich 2002; Torgerson 2006) and if left 
untreated, children do not tend to live beyond 2 years of life due to sepsis and other 
complications (van der Vliet and Nieuwenhuis 2007).  
Currently, the only way to distinguish tTregs is the evaluation of the Treg-specific 
demethylated region (TSDR), an evolutionarily conserved noncoding element within the 
FoxP3 gene locus, which is fully demethylated in tTregs (Toker et al. 2013). Whilst in the 
mouse the expression of neuropilin-1 has helped in distinguishing between tTregs and 
pTregs (Weiss et al. 2012; Yadav et al. 2012) in human, this is not possible (Milpied et al. 
2009). 
 
1.6.1.3 Periphery-derived and in vitro-induced CD4+ Tregs  
pTregs and iTregs are altered states of differentiation of conventional CD4+ T cells which 
their suppressive ability can be temporary and thus controversially in the T cell field, it is 
sometimes not defined as a unique cell lineage per se (Helmut Jonuleit and Schmitt 
2003) , but rather a ‘phase’. 
pTregs and iTregs are Tregs that are induced to be suppressive but are different in that 
pTregs are derived from in vivo conditions, whereas iTregs are derived from ex vivo 
conditions. Among pTregs and iTregs, arising from conventional CD4+CD25− T cells 
(Tconv) in the periphery under specific conditions, are the T helper (Th) 3 cells and the 
type-1 regulatory T cell (Tr1). The presence of transforming growth factor beta 1 (TGF-
β) and IL-4 promotes the induction of Th3 cells which in turn predominately secretes 
immunosuppressive TGF-β (Weiner 2001), whereas the presence of IL-10 and interferon 
gamma (IFNγ) induces Tr1 cells which predominantly secretes IL-10 into the 




Another type of pTregs are the induced CD4+CD25+FoxP3+ pTregs which are generated 
from peripheral CD4+FoxP3− T cells upon activation and in the presence of TGF-β and IL-
2 (Kanamori et al. 2016); these Tregs display similar cell surface markers as tTregs and 
function by contact-dependent mechanisms and the release of immunosuppressive 
cytokines. TSDR methylation status is a key to distinguishing between the thymus-
derived CD4+CD25+FoxP3+ and the peripheral-derived CD4+CD25+FoxP3+ Tregs. 
Both Tr1 and Th3 cells are principally associated with mucosal immunity since Tr1 cells 
have been used to therapeutically treat Crohn’s disease (Desreumaux et al. 2012), 
however due to these cells inherent instability it questions the potential of these cells in 
clinical treatments (A M Thornton and Shevach 2000; Q. Chen et al. 2011).  
As abovementioned, whilst in the mouse the expression of neuropilin-1 has helped in 
distinguishing between tTregs and pTregs (Weiss et al. 2012; Yadav et al. 2012) in 
human, this is not possible (Milpied et al. 2009). However, it has been suggested from 
mouse and human studies that Helios expression may be able to differentiate between 
tTregs which are Helios+ and pTregs which are Helios- (A. K. Singh and McGuirk 2016; 
Fabricius and Ramanathan 2016). Moreover, the evaluation of TSDR methylation status 
can only be a tool in diagnosis or clinical trial monitoring but not used for Treg isolation, 
given that cells will have to be permeablised for this method of identification.  
In 2009, Miyara et al. demonstrated that human Tregs in peripheral blood are 
heterogeneous and consists of three main subpopulations based on their diverse 
functional ability and their differential expression levels of FoxP3 and CD45RA (Miyara 
et al. 2009). Tregs can be divided into (i) naïve/resting and very stable cells expressing 
CD45RA+FoxP3low; (ii) effector Tregs expressing CD45RA−FoxP3high; and (iii) cytokine-
producing Tregs, expressing CD45RA−FoxP3low.  
The naïve/resting Treg population are considered the ‘real Tregs’; they are potently 
suppressive and fully demethylated in the FoxP3 locus (Romano et al. 2017). Under in 
vitro conditions, the naïve/resting Treg population proliferates whereas the effector 
Treg population die whilst exerting suppression. Although Sakaguchi’s group suggested 
that the cytokine-secreting CD45RA−FoxP3low population was ‘non-suppressive’ (Miyara 




suppressive (Afzali et al. 2013). Furthermore, this CD45RA−FoxP3low population contain 
cells with Th17 cell potential (Miyara et al. 2009; Scottà et al. 2013; Afzali et al. 2013). 
 
1.6.1.4 CD8+ Tregs 
As previously mentioned, CD8+ Tregs are not as well-characterised as CD4+ Tregs. 
Nonetheless, CD8+ Tregs are similar to their CD4+ counterparts in that they can be 
derived naturally or induced (Pomié, Ménager-Marcq, and van Meerwijk 2008). There 
are 4 main types of CD8+ Tregs: mouse and human CD8+CD25+FoxP3+CD28- T cells 
(Churlaud et al. 2015; Najafian et al. 2003), mouse CD8+Qa-1+ T cells (Hu et al. 2004), 
mouse CD8+ CD122+CD49low T cells (Akane et al. 2016) and rat CD8+CD45RClow T cells 
(Xystrakis et al. 2004). CD8+ Tregs have been shown in animal models to be efficient in 
preventing experimental autoimmune encephalomyelitis (EAE) (Sinha, Itani, and 
Karandikar 2014) and colitis principally driven by their role of secreting potent 
immunosuppressive cytokines (Endharti et al. 2011). Bezie et al. showed that rodent 
and human CD8+ Tregs produce IL-34, and this cytokine promoted transplant tolerance 
by inhibiting allo-antibody production in rat cardiac allograft models (Bézie et al. 2015). 
Taken together, these studies compliment other studies which demonstrated that in 
human subjects, low frequencies of CD8+ Tregs were associated with a higher incidence 
of systemic erythematosus (SLE) (Filaci et al. 2001; Tulunay et al. 2008), inflammatory 
bowel disease (Brimnes et al. 2005) and multiple sclerosis (MS) (Frisullo et al. 2010). 
Thus, although CD8+ Tregs are less well-characterised in literature compared to CD4+ 
Tregs, it is evident that CD8+ Tregs contributes to the prevention of autoimmune 
diseases.  
For this thesis, all the ‘Tregs’ referred from here onwards will be the CD4+ Tregs unless 
otherwise stated.  
 
1.6.2 Phenotypical characterisation of Tregs in mouse and human 
Since the discovery of Tregs, their phenotypical characterisation has been elucidated to 
some extent, although to date, there is not a unique definitive marker to distinguish 




combination of different cell markers as outlined below. Some of these cell markers 
play a role in Treg mechanisms of suppression which are further discussed below. 
 
1.6.2.1 CD25 
As abovementioned, Sakaguchi et al. discovered CD25 expression as an important 
marker of mouse Tregs (S Sakaguchi et al. 1995). CD25 is the IL-2 receptor α chain, 
which is part of the IL-2 receptor (IL-2R) complex with the β and γ chains which together 
provides a high affinity for IL-2. Given that IL-2 is a T cell growth factor and is essential 
for their survival and clonal expansion, it is transiently upregulated on activated 
conventional human T cells (Kmieciak et al. 2009), rendering this marker not exclusive 
to Tregs. However, in human conventional T cells, the CD25 expression is of 
intermediate levels compared to human Tregs where they have high expression of 
CD25, thus the CD25hi expression can be used alongside other characterisation criteria 
to diverge the two populations.  
 
1.6.2.2 FoxP3 
It was not until 2003, the transcriptional regulator FoxP3 was discovered as a master 
control gene for mouse Tregs and their expression is important for mouse Treg 
definition (Fontenot, Gavin, and Rudensky 2003; S. Hori, Nomura, and Sakaguchi 2003; 
Khattri et al. 2003). In the mouse it is present exclusively on Tregs and thus it is an 
appropriate marker to define them. However, in human, FoxP3 expression is not 
exclusive to human Tregs given that human CD4+CD25- conventional T cells transiently 
upregulate FoxP3 expression following their activation (Kmieciak et al. 2009). As 
explained above, one of the ways to identify bona fide Tregs is the evaluation of the 
TSDR (Romano et al. 2017), which is fully demethylated in Tregs but methylated in 
conventional T cells. Tregs can maintain a stable expression of FoxP3 via the epigenetic 
modification of the TSDR, which is an evolutionarily conserved non-coding element of 






Although TSDR analysis and FoxP3 expression are relatively reliable methods of 
identifying Tregs, it does require cells to be lysed or permeablised, respectively, 
rendering this method of Treg identification as an in vitro analysis rather than employed 
as a means of isolation of Tregs. Thus, the identification of cell surface marker(s) that 
are differentially expressed by Tregs and activated conventional T cells are essential to 
separate these two populations of cells. CD127 is the IL-7 receptor α chain found on the 
cell surface which is highly expressed by conventional T cells but Tregs have a low to 
negative expression of this molecule (W. Liu et al. 2006). In 2006, Lui et al. discovered 
that CD127 expression is inversely correlated with FoxP3 expression (W. Liu et al. 2006) 
thus CD127 is so far the best marker to distinguish and isolate human Tregs in 
combination with CD4+ and CD25high expression (Romano et al. 2017). Indeed, cell 
sorting using the criteria of CD4+CD25hi and CD127lo for human Tregs is of current 
practice for the isolation of pure Tregs.     
 
1.6.2.4 CTLA-4 
Cytotoxic T lymphocyte associated protein 4 (CTLA-4) is an inhibitory protein related to 
the T cell costimulatory molecule CD28. Signalling through CD28 promotes T cell 
activation whilst signalling through CTLA-4 suppresses T cell activation. Despite their 
contrasting functions, both molecules engage with the same ligands of CD80 and CD86. 
CTLA-4 uses a diverse array of mechanisms to suppress target cells. CTLA-4, which is 
constitutively expressed on Tregs, is an indispensable regulator of peripheral tolerance, 
however it is not exclusive to Tregs as it is also found present on activated conventional 
T cells (Tai et al. 2012). CTLA-4 is predominately an intracellular protein and thus like for 
FoxP3 Tregs need to be permeablised, rendering CTLA-4 expression helpful for in vitro 
analysis of Tregs but not for their isolation. 
 
1.6.2.5 Helios 
Helios is an Ikaros transcription factor family member which its expression is present in 
100% of CD4+CD8-FoxP3+ thymocytes but in peripheral lymphoid tissues of mouse and 




Nevertheless, Thornton et al. described that Helios expression can be used to 
differentiate tTregs from pTregs (Angela M Thornton et al. 2010). However, subsequent 
studies indicated that this is not possible as Helios could be induced in pTregs 
(Gottschalk, Corse, and Allison 2012; Akimova et al. 2011) and that Helios+ and Helios- 
Tregs are present in the repertoire of tTregs (Elkord 2016; Akimova et al. 2011). Despite 
this, human FoxP3+Helios+ Tregs are more suppressive compared with FoxP3+Helios- 
Tregs (Elkord, Samid, and Chaudhary 2015), and Helios can work cooperatively with 
FoxP3 to enhance Treg function (Takatori et al. 2015).  
 
1.6.2.6 CD45RA and CD45RB 
CD45RA is an isoform of CD45 which is found mainly expressed on naïve T cells. After 
TCR activation, when a naïve T cell becomes a memory T cell, CD45RA expression is 
downregulated whilst CD45RO is upregulated. Thus, naïve T cells are defined as 
CD45RA+CD45RO- and memory/activated T cells are defined as CD45RA-CD45RO+ 
(Machura et al. 2008).  
As described above, Miyara’s findings showed that CD45RA+ Tregs constitutively express 
FoxP3 and CD25 (Miyara et al. 2009). Given the complication of activated conventional 
T cells upregulating FoxP3 and CD25 expression following their activation (Kmieciak et 
al. 2009), CD45RA and CD45RO expression can differentiate between naïve Tregs from 
activated conventional T cells, thus facilitating ‘pure’ Treg identification and isolation.  
However, in adults approximately 80% of tTregs are CD45RO+, with the population of 
CD45RA+ Tregs decreasing with age. The CD45RO+ Tregs are more highly proliferative 
compared to the CD45RA- Tregs, which was likely due to the Treg activated status (N. J. 
Booth et al. 2010). There is a subpopulation of Tregs which express low or high levels of 
CD45RB. The expression of CD45RB can further define the memory cell populations 
(Horgan et al. 1994).  
 
1.6.2.7 CD39 and CD73 
CD39 and CD73 are both cell surface bound enzymes (ectoenyzmes) that are found on 




inflammatory microenvironment (Antonioli et al. 2013). The function of CD39 and CD73 
will be further discussed in section 1.6.3.1. 
 
1.6.2.8 Co-stimulatory and inhibitory receptors 
Treg activation and expansion requires co-stimulatory signals. Members of the tumour 
necrosis factor (TNF) receptor (TNFR) superfamily such as glucocorticoid-induced TNFR-
related protein (GITR) are present on Tregs. Furthermore, the majority of freshly 
isolated Tregs express high levels of GITR (Horgan et al. 1994; McHugh et al. 2002), 
whilst in resting conventional T cells they express low levels, but its expression is 
upregulated after activation (Ephrem et al. 2013). 
Other members of the TNFR superfamily such as OX40, TNFR2 and CD27 are also 
present on Tregs, although these can also be upregulated in conventional T cells upon 
activation. Vu et al. demonstrated that stimulating OX40 on FoxP3+ Tregs resulted in 
these Tregs reducing their ability to suppress T effector cell (Teffs) proliferation, IFNγ 
secretion and Teff-mediated transplant rejection (Vu et al. 2007).  
Koenen et al. demonstrated that the CD4+ Tregs subpopulations of CD27+ and CD27- 
although are both highly suppressive, the CD27+ Treg subpopulation was able to 
suppress ongoing T cell responses (Hans J P M Koenen, Fasse, and Joosten 2005), thus 
CD27+ expressing Tregs could be a favourable Treg subset in terms of suppressive 
potency compared to CD27- Tregs.  
Other markers have been used to identify various subpopulations of Tregs such as the 
expression of the co-inhibitory molecules programmed cell death protein 1 (PD-1), the 
expression and function of lymphocyte-activation gene 3 (Lag-3) and the expression of 
HLA class II molecule HLA-DR.  
 
1.6.2.9 Homing receptors 
The expression of homing receptors is important for Tregs to traffic and home to certain 
areas in vivo. Homing receptors can also be used to identify Tregs and their 
subpopulations. For example, human naïve CD45RA+ Tregs express various lymphoid 




both allow entry into lymph nodes and C-X-C chemokine receptor type 4 (CXCR4) (P. 
Hoffmann et al. 2006). Whereas, for memory T cells there are two subsets with distinct 
homing receptor expression patterns and different effector functions. The CCR7- 
memory T cells express markers for migrating to the site of inflamed tissues and exert 
immediate effector function, whereas the CCR7+ memory T cells express homing 
receptors to migrate to the lymph nodes but do not exert immediate effector function 
(Sallusto et al. 1999).  
 
1.6.3 Treg suppression mechanisms  
Tregs employ a plethora of contact dependent and independent mechanisms to exert 
their suppressive function on different target cells such as CD4+ and CD8+ T cells, 
macrophages, DCs, NK cells and B cells to maintain immune tolerance. Thornton and 
Shevach demonstrated that Tregs require TCR stimulation to suppress in an antigen 
non-specific manner (A M Thornton and Shevach 2000). Novel mechanisms of Treg 
suppression are still being discovered, thus Treg suppression mechanisms and their 
biology is not fully elucidated. It is not clear which suppression mechanism(s) pre-
dominates during an immune response, but it could be conceived that an arsenal of 
these mechanisms may be employed depending on the target cell or the 
microenvironment it is in.  
The various suppressive mechanisms used by Tregs could be broadly divided into five 
main ‘modes of action’; metabolic interference; inhibitory cytokine release; cytolysis; 
targeting APCs/inhibition of maturation (A M Thornton and Shevach 2000) and more 
recently the release of inhibitory extracellular vesicles (Tung et al. 2018; Lesley Ann 
Smyth et al. 2013; X. Yu et al. 2013; Aiello et al. 2017; Azimi et al. 2018; Torri et al. 2017; 





Figure 1.2- Treg suppression mechanisms 
Schematic diagrams illustrating the various Treg suppression mechanisms. (A) Metabolic 
interference (B) Inhibitory cytokine release (C) Cytolysis (D) Inhibition of maturation and 




1.6.3.1 Metabolic interference 
Teffs depend on IL-2 for survival and proliferation; Tregs constitutively express high 
levels of CD25, thus allowing Tregs to rapidly deplete and consume IL-2 from the 
microenvironment and thus limiting its availability for Teffs survival and function (S 
Sakaguchi et al. 1995). While earlier reports have suggested that this was not a bona 
fide Treg suppression mechanism (Fontenot et al. 2005; Duthoit et al. 2005), another 
report has suggested that Tregs may be involved in cytokine (in particular IL-2) 
deprived-mediated apoptosis (Pandiyan et al. 2007). 
Additionally, the co-operative function of CD39 and CD73 ectoenzymes can together 
facilitate the conversion of pro-inflammatory adenosine triphosphate (ATP) into anti-
inflammatory adenosine. Firstly, CD39 hydrolyses ATP/adenosine diphosphate (ADP) 
into adenosine monophosphate (AMP); secondly, CD73 catalyses the conversion of AMP 
into adenosine (Antonioli et al. 2013) which suppressed Teffs function through 
activating the A2a receptor (Deaglio et al. 2007; Borsellino et al. 2007; Kobie et al. 2006). 
Furthermore, the linkage of adenosine to the A2a receptor also inhibited IL-6 expression 
whilst increasing the production levels of TGF-β which promoted the induction of 
adaptive Tregs (Zarek et al. 2008).  
Tregs can communicate with Teffs via gap junctions; these are membrane-bound 
channels that connect between cells to allow exchange of biological material. Tregs can 
harbour high amounts of cyclic adenosine monophosphate (cAMP), which is a second 
messenger that potently inhibits the synthesis of IL-2 and inhibits the proliferation of 
Teffs; Tregs can transfer cAMP into target cells via gap junctions (Bopp et al. 2007) as 
another means of metabolic interference. In addition, Tregs have the potential to 
deprive target cells of their energy sources via the induction of indoleamine 2, 3-
dioxygenase (IDO) production (Yan et al. 2010). IDO is an enzyme that catalyses the 
degradation of tryptophan through the kynurenine pathway, which depletes tryptophan 
from the microenvironment leading to limiting energy resources/amino acids for Teffs 
growth and expansion (Yan et al. 2010).  
 
1.6.3.2 Inhibitory cytokine release 
Tregs can release immunosuppressive cytokines such as IL-10, IL-35 and TGF-β to 




Hamilton, and Vignali 2015; Wan and Flavell 2007). Asseman et al. showed that the 
transfer of CD45RBhigh T cells induces intestinal inflammation but can be prevented with 
the addition of CD45RBlow T cells. These CD45RBlow T cells’ suppressive ability was 
dependent on IL-10, as IL-10 deficient CD45RBlow T cells did not prevent colitis (Asseman 
et al. 1999). Other in vivo studies on infection and EAE models have also shown the 
importance of IL-10 for Treg function (Belkaid 2007; McGeachy and Anderton 2005). 
Rudensky’s group used mice with conditional knock out of IL-10 gene in the FoxP3 gene 
locus induced by Cre recombinase to test the importance of IL-10 activity by Tregs. The 
authors showed that ablation of IL-10 does not affect Treg development nor does it 
cause systemic autoimmunity. However, they did show that IL-10 produced by Tregs 
was important for maintaining immunity at the environmental interfaces within the 
colon and lungs (Rubtsov et al. 2008).  
Human and mouse Tregs are able to produce high levels of both membrane-bound and 
soluble TGF-β. Blocking TGF-β reduced the suppressive potency of Tregs towards T cell 
proliferation (K Nakamura, Kitani, and Strober 2001; Kazuhiko Nakamura et al. 2004; 
Megan K Levings et al. 2002). On the contrary, some groups have shown that TGF-β is 
not involved in Treg-mediated suppression of T cells (Clare Baecher-Allan, Viglietta, and 
Hafler 2002; Piccirillo et al. 2002; Godfrey et al. 2005; Oberle et al. 2007). However, this 
could be due to the different starting cell populations and purity used for the 
experiments and the different experimental conditions.    
 
1.6.3.3 Cytolysis 
Human Tregs express granzyme A and kill CD4+ T cells in a perforin-dependent cytotoxic 
manner (Grossman et al. 2004). Whereas murine Tregs killing is partially granzyme B-
dependent without the requirement of perforin (Noelle David C Gondek, Lu, and 
Quezada 2018). Tregs also express death ligands TNF-related apoptosis-inducing ligand 
(TRAIL) (Ren et al. 2007) and FasL (Strauss, Bergmann, and Whiteside 2009), which upon 
interaction with target cell death receptor expressed by CD8+ T cells initiate a cascade 
of signalling events to induce caspase-related cell death. Galectin-9, which binds to T 
cell immunoglobulin and mucin-domain containing-3 (TIM-3) found on Teffs, led to 





1.6.3.4 Targeting of APCs 
Tregs are the only T cell subpopulation that constitutively expresses CTLA-4; it binds 
CD80/CD86, the co-stimulatory molecules expressed by APCs, to block their binding to 
CD28, thus limiting T cell activation. Furthermore, CTLA-4 can also downregulate DCs’ 
activity via trans-endocytosis or extraction of CD80 and CD86 resulting in diminished co-
stimulation (Qureshi et al. 2011). Recently, in 2017 Mavin et al. demonstrated that 
human Tregs mediate transcriptional modulation of DCs (Mavin et al. 2017). The 
authors showed that DCs that had been treated with Tregs caused a semimature 
phenotype and morphology and further assessed their gene expression. Given that NF-
kB signalling pathway plays an important role in DC maturation, the authors further 
investigated NF-kB-signalling related genes. Wnt5a was found to be higher expressed by 
DCs that had been treated with Tregs compared to mature DCs. The authors showed 
that in the absence of a Wnt5a inhibitor, DCs which were treated with Tregs showed a 
decreased surface expression of maturation and costimulation markers; CD38, CD83, 
CD80 and CD86 compared to mature DCs. This was partially reversed in the presence of 
the Wnt5a inhibitor. Thus, regulation of Wnt5a is a possible molecular tool used by 
Tregs to modulate DC reprogramming during their maturation process (Mavin et al. 
2017).  
 
1.6.3.5 Extracellular vesicles  
Recently, a novel mechanism of Treg suppression was discovered by us and others 
(Tung et al. 2018; X. Yu et al. 2013; Lesley Ann Smyth et al. 2013; Aiello et al. 2017; 
Azimi et al. 2018; Torri et al. 2017; Okoye et al. 2014). It refers to the release of nano-
sized extracellular vesicles (EVs), including exosomes, that are immunomodulatory. 
Treg-derived EVs inhibited target cell functions in vitro (Tung et al. 2018; Lesley Ann 
Smyth et al. 2013; X. Yu et al. 2013; Aiello et al. 2017; Okoye et al. 2014; Torri et al. 
2017; Azimi et al. 2018) and functioned in vivo (Okoye et al. 2014; X. Yu et al. 2013; 






1.6.4 Tregs in the clinic  
1.6.4.1 Source of Tregs and their isolation 
Due to the suppressive characteristic of Tregs, different laboratories have considered 
using Tregs in the clinic to treat various autoimmune diseases, prevent graft versus host 
disease (GvHD) and prevent solid organ transplant rejection. Thus, the need for Tregs 
isolated in a good manufacturing practice (GMP) manner that can be used for patients 
was required. The majority of preclinical Treg studies source the Tregs from peripheral 
blood or umbilical cord blood (Romano et al. 2017). A seminal report by Hoffman et al. 
demonstrated a GMP procedure for the isolation of CD4+ CD25+ T cells from standard 
leukapheresis products. The isolation of these cells was performed using a CliniMACS 
system which involves a clinical-grade magnetic enrichment of cells processed within a 
sterile and closed machine. This procedure consisted of two main steps; the first step 
involved depletion of CD19+ cells and the second step involved enrichment of cells 
expressing CD25 molecules (Petra Hoffmann et al. 2006).  
An alternative strategy to isolate Tregs is the flow-cytometry-based purification 
approach (Romano et al. 2017). The best marker to distinguish and isolate Tregs in 
combination with CD4 and CD25 is CD127 (W. Liu et al. 2006); its expression inversely 
correlates with FoxP3 and suppressive Treg function (W. Liu et al. 2006).  
 
1.6.4.2 Treg expansion 
From animal studies it was observed that there is a difference between freshly isolated 
and cultured mouse tTregs in their suppressive ability as shown by Thornton and 
Shevach (A M Thornton and Shevach 2000). Thornton and Shevach demonstrated that 
cultured tTregs can suppress the stimulation of CD4+CD25- T cells 4- to 6-fold more 
efficiently in comparison to freshly isolated tTregs (A M Thornton and Shevach 2000), 
this suggests that in vitro expansion and culturing conditions can increase the 
suppressive potency of these cells.  
Considering the relatively low number of Tregs present in peripheral blood and 
umbilical cord blood, the infusion of large numbers of freshly isolated Tregs is difficult 
to achieve. Therefore, to attain a higher number of Treg cells for infusion into patients 




expanded ex vivo using anti-CD3/CD28-coated beads along with high doses of IL-2 
(Romano et al. 2017). The host laboratory has finished two clinical trials in kidney and 
liver transplant patients using expanded Tregs. 
A potential issue of Treg isolation using the immunomagnetic approach is that the 
resultant cells can be contaminated with Teffs. The host laboratory has developed Treg 
expansion protocols using rapamycin and all-trans retinoic acid (ATRA) to minimise the 
contaminating Teffs population whilst favouring the expansion of Tregs. Rapamycin is 
an mTOR inhibitor which significantly decreases the undesired expansion of Teffs whilst 
permitting Tregs to proliferate due to their independency of the mTOR pathway for cell 
cycle progression (Thomson, Turnquist, and Raimondi 2009). Furthermore, rapamycin 
confers to the expanded Tregs a higher stability and suppressive capacity in vitro and in 
GvHD mouse models (Romano et al. 2017). ATRA affects T cell fate by contributing to 
Treg differentiation in the presence with TGF-β, however the effect of ATRA on tTregs 
remain controversial and therefore not currently used for GMP Treg expansion 
protocols. Tregs can be skewed to express certain homing receptors by culturing them 
in the presence of specific drugs. The host lab has previously published a report 
describing how rapamycin and ATRA treatment on Tregs can confer them with specific 
homing receptor expression patterns. Namely, rapamycin treatment on Tregs induced 
the co-expression of skin homing receptors CCR4 and cutaneous lymphocyte-associated 
antigen (CLA), whereas the ATRA treatment induced the co-expression of liver and gut 
homing receptors CCR9 and α4β7 integrin, respectively. The dual treatment of 
rapamycin and ATRA resulted in expression of a combination of homing receptors 
featured by the treatment of each individual drug (Scottà et al. 2013). Despite the 
success and the demonstration so far that Tregs are safe there is always a risk that 
Tregs once injected in vivo are not stable, as they have been shown to be plastic 
(Shimon Sakaguchi et al. 2013; Shohei Hori 2014; Beyer and Schultze 2011). 
 
1.6.5 Treg plasticity 
Several studies have suggested that inflammatory environments can subvert human 
FoxP3+ Treg function by converting them to Teffs in vivo (Zhou et al. 2009; Waldmann et 




humans, the longevity of Tregs and the trafficking of Tregs are still not completely 
understood. But given the fact that the usage of Tregs may enter the clinical arena as a 
potential standard therapy for transplant patients, it must be a very stable cell 
population. However, as studies have shown that Tregs may lose their suppressive 
ability as well as potentially converting to a Th17-like cell whereby they produce high 
amounts of IL-17 to promote a pro-inflammatory microenvironment (H. J. P. M. Koenen 
et al. 2008; X. O. Yang et al. 2008) suggests that Tregs may change once inside a 
transplant patient. Thus, a combinatory or a more robust therapy along with Tregs may 
be required to ensure an immunoregulatory environment.  
 
1.7 Extracellular Vesicles 
The paradigm of intercellular communication which is a vital feature of multicellular 
organisms has until recently been anticipated to be mediated via direct cell-to-cell 
contact or via the exchange of secreted molecules. An increasing number of 
experimental reports have revealed a third mechanism of intercellular communication 
via the cell-to-cell transfer of EVs. EV is a collective umbrella term used to describe 
various types of small particle structures secreted from cells into the extracellular 
space.  
The nomenclature used in early EVs research has been lax and many earlier published 
reports use EV terminology interchangeably, although no consensus was set to define 
categories of EVs. However, it is now becoming clearer and more appreciable to classify 
EVs into 3 main categories; exosomes, microvesicles and apoptotic bodies.  
 
1.7.1 Brief history of EVs 
Originally in 1981, the term ‘exosomes’ was used to describe vesicles ranging from 40-
1000nm that are released from cultured neoplastic cells (Trams et al. 1981), although 
their subcellular location of release was unclear.  
Then in 1983, Harding et al. (Harding, Heuser, and Stahl 1983) and Pan and Johnstone 
(Pan and Johnstone 1983) published two independent papers describing the release of 




multivesicular endosome (MVE) fusion with the plasma membrane, although in these 
publications the term ’exosomes’ was not used but ‘vesicles’. Later in 1989, Johnstone 
et al. coined these late-endosome-derived vesicles ‘exosomes’ (Johnstone, Bianchini, 
and Teng 1989). However, after this publication by Johnstone et al. in 1989, the interest 
in exosomes research declined due to the scepticism surrounding the notion that late 
endosome contents were considered to be destined for degradation by the lysosome 
and thus held doubtfulness in functional roles (Johnstone, Bianchini, and Teng 1989).    
The seminal study by Raposo et al. in 1996 re-ignited interest in exosomes research 
when the authors discovered that human and mouse B cells secrete antigen presenting 
vesicles which induced antigen-specific MHC class II-restricted T cell responses and 
suggested their potential functional in vivo role (G Raposo et al. 1996). Since Raposo et 
al.’s publication (G Raposo et al. 1996), many groups have reported EVs release from 
various cell types including immune and non-immune cells.  
 
1.7.2 Categories of EVs  
As abovementioned, EVs classification is generally divided into 3 main categories of 
exosomes, microvesicles and apoptotic bodies which are defined by their size and 
biogenesis pathway. Exosomes are 30-100nm sized in diameter with a reported 
maximum size of 150nm (Colombo, Raposo, and Théry 2014) and formed within 
endocytic cellular compartments called multivesicular bodies (MVB), whereby the MVB 
fuses with the plasma membrane allowing their release (Clotilde Théry, Zitvogel, and 
Amigorena 2002); microvesicles are 500-1000nm sized in diameter and derived from 
the outward budding of the plasma membrane (Willms et al. 2016), although smaller 
vesicles approximately 100nm sized can also bud from the plasma membrane (A. M. 
Booth et al. 2006) and apoptotic bodies are 50-2000nm sized and derived from the 
outward blebbing and disintegration of apoptotic cells (Willms et al. 2016). 
Notably, other types of EVs have been reported in literature such as ectosomes (Hess et 
al. 1999), shedding vesicles (Cocucci, Racchetti, and Meldolesi 2009), microparticles 
(György et al. 2011) and exosome-like vesicles (Islam et al. 2008). But it is unclear 
whether these EVs fall into one of the 3 main categories described above, or whether 




request in the EVs research field to standardise the terminology and methodology used 
to isolate EVs and criteria followed in order to accurately define each category of EVs.  
Most cell types release EVs (Clotilde Théry, Zitvogel, and Amigorena 2002). EVs can be 
found in various bodily fluids such as urine, blood, plasma, serum, semen, breast milk, 
saliva, amniotic fluid, cerebrospinal fluid, ascite fluid and bile (Clotilde Théry, Zitvogel, 
and Amigorena 2002; Colombo, Raposo, and Théry 2014; G Raposo et al. 1996).  
 
1.7.3 EVs biogenesis 
The endocytic pathway is a highly regulated process. The initial step of exosomes 
biogenesis involves the inward budding of the plasma membrane to form an early 
endosome which is aided by a variety of protein complexes such as the endosomal 
sorting complexes required for transport (ESCRT). In close proximity to these early 
endosomes, an assembly of extracellular receptors, CD markers, cytosolic components 
or other cellular components are recruited to these areas. The early endosome then 
invaginates inwards to start the formation of intraluminal vesicles in their lumen. Whilst 
the intraluminal vesicles are being formed the encapsulation of specific cellular 
components are sorted and packaged into the intraluminal vesicles. Once all the 
intraluminal vesicles are formed, the endosome is now known as MVB. The MVB 
migrates to the plasma membrane whereby it fuses with the plasma membrane to 
release the intraluminal vesicles into the extracellular space. Once the intraluminal 
vesicles are released from the cell they are known as exosomes (Figure 1.3). 







Figure 1.3- Biogenesis of exosomes 
Schematic diagram illustrating the biogenesis of exosomes and the involved proteins and 
molecules during this exosome secretion process.  
 
The biogenesis of microvesicles is different to that of exosomes. Microvesicles 
biogenesis involves the assembly of molecular cargo to the limiting plasma membrane. 
The rearrangement of membrane lipids and the interaction of contractile machinery at 
the plasma membrane level permits the vesicle outward budding process (D’Souza-
Schorey and Clancy 2012). During the microvesicles formation process, specific 
biological components are selected to enter the microvesicles and once formed, the 
microvesicles are blebbed or pinched from the plasma membrane to allow their release 
into the extracellular space.   
The biogenesis of apoptotic bodies only occurs during programmed cell death (Akers et 
al. 2013). The cells that are programmed to die will go through various stages which 
start with the condensation of the nuclear chromatin, subsequently the membrane 
starts to disintegrate by blebbing, and during the blebbing process cellular components 






1.7.4 EVs characteristics and content 
Due to some overlap in exosomes, microvesicles and apoptotic body sizes and protein 
content, it makes the discrimination of these different types of EVs challenging.  
Exosomes are saucer shaped vesicles with a lipid bilayer and float at a density of 1.13-
1.19g/ml-1 in sucrose gradients (Clotilde Théry, Zitvogel, and Amigorena 2002). Thery et 
al. explains that exosomes comprise of proteins derived from the cell cytosol, plasma 
membrane and endosomal compartments but not from endoplasmic reticulum, Golgi 
apparatus, mitochondria or the nucleus (Clotilde Théry, Zitvogel, and Amigorena 2002). 
However, in contrast, Pols and Klumperman state that CD63 tetraspanin is synthesised 
in the endoplasmic reticulum (Pols and Klumperman 2009), and CD63 is a common 
marker of exosomes (Pols and Klumperman 2009; Clotilde Théry, Zitvogel, and 
Amigorena 2002). Furthermore, mitochondrial-derived deoxyribonucleic acid (DNA) can 
be found in exosomes (Sansone et al. 2017). This discrepancy could be due to different 
cell sample type and highlights that EVs may vary in content depending on the parent 
cell type. 
On the contrary, exosomes indeed contain various proteins that are common 
irrespective of what cell type they originate from. For example, mouse and human DC-
derived exosomes contain protein of which 80% of these are conserved between the 
two species (Clotilde Théry, Zitvogel, and Amigorena 2002). However, they also can 
carry proteins that reflect the specific parent cell (Ventimiglia and Alonso 2016). In 
particular, the contents that get packaged into exosomes depend on the parent cell 
lineage and state (whether it is resting or activated, immature or mature) and /or the 
stimulus type (Robbins and Morelli 2014). 
Noteworthy, cells can host remarkably different populations of MVBs. For example, in 
epithelial cells, the EVs that were released from the apical and basolateral sides of the 
cells differed in their contents even though these EVs are derived from the same cell 
(Qiuhong Chen et al. 2016). Indeed, it is widely reported that exosomes are 
heterogenous and their composition is influenced by modifications in culture conditions 
and differentiation states of the secreting cells (Colombo, Raposo, and Théry 2014).  For 




and IFNγ can affect the protein and ribonucleic acid (RNA) that get packaged into EVs 
released by DCs (Segura et al. 2005).  
EVs can encompass various biological materials including micro-RNA (miRNA), mRNA, 
proteins, lipids, cytokines, MHC molecules, CD molecules, adhesion molecules, heat 
shock proteins, signal transduction proteins, trafficking proteins, antigens/peptides, 
enzymes, chemokines and other biological materials. Due to the proficiency in carrying 
biological material and their mobility both locally and systemically it marks EVs as 
efficient transport vehicles that conduct important cell-to-cell communication.   
EVs encompass various proteins consisting of CD63, CD81, CD9, ESCRT, neutral 
sphingomyelin phosphodiesterase (nSMase), Rab proteins, heat shock proteins, lipid 
and nucleic acid amongst other biological materials. There are various ways to isolate 
and describe EVs, however the minimal requirements of biochemical, biophysical, 
phenotypical and functional criteria including the methodical approach to EV isolation 
and characterisation are discussed in detail by Lotvall et al. (Lötvall et al. 2014) and 
Witwer et al. (Kenneth W. Witwer et al. 2013).  
 
1.7.4.1 Expression of CD63, CD81 and CD9 in EVs 
Of the most commonly found proteins in EVs are CD63, CD81 and CD9. These are part 
of the transmembrane 4 superfamily, which is also known as the tetraspanin family. 
These are cell surface proteins that have 4 hydrophobic domains and are mediators of 
various signal transduction processes.  
These tetraspanins interact with MHC molecules and integrins which aid their role in 
organising large molecular complexes and membrane components to facilitate the 
assembly of signalling molecules required for essential cellular events (Clotilde Théry, 
Zitvogel, and Amigorena 2002). These cellular events include the regulation of cell 
development, activation, growth and proliferation.  
CD63 is the first characterised tetraspanin (Pols and Klumperman 2009). The 
enrichment of tetrespanins in exosomes is from 7-124 folds higher compared to their 
parent cells (Andreu and Yáñez-Mó 2014). CD63 and CD81 are the most commonly used 




recently discovered that CD63 and CD81 can be present in exosomes, microvesicles and 
apoptotic bodies derived from the same parental cells (Crescitelli et al. 2013), rendering 
CD63 and CD81 not exosome-specific per se. The presence of CD9 in EVs are not 
consistently found in exosomes (Crescitelli et al. 2013). On the other hand, primary B 
cell-derived exosomes contain CD9 and CD81 but did not express CD63 (Saunderson et 
al. 2008), thus highlighting the heterogeneity of EV contents. 
The function of these tetraspanins is most well-documented in terms of their relation to 
the parent cells as opposed to their function in the EVs. Nonetheless, these tetraspanins 
has been described to be involved in EVs cargo sorting (including proteins and RNA), EVs 
targeting and uptake and antigen presentation (Andreu and Yáñez-Mó 2014). 
Tetraspanins organised in tetraspanin enriched microdomains (TEMs) on immune cell’s 
surface are involved in antigen presentation by recruiting proteins to TEMs forming 
complexes to initiate immune synapse formation. The major role CD81 plays in this has 
been highlighted by Mittelbrunn et al., where the authors describe that CD81 is found 
in the central supramolecular activation complex (c-SMAC) (Mittelbrunn et al. 2002), 
and facilitates the process of immune synapse formation in the T cell via the interaction 
of CD3 and intercellular adhesion molecule 1 (ICAM-1) (Rocha-Perugini et al. 2013), thus 
facilitating an efficient T cell activation. In APCs, CD81 has been suggested to interact 
with MHC molecules (Wright, Moseley, and van Spriel 2004), which can enhance 
formation of MHC-II multimer and enhance antigen presentation (Unternaehrer et al. 
2007; Poloso, Denzin, and Roche 2006; Kropshofer et al. 2002).  
Edgar et al. showed that CD63 was essential in the biogenesis of small intraluminal 
vesicles in MVB of HeLa cells (Edgar, Eden, and Futter 2014), thus CD63 is not only a 
marker of EVs but may also play an essential role in their biogenesis. 
    
1.7.4.2 ESCRT and nSMase  
The ESCRT consists of approximately 20 proteins assembled into 4 complexes (ESCRT-0, 
-I, -II and -III) which is associated with accessory proteins such as Alix and tumour 
susceptibility gene 101 (Tsg101).  
The ESCRT-0 complex identifies and sequesters ubiquitinated transmembrane proteins 




membrane biogenesis of buds with selected cargo. The ESCRT-III complex then 
promotes the vesicle scission (Hanson and Cashikar 2012). Alix is involved in exosome 
biogenesis and sorting of syndecans via its interaction with syntenin (Baietti et al. 2012). 
Babst et al. demonstrated that Tsg101 mutant cells were defective in the transport of 
membrane proteins to the late endosomal compartments (Babst et al. 2000), which 
highlights the important role Tsg101 plays in the normal trafficking of membrane 
proteins in the endocytic pathway. 
However, in the cells that lack ESCRT machinery, MVBs and exosomes are still able to be 
formed and CD63+ EVs produced, suggesting an exosome biogenesis pathway that is 
ESCRT-independent (Stuffers et al. 2009), and as explained above could be CD63-driven. 
This ESCRT-independent pathway involves nSMase. In the nSMase pathway, nSMase 
hydrolyses sphingomyelin into ceramide, and phospholipase D2 hydrolyses 
phosphatidylcholine into phosphatidic acid. These two lipid metabolising enzymes can 
produce lipids in the limiting membrane of MVB which initiates the inward invagination 
of intraluminal vesicles which thus are independent of the ESCRT pathway. Whether the 
ESCRT or nSMase pathway of exosome biogenesis occurs can influence what cargo gets 
packaged into the contents of exosomes (Colombo, Raposo, and Théry 2014).  
 
1.7.4.3 Rab proteins 
Rab proteins are essential for transport of endosomal structures in cells. Rab proteins 
play a role in vesicle budding, vesicle movement with actin and tubulin networks and 
membrane fusion of MVBs. There are approximately 70 different Rab proteins in 
humans, which most are involved in vesicles trafficking. In 2002, Savina et al. published 
the first report of Rab protein Rab11 to be involved in exosome secretion, the authors 
showed that Rab11-deficient K562 cells had a significant decrease of exosomes 
production (Savina, Vidal, and Colombo 2002). Later studies showed that Rab35 (C. Hsu 
et al. 2010) and Rab27αβ (Ostrowski et al. 2010) were also involved in the fusion of late 
endocytic compartments and MVBs with the plasma membrane to initiate secretion of 





1.7.4.4 Heat shock proteins 
Heat shock protein (HSP)70 and HSP90 are commonly found in EVs secreted from 
various cell types. These ubiquitous proteins play a role in antigen presentation by 
binding to antigenic peptide and loading them onto MHC molecules (Srivastava 2002).   
 
1.7.4.5 Lipids 
EVs contain a mixture of lipids, mainly consisting of ceramide, sphingomyelin, 
cholesterol, phosphatidylserine and saturated fatty acids. These components together 
with flotillins provide EVs with a detergent-resistance property (Wubbolts et al. 2003; 
Colombo, Raposo, and Théry 2014) and thus this property adds further protection from 
degradation whilst in transit to their destination target cell.  
 
1.7.4.6 Nucleic acids 
Almost all cells harbour miRNAs, but the miRNA repertoire of different cell types vary 
tremendously (Turner, Schnorfeil, and Brocker 2011; Ha 2011). Previously, it was 
thought that mainly cells carried nucleic acids until in 2007, Valadi et al., who were the 
first group to demonstrate that exosomes also carry nucleic acids (Valadi et al. 2007). 
Namely these were mRNAs and miRNAs and these exosomal-associated RNA molecules 
served as a novel means of cell-to-cell communication. This breakthrough study showed 
that human cells which were treated with mouse exosomes, contained mouse proteins. 
The presence of mouse protein in the human cells could only have derived from the 
mouse exosomes. The mouse exosomes contained the relevant mRNA coding for this 
protein which indicated that mRNA transported in exosomes were functional and had 
been translated into protein in the target cell (Valadi et al. 2007).  
Noteworthy, miRNA can be associated to Ago2 protein (Arroyo et al. 2011) and high-
density lipoproteins (Vickers et al. 2011) which these proteins aid their transport in a 
cell-free and EV-free manner.  
Exosomal RNA consists mainly of small RNA including mRNA and miRNA but lacks 18S 




ribosomal RNA, specific transfer RNA (tRNA) fragments, vault-RNA and Y-RNA have also 
been found within EVs (Colombo, Raposo, and Théry 2014).  
miRNA is a non-coding RNA molecule that is approxiamately 22 nucleotides long and 
function in RNA silencing and post-transcriptional regulation of gene expression by 
inhibitng mRNA translation into protein. Several studies have demostrated that EVs are 
a rich source of miRNAs, more often enriched compared to their parent cell miRNA 
contents (Clotilde Théry, Zitvogel, and Amigorena 2002; Robbins and Morelli 2014; 
Villarroya-Beltri, Gutiérrez-Vázquez, Sánchez-Madrid, et al. 2013).                             
Importantly, EVs offer a protective route of miRNA transfer between cells. As EVs have a 
lipid bilayer of ceramide and cholesterol and can encapsulate contents and evade 
degradation by the complement system by having the presence of CD55 and CD59 on 
its surfaces together can evade degradation by proteinases and ribonucleases (RNase) 
(Robbins and Morelli 2014).  
The miRNA cargo of EVs is not a random process but a regulated sorting mechanism is 
in place to select specific miRNAs to be packaged into EVs. This was demonstrated by 
Villarroya-Beltri et al. in 2013. These authors showed that sumoylated hnRNPA2B1 
controls which miRNAs are packaged into exosomes through its interaction with specific 
motifs (Villarroya-Beltri, Gutiérrez-Vázquez, Sánchez-Cabo, et al. 2013).   
Importantly, EVs are not mere smaller versions of the parent cells (Srivastava 2002). 
Blanchard et al. demonstrated the T cell derived exosomes lacked the abundant parent 
cell-surface CD45 and CD28 but did however contain TCR/CD3ζ complexes. Given that 
the parent T cell has high abundance of CD45, CD28 and TCR/CD3ζ complexes, but only 
TCR/CD3ζ complexes were found on the exosomes suggests a specific packaging 
mechanism in the cargo of EVs (Blanchard et al. 2002). Indeed, this is also the case for 
other cell types such as DCs. Thery et al. demonstrated that DCs which are rich in Fc 
receptors produced exosomes which lacked these cell surface molecules (C Théry et al. 





1.7.5 EVs interaction with target cells 
The binding of EVs to the target cell surface can be facilitated by the presence specific 
receptors. For example, Nolte-‘t et al. demonstrated that activated T cells bind DC EVs 
through the interaction of leukocyte function-associated antigen-1 (LFA-1) rather than 
on TCR specificity (Nolte-’t Hoen et al. 2009). The modest binding of EVs to target cells 
may be adequate to initiate biochemical changes in the target cell, as demonstrated by 
Denzer et al. (Denzer et al. 2000) and Segura et al. (Segura et al. 2007), whereby APC 
EVs which displayed MHC-peptide complexes can activate antigen specific T cells. In 
other scenarios, the contents of EVs must be transported inside the target cells. The 
internalisation of EVs into target cells can occur through various phagocytosis and 
endocytosis mechanisms. The internalisation of EVs is necessary for its contents such as 
miRNA to be released into the target cell gene processing machinery for gene silencing 
to occur (Colombo, Raposo, and Théry 2014).  
The delivery route of EVs towards target cells may be protected not just by the lipid 
bilayer that surrounds them but also by functional markers. For example, Clayton et al. 
demonstrated that APC exosomes expression of CD55 and CD59 protected the 
exosomes from complement-mediated degradation (Aled Clayton et al. 2003).  
 
1.7.6 Immune cell derived EVs 
The secretion of EVs from T cells and Tregs are in a calcium (Ca2+)-dependent manner 
(Okoye et al. 2014; Blott and Griffiths 2002), and thus cell activation releases their EVs. 
On the contrary, other cell types such as Epstein-Barr virus (EBV)-transformed B cells, 
DCs and epithelial cells constitutively release EVs (G van Niel et al. 2001; C Théry et al. 
1999; G Raposo et al. 1996). 
Several studies have shown that immune and non-immune cells release EVs that can 
modulate the immune system, mediating an activated or a suppressed immune 
response (Robbins and Morelli 2014), thus highlighting the potential of EVs treatment in 
immune therapy. EVs can act as both anti-inflammatory and pro-inflammatory factors 
depending on the cell from which they originate from and from the parent cell status 




1.7.7 T cell derived EVs 
The 7 publications described in section 1.7.8 are the only publications to date and to 
the best of my knowledge, demonstrating Treg EVs. However, a multitude of research 
has been conducted on T cell EVs and contrary to Treg EVs which all the publications so 
far have shown they are immunosuppressive; T cell EVs can both suppress and promote 
the immune response. The pleiotropic role of T cell EVs could be due to various factors 
including their parent cell status, packaged contents and their target cell. 
T cell EV contents have been explored more extensively than Treg EV contents. In 2002, 
Blanchard et al. demonstrated that T cell derived exosomes comprise the TCR/CD3ζ 
complex which give T cell exosomes the potential to deliver activation signals to cells 
bearing the complementary peptide/MHC complexes. These exosomes also contained 
proteins of the transduction pathway, Src-like tyrosine kinases and adhesion molecules 
(Blanchard et al. 2002). Whether these proteins are functional in these exosomes was 
not clear at the time. Since this publication in 2002, more studies have unravelled the 
roles and functions of T cell EVs.  
 
1.7.7.1 Immunosuppressive T cell EVs 
In 2004, Nolte-‘t Hoen et al. demonstrated that MHC-II/peptide complexes-bearing 
vesicles derived from anergic T cells can be taken up by APCs and endowed them with 
immune-suppressive properties. These vesicles also contained CD80, CD86, CD2, CD54 
and CD25 which may have contributed to their immunosuppressive ability. 
Furthermore, the transfer of bioactive material from T cells to APCs does not require 
antigen-specific cell-to-cell contact but can be mediated via vesicles suggested that 
vesicles can play an important role in immune responses (Nolte-'t Hoen et al. 2004). 
In 2011, Zhang et al. demonstrated that ovalbumin (OVA)-antigen-specific CD4+ T cell 
derived exosomes can inhibit DCOVA mediated CD4+ T cell proliferation in vitro and 
functioned in vivo to inhibit CD8+ cytotoxic T lymphocyte (CTL) responses. These T cell 
exosomes expressed CD4, TCR, LFA-1, CD25 and FasL (H. Zhang et al. 2011), whether 
these molecules contributed to the immunosuppressive responses was unclear. 
Nonetheless, these authors demonstrated that the interactions of the peptide/MHC 




exosomes into these DCs. Thus, demonstrating that exosomes express markers that can 
enable them to enter target cells to modulate their function (H. Zhang et al. 2011).  
In 2011, Mittlebrunn et al. demonstrated that T cells release miRNA-containing 
exosomes into APCs in a unidirectional manner that is antigen-driven and occurs during 
the immunological synapse. APCs which received these exosomal miRNA had their gene 
expression modulated (Mittelbrunn et al. 2011), supporting the notion that exosomes 
safely deliver biological materials which are functional in the target cells. Specifically, 
miR-355 was shown to be transferred from T cells to their exosomes and this exosomal 
miR-355 was delivered into APCs which downregulated SOX-4 three prime untranslated 
region (3’UTR) mRNA expression levels, a target of miR-355. Hence, these authors 
experimentally demonstrated that exosomes carried and offered a protected vehicle of 
miRNA passage into target cells.      
In 2013, Bryniarski et al. demonstrated that CD8+ suppressor T cell exosome-like 
nanovesicles can be manipulated by coating the surface of exosomes with antibody light 
chains to facilitate their uptake via an antigen specific manner into target Teffs. 
Furthermore, these nanovesicles can be transfected with specific miRNA. Additionally, 
these authors discovered that nanovesicle-associated miR-150 as a mediator of 
immunosuppression. These nanovesicles carried and delivered miR-150 into antigen 
specific targeted cells and was shown to inhibit allergic contact dermatitis in mouse 
models (Bryniarski et al. 2013) and thus highlights that manipulation of nanovesicles is 
possible and importantly that these manipulated nanovesicles can function in vivo.   
Not only can T cell EVs modulate target cell functions by inhibiting their cellular 
machinery but can also cause target cell death as a means of suppressing their cell 
expansion numbers. For instance, various studies have shown that T cells can release 
APO2L (Martínez-Lorenzo et al. 1999; Monleón et al. 2001) and membrane-associated 
and FasL-containing exosomes which can induce target cell death (Monleón et al. 2001; 





1.7.7.2 Immune promoting T cell EVs 
However, as explained above, T cell EVs can also promote the immune response.  
In 2012, Wahlgren et al. showed that activated CD3+ T cells released exosomes which 
work in unison with IL-2 to promote proliferation of resting autologous T cells and 
modulate their cytokine production profiles (Wahlgren et al. 2012). Interestingly, 
exosomes together with IL-2 generated secretion of more cytokines and at higher 
concentrations than exosomes or IL-2 alone. Noteworthy, chemokine ligand (CCL)-4 was 
secreted by T cells stimulated with exosomes plus IL-2 together but CCL4 was not 
secreted if the treatment consisted of exosomes or IL-2 alone.  
Various studies have shown that T cell EVs can promote inflammation by inducing 
monocytes to produce pro-inflammatory cytokines TNFα and IL-1β (Scanu et al. 2008; 
Carpintero et al. 2010; Zakharova, Svetlova, and Fomina 2007).  
Taken together, various studies have shown that immune cell-derived EVs modulate the 
immune response by altering the cytokine production of target cells to provide either 
an anti-inflammatory or pro-inflammatory micro-environment. 
In recent years, Tregs have been shown by us and other groups to release EVs. 
 
1.7.8 Treg cell derived EVs 
1.7.8.1 Mouse 
Importantly, to date, various groups have demonstrated that mouse (Lesley Ann Smyth 
et al. 2013; Tung et al. 2018; Okoye et al. 2014), rat (X. Yu et al. 2013; Aiello et al. 2017) 
and human (Torri et al. 2017; Azimi et al. 2018) Tregs release EVs that are 
immunomodulatory. The host laboratory, in 2013 were the first to demonstrate that 
mouse Tregs release immunomodulatory exosomes upon TCR activation (Lesley Ann 
Smyth et al. 2013). These Treg exosomes were able to suppress the proliferation of 
CD4+CD25- T cells in vitro and significantly reduced their production levels of pro-
inflammatory cytokines IL-2 and IFNγ, thus creating an anti-inflammatory 
microenvironment. The presence of the ectoenzyme CD73 on Treg exosomes was 
discovered to contribute in part to their immunosuppressive ability (Lesley Ann Smyth 




immunosuppression. These authors explained that CD39 is a cell surface located 
enzyme found on Tregs that catalyses pro-inflammatory ATP into AMP, which CD73, 
found on Treg exosomes converts to anti-inflammatory adenosine. Activated Teffs 
express adenosine receptors A2aR (Chhabra et al. 2012; L. Han et al. 2017; Leone et al. 
2018) which facilitates the uptake of this exosome-converted adenosine and 
subsequently this initiates intracellular cAMP production resulting in decreased cytokine 
production and thus preventing T cell pro-inflammatory responses (Baietti et al. 2012). 
CD73 expression on mouse Treg exosomes contributed to their immunosuppressive 
ability (Lesley Ann Smyth et al. 2013), but also other molecules are likely involved. This 
was addressed in 2014 by Okoye et al. Firstly, the authors confirmed the findings of the 
host laboratory that mouse CD4+ CD25+ Tregs released exosomes upon their activation 
(Okoye et al. 2014). Secondly, Okoye et al. also suggested that activated Treg cells 
released more CD63+ exosomes per cell compared to activated or stimulated naïve CD4+ 
cells; naïve CD8+ cells; B cells; Th17 cells or Th1 cells, and their release are regulated by 
IL-2, amphiregulin and ATRA (Okoye et al. 2014).  On deeper analysis, the authors found 
that Treg cell release of exosomes were influenced by changes in intracellular calcium, 
hypoxic conditions and the biosynthesis of ceramide (Okoye et al. 2014), similar to the 
findings by other groups showing that these factors also regulate exosome release 
(Savina et al. 2003; H. W. King, Michael, and Gleadle 2012; Trajkovic et al. 2008).  
The mouse Treg exosomes contained pre-mature miRNA, mature miRNA and mRNA, of 
which the Treg exosomal miRNA repertoire were differential compared to the miRNA 
profile found in the parent cells, Th1 cell exosomes or Th2 cell exosomes (Okoye et al. 
2014), suggesting potential diverse roles for Treg exosomes. Indeed, mouse Treg 
exosomes transferred Let-7d from the parent Treg cell into Th1 cells and inhibited 
target mRNA resulting in their suppressed proliferation in vitro and importantly, these 
EVs functioned in vivo to prevent autoimmune disease.  
Recently, another mouse Treg EV paper was published by myself and the host 
laboratory in 2018 (Tung et al. 2018). We demonstrated the novel finding that mouse 
Treg EVs are acquired by BM-DCs and altered their cytokine production. Namely, these 
Treg EV-treated bone marrow-derived DCs (BM-DCs) significantly reduced the 
production of pro-inflammatory IL-6 whilst increasing their immunosuppressive IL-10 




contained miR-150-5p and miR-142-3p, which was transferred into BM-DCs. Given that 
both miRNAs have previously been reported to affect DC cytokine production (Lesley A 
Smyth et al. 2015), it was possible that these EV-associated miRNAs that were 
transferred into BM-DCs modulated their function by affecting their cytokine 
production, thus creating a ‘tolerogenic’ phenotype. These findings will be presented 
and discussed in Chapter 3. 
 
1.7.8.2 Rat 
Rat Tregs releasing immunomodulatory EVs have also been reported in literature (X. Yu 
et al. 2013; Aiello et al. 2017).  
In 2013, Yu et al. demonstrated that the adoptive transfer of rat Treg derived exosomes 
into a rat model of kidney transplantation prolonged the survival of the allograft (X. Yu 
et al. 2013). In particular, donor Treg derived exosomes were more suppressive towards 
T cell proliferation and prolonged allograft survival longer than autologous Treg derived 
exosomes. Conversely, these authors also showed that B cell derived exosomes induced 
rather than suppressed T cell proliferation, possibly due to the presence of allergen-
derived peptides that induce T cell responses (X. Yu et al. 2013). However, the 
molecular mechanism driving rat Treg exosomes suppressive ability was not addressed 
by these authors. 
Nonetheless, in 2017, Aiello et al. provided deeper insights into the role of rat Treg 
derived EVs (Aiello et al. 2017). The authors used rat DCs that maintained their 
immature state by genetic transfer of dominant negative form of inhibitor of nuclear 
factor kappa-B kinase subunit beta (IKK2) and co-cultured these with T cells. This co-
culture produced a unique population of Tregs (dnIKK2-Treg). These Tregs produced 
immunomodulatory EVs that suppressed T cell proliferation. These EVs contained 
miRNA including miR-503 which they suggest when transferred into target cells 
contributed to blocking cell cycle progression, additionally, nitric oxide synthase (iNOS) 
enzyme was found inside Treg EVs which can induce apoptosis in target cells. 
Furthermore, these Treg EVs converted naïve T cells into induced Tregs, demonstrating 








During the course of my PhD studies, it was published that human Tregs, akin to their 
murine counterparts, also release immunomodulatory EVs (Torri et al. 2017; Azimi et al. 
2018).  
In 2017, Torri et al. were the first group to report that human Tregs release 
immunomodulatory EVs (Torri et al. 2017). These authors isolated EVs from Th1, Th17 
and Treg cells and compared their miRNA repertoire. miR-146a-5p, miR-150-5p and 
miR-21-5p were identified as being enriched in Treg EVs. The authors described that 
Treg EVs suppressed T cell proliferation, which they linked to Treg EV-associated miR-
146a-5p given that two relevant targets of miR-146a-5p, Stat1 and Irak2 expression was 
significantly decreased in target cells that were treated with Treg EVs compared to Th17 
EVs (which contained significantly less miR-146a-5p expression levels). Stat1 and Irak2 
are two genes that are up-regulated upon stimulation of naïve T cells (Torri et al. 2017), 
and thus the suppressed expression of these genes may prevent their maturation.  
In 2018, Azimi et al. (Azimi et al. 2018) confirmed the findings of Torri et al. (Torri et al. 
2017) that human Treg exosomes are immunomodulatory. Azimi et al. compared the 
Treg exosomes derived from healthy controls and MS patients and found that both 
types of exosomes were suppressive and induced apoptosis of conventional T cells, but 
the MS Treg exosomes were less potent than that of healthy controls (Azimi et al. 
2018), suggesting that they were impaired.  
 
1.7.9 EVs that induce Tregs  
EVs derived from other cells types can induce Treg cell populations. For example, the 
study by Cai et al. demonstrated that TGF-β1 gene-modified DCs exosomes can induce 
CD4+ FoxP3+ Tregs via TGF-β1 in vitro and in vivo. These authors found increased iTregs 




(IBD) mice. These iTregs prevented Th17-mediated inflammatory damage in IBD murine 
models better than TGF-β1 cytokine alone (Z. Cai et al. 2012).  
In 2008, Wang et al. reported that thymus-derived exosome-like particles also induce 
FoxP3+ Treg cell populations, which was likely driven by the presence of TGF-β in these 
particles. These particles induced CD4+ CD25- T cells to convert into functionally 
suppressive Tregs capable of suppressing the proliferation of CD4+ CD25- T cells both in 
vitro and in vivo (G.-J. Wang et al. 2008).  
Furthermore, EVs derived from other cell types such as mesenchymal stem cells (MSCs) 
stimulated with TGF-β and IFNγ promoted Treg differentiation (Q. Zhang et al. 2018) 
and EVs derived from tumour cells can also induce, expand and enhances Treg 
population and their suppressive functions (Szajnik et al. 2010).   
 
1.7.10 EVs in transplantation 
EVs have been involved in various aspects of transplantation, for example as a means of 
cell-free therapy. As previously mentioned, the adoptive transfer of rat Treg EVs can 
prolong rat kidney transplant survival (X. Yu et al. 2013; Aiello et al. 2017). Whether 
human Treg EVs can also similarly prolong allograft survival has thus far not been 
demonstrated and is one of the aims of my PhD thesis. Nonetheless, EVs derived from 
other cell types have shown potential in promoting allograft survival. For example, Li et 
al. showed that immature DC exosomes given together with rapamycin induce 
transplant tolerance in mouse heart allografts. Donor DC exosomes prolonged the 
allograft survival longer than recipient DC exosomes. Furthermore, the authors showed 
that the activation and proliferation of alloreactive T cells were suppressed more 
potently when donor DC exosomes were used in combination with rapamycin 
compared to donor DC exosomes treatment alone. The combined treatment induced 
CD4+CD25+ Treg cell populations in the spleen which may explain, in part, the inhibition 
of alloreactive T cells (X. Li et al. 2012). In 2016, Song et al. (Song et al. 2016) reported a 
similar finding to Wang et al. (G.-J. Wang et al. 2008) that exosomes can covert Teffs to 
Tregs. Song et al. demonstrated that donor exosomes can induce Tregs in vivo which 
were donor antigen specific and capable of inhibiting immune inflammation in the 




identified the presence of matrix metallopeptidase 1a (MMP1a), which this induced 
CD4+ T cell to express FoxP3 and TGF-β via inhibiting the Th2 transcription factor 
GATA3. Hence, this study showed that exosomes can polarise CD4+ T cells and convert 
Th2 cells to Tregs (Song et al. 2016). 
In rat models of cardiac allograft transplantation, the adoptive transfer of donor DC 
exosomes together with short-term suboptimal doses of immunosuppression that 
blocks DC maturation can induce donor-specific allograft tolerance by inhibiting the 
anti-donor proliferative responses (Peche et al. 2006).  
However, on the other end, EVs can induce allo-immune T cell responses that 
exacerbate transplantation outcomes. For instance, the passenger leukocyte theory 
described in 1957 by Snell (Snell 1957), has recently been revisited by Marino et al. 
(Marino et al. 2016) and Liu et al. (Q. Liu et al. 2016). Marino et al. demonstrated that 
donor exosomes which carry donor MHC are taken up by recipient APCs (semi direct-
pathway of allorecognition) and these cross-dressed recipient APCs could induce pro-
inflammatory alloimmune T cell responses in transplant models, thus APCs cross-
dressed with exosomes could trigger the transplant rejection process (Marino et al. 
2016).  Liu et al. also showed a similar finding in cardiac transplants in mice (Q. Liu et al. 
2016).  





1.8 Hypothesis and Aims 
1.8.1 Hypothesis 
Mouse Treg EVs can transfer miRNAs into target bone marrow-derived DCs (BM-DCs) to 
modulate their phenotype and cytokine production to promote an immunoregulatory 
microenvironment.  
Human Tregs release EVs that contain miRNAs, these miRNAs are transferred into target 
T cells (T responders (Tresps)). Human Treg EVs can suppress the proliferation of Tresps 
and modulate their production of pro-inflammatory cytokines. These human Treg EVs 
can also function in vivo to promote transplant allograft tolerance.  
 
1.8.2 Aims 
This PhD project aimed to further characterise mouse and human Treg derived EVs. The 
following aims were set: 
(1) Investigate the miRNA content of mouse Treg EVs and assess if they can be 
transferred into BM-DCs and alter BM-DC cytokine production profiles. 
(2) Characterise human Treg EVs and test their in vitro suppressive ability and their 
ability to modulate the cytokine production profile by Tresps. 
(3) Investigate the miRNA repertoires contained within human Treg EVs and 
perform bioinformatics to predict which mRNAs these miRNAs can target. 
(4) Assess the efficacy with which human Treg EVs protect against alloimmune-














Chapter 2 - Materials and Methods 
2.1 Mice subjects 
2.1.1 Subjects 
Female C57BL/6 (B6) and BALB/c mice (approximately 8 weeks old) were purchased 
from Harlan, UK.  
BALB/c RAG2-/- γc-/- (BRG) mice (approximately 10-12 weeks old), knockout for the 
recombinant-activating gene 2 (RAG-2) and the IL-2 common gamma chain (γc) genes 
were bred in house in Biological Sciences Unit of New Hunt’s House, King’s College 
London, UK. 
B6, BALB/c and BRG mice were all housed in the Biological Sciences Unit and kept under 
specific pathogen free conditions. All animal experimental procedures were conducted 
under sterile conditions in accordance to Home Office regulations under the project 
licence (PPL) number 70/7302. 
Rab27αashen/ashen β-/- knock-out (Rab27DKO) mice, knockout for the Rab27 member 
(consisting of two closely related homologs of Rab27α and Rab27β) of the Rab 
subfamily of GTPases were generated in a B6 background (Tolmachova et al. 2007). 
These mice were a kind gift from Dr Tanya Tolmachova of Imperial College London, 
London, UK.  
Rosa26-ERT2-Cre Dicerfloxed/floxed (Dicer KO), which are conditional knockout mice for the 
Dicer gene expression in the presence of tamoxifen were a kind gift from Dr Mark 
Wilson of National Institute for Medical Research/Francis Crick Institute, London, UK 
and Genentech, California, United States of America (USA).  
 
2.1.2 Reagent preparations 
All following reagents were sterile filtered through 0.22µm pore size hydrophilic, 
polyethersulpfone membrane, gamma irradiation sterilised and low protein binding 
filter unit (Merck Millipore, Burlington, Massachusetts, USA) in a class II biological safety 




2.2 Mouse cell isolation and culture 
2.2.1 Media  
2.2.1.1 Mouse complete media 
Cells were grown in Roswell Park Memorial Institute (RPMI)-1640 (Thermo Fisher 
Scientific, Waltham, Massachusetts, USA) supplemented with 10% heat-inactivated fetal 
calf serum (FCS) (General Electric (GE) Healthcare, Chicago, Illinois, USA), 100 units/mL 
penicillin and 100µg/mL streptomycin, 2mM L-glutamine, 10mM HEPES and 50µM 2-
mercaptoethanol (all Thermo Fisher Scientific).  
 
2.2.1.2 Mouse EV-free complete media 
The same formulation as above ‘mouse complete media’ but with the heat-inactivated 
FCS, ultracentrifuged at 100,000g with a Beckman Type 70.1 Ti rotor on a Beckman L8-
60M ultracentrifuge machine for 18 hours at 4°C to deplete serum EVs prior to 
preparing ‘mouse EV-free complete media’. 
 
2.2.2 BALB/c mice BM-DCs isolation and culture  
Bone marrow was extracted from the tibia, femur and pelvic bones of BALB/c mice 
using a 27Gx½” needle (BD Biosciences, Franklin Lakes, New Jersey, USA) and a syringe 
filled with RPMI-1640. The harvested bone marrow was then passed through a 70µm 
nylon cell strainer (Falcon®, Corning, New York, USA) to gain a single cell suspension. 
Red blood cells (RBCs) were lysed for 2-5 minutes with ammonium chloride potassium 
(ACK) lysing buffer (150mM NH4Cl, 10mM KHCO3 0.1mM Na2 EDTA in dH20; made in-
house) at room temperature and cells subsequently washed with RPMI-1640. RBC-lysed 
cells were incubated with a mixture of 300µL each of rat anti-mouse CD4 (YTS-191), CD8 
(YTS-169), MHC class II (M5-114) and B220 (RA3-3A1) purified antibodies (made in-
house from hybridoma cell lines) for 30 minutes at 4°C under rotation. Cells were 
washed in RPMI-1640 to remove any unbound antibodies before incubation with pre-
washed Dynabeads™ (magnetic beads pre-coated with polyclonal anti-rat IgGs) (Thermo 
Fisher Scientific) for 30 minutes at 4°C under rotation. Dynabeads™ which captured 




separation using a magnet. The supernatant containing BM-DC progenitor cells were 
then washed in RPMI-1640 and counted with trypan blue solution (Sigma-Aldrich, St. 
Louis, Missouri, USA) exclusion of any dead/comprised cells. BM-DC progenitors were 
then cultured at 1x106 cells/mL/well in 24-well plates with ‘mouse complete media’ 
supplemented with 40ng/mL granulocyte macrophage colony-stimulating factor (GM-
CSF; made in-house; (Tsang et al. 2008)). On days 2 and 4 of culture, non-adherent cells 
and media were removed then fresh ‘mouse complete media’ containing 40ng/mL GM-
CSF was replenished. On day 6, ‘clustering’ profile/morphology of BM-DCs was observed 
under light microscopy before use (Figure 2.1). BM-DCs were gamma-irradiated (30 
Gray (Gy)) and washed twice with ‘mouse complete media’ prior to usage for mouse 
Treg stimulations. For co-culture experiments, the BM-DCs were not irradiated. Cell 
cultures were maintained in a humidified incubator at 37°C in the presence of 5% (v/v) 
CO2. 
 
Figure 2.1- BM-DCs ’clustering’ morphology profile under light microscopy. 
BALB/c BM-DCs were generated from DC progenitors cultured in GM-CSF for 6 days. 
Representative picture of BM-DC colonies at Day 6 (end of culture) Original objective 
10X.    
 
2.2.3 Rosa26-ERT2-Cre Dicerfloxed/floxed BM-DC isolation and culture 
Bone marrow was harvested, and RBC lysed as described above (section 2.2.2). Bone 
marrow cells were then re-suspended at 10x106/mL in ‘mouse complete media’ 
supplemented with 200ng/mL recombinant mouse GM-CSF (Peprotech EC, 
Hammersmith, London, UK) and with a final concentration of 200nM of 4-
hydrotamoxifen (4-OHT) (a kind gift from Dr Mark Wilson of National Institute for 




(Sigma-Aldrich)) in 90mm petri dishes at a total volume of 10mL. On days 2, 5 and 7, the 
media was changed with fresh media (above formulation) with a final concentration of 
200nM of 4-OHT or the equivalent of vehicle alone. On day 10, BM-DCs were harvested 
for experiments. Cell cultures were maintained in a humidified incubator at 37°C in the 
presence of 5% (v/v) CO2. Figure 2.2 shows the Dicer Cre-LoxP system used.  
 
 
Figure 2.2- Schematic diagram of conditional knock-out of Dicer using Cre-LoxP system 
 
2.2.4 Mouse Treg isolation  
The spleen and lymph nodes of B6 and Rab27DKO mice were harvested and CD4+CD25+ 
T cells isolated using Dynabeads™ FlowComp™ Mouse CD4+CD25+ Treg Cells Kit 
(Thermo Fisher Scientific) according to manufacturer’s protocols. Briefly, this protocol 
involved the negative selection for CD4+ T cells and the subsequent positive selection 
for CD25+ cells using antibody coated magnetic beads. CD4+CD25+ Tregs were 
stimulated with gamma-irradiated (30 Gy) BALB/c BM-DCs at a ratio of 4:1 of Tregs:BM-
DCs in ‘mouse complete media’ in a total volume of 1.5mL in 24-well plates. 10 
international units (IU)/mL of recombinant human IL-2 (Proleukin®, Prometheus 
Laboratories Inc., California, USA) were added to Tregs on days 1, 2 and 4 post-
stimulation. Cell cultures were maintained in a humidified incubator at 37°C in the 





2.2.5 Generation of mouse Treg lines  
To expand alloantigen-specific mouse Tregs with direct specificity, the B6 Tregs or 
Rab27DKO Tregs were stimulated weekly with irradiated BALB/c BM-DCs at 4:1 ratio of 
Tregs:DCs. Similarly, to expand alloantigen-specific mouse T cell with direct specificity, 
the B6 T cells were stimulated weekly with irradiated BALB/c BM-DCs at 4:1 ratio of T 
cells:DCs (Figure 2.3), in the presence of 10IU/ml IL-2 (Proleukin®) in 24-well plates.  
 
 
Figure 2.3- Diagram showing the isolation of mouse CD4+CD25+ Tregs and expansion of 
alloantigen-specific Tregs  
 
2.3 Flow cytometry 
2.3.1 Phenotypic analysis of mouse cells 
All immunostaining was performed in fluorescence-activated cell sorting (FACS) buffer. 
FACS buffer consisted of 2% FBS and 1mM EDTA in phosphate buffered saline (PBS; all 
Thermo Fisher Scientific). Staining was performed using 3-4x105 mouse cells per 
staining panel in a final volume of 100µL of FACS buffer. Cells were incubated with 
5µg/mL of αCD16/CD32 antibody (clone 93) (Thermo Fisher Scientific) for 30 minutes at 




incubated with fluorescently-conjugated antibodies specific to the antigens of interest 
(or respective isotype control) and at the manufacturer’s recommended concentrations 
(Table 2.1) for 30 minutes at 4°C. After the cell surface staining incubation, cells were 
washed twice with FACS buffer and acquired on BD LSR-Fortessa™ (BD Biosciences) and 
analysed using FlowJo® software (TreeStar, Ashland, Oregon, USA). Alternatively, if cells 
required intracellular staining the following steps was performed.  
For intracellular staining, cells were fixed and permeablised with FoxP3/Transcription 
Factor Staining Buffer (Thermo Fisher Scientific) according to manufacturer’s protocols. 
Briefly, cell pellets were incubated with 500µL of fixation/permeablisation buffer for 30 
minutes at 4°C and washed twice with permeablisation buffer. Fluorescently-conjugated 
antibodies (or respective isotype controls) (Table 2.1) were then added to cells in a final 
volume of 100µL permeablisation buffer and vortexed thoroughly then incubated for 30 
minutes at 4°C. Following incubation, cells were washed twice in permeablisation buffer 
prior to acquisition on BD LSR-Fortessa™ and analysed using FlowJo®. 
 
Table 2.1- Summary of the fluorescently-conjugated antibodies used for staining mouse 
markers 
 
2.4 Mouse Treg suppression assays 
2.4.1 CD4+ T responder cell isolation  
Spleens of B6 mice were harvested and passed through a 70µm nylon cell strainer 
(Falcon®, Corning) to gain a single cell suspension and RBCs were lysed. ‘Dynabeads™ 
Untouched™ Mouse CD4 Cells Kit’ (Thermo Fisher Scientific) was used according to 
manufacturer’s protocols to isolate CD4+ T responder cells (Tresps). Briefly, cell pellet 
was re-suspended in 500µL buffer 1 (provided in kit) and 100µL ‘CD4 mixture’, which 
Localisation Specificity Flourochrome Host species Isotype Clone Manufacturer/Company Catalougue Number
Extracellular CD4 FITC Rat IgG2a, kappa RM4-5 eBioscience 11-0042-85
Extracellular CD11c PerCP-Cy5.5 Armenian hamster IgG N418 eBioscience 45-0114-80
Extracellular CD25 PE Rat IgG1, lambda PC61.5 eBioscience 12-0251-82
Extracellular CD39 PE Rat IgG2b, kappa 24DMS1 eBioscience 12-0391-82
Extracellular CD40 PECy7 Rat IgG2a, kappa 3/23 BioLegend 124621
Extracellular CD73 PE Rat IgG1 eBioTY/11.8 eBioscience 12-0731-82
Extracellular CD80 BV421 Armenian hamster IgG 16-10A1 BioLegend 104725
Extracellular CD86 PE Rat IgG2a, kappa GL1 eBioscience 12-0862-81
Extracellular MHC I (H-2Kd) PE Mouse IgG2a SF1-1.1.1 eBioscience 12-5957-82
Extracellular MHC II (IAd) FITC Mouse IgG3, kappa 39-10-8 Biolegend 115005
Intracellular CTLA4 APC Armenian hamster IgG UC10-4B9 eBioscience 17-1522-80




contains a mixture of rat IgGs that bind to mouse CD8+ T cells, B cells, NK cells, 
monocytes, macrophages, granulocytes, DCs and erythrocytes. The mixture was 
incubated for 30 minutes at 4°C under rotation. Cells were washed in RPMI-1640 to 
remove any unbound antibodies before incubation with 1mL pre-washed Dynabeads™ 
for 30 minutes at 4°C under rotation. Dynabeads™ which captured non CD4+ T cells 
were removed by magnetic separation. The supernatants containing CD4+ T cells were 
then washed in RPMI-1640 and counted with trypan blue solution exclusion of any 
dead/comprised cells.  
 
2.4.2 APC isolation 
Mouse splenocytes depleted of RBCs were obtained as described above (section 2.2.4). 
Remaining cells were incubated with a mixture of 300µL each of rat anti-mouse CD4 
(YTS-191) and CD8 (YTS-169) purified antibodies (made in-house) for 30 minutes at 4°C 
under rotation. Cells were washed in RPMI-1640 before incubation with pre-washed 
Dynabeads™ (Thermo Fisher Scientific) for 30 minutes at 4°C under rotation. The cells 
were washed in RPMI-1640 and resuspended in ‘mouse complete media’ 
 
2.4.3 Suppression assay set up  
CD4+ Tresps proliferation was assessed by either 3H-thymidine incorporation or by 
carboxyfluorescein succinimidyl ester (CFDA-CFSE; Thermo Fisher Scientific) dye 
dilution. For CFDA-CFSE-based suppression assays, 5µM CFDA-CFSE was added to CD4+ 
Tresps and incubated at 37°C for 10 minutes. After incubation CFDA-CFSE staining was 
quenched by addition of 10% FCS in RPMI-1640 for 5 minutes and subsequent 
centrifugation.  
5x104 CFDA-CFSE labelled B6 CD4+ Tresps were stimulated with 1x105 BALB/c APCs and 
1µg/mL of anti-mouse CD3ɛ antibody (clone 145-2C11; BD Biosciences). This cell 
mixture was co-cultured with or without 5x104 direct allospecific Tregs, direct 
allospecific T cells, Rab27DKO Tregs. Co-cultures were set up in a 96-well round bottom 
plate with a final volume of 200µL in ‘mouse complete media’. Cell co-cultures were 




hours of incubation, Tresps proliferation was assessed by CFSE dilution and acquired by 
BD LSR-Fortessa™ and analysed using FlowJo® software (TreeStar). 
Alternatively, for 3H-thymidine incorporation-based antigen specific suppression assays, 
cell co-cultures were set up as described above but without the addition of anti-mouse 
CD3ɛ antibody (clone 145-2C11; BD Biosciences). In the final 18 hours of the 72 hours 
incubation, cells were pulsed with 1µCi 3H-thymidine per well (Amersham GE 
Healthcare, Buckinghamshire, UK). After the final 18 hours of incubation, well contents 
were transferred onto glass fibre Printed Filtermat A (PerkinElmer, Waltham, 
Massachusetts, USA), dried by microwave oven for 2 minutes and filtermats were 
placed inside sample bags for betaplate™ plastic wallets (PerkinElmer). 15mL of 
Betaplate Scintillation fluid (PerkinElmer) was added and the plastic wallet sealed. These 
were then placed into fliter mat holders to measure cell proliferation by using a 1205 
Betaplate® liquid scintillation counter (LKB Wallac, Victoria, Australia). Data output is 
presented as counts per minute (cpm), representing cells in which 3H-thymidine has 
been incorporated upon cell division.  
 
2.5 Mouse Treg activation and EV isolation  
2.5.1 Media 
The same formulation as ‘mouse complete media’ but with the heat-inactivated FCS (GE 
Healthcare) ultracentrifuged at 100,000g with a Beckman Type 70.1 Ti rotor on a 
Beckman L8-60M ultracentrifuge machine for 18 hours at 4°C to deplete serum EVs 
prior to preparing ‘mouse EV-free complete media’  
 
2.5.2 Treg Activation and Isolation procedure 
150cm2-sized flasks (Falcon®, Corning) were coated with 5µg/mL αCD3 (clone: 
145.2C11; BD Biosciences) and 10µg/mL αCD28 (clone: 61109; R&D Systems, 
Minneapolis, Minnesota, USA) in a total volume of 4mL in PBS, incubated at 37°C for 2 
hours or alternatively at 4°C overnight. After the incubation period, the flasks were 




30-50x106 mouse Tregs were washed in RPMI-1640 three times before re-suspension in 
‘mouse EVs-free complete media’. Mouse Tregs were then added to the pre-washed 
flasks. Cell cultures were maintained in a humidified incubator at 37°C in the presence 
of 5% (v/v) CO2 for 24 hours. After 24 hours, cells were assessed for their activation 
status by staining with anti-mouse anti-CD69 antibody (clone H1.2F3; Thermo Fisher 
Scientific) and cells were acquired on BD LSR-Fortessa™ (BD Biosciences) and analysed 
using FlowJo® software (TreeStar). 
Supernatant were then collected and centrifuged at 581g for 5 minutes to pellet cells 
and cellular debris. Cell-free supernatant were then filtered with gentle pressure 
through hydrophilic, low protein binding, polyethersulfone, gamma sterilised 0.22µm 
pore-sized filter unit (Merck Millipore) to remove large vesicles such as microparticles 
but allowing smaller EVs including exosomes (approximately sized between 50-150nm) 
to pass through (Lesley Ann Smyth et al. 2013).  
This EV-containing supernatant were then further purified using two different methods 
depending on the experimental question at hand and of which is optimal for addressing 
the research study question. One of these methods employs the gold standard 
ultracentrifugation (Lesley Ann Smyth et al. 2013). EVs were pelleted at 100,000g using 
Beckman L8-60M ultracentrifuge with Beckman Type 70.1 Ti rotor for 1.5 hours at 4°C 
(Clotilde Théry et al. 2006). The supernatant was discarded and EVs pellet washed in 
PBS before undergoing ultracentrifugation at 100,000g for a further 1.5 hours at 4°C. 
The EVs pellet was re-suspended in PBS for transmission electron microscopy (section 
2.6) and NanoSight LM-10 analysis (section 2.7).  
The second method involved the use of the exosome precipitation solution ExoQuick-
TC™ (EQ; Systems Biosciences, SBI, Palo Alto, California, USA) (Tung et al. 2018; Okoye 
et al. 2014).  ExoQuick-TC™ was used according to manufacturer’s protocols which 
involved mixing 1mL of ExoQuick-TC™ to every 5mL of conditioned cell culture media 
(which has cells and cell debris prior removed) and incubation at 4°C overnight. The 
next day, the mixture was centrifuged at 1500 x g for 30 minutes and the supernatant 
discarded. EVs pellet was then re-suspended in ‘Lysis buffer’ (Systems Biosciences, SBI) 
(see section 2.10 for subsequent exosomal RNA extraction steps).  Figure 2.4 shows the 









Figure 2.4- Diagram showing the different steps taken to isolate EVs via 
ultracentrifugation and ExoQuick-TC™.  
 
2.6 Transmission electron microscopy analysis 
EVs were isolated using ultracentrifugation and re-suspended in PBS. EVs were added to 
Formvar/carbon films with copper grids (TAAB Laboratory Equipment Ltd, Aldermaston, 
Reading, UK) before being fixed with 2% glutaraldehyde (Sigma-Aldrich) in PBS for 5 




were then stained with 3% uranyl acetate and 2% methyl cellulose (both Sigma-Aldrich) 
in PBS for 20 minutes. Excess fluid was removed using filter papers and grids were air-
dried for 5 minutes prior to analysis on transmission electron microscope (FEI Tecnai™ 
G2 20, Netherlands). All steps were performed at room temperature. 
 
2.7 NanoSight analysis 
EVs were isolated using both ultracentrifugation and ExoQuick-TC™ methods and 
diluted (1:1000) in 0.1µm pre-filtered PBS. 1mL of EV dilutions were taken up in a 1mL 
syringe and placed into the NanoSight LM10 probe for acquisition. NanoSight LM10 
machine was used along with the software nanoparticle tracking analysis (NTA) version 
3.2 Dev Build 3.2.16. Settings of SOP Standard Measurement script, laser type Blue 488, 
sCMOS camera, camera level of 11 and detection threshold of 5 was used consistently 
in all samples. 30 seconds videos and 3 readings were taken for each sample to gain 
average measurements of mean, mode, standard deviation, standard error and 
concentration of particles.  
 
2.8 EVs co-culture with BM-DCs 
Mouse Treg EVs were isolated via ExoQuick-TC™ using 40x106 unlabelled or CFSE-
labelled Tregs and the unstained EVs or CFSE+ EVs pellet was resuspended in 50µL 
volume. BALB/c BM-DCs or Rosa26-ERT2-Cre Dicerfloxed/floxed BM-DCs were isolated as 
described above (sections 2.2.2 and 2.2.3). 4x105 BM-DCs (harvested on Day 6 of 
culture) were plated in 48 well plates and 40x106 Treg derived unstained EVs or CFSE+ 
EVs were added, with a final volume of 400µL in ‘mouse complete media’. After 4 hours, 
100ng/ml of LPS (Sigma-Aldrich) was added, and after a total of 24 hours of incubation, 
supernatant of the co-cultures was harvested and stored in -20°C for cytokine analyses. 
Cell co-cultures were maintained in a humidified incubator at 37°C in the presence of 
5% (v/v) CO2.  
For uptake of CFSE+ EVs into BM-DCs, the cells were washed two times in cold PBS prior 
to re-suspension in FACS buffer. Cells were acquired on a BD LSR-Fortessa™ and data 




For co-culture of EVs with Rosa26-ERT2-Cre Dicerfloxed/floxed BM-DCs miRNA analysis, the 
cells were washed twice in cold PBS to remove unbound EVs. The cell pellet was the 
resuspended in 750μL of TRIzol® Reagent (Thermo Fisher Scientific) for RNA extraction 
(see section 2.9).  
 
2.8.1 Mouse cytokine analysis/Cytometric Bead Array (CBA) 
Frozen supernatants from ‘EVs co-cultures with BM-DCs’ (section 2.8), were thawed 
and supernatant mixed via pipetting. ‘CBA Mouse/Rat Soluble Protein Master Buffer Kit’ 
from BD Biosciences was used to measure cytokine presence and concentrations 
according to manufacturer’s protocols. The BD™ CBA Flex Set Capture beads to detect 
IL-10, TNF, IL-6 and IL-12 were purchased from BD Biosciences. Briefly, all the capture 
beads were mixed together and diluted with Capture Bead Diluent (provided in kit) and 
50μL of this mixture was added to the assay wells. Subsequently, 50μL of co-culture 
supernatant was added to the assay wells, mixed and incubated for 1 hour at room 
temperature. After the incubation period, 50μL of mixed PE Detection Reagent 
(provided in kit) was added to the assay well, mixed and incubated for 1 hour at room 
temperature. Assay wells were washed twice with Wash Buffer (provided in kit) before 
acquisition. Samples were acquired using a BD LSR-Fortessa™ and data analysed using 
FCAP Array v.3 software (BD Biosciences). 
 
2.9 BM-DC and Treg EVs co-culture RNA extraction  
BM-DCs were cultured with or without Treg EVs were used. BM-DCs were washed three 
times with cold PBS. The cell pellet was resuspended in 750μL of TRIzol® Reagent 
(Thermo Fisher Scientific) and vortexed for 2 minutes, and subsequently incubated for 5 
minutes at room temperature. 150μL chloroform (Sigma-Aldrich) was added to the 
mixture and vortexed for 15 seconds and incubated for 3 minutes at room temperature. 
The tubes were then centrifuge at 12,000g for 15 minutes at 4°C. The aqueous phase 
(top layer) consisting of approximately 400μL was harvested and 1.5 volumes (600μL) of 
100% ethanol was added. The mixture was then transferred to RNeasy spin columns 




PRE (provided in RNeasy® Mini Kit, Qiagen) was added to the columns and centrifuged 
at 8000g for 15 seconds. The columns were then centrifuged at 8000g for 2 minutes to 
dry them.  30μL of RNase-free water (Qiagen) was added to column membrane and 
centrifuged at 8000g for 1 minute to elute the RNA. The eluted RNA was stored at -80°C 
until use. 
 
2.10 Mouse Treg EVs and T cell EVs RNA extraction 
30-50x106 cell-derived EVs were isolated using ExoQuick-TC™ and the RNA was 
extracted from EVs using SeraMir™ columns (Systems Biosciences, SBI) according to 
manufacturer’s protocols. Briefly, the EV pellet was resuspended in 350μL Lysis Buffer 
(provided in kit); vortexed for 15 seconds and incubated for 5 minutes at room 
temperature. 200μL of 100% ethanol was added and vortexed for 10 seconds. The 
mixture was transferred to the SeraMir™ columns and collection tube and centrifuged 
at 16,000g for 1 minute. The column was washed with 400μL Wash Buffer (provided in 
kit) and centrifuged at 16,000g for 1 minute. The column was centrifuged again at 
16,000g for 2 minutes to dry the column. 30μL of RNase-free water was added to 
column membrane and centrifuged at 380g for 2 minutes to load the membrane with 
the water then centrifuged at 16,000g for 1 minute to elute the RNA. The eluted RNA 
was stored at -80°C until use. 
 
2.10.1 DNA removal from RNA  
The RNA preparations were treated to remove any contaminating DNA. 50μL RNase-
free water, 10μL 10X DNase buffer and 10μL Turbo DNase (all Thermo Fisher Scientific) 
was added to the eluted RNA. The mixture was incubated at 37°C for 1 hour. 
Subsequently, an equal volume (100μL) of phenol/chloroform (Sigma-Aldrich) was 
added and centrifuged at 16,000g for 10 minutes. The aqueous phase was harvested, 
and 1.5 volumes of 100% ethanol were added. The mixture was passed through RNeasy 
spin columns and further processed as described above (section 2.9). The eluted DNA-





2.10.2 NanoDrop™ and Bioanalyser 
NanoDrop™ spectrophotometer (Thermo Fisher Scientific) and 2100 Agilent Bioanalyzer 
version 2.6 (Agilent Technologies, Santa Clara, California, USA) with Eurkaryote Total 
RNA Nano chips (Agilent Technologies) were used to assess RNA concentration and RNA 
integrity. Both machines were used according to the manufacturer’s guidelines.  
 
2.11 Mouse miRNOME screen and real-time PCR validation assays 
For the miRNOME screen, reverse transcription was performed using Megaplex™ RT 
Primers, Pools A v2.1 and Pool B v3.0 with the TaqMan® MicroRNA Reverse 
Transcription Kit (Thermo Fisher Scientific) according to the manufacturer’s protocols. 
The cDNA was then pre-amplified by mixing 7.5µL reverse-transcribed miRNA, 20 µL of 
TaqMan® PreAmp Master Mix (2X), 8.5 µL of dH2O and 4 µL of Megaplex™ PreAmp 
primers Pool A or Pool B (10X) (all Thermo Fisher Scientific). The mixtures were then 
subjected to the pre-amplification procedure consisting of thermal conditions of 95°C 
for 10 minutes, 55°C for 2 minutes, 72°C for 2 minutes, then 16 cycles of the following: 
95°C for 15 seconds and 60°C for 4 minutes, this was then completed with a final step 
of 99.9°C for 10 minutes (Pergoli et al. 2017).    
The pre-amplified DNA was diluted 1:20 in dH2O. Equal volume of TaqMan OpenArray® 
Real Time PCR Master Mix (2X; Thermo Fisher Scientific) was added. 7µL of this mixture 
was then added with the MicroLab STAR Let instrument (Hamilton Robotics, 
Birmingham, UK) into the 384-well OpenArray® plate (Thermo Fisher Scientific). The 
QuantStudio™ AccuFill System Robot (Thermo Fisher Scientific) was used to load the 
reaction mix from the 394-well OpenArray® plate into a TaqMan™ OpenArray® Human 
miRNA panel (Pergoli et al. 2017). miRNA was detected using QuantStudio™ 12K Flex 
Real-Time PCR System and the OpenArray® Platform (QS12KFlex) according to the 
manufacturer’s instructions (Thermo Fisher Scientific). miRNA expression was assessed 
using the relative quantification 2-ΔCrt method (Livak and Schmittgen 2001).  
For miRNOME validation assays and for cellular miRNA detection, cDNA was synthesised 
using miScript II RT Kit (Qiagen) and real-time PCR assays using QuantiTect SYBR® Green 




(UCUCCCAACCCUUGUACCAGUG), miR-142-3p (UGUAGUGUUUCCUACUUUAUGGA), 
miR-384-5p (UGUAAACAAUUCCUAGGCAAUGU) and RNU6 primers were purchased 
from Qiagen. Real-time PCR assays were performed using ViiA™ 7 Real-Time PCR system 
(Thermo Fisher Scientific). All samples for miRNOME and individual real-time PCR assays 




2.12.1 Hybridoma cell culture  
2.12.1.1 Media 
‘Hybridoma PFHM-II media’ were prepared as follows: Gibco® Protein Free Hybridoma 
Medium (PFHM-II) supplemented with 100 units/mL penicillin, 100µg/mL streptomycin, 
10mM HEPES and 50µM 2-mercaptoethanol (all Thermo Fisher Scientific). 
‘Hybridoma RPMI media’ were prepared as follows: RPMI-1640 supplemented with 5% 
heat-inactivated FCS, 100 units/mL penicillin and 100µg/mL streptomycin (all Thermo 
Fisher Scientific).  
 
2.12.1.2 Hybridoma cell culture and purification of produced antibody anti-human 
αCD28.2 
αCD28.2 antibody was purified from a hybridoma cell line and using Two-Compartment 
Bioreactor cell culture flasks (CELLine CL350, Integra Biosciences, Zizers, Switzerland) 
according to manufacturer’s protocols. Briefly, a hybridoma cell line producing αCD28.2 
antibody was thawed and cultured in ‘hybridoma RPMI media’ for 10 days to achieve a 
log growth phase. 7-8x106 cells were resuspended in 5mL of ‘Hybridoma PFHM-II’ and 
inoculated in the ‘cell compartment’ of the Two-Compartment Bioreactor cell culture 
flask, subsequently 250mL of ‘hybridoma RPMI media’ was added to the ‘medium 
compartment’. After 1 week of culture, cells were harvested and centrifuged at 300g for 
5 minutes. The supernatant containing αCD28.2 antibody was collected and stored at 
4°C. The cell pellet was resuspended in ‘Hybridoma PFHM-II’ and counted. 7-8x106 cells 




RPMI media’ (in the ‘medium compartment’. This process was repeated every 3-4 days 
until 15mL of supernatant containing αCD28.2 antibody was collected. Cell cultures 
were maintained in a humidified incubator at 37°C in the presence of 5% (v/v) CO2. 
αCD28.2 antibody was concentrated using a three-step filtration system. Supernatant 
containing the αCD28.2 antibody was filtered using a 0.22μm-sized filter unit. 
Centriprep® 30K Centrifugal Filter Device (Merck Millipore) was then used to filter 
contaminants of ≤30 kDa size, retaining molecules of >30kDa size.  The filter devices 
were washed with PBS before use. 15mL of the supernatant was transferred into the 
‘sample container’ part of the device, then the ‘filtrate collected’ was added. Devices 
were centrifuged at 1500g for 20 minutes at 4°C. Supernatant that was depleted of ≤30 
kDa size molecules was collected from the ‘sample container’ compartment.  The 
collected supernatant was further filtered using an Amicon® Ultra-15 100K Centrifugal 
Filter Device (Merck Millipore), which filters molecules <100 kDa size. Supernatant from 
the previous step was transferred into the filter device and centrifuged at 4000g for 30 
minutes at 4°C. Purified antibody was collected from the ‘filter device’. 
Concentrated αCD28.2 antibody was quantified using the Pierce™ bicinchoninic acid 
(BCA) Protein Assay Kit (Thermo Fisher Scientific), according to manufacturer’s 
protocols. Absorbance was measured at 540nm and protein concentration was 
calculated from a protein standard curve. αCD28.2 antibody concentrations were 
adjusted to 1mg/mL with sterile PBS, aliquoted and stored at -20°C until use. 
 
2.13 Human cell isolation and culture 
2.13.1 Subjects 
All human blood and skin samples were obtained from anonymised healthy donors with 
written informed consent and full ethical approval. Donor peripheral blood contained 
within leukocyte-enriched blood cones which were provided by National Blood Service 
(NHS Blood and Transplantation, Tooting, London, UK) with ethical approval from the 
Institutional Review Board of Guy’s Hospital; reference 09/H0707/86. Human skin 








‘Human complete media’ were prepared as follows: X-VIVO™ 15 (Lonza, Basel, 
Switzerland) supplemented with 5% heat-inactivated human serum (HS) (Biowest, 
Riverside, Missouri, USA).  
‘Human EVs-free complete media’ were prepared as follows: X-VIVO™ 15 (Lonza) 
supplemented with 5% heat-inactivated FCS (Thermo Fisher Scientific) previously 
ultracentrifuged at 100,000g with a Beckman Type 70.1 Ti rotor on a Beckman L8-60M 
ultracentrifuge machine for 18 hours at 4°C to deplete serum EVs prior to preparing 
‘human EVs-free complete media’. 
 
2.13.3 Human peripheral blood mononuclear cells (PBMCs) isolation 
Human PBMCs were isolated from the blood of healthy donors. Leukocyte-enriched 
blood cones were diluted 8-fold with PBS prior to carefully layering it over 15mL of the 
density gradient medium Lymphoprep™ (StemCell™ Technologies, Vancouver, British 
Columbia, Canada). This was then centrifuged at 940 x g for 20 minutes with no brake. 
The buffy coat containing total PBMCs present at the plasma:Lymphoprep™ interface 
was collected and washed 3 times in PBS to remove any contaminate platelets. Total 
PBMCs were cryopreserved in cell freezing medium (consisting of 90% heat-inactivated 
FCS and 10% dimethyl sulfoxide (DMSO; Sigma-Aldrich)) and frozen in -80°C for 24 
hours prior to immediate storage in liquid nitrogen until use. For CD25- PBMCs 
collection, the total PBMCs population were then depleted of Tregs by the positive 
selection of CD25+ cells. Total PBMCs were mixed with CD25 MicroBeads II (Miltenyi 
Biotec, Cologne, Germany) and incubated at 4°C under rotation for 15 minutes. Cells 
were then washed to remove excess CD25 MicroBeads II and re-suspended in 3mL 
MACS buffer (consisting of 0.5% BSA and 2mM EDTA in PBS). Cells were passed through 
a pre-primed 50µm pre-separation filter, LS column and a MACS separator magnet (all 




were cryopreserved in cell freezing medium and frozen in -80°C for 24 hours prior to 
immediate storage in liquid nitrogen until use.    
 
2.13.4 Human CD4+ CD25+ Treg and CD4+ CD25- conventional T effector cell (Teffs) 
isolation and culture 
Human CD4+CD25+ Tregs and autologous CD4+CD25- Teffs were isolated from the blood 
of healthy donors. This process involved a negative selection for CD4+ T cells and the 
subsequent positive selection for CD25+ cells for Tregs.  
Leukocyte-enriched blood cones were diluted 2-fold with PBS and incubated with 
Rosette Sep™ Human CD4+ T cell Enrichment Cocktail (StemCell™ Technologies) (150µL 
of this was used for every 5mL of blood derived from the blood cone) for 30 minutes at 
room temperature. This process allowed for non-CD4+ cells, namely cells which 
expressed CD8, CD16, CD19, CD36, CD56, CD66b or TCRγ/δ to be labelled and 
crosslinked to red blood cells. After the incubation period, the blood was further diluted 
by 4-fold with sterile PBS and carefully layered on top of 15mL of Lymphoprep™ 
(StemCell™ Technologies) and centrifuged at 940g for 20 minutes with no brake. The 
buffy coat containing CD4+ T cells were collected and CD25 MicroBeads II (Miltenyi 
Biotec) was used to separate CD4+ CD25+ Tregs and CD4+ CD25- Teffs as mentioned 
above. CD4+ CD25+ Tregs were collected by removing the LS columns holding the CD25+ 
cells from the MACS separator magnet and eluting them by gentle force with the 
plunger. The purity of CD4+ CD25+ cells were >94% as tested by immunostaining cells 
immediately following isolation with CD4 (clone OKT4; Thermo Fisher Scientific) and 
CD25 (clone 2A3; BD Biosciences) (Figure 4.1).  
Purified CD4+CD25+ T cells were activated using Dynabeads® Human T-Activator 
CD3/CD28 for T Cell Expansion and Activation (αCD3/CD28 beads; Thermo Fisher 
Scientific) at a 1:1 ratio of cells:beads. CD4+CD25+ T cells were added at 1x106 cells/mL 
per well of a 24-well plate in the presence of 100nM rapamycin (LC-Laboratories, 
Woburn, Massachusetts, USA) using human complete media.  
1000 international units (IU) of IL-2/mL and 100nM rapamycin in ‘human complete 
media’ was added to CD4+CD25+ T cells every second day thereafter. Human Tregs were 




magnetic separation and adding cells to ‘human complete media’ containing 
αCD3/CD28 beads, rapamycin and IL-2 at the above concentrations. Suppressive 
capacity and phenotype were tested after 2 stimulations and cells were used for 
experiments after confirmation of their suppressive function (approximately day 20-22 
of culture). 
Purified CD4+CD25- T cells were activated using Dynabeads® Human T-Activator 
CD3/CD28 for T Cell Expansion and Activation (αCD3/CD28 beads) at a 1:1 ratio of 
cells:beads. CD4+CD25- T cells (Teffs) were added at 1x106 cells/mL per well of a 24-well 
plate. Teffs received 100IU/mL of recombinant IL-2 every 2 days. Cells were maintained 
in a humidified incubator at 37°C with 5% CO2.      
Remaining freshly isolated CD4+CD25- T cells were cryopreserved in cell freezing 
medium and used later as Tresps for ‘human suppression assays’ (section 2.16).  
 
2.14 Flow cytometry 
2.14.1 Phenotypic analysis of human cells 
All immunostaining was performed in FACS buffer using 2-4x105 human cells per 
staining panel in a final volume of 100µL. The cells were than incubated with 
fluorescently-conjugated antibodies specific to the antigens of interest (or respective 
isotype control) and at the manufacturer’s recommended concentrations (Table 2.2) for 
30 minutes at 4°C.  
For intracellular staining, cells were fixed and permeablised with FoxP3/Transcription 
Factor Staining Buffer (Thermo Fisher Scientific) according to manufacturer’s protocols. 
Briefly, cell pellets were incubated with 500µL of fixation/permeablisation buffer for 30 
minutes at 4°C and washed twice with permeablisation buffer. Fluorescently-conjugated 
antibodies (or respective isotype controls) were then added to cells in a final volume of 
100µL permeablisation buffer and vortexed thoroughly then incubated for 30 minutes 
at 4°C. Following incubation, cells were washed twice in permeablisation buffer prior to 






Table 2.2- Summary of the fluorescently-conjugated antibodies used for staining human 
markers 
 
2.15 Human Treg and Teffs activation and EV isolation   
At day 20 post human Treg isolation, Tregs and Teffs were rested by depletion of 
activation beads and culture media and Tregs were given low-dose IL-2 at 100IU/mL 
only (no addition of rapamycin), Teffs were given 10IU/mL of IL-2. Cells were incubated 
for 48 hours before activation for EV release. 12-well TC plates were coated with 
5µg/ml αCD3 (clone: OKT3; Thermo Fisher Scientific) and 10µg/ml αCD28 (clone: 
αCD28.2) in a total volume of 0.5mL in PBS, incubated at 37°C for 2 hours or 
alternatively at 4°C overnight. After the incubation period, the wells were washed with 
PBS. Human Tregs or Teffs were washed three times in X-VIVO™ 15 before re-
suspension in ‘human EVs -free complete media’, no addition of IL-2 or rapamycin was 
added.   
3x106 human Tregs or Teffs were then added to the pre-washed wells at a volume of 
1mL per well. Cell cultures were maintained in a humidified incubator at 37°C in the 
presence of 5% (v/v) CO2 for 24 hours. After 24 hours, cells were assessed for their 
activation status by CD69 expression levels by flow cytometry analysis. 
Supernatant were then collected, and differential centrifugation was performed as 
previously described (Clotilde Théry et al. 2006). The differential centrifugation involved 
the supernatant to be centrifuged at 300g for 10 minutes to pellet cells and dead cells. 
The supernatant from the previous step was collected and centrifuged at 2000g for 10 
Localisation Specificity Flourochrome Host species Isotype Clone Manufacturer/Company Catalougue Number
Extracellular CD3 APC-H7 Mouse IgG1, kappa SK7 BD Biosciences 560275
Extracellular TCRαβ APC Mouse IgM, kappa T10B9.1A-31 BD Biosciences 563826
Extracellular CD4 PerCP-Cy5.5 Mouse IgG2b, kappa OKT4 eBioscience 45-0048-42
Extracellular CD25 BV605 Mouse IgG1, kappa 2A3 BD Biosciences 562661
Extracellular CD127 FITC Mouse IgG1, kappa eBioRDR5 eBioscience 11-1278-42
Extracellular CD39 PE-Cy7 Mouse IgG1, kappa eBioA1 eBioscience 25-0399-42
Extracellular CD73 PE Mouse IgG1, kappa AD2 eBioscience 12-0739-42
Extracellular CD69 PerCP Mouse IgG1, kappa FN50 BioLegend 310928
Extracellular CD62L BV605 Mouse IgG1, kappa DREG-56 BD Biosciences 562719
Extracellular CCR4 BV605 Mouse IgG1, kappa L291H4 BioLegend 359418
Extracellular CD45 PE Mouse IgG1, kappa 2D1 eBioscience 12-9459-42
Extracellular/Intracellular CD63 PE Mouse IgG1, kappa H5C6 eBioscience 12-0639-42
Extracellular/Intracellular CD63 FITC Mouse IgG1, kappa H5C6 BD Biosciences 561924
Extracellular/Intracellular CD81 PE-Cy7 Mouse IgG1, kappa 5A6 BioLegend 349512
Extracellular/Intracellular CD9 PE Mouse IgG1 eBioSN4 eBioscience 12-0098-42
Intracellular FoxP3 eFluor 660 Rat IgG2a, kappa PCH101 eBioscience 50-4776-42




minutes to remove cellular debris. The supernatant from the preceding step was 
collected and ultra-filtered with gentle pressure through a 0.22µm pore-sized filter to 
remove large vesicles. This EVs-rich supernatant was then further purified using two 
different methods as described above for ultracentrifuge and ExoQuick-TC™.   
EV isolation via ultracentrifuge was employed for transmission electron microscopy, 
NanoSight LM-10 analysis and phenotyping of EVs; EV pellet was re-suspended in PBS. 
Whereas, EV isolation via ExoQuick-TC™ was employed for EV RNA extraction, EV 
suppression assays with subsequent cytokine bead array analysis and for the in vivo 
experiments. EVs derived from ExoQuick-TC™ was re-suspended in RLT buffer (Qiagen) 
for RNA extraction; ‘human EVs-free complete media’ for EV suppression assays with 
cytokine bead arrays analysis; and sodium chloride (NaCl) 0.9% w/v saline (B Braun, 
Sheffield, UK) for in vivo analysis.  
 
2.15.1 Phenotypical analysis of EVs 
For phenotyping Treg EVs, EVs were isolated using ultracentrifugation. 50x106 human 
Tregs were used per EV phenotyping experiments. The EV pellets were resuspended in 
a total volume of 50µL of PBS. The EVs were incubated with 4µm aldehyde/sulphate 
latex beads (Thermo Fisher Scientific) for 15 minutes to allow EVs to adhere to the latex 
beads. 10µg bovine serum albumin (BSA) (Sigma-Aldrich) in PBS was added to latex 
beads+ EVs and the mixture was incubated under rotation at room temperature for 75 
minutes to block non-specific binding areas. EVs/latex beads were washed in PBS and 
centrifuged at 300g for 5 minutes. 100mM glycine (Sigma-Aldrich) was mixed with the 
EVs/latex beads pellet and incubated for 30 minutes at room temperature. EVs/latex 
beads were washed three times in 3% FCS in PBS (Lesley Ann Smyth et al. 2013).   
The EVs/latex beads pellet was resuspended in 100µL in 3% FCS in PBS. 5µLs of 
fluorochrome-conjugated antibodies (Table 2.2) were added to the EVs/latex beads 
mixture and incubated for 30 minutes at 4°C. After incubation, EVs/latex beads were 
washed twice in 3% FCS in PBS before acquisition on BD LSR-Fortessa™ and analysed 





2.16 Human cell and EVs CTV-based suppression assays 
The suppressive capacity of human Tregs and Teffs were assessed after 20-22 days of 
expansion. Previously frozen CD4+CD25- Tresps autologous to the Tregs and Teffs were 
thawed. Tresps were washed twice in PBS. Next, Tresps were incubated with 2µM 
CellTrace Violet (CTV) (Thermo Fisher Scientific) for 20 minutes at 37°C. The labelling 
reaction was quenched with ‘human complete media’ and incubated for 5 minutes. 
Cells were washed twice in ‘human complete media’. Human Tregs were harvested and 
remaining αCD3/CD28 beads removed by using a magnet. Cells were washed and 
resuspended in ‘human complete media’.   
1x105 CTV-labelled autologous CD4+ Tresps were stimulated with αCD3/CD28 beads at a 
1:40 ratio of bead:Tresps in a volume of 100µL plated in a 96-well round bottom plate. 
Varying numbers of Tregs at indicated ratios were added, and final volume of 200µL per 
well was achieved by addition of ‘human complete media’. Alternatively, Treg EVs or 
Teff EVs isolated via ExoQuick-TC™ and derived from autologous 5, 10, 35 or 50x106 
Treg or Teff cells were added.  
Cells/EVs co-cultures were maintained in a humidified incubator at 37°C in the presence 
of 5% (v/v) CO2. After 5 days of incubation, co-cultures were pelleted and supernatant 
harvested and stored at -20°C for cytokine analyses. Tresp proliferation was assessed by 
CTV dilution by acquisition on a BD LSR-Fortessa™ and data analysed using FlowJo® 
software.  
 
2.16.1 Human CBA assays 
Frozen supernatant from the human cell/EV co-cultures suppression assays (section 
2.16) were defrosted and mixed via pipetting. Cytokine presence was measured using 
Human Th1/Th2/Th17 Kit BD™ Cytometric Bead Array kit (BD Biosciences). Briefly, 10μL 
of mixed Capture Beads were added to V-bottom 96 well culture plates (CellStar®, 
Greiner Bio-One, Kremsmunster, Austria). 50μL of co-culture supernatant and 10μL of 
Human Th1/Th2/Th17 PE Detection Regent was then added. Mixtures were incubated 
for 3 hours at room temperature in the dark. To wash samples, 100μL of Wash Buffer 




200μL of Wash Buffer were added to the wells and centrifuged at 200g. The 
supernatant was aspirated, and capture beads pellet was resuspended in 300μL of 
Wash Buffer. Cytokine standards were prepared using the supplied kit reagents. 
Samples were acquired on a BD LSR-Fortessa™ and data analysed using FCAP Array v.3 
software.  
 
2.17 Human Tresps co-culture with CFSE+ Treg EVs  
Human Treg EVs were isolated via ExoQuick-TC™ using 50x106 CFSE-labelled Tregs 
(section 2.4.3 for CFDA-CFSE labelling procedure) and the CFSE+ EVs pellet was 
resuspended in 50µL volume of ‘human complete media’.  
Human autologous Tresps were defrosted from frozen stocks. 5x105 Tresps were plated 
in 48-well plates and 50x106 Treg derived CFSE+ EVs were added, with a final volume of 
500µL in ‘human complete media’. Cells/EVs co-cultures were maintained in a 
humidified incubator at 37°C in the presence of 5% (v/v) CO2 for 24 hours. Tresps were 
washed thoroughly twice in cold PBS prior to re-suspension In FACS buffer. Cells were 
acquired on a BD LSR-Fortessa™ and data analysed using FlowJo® software.  
 
2.18 Human cell and EVs RNA extraction 
2x106 resting human Tregs or the autologous resting Teffs were washed in PBS and 
resuspended in 700μL RLT buffer (Qiagen) containing 1% 2 β-mercaptoethanol (Sigma-
Aldrich) and vortexed to complete homogenises (Eldh et al. 2012; Okoye et al. 2014). 
50x106 autologous Treg EVs or autologous Teff EVs were isolated using the ExoQuick-
TC™ method and the EVs pellet was resuspended in 700μL RLT buffer containing 1% 2 
β-mercaptoethanol and vortexed. All cells and EVs preparation were then stored in -
80°C until RNA isolation. Samples were thawed and vortexed, 3.5 times the ethanol was 
added and mixed by pipetting. The samples were then passed through RNeasy spin 
columns and the columns were subsequently washed twice with RPE buffer (Qiagen), 
and the membrane dried by brief centrifugation. 30μL of RNase-free water was added 




2.19 Human cell and EVs miRNOME screen and real-time PCR validation 
assays 
RNA samples were shipped to Exiqon and a complete miRNA analysis (miRNOME) was 
undertaken. Briefly, according to the company, miRNA was polyadenylated and reverse 
transcribed into cDNA. cDNA and ExiLENT SYBR® Green master mix were transferred 
into miRCURY LNA™ Universal RT microRNA PCR Human panels I+II (all Qiagen), which 
were preloaded with primers. Amplification was performed using a Roche Lightcycler 
480. Global mean normalisation was used as the normalisation method for the 
miRNOME as this was the most stable normaliser for this screen. Validation of the 
human miRNOME results was performed by individual qPCR assays as described above 
(section 2.11).  
 
2.20 Bioinformatics 
Bioinformatic tool microRNA.org (www.microrna.org) was used to map the 3’-UTR of 
IFNγ, IL-2 and IL-6 mRNAs and to in silico predict their associated miRNA targets, along 
with the algorithms of mirSVR and PhastCons scores. Another bioinformatic tool mirTAR 
(mirtar.mbc.nctu.edu.tw/human/) was used to in silico predict miRNAs to target 
multiple genes in KEGG pathways.  
 
2.21 Humanised mouse skin transplant in vivo (xenograft) model 
Human skin samples were donated by healthy donors, who had abdominoplasty or 
reduction mammoplasty surgery. Human skin was transplanted onto mice within 24 
hours from the time of skin explant from patients. The skin was disinfected with 
100units/mL penicillin and 100µg/mL streptomycin in PBS. Split-thickness skin explants 
were processed using an electrical dermatone using firm pressure to obtain a uniform 
0.5-0.7mm thickness of the upper layers of the donor human skin which included the 
epidermal and dermal layers. Skin explants were cut into 1.5cm2 grafts using a sterile 
scalpel and kept moist by wrapping skin explants in sterile gauze swabs that were pre-
soaked with 100 units/mL penicillin and 100µg/mL streptomycin in PBS and stored at 




Transplantation of human skin grafts onto 10-12 weeks old BRG mice were performed 
as previously described (P. Sagoo et al. 2011; Putnam et al. 2013). Mice were injected 
with 2µg Vetergesic Multidose analgesia (Alstoe Ltd, Laval, France) by the subcutaneous 
route and put under general anaesthesia using Isoflurane (Merial, Sandringham, UK). A 
small area of skin on the dorsal (back) of the mice were shaved and disinfected with 
Vetasept povidone-iodine antiseptic solution (Animalcare Ltd., York, UK). Subsequently, 
a 1.5cm2-sized mouse skin excision was made and replaced with the human skin graft. 
The human skin graft was adhered onto the mouse skin using Vetbond™ Tissue 
Adhesive (3M™, Maplewood, Minnesota, USA) and Fucidin® fusidic acid cream (LEO 
Pharma, Ballerup, Denmark) was applied liberally over the allograft and adjoining edges 
of mouse and human skin. A three-layer dressing was applied to mice which consisted 
of the first layer of OpSite® Spray Dressing (Smith & Nephew plc, London, UK); the 
second layer of Jelonet paraffin gauze dressing (Smith & Nephew plc); and the third 
layer of Tegaderm™ Transparent Film Dressing (3M™), which was wrapped around the 
mid-body section of the mice to secure the allograft and above components.  
Mice were checked weekly and allografts were allowed to engraft for 5-6 weeks, after 
which the mice were intravenously (via the tail vein) injected with saline (B Braun) or 
5x106 CD25- PBMCs ± 1x106 Tregs or ± 50x106 Treg EVs or ± 50x106 Teff EVs or ± ‘media 
pellet’. 50x106 Treg EVs were isolated either by ultracentrifugation or ExoQuick-TC™. 
50x106 Teff EVs and ‘media alone pellet’ were isolated using ExoQuick-TC™. Total 
injection volume was 300µL and saline was used as the resuspension buffer for all cells 
and EVs. Anti-Gr1 injections were administered bi-weekly via intraperitoneal route. 
Mice were monitored twice weekly to check their general health and to detect any 
changes in skin allograft morphology and mice were weighed twice weekly to detect for 
signs of xeno-GvHD. At week 4, a sample of peripheral blood was collected via the tail 
vein to assess human immune cell engraftment by immunostaining for human and 
mouse CD45+ cell and acquired by flow cytometry. 5 weeks post cell ± EVs injection; 
mice were culled by CO2 over administration and neck dissociation. Photographs of 
mice with the human skin allografts were taken on a 12-megapixel camera using natural 
light settings on a white background. Human skin allografts with a small surrounding 
area of mouse skin were carefully excised for histological analysis. Spleens were 




2.22 Histology preparation of slides  
After excision of the transplanted human skin, the skin explant was placed flat inside 
Peel-A-Way® disposable embedding molds (histomold) (Polysciences Inc., Pennsylvania, 
USA) containing optimal cutting temperature (OCT) compound (Thermo Fisher 
Scientific) and frozen over dry ice. Skin sections were cut using a cryostat (Leica 
Biosystems, Wetzlar, Germany) at a thickness of 8µm, mounted onto poly-L-lysine 
adhesion slides (Thermo Fisher Scientific) and air dried for 2 hours at room temperature 
in the dark before storage in -80°C.  
 
2.22.1 H&E staining 
Slides containing skin sections were removed from -80°C and left to air dry for 10 
minutes before being fixed with 10% formalin (Thermo Fisher Scientific) for 5 minutes 
and washed with running tap water for 1 minute. To stain the nuclei, skin sections were 
immersed in haematoxylin solution, gill number 3 (Sigma-Aldrich) for 1 minute. To 
remove excess haematoxylin, slides were placed under running tap water for 1-3 
minutes until the desired stain intensity. Skin sections were placed in 1% acid alcohol 
for 5-8 seconds to remove cytoplasmic staining (differentiation) and subsequently 
placed under running tap water. Skin sections were then placed in 1% eosin (Sigma-
Aldrich) for 20-30 seconds and washed under running tap water for 10 seconds. Slides 
were then dehydrated in 70% alcohol twice using different changes of solution, and 
then slides were placed in 100% alcohol for 2 minutes. Subsequently, the slides were 
placed in two changes of xylene (Sigma-Aldrich) to remove the alcohol. 2-3 drops of DPX 
mount solution (Sigma-Aldrich) was added to slides and a clear 1.5mm thickness 
coverslip was placed on top and allowed to air dry.  
 
2.22.2 Confocal immunostaining and microscopy 
Slides containing skin sections were fixed with 4% paraformaldehyde (Sigma-Aldrich) for 
15 minutes at room temperature. Sections were then washed 3 times with PBS for 10 
minutes and with a gentle rocking motion. Slides were blotted with tissue paper closely 




around the section to create a hydrophobic barrier to enclose the sections. Blocking 
solution consisting of 10% goat serum, 0.1% fish skin gelatin, 0.1% Triton™ X-100 and 
0.5% Tween® 20 (all Sigma-Aldrich) in PBS were added to sections and incubated for 1 
hour at room temperature. After incubation, the slides were tilted and excess blocking 
solution blotted on paper towels. Whilst the sections were still moist, the primary 
antibodies mixture (Table 2.3) were added and sections incubated overnight at 4°C, in 
the dark. Sections were then washed twice in PBS for 10 minutes each time and with a 
gentle rocking motion. Secondary antibodies and DAPI (Table 2.3) were added to the 
sections and incubated for 1 hour at room temperature, in the dark. Sections were 
washed 3 times in PBS for 5 minutes each time and with a gentle rocking motion. 
Sections were mounted with Fluorescence Mounting Medium (Agilent Technologies) 
and a 1.5mm thick clear coverslip was placed on top and slides were stored at 4°C and 
in the dark until acquisition. Images were taken on a Tei Nikon inverted confocal 
microscope (Nikon, Minato, Tokyo, Japan), using a 20x objective lens. A large image 
consisting of 4 fields of view with a 2x2 orientation was taken with the edges blended to 
create a single large image. Maximum intensity projection (MaxIP) images consisting of 
5 z-stacks (1.1µm apart) were acquired. Image analysis was performed on Nikon 
Instrument Software (NIS) Elements and quantification analysis was performed on Fiji is 
just ImageJ (FIJI) imaging software using consistent settings.  
  
Table 2.3- Summary of the primary and secondary antibodies and DAPI used for staining 
human skin allograft 
 
2.23 Imaging EVs 
50x106 Treg cell derived EVs were isolated using ExoQuick™. The EV pellet was 
resuspended in 90µL of PBS. 1µM CFDA-CFSE was added to the EV pellet. 2µL of anti-
human CD63- PE (clone H5C6; Table 2.2) was added and mixture was vortexed for 10 
Layer Specificity Flourochrome Host species Isotype Clone Manufacturer/Company Catalougue Number
Primary CD45 N/A- purified Mouse IgG1, kappa HI30 eBioscience 14-0459-82
CD3 N/A- purified Rabbit IgG polyclonal Dako A045229-2
CD31 N/A- purified Rabbit IgG polyclonal Abcam ab28364
Involucrin N/A- purified Mouse IgG1 SY5 Sigma Aldrich I9018
Ki67 N/A- purified Rabbit IgG polyclonal Abcam ab15580
Secondary Goat-anti mouse AF555 Goat IgG polyclonal Invitrogen A-21422
Goat-anti rabbit AF647 Goat IgG polyclonal Invitrogen A-21244




seconds. Samples were then incubated for 45 minutes at 37°C. Samples were 
centrifuged at 16,000g for 1 minute. EVs were assessed on Amnis ImageStreamX Mark II 
(Leica Biosystems, Wetzlar, Germany).  
 
2.24 Lentiviral particle production 
2.24.1 Media 
‘Dulbecco’s Modified Eagle medium (DMEM) complete media’ were prepared as 
follows: DMEM- low glucose (1000mg/L glucose) (Sigma-Aldrich) supplemented with 
10% heat-inactivated FCS, 100 units/mL penicillin and 100µg/mL streptomycin and 
2mM L-glutamine (all Thermo Fisher Scientific).  
‘DMEM serum-free media’ were prepared as follows: DMEM- low glucose (1000mg/L 
glucose) (Sigma-Aldrich) supplemented with 2mM L-glutamine. 
 
2.24.2 HEK293Ts 
Human embryonic kidney (HEK) 293T cells were a kind gift from Dr Gilbert Fruhwirth 
(Division of Imaging Sciences and Biomedical Engineering, King’s College London, 
London, UK). HEK293T cells were maintained in ‘DMEM complete media’ and passaged 
when cell cultures reached 80-90% confluency. To harvest these adherent cells, cells 
were washed in PBS and incubated with 0.05% Trypsin-EDTA (Thermo Fisher Scientific) 
for 4-5 minutes at room temperature before harvesting detached cells. Washed cells 
were counted and re-seeded at optimal concentrations for further expansion for a 
maximum of 10 passages. Cell cultures were maintained in a humidified incubator at 
37°C in the presence of 5% (v/v) CO2. 
 
2.24.3 Plasmids/constructs 
The eGFP-CD63 and mCherry-CD63 plasmids were a kind gift from Professor Tony Ng 
(Cancer Cell Biology & Imaging, King’s College London). pMDLg/pRRE and pRSV-Rev 
(packaging plasmids) and pCMV-VSV-G (envelope plasmids) were a kind gift from Dr 




College London, London, UK). eGFP-CD63 and mCherry-CD63 plasmid maps are 
included in Appendix 1 and 2, respectively. 
 
2.24.4 Bacterial transformation of competent cells 
Plasmid DNA was reproduced by transforming One Shot® Stbl3™ chemically competent 
Escherichia coli cells (Thermo Fisher Scientific). Cells were thawed on ice and 100ng 
plasmid DNA in <2.5μL volumes (typically 1μL) were added to the vial of 25μL of cells. 
The tube was tapped gently to mix the components and incubated on ice for 30 
minutes. The cells were then heat-shocked in a 42°C water bath for 45 seconds and 
immediately placed on ice for 2 minutes. 250μL of pre-warmed super optimal broth 
with catabolite repression (SOC) media was added to the vial. Vials were placed in a 
shaking 37°C incubator. 25μL and 80μL of the transformed cells were spread on pre-
warmed Lysogeny broth (LB)-agar (Sigma Aldrich) plates containing 100μg/mL ampicillin 
(Sigma Aldrich) and incubated at 37°C overnight. The next day, single bacterial colonies 
were picked using a sterile pipette tip and placed in 2mL L-broth medium containing 
100μg/mL ampicillin and incubated for 12-16 hours at 37°C with shaking conditions. A 
glycerol stock was prepared by adding 50% glycerol (in dH20) with equal volume of 
transformed cells mixture (typically 200µL total volume was prepared). Glycerol/cells 
stocks were stored in -20°C. Remaining cells were further processed for Miniprep DNA 
purification. 
 
2.24.5 Miniprep DNA purification preparations 
Wizard® Plus SV Minipreps DNA purification system (Promega, Madison, Wisconsin, 
USA) were used according to manufacturer’s protocols. The first step involved 
centrifuging the transformed cells at 4000g for 10 minutes at 4°C to pellet the cells. 
250µL of Cell Resuspension Solution was then used to resuspend the cell pellet. 250µL 
of Cell Lysis Solution was added and the tube was inverted 4 times to mix thoroughly. 
10µL of Alkaline Protease Solution was added and the tubes were inverted 4 times to 
mix and incubated for 5 minutes at room temperature. To neutralise the reaction, 
350µL of Neutralisation Solution was added and the tube inverted 4 times. The tubes 




supernatants, which were the cleared lysate, were then transferred into the Spin 
Columns held in place by the Collection Tube. The column and tubes were centrifuged 
at 12,000g for 1 minute and the flow-through was discarded. To wash the column and 
DNA, 750µL of Wash Solution was added to the column, this was then centrifuged at 
12,000g for 1 minute and the flow-through discarded. This wash step was repeated but 
with 250µL of Wash Solution. To dry spin column, this was centrifuged at 12,000g for 2 
minutes. The spin column was then transferred into a new collection tube and 
centrifuged at 12,000g for 1 minute to drain any residual solution. The spin column was 
then transferred into a 1.5mL Eppendorf tube and 50µL of nuclease-free dH2O was 
added to the membrane of the spin column and centrifuged at 12,000g for 1 minute. To 
increase the yield of DNA, the eluate was transferred back into the same column 
membrane and centrifuged again at 12,000g for 1 minute. The eluted DNA was stored 
at -20°C.  
 
2.24.6 Restriction enzyme digest of plasmid 
Enzymes EcoR1-HF® and Age1-HF® (New England BioLabs, Ipswich, Massachusetts, USA) 
were selected as the diagnostic restriction enzymes to test that the eGFP -CD63 and 
mCherry -CD63 plasmids were of the correct size. 0.5μL of EcoR1-HF® (= 10 units) and 
0.5μL Age1-HF® (= 10 units) enzymes (both New England BioLabs) were added to 400ng 
of plasmid DNA with CutSmart® buffer (10X) (New England BioLabs) and nuclease-free 
dH2O to a final volume of 20μL. The mixture was incubated at 37°C for 1 hour. The DNA 
was added into a 0.7% agarose (Sigma-Aldrich) electrophoresis gel prepared in Tris-
acetate-EDTA (TAE) buffer (Thermo Fisher Scientific) and containing GelRed® nucleic 
acid gel stain (10,000X) (Biotium, California, USA) at the manufacturer’s recommended 
volume of 10μL per 100mL of gel mixture. 10μL (at the concentration of 100μg/mL) of 
Quick-Load® 2-Log 0.1-10kb DNA ladder (New England BioLabs) was added to the well 
lanes as a reference for different DNA sizes. The digested DNA product (20μL) was 
mixed with DNA Gel loading purple dye (6X) (New England BioLabs) before loading into 
the well lanes. Gel electrophoresis was conducted at 80 volts for 90-120 minutes before 
visualisation under a GelDOC-It® Imager UV transilluminator (UVP, California, USA). 




correct orientation, as assessed by restriction enzyme digest size products, this clone 
was selected for Maxiprep DNA purification.  
 
2.24.7 Maxiprep DNA purification preparations 
To prepare cells for Maxipreps, the pre-made glycerol stocks of transformed cells were 
defrosted and 50µL of the transformed cells/glycerol stocks were added to 200mL of L-
broth medium containing 100μg/mL ampicillin. This was incubated for 12-16 hours at 
37°C with shaking conditions.  
A Plasmid Maxi Kit (Qiagen) was used according to manufacturer’s protocols. This 
involved harvesting the bacterial cells centrifuging them at 6000g for 15 minutes at 4°C 
to pellet the cells. 10mL of Buffer 1 was used to resuspend the cell pellet. 10mL of 
Buffer P2 was then added and the tube inverted 6 times to mix and was incubated for 5 
minutes at room temperature. Then 10mL of chilled Buffer P3 was added and tube 
inverted 6 times to mix. The tube was incubated on ice for 20 minutes. Subsequently, 
the tubes were centrifuged for 20,000g for 30 minutes at 4°C. Meanwhile, 10mL of 
Buffer QBT was added to QIAGEN-tip to equilibrate it and flow-through was discarded. 
After the centrifugation, the supernatant was applied to the QIAGEN-tip (provided in 
kit) and allowed to flow-through by gravity flow. The QIAGEN-tip was washed twice with 
30mL of Buffer QC. To elute the DNA, 15mL of Buffer QF was added and collected into a 
50mL tube. To precipitate the DNA, 10.5mL (0.7 volumes) of isopropanol was mixed 
with the eluted DNA and centrifuged at 4025g for 1 hour at 4°C. The supernatant was 
carefully decanted. The DNA pellet was then washed with 5mL of 70% ethanol and 
centrifuged at 4025g for 20 minutes at 4°C. The supernatant was carefully pipetted off. 
The DNA pellet was left to air dry for 10 minutes before resuspending the DNA in 250µL 
of nuclease-free water. The DNA was stored in -20°C.  
 
2.24.8 Lentiviral particle production  
Lentiviral particles were generated using a 3rd generation packaging system approach 
(Dull et al. 1998). 5.25x106 HEK293Ts were seeded in T75 flasks 18-24 hours prior to 




of interest; Appendix 1 and 2), pMDLg/pRRE and pRSV-Rev (packaging plasmids) and 
pCMV-VSV-G (envelope plasmids) were mixed at a 4: 1.5: 1.5: 1 ratio (w/w/w) in ‘DMEM 
serum-free media’. Tranfection agent, polyethylenimine (PEI; Sigma Aldrich), was added 
to this mixture at a PEI:DNA ratio of 3:1 (w/w) and incubated for 15 minutes at room 
temperature. HEK293Ts were visualised under light microscopy to ensure they had 
adhered to the flask surface and consisted of 70-90% confluency prior to removal of the 
culture supernatant. Media was replaced with the DNA/DMEM/PEI mixture and ‘DMEM 
complete media’ added at a final volume of 8mL before being incubated for 48-56 
hours at 37°C in the presence of 5% (v/v) CO2. Transfection efficiency was visually 
assessed by fluorescence microscope prior to harvesting the viral particles within the 
culture media. The supernatant of the HEK293Ts containing the viral particles were 
harvested and filtered through a 0.45μm filter to remove cell debris. Cold PEG-it™ Virus 
Precipitation Solution (Systems Biosciences, SBI) were then added to the filtered 
supernatant at a 1:4 ratio of PEG-it™:supernatant (v/v) and incubated at 4°C for 18 
hours. The viral particles were then pelleted by centrifugation at 2500g for 30 minutes 
at 4°C before resuspension in a 10th of the original PEG-it™:supernatant volume in 
‘human complete media’ and stored at -80°C until usage.  
 
2.24.9 Transduction of human Tregs with lentiviral particles 
4.8µg of RetroNectin® (Takara, Kusatsu, Shiga Prefecture, Japan) in PBS was added each 
well of a non-tissue-culture-treated 24 well plate (Falcon®, Corning) and incubated at 
4°C overnight. Each well was washed with PBS prior to adding 50µl of thawed lentiviral 
particles. 0.5x106 human Tregs (day 3 post-isolated Tregs and stimulated with anti-
CD3/CD28 beads) were added per well of RetroNectin®-coated wells and spinoculated 
at 600g for 1 hour at 30°C, after which cells were incubated at 37° in the presence of 5% 
(v/v) CO2. On days 7 and 10 post transduction, the transduction efficiency was tested by 
flow cytometry assessment of eGFP or mCherry expression on a BD LSRFortessa™ and 





2.25 Fluorescence-assisted cell (FACS) sorting 
On day 10, transduced human Tregs were harvested and activation beads removed by 
magnetic separation. Cells were washed twice with FACS buffer and resuspended at a 
maximum concentration of 20x106 cells per 1mL. Cells were gated on high eGFP+ or 
high mCherry+ expression and purified using a BD FACSAria II (BD Biosciences). Cells 
were sorted into ‘human complete media’.  
 
2.26 Statistical Analysis 
For two group comparisons, two-tailed Student t-test was used for statistical 
significance analysis. For three or more group comparisons, One-way ANOVA with 
Tukey multiple comparison post-hoc test was used to test statistical significance. Data 
represent mean +/- standard deviation (SD) or +/- standard error of the mean (SEM). 
















Chapter 3 - Characterisation of Mouse Treg EVs 
3.1 Introduction 
3.1.1 CD4+ CD25+ Mouse Treg derived EVs 
In 2013, my host laboratory was the first group to demonstrate that mouse CD4+ CD25+ 
Tregs release CD63+ CD81+ EVs upon activation (Lesley Ann Smyth et al. 2013). They 
showed that these EVs were able to suppress the proliferation of CD4+CD25- T cells in 
vitro. Furthermore, these EVs’ suppressive capacity was dose dependent with Treg EVs 
derived from 8x107, 5x107 and 3x107 Tregs providing a 50%, 30% and 25% inhibition of 
CD4+CD25- T cell proliferation, respectively. However, the authors did not state the 
number of EVs produced per cell. Nonetheless, the pro-inflammatory cytokines that 
activated CD4+CD25- T cells produce, IL-2 and IFNγ, were significantly reduced by the 
presence of Treg EVs (Lesley Ann Smyth et al. 2013).  
 
3.1.2 EV release is important for Treg function 
In 2014, Okoye et al. (Okoye et al. 2014) confirmed and expanded the findings of Smyth 
et al. (Lesley Ann Smyth et al. 2013). They showed that mouse CD4+ CD25+ Tregs 
released exosomes upon their activation, although these were only on the freshly 
isolated Tregs whereas Smyth et al. used both freshly isolated mouse Tregs and mouse 
Treg cultured lines. Okoye et al. also suggested that the release of exosomes was an 
essential component for Tregs to functionally suppress target cells (Okoye et al. 2014). 
Rab27α and Rab27β proteins have previously been shown to be involved in docking of 
multivesicular endosomes to Rab27 effector proteins on the plasma membrane of the 
cell; demonstrating that Rab27α and Rab27β have important roles in exosome release 
by various cells, which were experimentally confirmed by various groups (M. Fukuda 
2013; Ostrowski et al. 2010; R. K. Singh et al. 2012). Rab27ashen/ashenRab27β-/- double 
knockout mouse (Rab27αβ DKO) derived from Tregs released less exosomes than 
control Tregs. Furthermore, Rab27αβ proteins are required for Treg-mediated 
suppression given that Rab27αβ DKO Tregs did not prevent T cell proliferation. 
Additionally, the Rab27αβ DKO Tregs were unable to prevent inflammatory disease in 




loss and increased IFNγ expression levels compared to control mice. Hence, this 
highlights the importance of Rab27αβ-dependent release of exosomes for Treg 
functions in vitro and in vivo (Okoye et al. 2014). Rab27αβ DKO Tregs were impaired in 
their ability to transport dsRNA into conventional T effector cells, deducing that an 
exosomal-release-related pathway plays a principal role for transferring RNA into target 
T cells. Interestingly, the Rab27αβ DKO Tregs had a similar phenotype, transcriptional 
profile and tetraspanin expression levels to wild type Tregs despite not being able to 
suppress Th1 cell proliferation, suggesting that exosome release from Tregs is a major 
contributor to Treg-mediated suppression in vitro (Okoye et al. 2014). 
 
3.1.3 Regulated release of EVs from Tregs  
Activated Tregs released more CD63+ exosomes per cell compared to activated or 
stimulated naïve CD4+ cells; naïve CD8+ cells; B cells; Th17 cells or Th1 cells (Okoye et al. 
2014). Tregs are known to be regulated by various compounds including IL-2 (Fontenot 
et al. 2005; Boyman et al. 2006), amphiregulin (Areg) (Zaiss et al. 2013) and ATRA 
(Nolting et al. 2009), these compounds were also shown to regulate the release of 
mouse Treg exosomes (Okoye et al. 2014). Treg release of exosomes were influenced by 
changes in intracellular calcium, hypoxic conditions and the biosynthesis of ceramide 
(Okoye et al. 2014), similar to the findings by other groups showing that these factors 
also regulate exosome release from other cell types (Savina et al. 2003; H. W. King, 
Michael, and Gleadle 2012; Trajkovic et al. 2008).  
 
3.1.4 Suppressive molecules expressed by Treg EVs 
Smyth et al. showed that Treg EVs displayed CD73, CD25 and CTLA-4 molecules on their 
surfaces which are molecules also found on the parent cell, these molecules were 
shown previously to be involved in different mechanisms of immunosuppression (see 
section 1.6.3). Albeit CTLA-4 presence on these Treg EVs, this was redundant as the 
authors demonstrated that blocking CTLA-4 did not affect their suppressive capabilities. 
In addition, although CD25 molecules were found on Treg EVs, it was also found on the 




instead pro-inflammatory the authors suggested that CD25 was not involved in 
immunosuppression; however, this was not clarified experimentally by the authors. 
Instead, the authors demonstrated that the presence of CD73 on Treg EVs contributed 
to the immunosuppression observed. CD39 is a cell surface-located enzyme that 
catalyses pro-inflammatory ATP into AMP. AMP is then taken up by the ectoenzyme 
CD73 that converts AMP to anti-inflammatory adenosine. Adenosine is taken up by 
adenosine receptors A2aR which are found on activated Teffs (Chhabra et al. 2012; L. 
Han et al. 2017; Leone et al. 2018), this initiates intracellular cAMP production resulting 
in decreased cytokine production and thus preventing T cell pro-inflammatory 
responses (Romio et al. 2011). Given that adenosine was detected in the co-cultures of 
CD73+ Treg EVs with exogenous 5’AMP, it firstly confirmed that the CD73 molecules 
present on Treg EVs were functional in converting 5’AMP into adenosine. Secondly, 
from the results it is plausible that the release of EVs bearing CD73 on their surfaces 
increased the surface area in which this ectoenzyme could function within the local 
microenvironment, and thus ultimately promoting the various ways in which Tregs can 
suppress and function. Smyth el al. suggested that this occurrence could explain the 
observed inhibition of T cell responses (Lesley Ann Smyth et al. 2013). However, when 
the authors inhibited CD73 activity on EVs through the use of a CD73 chemical inhibitor 
APCP, this accounted for most of the immunosuppression observed, although some 
level of immunosuppression was unaccounted for, suggesting that other factors or 
molecules may be involved in driving Treg EVs to suppress T cell proliferation and pro-
inflammatory cytokine production. Given that EVs can act like vehicles to deliver not 
only cell surface molecules but also other types of biological material such as RNA, 
proteins, cytokines and DNA into target cells (Clotilde Théry, Zitvogel, and Amigorena 
2002; Colombo, Raposo, and Théry 2014; McKelvey et al. 2015; Graça Raposo and 
Stoorvogel 2013), it is conceivable that mouse Treg EVs could be carrying more than 
just CD73 to promote inhibition of T cell responses.  
 
3.1.5 miRNA contained within EVs  
Importantly, mouse Treg exosomes contained pre-mature miRNAs, mature miRNAs and 




releasing RNA-containing exosomes (Mittelbrunn et al. 2011; Ventimiglia and Alonso 
2016; X. Wang et al. 2018). The Treg exosomal miRNA repertoire were different 
compared to the parent cells, or exosomes isolated from Th1 or Th2 cells (Okoye et al. 
2014), indicative of potential diverse roles for Treg exosomes. In particular, Let-7d 
contained in Treg exosomes were found to contribute to their suppressive ability by 
inhibiting Th1 cell proliferation and IFNγ production. Let-7d was demonstrated to be a 
major contributor for Treg exosomes-mediated immunosuppression both in vitro and in 
vivo. Additionally, miRNA transcripts present in Treg exosomes were linked to molecular 
pathways that suppress T cells, suggesting that miRNA molecules could play a role in 
inhibition of protein synthesis or regulation of gene expression in the target T cells 
leading to an anti-inflammatory outcome (Okoye et al. 2014). 
However, to test this possibility, miRNA deficient cells and exosomes were required. A 
commonly used miRNA deficient system is Dicer (Lewis and Steel 2010; Krill et al. 2013; 
Bernstein et al. 2003; Kanellopoulou et al. 2005; Park, Choi, and McManus 2010). Dicer 
is an enzyme required to cleave double stranded premature miRNA into functional 
mature miRNA strands (Lewis and Steel 2010; Bernstein et al. 2003; Kanellopoulou et al. 
2005; Park, Choi, and McManus 2010; Krill et al. 2013). Okoye et al. demonstrated that  
the Dicer-/- Treg exosomes were unable to modulate Th1 cell proliferation and IFNγ 
cytokine production like their wild-type Treg exosomes counterparts. Dicer-/- T cells 
received miRNAs from Tregs when co-cultured together suggesting that miRNA in Tregs 
is transferred between cells (Okoye et al. 2014).  
Recently, work performed by another member of the host laboratory investigated the 
miRNA expression profile in Tregs and DCs. The intended aim of the miRNA screen was 
to investigate which miRNAs are highly expressed in murine Treg lines and hence most 
probable to be transferred into DCs which alter their function and phenotype in such a 
way to inhibit DCs from priming T cells. The results revealed differential expression 
levels of various miRNAs including miR-142-3p and miR-150-5p. Notably, miR-150 
expression levels were significantly higher in Tregs compared with DCs. These results 
are linked to the data generated and presented in this chapter. Namely, this chapter 
aimed to investigate whether these Tregs transferred miRNA via their EVs and thus 




3.2 Aims and objectives 
Aim 
As described in section 1.6.3, Tregs regulate the immune responses by acting on T cells 
and DCs. Okoye et al. demonstrated that mouse Treg exosomes can transfer miRNA into 
T cells to affect their function (Okoye et al. 2014), herein I investigated whether mouse 
Treg EVs transfer miRNAs to BM-DCs and in doing so modulate their phenotype and 
function. 
Objectives: 
(1) Investigate which miRNAs are associated with mouse Treg EVs, and of 
these, which were higher expressed compared to mouse FoxP3low T cell 
EVs. 
(2) Test if these mouse Treg and FoxP3low T cell EVs are acquired by BM-DCs.  
(3) Investigate whether mouse Treg EVs alter DC function by affecting co-
stimulatory molecule expression and cytokine production by BM-DCs.  
 
3.3 Results 
3.3.1 BALB/c BM-DCs phenotype 
BALB/c BM-DCs were generated from BALB/c mice bone marrow precursor cells 
cultured in the presence of GM-CSF, for 6 days, and harvested at the end of culture for 
phenotypic analysis by flow cytometry. The average percentage CD11c BM-DCs that 
were present in the cultures was 89.6±2.7% suggesting the presence of DCs. These cells 
also expressed CD80 (90.1±5.7%), CD86 (73.1±19.7%), H2Kd (MHC class I; 98.7±1.6%) 
and of IAd (MHC class II; 79.5±14.0%) (Figures 3.1-A-C), which are cell surface markers 
commonly found present on DCs and frequently used to identify them (Shortman and 
Liu 2002; Pulendran et al. 1997; Hua et al. 2012).  
 
3.3.2 Mouse Tregs and T cell phenotype 
In this chapter, two mouse cell lines with direct allospecificity (generated by co-culture 




cells were FoxP3high (Tregs) and the other expressed low levels of FoxP3 (FoxP3low T cell 
line). The background of the genetic information and the nomenclature of the strain of 
origin are presented in Table 3.1. A phenotypical analysis of Tregs and FoxP3low T cell 
lines generated demonstrated that 95.1±4.7% of Tregs expressed CD4+, of these 
87.5±9.2% expressed CD25+, and were FoxP3high and CD73+ (Figure 3.2-A). Whereas, 
97.0±4.8% of (control cells) T cells were CD4+ and 90.2±9.6% of these were CD25+ as 
well as FoxP3low and CD73low (Figure 3.2-B). In mouse, FoxP3 is a lineage-defining Treg 
transcription factor (S Sakaguchi et al. 1995), a high percentage of Tregs expressed this 
marker (80.6±10.1%) compared to the FoxP3low T cells (27.9±24.1%) (Figures 3.2-A-C). 
The percentage of Tregs expressing ectoenzyme CD73 were notably different between 
Tregs (98.9±0.6%) and FoxP3low T cells (42.2±8.6%) (Figures 3.2-A-C), as previously 
shown (Lesley Ann Smyth et al. 2013).   
 
Figure 3.1 Phenotype of BALB/c BM-DCs 
(A) Flow cytometry histograms showing the phenotype of BM-DCs following 
immunostaining cells with fluorescently-conjugated antibodies anti-mouse specific for 






Table 3.1- Mouse cell lines generated 
Mouse cell lines with genetic background 
Cell line






Kd antigen from BALB/c 
BM-DCs
CD4+ CD25+ Tregs isolated 
from Rab27αashen/ashen β-/- 
knock-out mice. Tregs were 
cultured with BALB/c BM-DCs 
on a weekly basis at a 4:1 
ratio of Tregs:DCs, to 
generate 'antigen-specific 
direct EV-deficient Tregs'
BALB/c BM-DCs BALB/c GM-CSF 
BM-DCs progenitors were 





GM-CSF +/- 4OHT 
(Tamoxifen) or ethanol 
(vehicle alone)
BM-DCs progenitors were 
cultured in the presence of 
GM-CSF with or without 4OHT 
(Tamoxifen) or 100% ethanol 
(vehicle). 
Direct Tregs and 
FoxP3low T cell
C57BL/6 
Kd antigen from BALB/c 
BM-DCs
CD4+ CD25+ Tregs/T cells 
isolated C57BL/6 mice. 
Tregs/T cells were cultured 
with BALB/c BM-DCs on a 
weekly basis at a 4:1 ratio of 
Tregs/T cells:DCs, to generate 
'antigen-specific direct 
Tregs/T cells'
were defined on cells that were immunostained with respective isotype controls (grey 
solid line). The percentage of immunostained cells within the gate are indicated within 
each plot. Mean fluorescent intensity values (MFIs) are indicated for isotype versus 
stained cells. The y-axis indicates the percentage of maximum expression. (B) Flow 
cytometry dot plots of the phenotype of BM-DCs. Gate positions were defined on cells 
that were immunostained with respective isotype controls. The percentage of 
immunostained cells within the quadrant gates are indicated within each plot. (C) 






Figure 3.2- Phenotype of mouse Tregs and FoxP3low T cells 
Flow cytometry histograms showing the phenotype of (A) Tregs and (B) FoxP3low T cells 
as determined by immunostaining cells with fluorescently-conjugated antibodies anti-
mouse specific for CD4, CD25, FoxP3 and CD73. Gate positions were defined on cells that 
were immunostained with respective isotype controls (grey solid line). The percentage of 
immunostained cells within the gate are indicated within each plot. Mean fluorescent 
intensity values (MFIs) are indicated for isotype versus stained cells. The y-axis indicates 




phenotype. Data shown is mean+SD from 6 individual experiments. Flow cytometry dot 
plots showing the phenotype of (D) Tregs and (E) FoxP3low T cells specific for CD4, CD25, 
FoxP3 and CD73. Gate positions were defined on cells that were immunostained with 
respective isotype controls. The percentage of immunostained cells within the quadrant 
gates are indicated within each plot. 
 
3.3.3 Generation and phenotype of Rab27αβ DKO Treg line 
As previously mentioned, Rab27αβ proteins are important for EV release from cells 
(Tolmachova et al. 2007; Okoye et al. 2014). To test the importance of EVs in Treg 
function, a Rab27αβ DKO mouse Treg line from Rab27αβ DKO mice (a kind gift from Dr 
Tanya Tolmachova of Imperial College London, UK) were generated. The Rab27αβ DKO 
Tregs were isolated from the Rab27αβ DKO mice spleen and lymph nodes using a 
negative selection for CD4+ cells and then a subsequent CD25+ positive selection. These 
Rab27αβ DKO Tregs were stimulated with BALB/c BM-DCs to generate BALB/c allo-
antigen specific Rab27αβ DKO Tregs. A phenotypical analysis of Rab27αβ DKO Tregs 
demonstrated that 82.4% of Tregs expressed CD4+, of these; 69.0% expressed CD25+; 
83.6% expressed FoxP3+ and 91.1% expressed CD73+ (Figures 3.3-A-C). Thus, Rab27αβ 






Figure 3.3- Phenotype of Rab27αβ DKO Tregs 
(A) The phenotype of Rab27αβ DKO Tregs was determined by immunostaining cells with 
fluorescently-conjugated antibodies anti-mouse specific for CD4, CD25, FoxP3 and CD73 
(green lines). Gate positions were defined on cells that were immunostained with 
respective isotype controls (grey solid line). The percentage of immunostained cells 
within the gate are indicated within each plot. Mean fluorescent intensity values (MFIs) 
are indicated for isotype versus stained cells. The y-axis indicates the percentage of 
maximum expression. (B) Bar graph of Rab27αβ DKO Tregs phenotype. Data represents 
one experiment. (C) Flow cytometry dot plots showing the phenotype of Rab27αβ DKO 
Tregs specific for CD4, CD25, FoxP3 and CD73 as determined by immunostaining. Gate 
positions were defined on cells that were immunostained with respective isotype 







3.3.4 Tregs, FoxP3low T cells and Rab27αβ DKO Tregs all inhibit T responder cells 
(Tresps) proliferation 
After confirming that the Treg lines and FoxP3low T cells expressed markers associated 
with Tregs and T cells, respectively, it was important to test whether these cells 
suppressed T cells. To accomplish this, suppression assays were set up as described in 
section 2.4. To test whether the Tregs suppressed alloreactive Tresps, a thymidine-
based suppression assay was used. Compared to the co-culture wells consisting of B6 
CD4+ Tresps with BALB/c APCs, the proliferation was significantly reduced in the 
presence of equal numbers (to Tresps) of Tregs (Figure 3.4-A). To further confirm that 
the Tregs were suppressive, a polyclonal suppression assay was performed using B6 
CD4+ Tresps, which were labelled with the proliferation dye CFDA-CFSE. These cells 
were then co-cultured with unstained BALB/c APCs and αCD3 antibody and the Tregs or 
FoxP3low T cells. By doing this, the responses of the B6 CD4+ Tresps were specifically 
detected compared to 3H-thymidine labelling, which is incorporated in all the dividing 
cells in the co-culture well. After 3 days of co-culture, the cells were harvested and 
acquired by flow cytometry to measure CFSE dilution.     
 
Tregs suppressed the CD4+ Tresps proliferation induced by APCs and αCD3 antibody and 
thus suppressed in a polyclonal manner (Figures 3.4-B and C), confirming the results 
obtained by using 3H-thymidine-based suppression assays (Figure 3.4-A). A similar 
suppression albeit to a lower level was observed with the FoxP3low T cell line, thus the 
FoxP3low T cell line was suppressive but not as potently suppressive as the Tregs (Figure 
3.4-D). Despite this observation, the FoxP3low T cell lines, because of its low expression 
of FoxP3 and CD73 was used as a control for future work characterising EVs produced 
by the Tregs.  
 
As mentioned in section 3.1.2, Okoye et al. demonstrated that Rab27αβ DKO Tregs 
were not able to suppress the proliferation of T cells, thus indicating the importance of 
EVs for Treg suppressive ability (Okoye et al. 2014). Tregs with direct allospecificity (by 
culturing with BALB/c BM-DCs) was generated from the Rab27αβ DKO mice. In contrast 
to the results from Okoye et al. (Okoye et al. 2014) the Rab27αβ DKO Tregs were 




numbers and also there were particles/EVs that were detected from the culture 
supernatant of these cells (data not shown). The Rab27αβ DKO Tregs were not fully 
characterised in terms of vesicle deficiency due to limited access to the Rab27αβ DKO 
mice. Consequently, the Rab27αβ DKO Tregs were not further used in analyses for this 
PhD project. Instead, only the FoxP3low T cell line was used as a control cell line to 






Figure 3.4- Tregs, FoxP3low T cells and Rab27αβ DKO Tregs inhibit Tresps proliferation 
(A) Alloantigen specific suppressive capacity of Tregs as tested by thymidine-based 
suppression assays. B6 CD4+ Tresps were stimulated with BALB/c APCs in the presence 
or absence of an equal number of Tregs. Co-cultures were performed for 3 days and 
proliferation was measured by 3H-thymidine incorporation. Data are representative of 
5 experiments. (B to E) B6 CD4+ T cells were stimulated with BALB/c APCs, αCD3 
antibody and in the (B) absence or presence of an equal number of (C) Tregs, (D) 
FoxP3low T cells or (E) Rab27αβ DKO Tregs. Polyclonal suppressive capacity of Tregs, 
FoxP3low T cells and Rab27αβ DKO Tregs was tested by CFSE-based suppression assays. 
Co-cultures were performed for 3 days and proliferation was measured by CFSE 
dilution. Percentage of proliferation gate was set from CFSE-stained unstimulated B6 
CD4+ T cells. Data are representative of 3 independent experiments.  
 
3.3.5 Mouse Tregs release EVs upon activation 
As mentioned above, mouse Tregs release exosomes upon activation as previously 
shown by Smyth et al. (Lesley Ann Smyth et al. 2013) and Okoye et al. (Okoye et al. 
2014). To confirm that the BALB/c allospecific Tregs studied in this project also released 
EVs, Tregs were activated using plate-bound αCD3/CD28 antibodies and 24 hours later 




electron microscopy (EM) and NanoSight analysis with Nanoparticle Tracking Analysis 
(NTA) software. Under the EM, the particles had a morphology that was ‘cup-shaped’ 
and approximately 100nm in diameter (Figure 3.5-A), as previously reported for 
exosomes (Colombo, Raposo, and Théry 2014; Clotilde Théry, Zitvogel, and Amigorena 
2002; Akers et al. 2013; Graça Raposo and Stoorvogel 2013). As processing EVs for EM 
analysis can modify the size of particles (Y. Wu et al. 2015), NanoSight was also used to 
confirm the particle sizes. Using NanoSight it was demonstrated that these particles had 
an average mean of 117.8 ± 4.6nm and an average mode of 82.0 ± 4.7nm (Figures 3.5-B 
and C), confirming the EM results (Figure 3.5-A). Due to the limited access to both EM 
and NanoSight equipment, the FoxP3low T cells EVs were not assessed by either 
modalities. Taken together, mouse Tregs released EVs upon activation and these EVs 
were cup-shaped and approximately 100nm in diameter. 
 
 
Figure 3.5- Mouse Tregs release EVs upon activation 
(A) Transmission electron microscopy image of EVs released from Tregs activated by 
plate-bound αCD3/CD28 antibodies following ultracentrifugation isolation. Scale bar 
indicates 50nm. A representative transmission electron microscopy image from 3 
independent experiments is shown. (B) Particle size distribution of Treg EVs isolated from 




αCD3/CD28 antibodies. Particles were measured on a NanoSight LM-10 instrument. 
Representative histogram showing the average EV sizes and their concentration, 
measured from 3 readings. Black lines show the mean value with red lines showing ± SD. 
Histogram is representative of 6 independent experiments. (C) Pooled data of NanoSight 
readings of Treg EVs mode and mean sizes of particles. N=6 individual samples. Each dot 
represents the average reading derived from 3 video NTA NanoSight measurements in 
each of the 6 individual samples. Bars show mean± standard deviation.  
 
3.3.6 Treg EVs and FoxP3low T cell EVs are acquired by BM-DCs 
Okoye et al. have previously shown that T cells can acquire Treg exosomes in vitro 
(Okoye et al. 2014). As mentioned in section 1.6.3, DCs represent key target cells of 
Tregs, therefore, to investigate whether DCs can acquire Treg EVs the following 
experiment was performed. CFSE-labelled Tregs or FoxP3low T cells (Figures 3.6-A and B, 
respectively) were activated with plate-bound αCD3/CD28 antibodies. To test that Tregs 
and FoxP3low T cells had been activated, the upregulation of CD69, an activation marker 
of T cells (Ziegler, Ramsdell, and Alderson 1994; Simms and Ellis 1996) was assessed 
(Figures 3.6-C and D, respectively). After confirmation of their activation state, the 
CFSE+ Treg EVs or CFSE+ FoxP3low T cell EVs were isolated from the supernatant and co-
cultured with BM-DCs for 24 hours. BM-DCs were washed extensively to remove 
unbound or unincorporated CFSE+ EVs. The presence of CFSE in BM-DCs were then 
evaluated by flow cytometry. Flow cytometric analysis showed that BM-DCs had 
acquired the CFSE+ Treg EVs and CFSE+ FoxP3low T cell EVs as their MFI had increased 
from 81 (BM-DCs alone) to 108 (BM-DCs co-cultured with CFSE+ Treg EVs) and 131 (BM-
DCs co-cultured with CFSE+ FoxP3low T cell EVs) (Figures 3.6-E and F, respectively), 







Figure 3.6- Treg EVs and FoxP3low T cell EVs are acquired by BM-DCs 
(A) Tregs or (B) FoxP3low T cells were labelled with CDFA-CFSE. Activation of (C) Tregs or 
(D) FoxP3low T cells was performed using plate bound αCD3/CD28 antibodies and 24 
 hours later, assessed by testing the upregulation of CD69 expression using flow 
cytometry. Grey solid line shows CD69 expression in unstimulated Tregs or FoxP3low T 
cells whereas orange shows the αCD3/CD28 activated cells. Supernatant was 
subsequently collected, cells and cell debris depleted and EVs isolated via 
ultracentrifugation. (E and F) BM-DCs were cultured alone (grey) or co-cultured with 
CFSE+ Treg EVs or CFSE+ FoxP3low T cell EVs for 24 hours. Flow cytometry histogram plots 
showing CFSE expression levels of BM-DCs cultured alone (grey) and BM-DCs co-cultured 
with (E) (red) CFSE+ Treg EVs or (F) (purple) CFSE+ FoxP3low T cell EVs. Mean fluorescent 
intensity values are indicated for isotype (top) versus stained cells (bottom). Data is 
representative of 3 independent experiments. The y-axis indicates the percentage of 






3.3.7 Mouse Treg EVs and FoxP3low T cell EVs are enriched in small RNA species 
Previous work has demonstrated that mouse Treg exosomes carry both mRNAs and 
miRNAs (Okoye et al. 2014). Furthermore, the same authors have shown that both 
types of RNA species are differentially expressed compared to their parent cells or Th1 
cell-derived exosomes (Okoye et al. 2014). To confirm firstly the presence of RNA in the 
EVs generated in this PhD project, and secondly that Tregs, Treg EVs or FoxP3low T cell 
EVs contained different types of RNA species, total RNA was isolated from the 
aforementioned cells and EVs or FoxP3low T cell EVs. The Agilent 2100 Bioanalyser was 
used to assess the RNA profiles and the results demonstrated that the Treg cellular RNA 
profile was different compared to both Treg EV RNA and FoxP3low T cell EV RNA. Treg 
cellular RNA contained the expected 18S and 28S RNA peaks (Figure 3.7-A), whereas the 
Treg EV RNA and FoxP3low T cell EV RNA did not contain 18S nor 28S RNA peaks (Figures 
3.7-B and C, respectively), in line with previous reports (Enderle et al. 2015; Lässer, Eldh, 
and Lötvall 2012; Eldh et al. 2012). Furthermore, these Treg EVs were enriched in small 
RNA molecules compared to the Tregs as seen by their higher fluorescent units (FU) 
levels at 170-200nt region (Figures 3.7-B and A).    
 
The method of EV isolation can influence or affect the type or amount of RNA recovery 
(Eldh et al. 2012). To test whether the gold standard ultracentrifugation or the 
ExoQuick-TC™ method of EV isolation differs in the recovery of RNA profile, both of 
these methods were compared using the same starting material. The Agilent 2100 
Bioanalyser results showed that the ExoQuick-TC™ method of EV isolation provided a 
higher amount of RNA recovery compared to ultracentrifugation method of EV isolation 
(Figures 3.7-D and E), in line with previously published reports (Rekker et al. 2014; 
Alvarez et al. 2012) and both methods of EV isolation recovered small RNA species.  
 
In summary, mouse Treg EVs are enriched in small RNAs and lack ribosomal RNA. 
Additionally, EV isolation via ExoQuick-TC™ provides a higher amount of RNA recovery 







Figure 3.7- Treg EVs and FoxP3low T cell EVs are enriched in small RNA species 
Agilent 2100 Bioanalyser analysis of RNA isolated from (A) Tregs, (B) Treg EVs or (C) 
FoxP3low T cell EVs on a total RNA Nanochip. Ribosomal RNA (rRNA) peaks are indicated 
as 18S and 28S subunits. The data is representative of 2 independent experiments. FU= 
fluorescence units and nt= nucleotides. (D and E) Two methods of EV isolation were 
tested in parallel to assess RNA recovery. Treg EVs was isolated using (D) ExoQuick-TC™ 
or (E) ultracentrifugation and then the same RNA isolation procedure was followed and 
RNA tested on the Agilent 2100 Bioanalyser.  
 
3.3.8 Mouse Treg EVs contain miRNAs that are differentially expressed compared to 
FoxP3low T cell EVs 
Okoye et al. have shown that mouse Treg exosomes from freshly isolated Tregs contain 
differential miRNAs compared with Th1 exosomes (Okoye et al. 2014). To investigate 
whether Treg EVs isolated from my Treg lines contain miRNAs that are differentially 
expressed compared to FoxP3low T cell EVs, a miRNOME was performed to detect for 
the presence and expression levels of 754 different miRNAs. 
 
EV miRNAs were profiled using a QuantStudio™ 12 K Flex Real-Time PCR system. A 
volcano plot (Figure 3.8-A) was produced to select miRNAs characterized by > 1 or 
<−1 difference between Treg EV and FoxP3low T cell EV content (Log2 (Fold Change) 
> 1 or <−1) with a log10 (p-value) > 1.301. Comparing the miRNA profiles of EVs derived 




both EVs (Figure 3.8-A and Table 3.2). However, several miRNAs were differentially 
detected including three identified miRNAs, miR-142-3p, miR-150-5p and miR-384-5p 
(Figures 3.8-B-D). This was further confirmed by individual qPCR assays. For example, 
miR-384-5p was present at significantly higher levels in FoxP3low T cell EVs (p= 0.0073) 
(Figure 3.8-D), whilst miR-142-3p was present at significantly higher levels in Treg EVs 
(p= 0.0319) (Figure 3.8-B). Interestingly, miR-150-5p, a miRNA shown recently to be 
present in EVs isolated from human CD4+ Tregs (Torri et al. 2017), was also found in 
murine Treg EVs and had significantly higher expression level compared to the 
FoxP3low T cell EVs (p= 0.0381) (Figure 3.8-C).  
 
Notably, although the volcano plot showed that miR-150 expression was not 
significantly different between Treg EVs and FoxP3low T cell EVs (Figure 3.8-A), from the 
individual qPCR assays the miR-150-5p expression was significantly higher in Treg EVs 
compared to FoxP3low T cell EVs (p= 0.0381; Figure 3.8-C), highlighting that individual 
qPCR assays are more sensitive than whole miRNA arrays (Git et al. 2010; Y. Chen et al. 
2009), possibly due to difference of normalisation tool used (Pabinger et al. 2014; Ling 
and Salvaterra 2011; Schwarzenbach et al. 2015). The best normalisation method for a 
large number of qPCR assays such as a miRNOME is a global mean normalisation which 
is a value above the mean expression value of all sample cohorts (Mestdagh et al. 
2009). Whereas, in individual qPCR assays, due to the small number of samples, a 
reference house-keeping gene or a reference miRNA which is expressed in similar levels 
is suggested (Mestdagh et al. 2009). snoRNA are small nucleolar RNAs, that are non-
coding but aid chemical modification of other RNAs such as ribosomal RNA, transfer 
RNA and small nuclear RNA (Scott and Ono 2011). snoRNA202, is generally used as a 
normalisation candidate (Brattelid et al. 2011), why snoRNA202 presented as enriched 
in Treg EVs compared to FoxP3low T cell EVs (Figure 3.8-A) is unclear, but due 
snoRNA202 being generally used as a reference gene, it suggested that it might be not 
involved in Treg EV-mediated actions and thus I did not further validate the expression 






Figure 3.8- Mouse Treg EVs contain miRNAs that are differentially expressed compared 
to FoxP3low T cell EVs 
Mouse Treg EVs and FoxP3low T cell EVs isolated by ExoQuick-TC™ were lysed and total 
RNA was purified and assessed using NanoDrop™ spectrophotometer and Agilent 2100 
Bioanalyser. EVs miRNA was reverse transcribed into cDNA and pre-amplified before 
miRNA detection using QuantStudio™ 12 K Flex Real-Time PCR System with the 
OpenArray® Platform. (A) The volcano plot shows the relationship between the p-value 
and the log fold change between Treg EVs versus FoxP3low T cell EVs miRNA expression 
levels. The dark blue line indicates the inverse log10 of the p-value = 0.05. n = 3 per group.  
(B to D) Bar graphs (mean + SEM) showing the relative quantity of (B) miR-142-3p, (C) 
miR-150-5p, and (D) miR-384-5p expressed by FoxP3low T cell EVs and Treg EVs as 
measured by qPCR assays and normalised relative to RNU6-2. Data pooled from 3 
individual experiments that were performed in technical triplicates. Statistical 
significance was determined using a two-tailed Student’s t-test where *p<0.05 and 





Table 3.2- miRNOME result summary of the top 40 miRNA detected 
Table showing the top 40 miRNAs that had higher expression levels in Treg EVs 
compared to FoxP3low T cell EVs. The last column shows the Benjamini-Hochberg 
values with the formula of (i/m)Q, i= the p-value’s rank, m= total number of tests and 
Q= the false discovery rate of 0.25 
miRNA Relative Quantity p-value Rank
Benjamini-Hochberg 
Procedure (i/m)Q
snoRNA202 6.453 0.006 1 0.00245098
miR-142-3p 3.633 0.020 2 0.004901961
miR-340-5p 2.017 0.042 3 0.007352941
miR-15b 3.152 0.077 4 0.009803922
miR-126 2.540 0.121 5 0.012254902
miR-152 3.458 0.122 6 0.014705882
miR-664 4.281 0.151 7 0.017156863
miR-222 3.589 0.183 8 0.019607843
miR-223-5p 3.271 0.200 9 0.022058824
let-7d 1.747 0.204 10 0.024509804
miR-685 1.443 0.251 11 0.026960784
miR-150 99.405 0.253 12 0.029411765
miR-2182 2.403 0.257 13 0.031862745
miR-200c 1.964 0.282 14 0.034313725
miR-34b-3p 4.031 0.283 15 0.036764706
miR-331 2.361 0.284 16 0.039215686
miR-132 1.999 0.285 17 0.041666667
miR-221 3.369 0.289 18 0.044117647
miR-139-5p 3.443 0.308 19 0.046568627
miR-212 2.230 0.322 20 0.049019608
miR-223-3p 3.300 0.334 21 0.051470588
miR-2138 3.840 0.336 22 0.053921569
miR-2134 4.523 0.355 23 0.056372549
miR-1198 1.532 0.388 24 0.058823529
miR-2146 2.386 0.416 25 0.06127451
miR-429 2.913 0.461 26 0.06372549
miR-328 1.604 0.473 27 0.066176471
miR-29a 1.775 0.872 28 0.068627451
miR-20b 5.306 1 29 0.071078431
miR-99b 4.508 1 30 0.073529412
miR-31 4.212 1 31 0.075980392
miR-203 3.515 1 32 0.078431373
miR-365 3.310 1 33 0.080882353
miR-362-3p 3.114 1 34 0.083333333
miR-342-3p 2.442 1 35 0.085784314
miR-155 2.427 1 36 0.088235294
miR-21 2.347 1 37 0.090686275
miR-148b 1.912 1 38 0.093137255
miR-125a-5p 1.683 1 39 0.095588235
miR-1897-5p 1.522 1 40 0.098039216




3.3.9 miR-150-5p and miR-142-3p expression levels are increased in BM-DCs following 
co-culture with Treg EVs  
Given the high expression of miR-142-3p and miR-150-5p in Treg EVs compared to 
FoxP3low T cell EVs (Figures 3.8-B and C, respectively), and that EVs can be transferred 
into BM-DCs (Figures 3.6-E and F), it led to the question of whether Treg EVs can 
mediate transfer of miR-142-3p and miR-150 into BM-DCs. To test this, the BM-DCs 
were co-cultured with Treg EVs or FoxP3low T cell EVs for 24 hours at a ratio of 100 
donor cell derived EVs to one recipient cell (Villarroya-Beltri, Gutiérrez-Vázquez, 
Sánchez-Madrid, et al. 2013). After 24 hours, BM-DCs were harvested, washed 
thoroughly and both miR-142-3p and miR-150-5p expression levels were measured 
by qPCR assays. It was observed that miR-142-3p expression was increased in BM-DCs 
co-cultured with Treg EVs as compared to BM-DCs cultured alone (p<0.0001) or with 
FoxP3low T cell EVs (p<0.0001) (Figure 3.9-A). In addition, miR-150-5p expression levels 
were increased in BM-DCs co-cultured with Treg EVs as compared to BM-DCs cultured 
alone (p<0.0001) or FoxP3low T cell EVs (p<0.0001) (Figure 3.9-B). This data suggested 
that miR-142-3p and miR-150-5p were both transferred to BM-DCs via Treg EVs.    
 
 
Figure 3.9- miR-150-5p and miR-142-3p expression levels are increased in BM-DCs 
following co-culture with Treg EVs  
Bar graphs show relative quantity of (A) miR-142-3p and (B) miR-150-5p expression 




or Treg EVs-treated BM-DCs (BM-DCs+ Treg EVs). BM-DCs were treated with EVs for 
24 hours, washed thoroughly and the expression levels of these miRNAs was measured 
by qPCR assays and normalised to RNU6-2. Data represents mean + SEM pooled from 3 
individual experiments that were performed in technical triplicates. Statistical 
significance was determined using One-way ANOVA and Tukey’s multiple comparison 
tests. ****p<0.0001  
However, miRNA can affect other miRNA expression levels (Matkovich 2014), and other 
factors could also influence miRNA expression induction or expression levels (S. Sun et 
al. 2017; Neilson et al. 2007; Gulyaeva and Kushlinskiy 2016; Van Wynsberghe et al. 
2011). Thus to further confirm that the observed change in miRNA was due to the 
uptake of EVs rather than an induction of these miRNAs in the recipient cell, Dicer 
deficient mice, lacking mature miRNAs were used as a source of BM-DCs (Okoye et al. 
2014).  
Dicer gene knockout is embryonically lethal in mice (Krill et al. 2013), thus conditional 
knock-out Dicerfloxed/floxed mice were used. Conditional deletion of the Dicer gene is 
possible as the Dicer gene was flanked by LoxP sites (Dicerfloxed/floxed) and Cre activity 
utilises a mutant estrogen hormone-binding domain (ERT) to keep Cre inactive unless 
tamoxifen is present. Rosa26 locus is ubiquitously expressed in mouse cells. Thus, this 
mouse strain expresses Cre-ERT from the ubiquitously expressed Rosa26 locus. 
Therefore, this mouse has an inducible deletion of Dicer in any cell that is treated with 
tamoxifen (Figure 2.2). 
 
To confirm that tamoxifen reduces Dicer expression levels in BM-DCs derived from Dicer 
conditional knock-out (Dicer-/-) mice, DC progenitors from bone marrow were cultured 
in the presence of GM-CSF and 4OH Tamoxifen or 98% ethanol (carrier/vehicle). First, 
the phenotypes of BM-DCs derived from these mice were assessed. As presented in 
Figures 3.10-A and C, 89.0±4.4% of the BM-DCs treated with 4OH Tamoxifen expressed 
CD11c. Of these 45.7±7.4% expressed IAb (MHC class II), 82.8±7.2% were CD80+, 
56.7±10.6% were CD86+ and 25.9±8.0% were CD40+. The expression of all these 
markers were similar to BM-DCs treated with ethanol (vehicle alone). As shown in 




expressed CD11c. Of these 51.8±2.6% expressed IAb (MHCII), 87.0±4.6% were CD80+, 
63.7±6.5% were CD86+ and 21.3±10.3% were CD40+.  
 
Next, the expression levels of miR-142-3p and miR-150-5p were assessed in BM-DCs 
cultured with 4OH Tamoxifen or ethanol to assess whether 4OH Tamoxifen mediated 
deletion of Dicer, which subsequently downregulates miRNA expression levels. The 
qPCR assays showed that miR-142-3p expression levels were significantly reduced by 
4OH Tamoxifen treatment compared to ethanol treatment (p=0.0448) (Figure 3.10-E). 
Similar results were obtained with miR-150-5p; the expression levels of miR-150-5p 
were significantly reduced in 4OH Tamoxifen-treated BM-DCs compared to ethanol-
treated BM-DCs (p<0.0001) (Figure 3-10-F). These results suggest that 4OH Tamoxifen 
reduced Dicer expression leading to lower miR-142-3p and miR-150-5p expression 
levels in the BM-DCs. Tetracycline-based reduction of gene expression is not always 
complete due to ‘leakiness’ in the system (De Veylder et al. 2000; Pham et al. 2008; 
Roney et al. 2016), which might explain the incomplete ablation of miRNA expression in 
these Dicer-/- BM-DCs treated with 4OH Tamoxifen. Furthermore, some miRNA 
generation is independent of Dicer activity (Herrera-Carrillo and Berkhout 2017; 
Cheloufi et al. 2010; J.-S. Yang, Maurin, and Lai 2012). In summary, BM-DCs from Dicer-/- 
mice expressed common BM-DC markers and 4OH Tamoxifen treatment did not affect 
BM-DC phenotype but did down-regulate the expression levels of miR-142-3p and miR-






Figure 3.10- Dicer-/- BM-DC phenotype and reduction of miRNA expression levels 
Flow cytometry histogram plots showing expression of CD11c, IAb (MHC Class II), CD40, 
CD80 and CD86 in (A) Dicer-/- BM-DCs treated with 4OH Tamoxifen (red line) or (B) Dicer-
/- BM-DCs treated with ethanol (vehicle alone; blue line). Gate positions were defined on 
cells that were immunostained with respective isotype controls (grey solid line). The 
percentage of immunostained cells within the gate are indicated within each plot. The y-
axis indicates the percentage of maximum expression. (C and D) Bar graph of pooled 
data of expression levels of BM-DCs markers for (C) Dicer-/- BM-DCs treated with 4OH 
Tamoxifen or (D) Dicer-/- BM-DCs treated with ethanol (vehicle alone). Data shown is 
mean+SD from 2-3 individual experiments. (E and F) The effect of 4OH Tamoxifen-




150-5p. Statistical significance was determined using Student t test. *p<0.05 and 
****p<0.0001    
Next, to confirm that miR-142-3p and miR-150-5p were transferred into BM-DCs via 
Treg EVs rather than an induction of these miRNAs in the recipient cell, the Dicer -/- 
BM-DCs were co-cultured with Treg EVs or FoxP3low T cell EVs. The co-culture of Treg 
EVs but not FoxP3low T cell EVs with Dicer−/− BM-DCs resulted in an increase in miR-142-
3p expression levels but this was not statistically significant (Figure 3.11-A). 
Nonetheless, a significant increase of miR-150-5p expression levels in Dicer−/− BM-DCs 
was observed after co-culture with Treg EVs (p<0.0001) but not with FoxP3low T cell EVs 
(Figure 3.11-B). As expected, the miR-150-5p expression levels in Dicer-/- BM-DCs with 
Treg EVs treatment was significantly higher than with FoxP3low T cell EVs (p<0.0001) 
(Figure 3.11-B).  
In summary, these data indicated that miRNAs present in Treg EVs, namely miR-142-
3p and miR-150-5p are acquired by BM-DCs.  
 





Bar graphs show relative quantity of (A) miR-142-3p and (B) miR-150-5p expression 
levels  in untreated Dicer-/- BM-DCs (Dicer-/- BM-DCs), FoxP3low T cell EVs-treated Dicer-/- 
BM-DCs (Dicer-/- BM-DCs+ FoxP3low T cell EVs) or Treg EVs-treated Dicer-/- BM-DCs (Dicer-
/- BM-DCs+ Treg EVs). Dicer-/- BM-DCs were treated with EVs for 24 hours, washed 
thoroughly and miRNA expression levels was measured by qPCR assays and normalised 
to RNU6-2. Data shown is mean + SEM representative of 2 experiments that were 
performed in technical triplicates. Statistical significance was determined using One-way 
ANOVA and Tukey’s multiple comparison tests. ****p<0.0001 and ns = not significant.   
 
3.3.10 Neither Treg EVs nor FoxP3low T cell EVs affected BM-DC phenotype 
Having shown that miRNAs are transferred from Treg EVs to BM-DCs, I next investigated 
whether this transfer affected BM-DCs phenotype. To investigate this, BM-DCs were 
treated with Treg EVs or FoxP3low T cell EVs prior to stimulation with or without LPS and 
their phenotype assessed by flow cytometry. As expected LPS-stimulated BM-DCs 
displayed higher CD80, CD86 and CD40 expression levels compared to unstimulated 
BM-DCs (Figure 3.12-A). Neither Treg EVs nor FoxP3low T cell EVs pre-treatment 
influenced the LPS induced expression of these (Figures 3.12-B and C, respectively). 
In summary, Tregs EVs and FoxP3low T cell EVs do not affect the expression of BM-DC 







Figure 3.12- Neither Treg EVs nor FoxP3low T cell EVs affect the phenotype of BM-DCs 
(A) Flow cytometry histogram plots showing the phenotype of BM-DCs that were 
cultured alone (grey solid line) or co-cultured in the presence of 100ng/mL LPS (black 
line) for the expression levels of CD80, CD86, CD40, CD11c and H2Kd (MHC class I). Flow 
cytometry histogram plots showing the phenotype of BM-DCs in the presence of 
100 ng/mL LPS (black line) and co-cultured with (B) Treg EVs (red line) or (C) FoxP3low T 
cell EVs (purple line) for 24 hours. BM-DCs were washed thoroughly and subsequently 
cells were immunostained with fluorescently-conjugated antibodies anti-mouse specific 
for CD80, CD86, CD40, CD11c and H2Kd (MHC class I). Data is representative of one 
experiment. The y-axis indicates the percentage of maximum expression. 
 
3.3.11 Treg EVs affect BM-DCs cytokine production 
Based on previous published work showing that miRNAs can modify cytokine 




and Nares 2015; Lesley A Smyth et al. 2015) and that other EV-associated miRNAs 
affect target cell cytokine production (Okoye et al. 2014; Lakhter et al. 2018), I 
investigated whether this was the case here. Thus, in order to investigate whether EVs 
might affect cytokine production by BM-DCs, the cytokine production by BM-DCs 
with or without Treg EV or FoxP3low T cell EV treatment was tested. 
BM-DCs were co-cultured with or without Treg EVs or FoxP3low T cell EVs and the 
presence and concentration of IL-6, TNF and IL-10 cytokines following exposure to LPS 
were tested. LPS-stimulated BM-DCs produced significantly more IL-6 (p<0.0001) and 
TNF (p=0.0003) compared to unstimulated BM-DCs (Figures 3.13-A and B, respectively). 
Furthermore, BM-DCs treated with LPS produced measureable levels of IL-10 compared 
to unstimulated BM-DCs (Figure 3.13-C). The additional treatment of Treg EVs or 
FoxP3low T cell EVs to BM-DCs prior to LPS stimulation significantly reduced the 
production levels of IL-6 (p<0.0001) (Figure 3.13-A). Similar patterns of results were 
obtained when TNF production levels were measured, but the differences were not 
significant (Figure 3.13-B). In contrast, the IL-10 production levels by BM-DCs stimulated 
with LPS were significantly increased when BM-DCs were co-cultured with Treg EVs 
(p<0.0001) but not in the presence of FoxP3low T cell EVs (no IL-10 detection). This was 
not due to the presence of IL-10 inside Treg EVs (data not shown) (Tung et al. 2018). 
 
Taken together, this suggests that Treg EVs and FoxP3low T cell EVs affect BM-DC 
cytokine production; Treg EVs reduced IL-6 whilst increasing IL-10 production levels by 
BM-DCs whereas FoxP3low T cell EVs reduced IL-6 but did not induce IL-10 production 
levels. Both Treg EVs and FoxP3low T cell EVs did not affect TNF production levels by BM-






Figure 3.13- Treg EVs affect BM-DCs cytokine production 
BM-DCs in the presence or absence of 100ng/mL LPS and co-cultured with or without 
Treg EVs or FoxP3low T cell EVs for 24 hours. The supernatant from the co-cultures were 
harvested to test for cytokine presence and concentration using cytometric bead array 
and flow cytometry. The presence of (A) IL-6, (B) TNF and (C) IL-10 cytokines from the co-
cultures were assessed. Data represents 2 independent experiments that were 
performed in technical triplicates. Bars show mean  +  SEM. Statistical significance was 
determined using One-way ANOVA and Tukey’s multiple comparison tests. ***p < 0.001, 
****p < 0.0001, ns= not significant and ND = not detected. 
 
3.4 Discussion 
In this thesis chapter, I confirmed previous findings that mouse Tregs release EVs 
(Lesley Ann Smyth et al. 2013; Okoye et al. 2014) that contained various miRNAs (Okoye 
et al. 2014), and that certain miRNAs were differentially expressed compared to 
FoxP3low T cell EVs. Tregs contained miR-142-3p and miR-150-5p (Tung et al. 2018), and 
the same miRNAs were also present and highly expressed in their EVs compared to 
FoxP3low T cell EVs. Treg EVs and FoxP3low T cell EVs can be acquired by BM-DCs. BM-
DCs increased their miR-142-3p and miR-150-5p expression levels following Treg EVs 
contact, suggesting that Treg EVs transferred miR-142-3p and miR-150-5p into BM-DCs. 




A Smyth et al. 2015), I assessed whether Tregs can modulate BM-DCs via EV-
associated miRNAs. BM-DCs that were in contact with Treg EVs and then stimulated 
with LPS have an altered cytokine production profile; IL-6 production levels were 
significantly reduced whereas IL-10 production levels were significantly increased. Given 
that miR-142-3p and miR-150-5p have been reported to affect cytokine production by 
target cells (Fordham, Naqvi, and Nares 2015; Lesley A Smyth et al. 2015), this 
suggested that it was possible that Treg EVs transferred functional miRNAs into BM-DCs 
that altered BM-DCs function of cytokine production to prevent a pro-inflammatory 
microenvironment and instead promote an anti-inflammatory milieu; hence Treg EVs 
may induce ‘tolerogenic’ BM-DCs. However, neither Treg EVs nor FoxP3low T cell EVs 
affected the expression levels of BM-DC co-stimulatory molecules CD80 and CD86 nor 
BM-DC cell markers CD40 or CD11c. Noteworthy, the FoxP3low T cells used in this thesis 
chapter originated from the Treg line and over time in culture, these cells had lost 
FoxP3 and CD73 expression.  
 
3.4.1 Rab27αβ DKO Tregs 
Rab27 proteins are involved in exosome release from the cell and thus Rab27αβ DKO 
Tregs do not release exosomes (Okoye et al. 2014). In my hands, Rab27αβ DKO Tregs 
were immunosuppressive in that they suppressed the proliferation of Tresps, which is in 
contrast to the report published by Okoye et al. (Okoye et al. 2014). Okoye et al. 
demonstrated that Rab27αβ DKO Tregs were not able to suppress T cell proliferation 
nor able to inhibit IL-2 or IFNγ cytokine production. They suggested the high 
dependency of exosomes in driving Treg cell-mediated suppression (Okoye et al. 2014). 
However, several differences in the suppression assay set up were evident in this thesis 
chapter compared to Okoye et al. (Okoye et al. 2014).  Firstly these authors used freshly 
isolated Rab27αβ DKO Tregs, whereas in this thesis chapter Rab27αβ DKO Tregs that 
were expanded in vitro were used; secondly, the authors used plate-bound αCD3 and 
soluble αCD28 antibodies to stimulate T cells, whereas in this thesis chapter, APCs were 
used to stimulate T cells; additionally, although a minor difference was the proliferation 
dye used, Okoye et al. used CellTrace™ Violet (Okoye et al. 2014), whereas in this assay, 
CFDA-CFSE was used. Collectively, these differences could explain the opposing results. 




expanded Rab27αβ DKO Tregs, as described by Thornton and Shevach. Thornton and 
Shevach showed that freshly isolated Tregs were not as suppressive as in vitro expanded 
Tregs, although in that study human Tregs  were used and not murine Tregs (A M 
Thornton and Shevach 2000). Despite Okoye et al. stating that Rab27αβ DKO Tregs are 
not suppressive, thus highlighting the great importance of exosomes for Treg 
suppressive functions (Okoye et al. 2014), it does query why various other suppression 
mechanisms that Tregs can use, such as those illustrated in Figure 1.2, did not play a 
role in suppressing T cells when the EV pathway was blocked? Given that Tregs have an 
extensive arsenal of suppressive mechanisms, yet not all target cell populations will be 
equally sensitive or affected by all Treg suppression mechanisms (Vignali 2012), 
suggests that Tregs maybe deploy certain selected mechanisms to suppress target cells 
whilst other mechanisms are not as frequently used, although this remains 
controversial.        
 
3.4.2 Treg EVs and FoxP3low T cell EVs are acquired by BM-DCs but their phenotype 
was not altered 
Treg EVs and FoxP3low T cell EVs are acquired by BM-DCs, which is in line with previous 
reports showing that human T cells mediate EV transfer of miRNA into APCs (B cells) 
during the immunological synapse (Mittelbrunn et al. 2011). However, it is possible 
that the EVs do not enter the target cell and instead only adhere to the surface of the 
BM-DCs. Indeed, reports have suggested that EVs can be incorporated or associated 
with target cells via various phagocytosis, endocytosis or receptor-ligand mediated 
pathways (McKelvey et al. 2015; Tian et al. 2014; Delenclos et al. 2017; Morelli et al. 
2004). Many studies have found that over expression of a specific miRNA in BM-DCs 
did not affect cell surface markers expression while the cytokine profile was affected, 
so my findings are in line with published data (Lesley A Smyth et al. 2015). It is 
possible that cytokine modulation of BM-DCs may be a more potent form of 
immunosuppression compared to downregulating co-stimulatory molecules of BM-
DCs. As described by Rutella et al., cytokine modulating tolerogenic DCs may 
promote in vitro induction of Tregs and in vivo prevention from post-transplantation 




Treg EVs modified BM-DCs cytokine to induce a Treg population would be interesting 
to investigate.  
3.4.3 Different EV isolation methods affect RNA recovery 
The EV isolation method influenced the amount of RNA recovery; ExoQuick-TC™ was 
more efficient than ultracentrifugation at recovering EV RNA as previously reported (Y.-
T. Tang et al. 2017). Treg cellular RNA and Treg EV RNA differed in their RNA profile, 
namely, Treg EVs and T cell EVs lacked the 18s and 28s ribosomal RNA peaks, as 
previously reported (Crescitelli et al. 2013; Eldh et al. 2012). As demonstrated by 
Crescitelli et al., exosomal RNA mainly consists of small RNA including mRNA and miRNA 
(Crescitelli et al. 2013). There are various published methods describing how to isolate 
and purify EVs, although no consensus has been approved as to what protocols should 
be followed. Nonetheless, in the EVs field, the general approach is to choose a protocol 
depending on what the experiment question is. For example, if EV RNA is being studied, 
it is more appropriate to use commercially available exosome precipitating reagents 
such as ExoQuick-TC™ over traditional methods such as the gold standard 
ultracentrifugation. The reason for choosing ExoQuick-TC™ over ultracentrifugation was 
due to the amount of EV RNA recovered (Y.-T. Tang et al. 2017), which could also reflect 
on the EVs recovery obtained from using this method. Therefore, I compared the 
ultracentrifugation and ExoQuick-TC™ methods of EV RNA isolation. Possible 
explanations of the observed results could be due to the notion that (i) 
ultracentrifugation does not recover the majority of EVs during processing (ii) ExoQuick-
TC™ precipitates ‘free’ (not bound to EVs) miRNA (iii) ExoQuick-TC™ precipitates 
proteins which miRNA may be bound to. Although careful steps were taken to remove 
contaminating cells and cell debris before the EVs isolation step, it cannot be 
completely excluded that the possibility of contaminating proteins could have been 
isolated together with EVs.  
 
3.4.4 miRNA modulate cytokine production 
Multiple miRNAs have been linked to the inhibition of pro-inflammatory cytokine 
production by DCs (Lesley A Smyth et al. 2015). Examples of this include miR-21, 




148/miR-152 which suppresses the production of both IL-6 and IL-12 cytokines (X. Liu 
et al. 2010). miR-21 was expressed in higher levels in Tregs compared to BM-DCs 
(Tung et al. 2018). Furthermore, miR-21, miR-148 and miR-152 were found present in 
the Treg EVs from the miRNOME screen. But I chose to focus on miR-142-3p and miR-
150-5p because these two miRNAs had a significantly higher expression level in Treg 
EVs compared to FoxP3 low T cell EVs. Both of these also have cytokine modulating 
properties as explained below. 
Ectopic expression of miR-142-3p in human DCs leads to decreased production of IL-
12, IL-6 and TNFα after TLR ligation (Fordham, Naqvi, and Nares 2015; Naqvi, 
Fordham, and Nares 2015). In mouse DCs, miR-142-3p directly targets the 3’UTR of 
IL-6 mRNA (Y. Sun et al. 2011). In 2013, Sun et al. transfected splenic CD11c+ murine 
DCs with pre-miR-142-3p and observed reduced endogenous levels of IL-6. On the 
other hand, knocking down miR-142-3p by transfecting DCs with a miR-142-3p 
“locked nucleic acid” (LNA) probe resulted in increased IL-6 production following LPS 
activation. This study also demonstrated miR-142-3p did not affect IL-10 cytokine 
levels post LPS activation (Y. Sun et al. 2011).   
King et al. demonstrated that miR-150 expression in human CD4+ T cells regulates IL-
10 production. Knockdown of miR-150 expression levels in primary T cells resulted in 
reduced IL-10 production levels following activation with anti-CD3 and CD46 
antibodies (B. C. King et al. 2016). Given these findings I suggest that transferring 
both miR-150-5p and miR-142-3p may be linked to the increased IL-10 and decreased 
IL-6 production levels, respectively, observed in BM-DCs treated with Treg EVs.  
Whether acquisition of other miRNAs, such as miR-21, also present in the Treg EVs 
resulted in production of IL-10 following TLR ligation requires further studies. miR-21 
has been shown to indirectly affect IL-10 production. Transfection of pro-miR-21 into 
RAW264.7 cells led to increased IL-10 production following LPS activation. The 
authors of this data concluded that LPS induced miR-21 which targets PDCA4, a 





Notably, miR-384-5p was significantly lower expressed in Treg EVs compared to 
FoxP3low T cell EVs. Qu et al. reports that miR-384 regulated the Th17/Treg balance 
during EAE pathogenesis (Qu et al. 2017). These authors demonstrated that 
overexpression of miR-384 in vivo resulted in exacerbated EAE conditions. miR-384 
promoted the differentiation of naive T cells into Th17 cells which produced elevated 
levels of pro-inflammatory IL-17 cytokine. The observation that Treg EVs expressed 
significantly lower levels of miR-384-5p compared to FoxP3low T cell EVs may be a 
possible mechanism to inhibit the induction of Th17 cells and instead promote Treg 
differentiation.   
It is possible that the modification of BM-DCs by Treg EVs may complement or aid the 
other pathways as outlined in section 1.6.3, used by Tregs to induce a ‘tolerant’ APC. 
Given that previous studies have used rat Treg EVs to induce tolerance in the setting 
of transplantation (X. Yu et al. 2013; Aiello et al. 2017) it is possible that the EVs is 
one of the major pathways by which Tregs function through modification of cytokines 
released by BM-DCs by transferring miRNAs. 
3.4.5 Other miRNA functions  
miR-142-3p can also attenuate phagocytosis. Overexpression of a miR-142-3p mimic 
in primary human monocytes and DCs reduced E.coli  fluorescent OVA as well as 
antibody-mediated phagocytosis, compared to controls (Naqvi, Fordham, and Nares 
2015; Naqvi et al. 2016). Overexpression of miR-142-3p in human DCs has been 
shown to affect at least 40 genes, some of which are associated with phagocytosis as 
well as cell signalling associated genes such as PKCα and cell mobility such as N-Wasp 
(Naqvi, Fordham, and Nares 2015). Overexpression of miR-142-3p in DCs has also 
been linked with decreased T cell activation, which was independent of any changes 
to MHC or co-receptor expression on the DCs (Naqvi et al. 2016). However, 
overexpression of this miRNA did not affect MHC class II, CD80 or CD86 expression 
levels compared to control and non-manipulated DCs (Naqvi et al. 2016), which I 
have also demonstrated with the treatment of Treg EVs (which contained miR-142-
3p) also did not alter the expression levels of CD80 nor CD86 by BM-DCs. Taken these 




to both Tregs and their EVs, I suggest that miRNA transfer by Tregs may play a key 
functional role in their suppressive function with respect to APCs function.  
Several studies have shown that miRNAs I found present in FoxP3low T cell EVs and 
Treg EVs directly affect validated target molecules present within the recipient cell. 
For example, c-Myb mRNA, an identified target for miR-150-5p, was downregulated 
in a miR-150-5p negative hepatocyte derived cellular carcinoma cell line following 
exposure to human Treg EVs containing this miRNA (Torri et al. 2017). It is therefore 
feasible that the miRNAs present in these EVs will affect their mRNA target.   
EVs have been shown to contain many other types of RNA species in addition to 
miRNAs some of which may modify cytokine expression. miRNAs constitutes only a 
small fraction of small RNAs found in immune and non-immune cell derived EVs and 
other RNA species have been identified including, snoRNA, piRNA, lincRNA, rRNA, 
tRNA (Nolte-’t Hoen et al. 2012) and Y RNA (Nolte-’t Hoen et al. 2012; Cambier et al. 
2017). Indeed, snoRNA202 was observed in the Treg EVs. Recently, Y RNA, identified 
in cardiosphere-derived cell exosomes, was linked to IL-10 expression and secretion 
(Cambier et al. 2017). Transfection of macrophages with this Y RNA led to increased 
production of this cytokine. Whether other RNA species are present in Treg EVs is out 
with the scope of this PhD project, however given the alterations to cytokine 
production observed in BM-DCs following treatment with Treg EVs it is possible that 
the changes observed are mediated by the transfer of a combination of RNA species 
or indeed a combination of miRNAs and cell surface proteins.  
In 2013, Bryniarski et al. published the first study demonstrating that CD8+ suppressor T 
cells release exosomes-like EVs that encompassed miR-150 and delivered it to Teffs in 
an antigen-specific manner. The exosomes-like EVs were primed to be antigen specific 
via a surface coating of antibody light chains, hence allowing the EVs a selective uptake 
by Teffs. The targeted delivery of the inhibitory miR-150 into Teffs resulted in inhibition 
of their cellular activity (Bryniarski et al. 2013). Bryniarski et al. went on to demonstrate 
that these EVs were able to function at the in vivo setting to inhibit contact sensitivity 





Similar to Okoye et al. (Okoye et al. 2014), we also found the presence of Let-7d in the 
Treg EVs, even though this was higher expressed in Treg EVs compared to FoxP3low T 
cell EVs this was not statistically significant from the miRNOME screen. However, given 
that Let-7d was shown to be the relevant miRNA involved in driving the 
immunosuppressive ability of Treg EVs in in vitro and in vivo settings, it raises the 
possibility that Let-7d in these Treg EVs used in this thesis chapter may also similarly be 
involved in immunosuppression.   
Transfer of several miRNAs with the potential to induce non-inflammatory cytokine 
release by BM-DCs may help create a ‘tolerogenic’ environment, although whether 
the same occurs in vivo and how this is modulated in autoimmune conditions has yet 
to be elucidated. This thesis chapter results could provide valuable information 
regarding the modification of Tregs for therapeutic use. Given that Tregs are 
currently used in clinical trials (Bluestone et al. 2015), creating Tregs that deliver 
miRNAs to DCs via EVs may help increase the efficacy of this therapy in patients 
receiving a transplant or with autoimmune diseases.  
3.5 Summary 
In summary, in this chapter I have shown that mouse Tregs release EVs that contain 
higher expression levels of miR-142-3p and miR-150-5p compared to FoxP3low T cell EVs. 
BM-DCs acquired miR-142-3p and miR-150-5p from Treg EVs leading to an altered BM-
DCs cytokine production profile; from a pro-inflammatory microenvironment to an anti-
inflammatory milieu; IL-6 was reduced whereas IL-10 was increased. These cytokine 
alterations may be related to miR-142-3p and miR-150-5p contained in Treg EVs. Hence 
Treg EVs may induce ‘tolerogenic’ BM-DCs. However, neither Treg EVs nor FoxP3low T 
cell EVs altered the expression of DC co-stimulatory molecules CD80, CD80 nor DC cell 









Characterisation of Human 





Chapter 4 - Characterisation of Human Treg EVs in vitro 
4.1 Introduction 
4.1.1 Human T cell derived EVs and their characterisation so far 
The full characterisation of human Tregs heterogeneity, phenotype and function is 
currently incomplete. Understanding the precise mechanisms of action of Tregs is 
important not only to shed some light into their biological role but also for optimising 
their use in the clinical setting. I have shown in Chapter 3 that murine Tregs produce 
EVs that regulate BM-DCs function, we know also from previous work that Treg EVs can 
target other cells, such as T cells directly (Lesley Ann Smyth et al. 2013; Okoye et al. 
2014; Aiello et al. 2017; X. Yu et al. 2013; Torri et al. 2017; Azimi et al. 2018). 
T cells releasing EVs has been well documented since many years ago (Ventimiglia and 
Alonso 2016). For example, a study in 2002 by Blanchard et al. demonstrated that 
human T cell derived exosomes contain the TCR/CD3/ζ  complex which provided T cell 
exosomes with the potential to deliver activation signals to cells bearing the 
complementary peptide/MHC complexes (Blanchard et al. 2002).  
In 2013, my host laboratory had published the first evidence that mouse Tregs release 
EVs (Lesley Ann Smyth et al. 2013), and in a review published in 2014, my host 
laboratory had stated that we had evidence that human Tregs also produced these 
vesicles (Agarwal et al. 2014). I had obtained the data to demonstrate the novel finding 
that human Tregs release EVs which were immunomodulatory (presented in this thesis 
chapter), however, since the commencement of my PhD studies, this novel finding had 
recently been published by two other groups in 2017 (Torri et al. 2017) and in 2018 
(Azimi et al. 2018).  
Torri et al. isolated ~150nm sized and cup-shaped EVs derived from Th1, Th17 and 
Tregs; the authors reported that Treg EVs, but not Th1 EVs or Th17 EVs, suppressed 
CD4+ T cell proliferation (Torri et al. 2017), which the authors attributed to specific 
miRNA content (see section 1.7.8.3 for more details). Azimi et al. (Azimi et al. 2018) 
confirmed the findings of Torri et al. (Torri et al. 2017) that human Treg exosomes are 
immunomodulatory. Azimi et al. compared human Treg exosomes derived from healthy 




induced apoptosis of conventional T cells, but the MS Treg exosomes were less potent 
than that of healthy controls (Azimi et al. 2018), suggesting that MS Treg exosomes 
were impaired.  
 
4.1.2 Time course release of EVs 
The presence of CD63 and CD81 are markers commonly used to define EVs (Clotilde 
Théry, Zitvogel, and Amigorena 2002; Colombo, Raposo, and Théry 2014). The 
expression levels of CD63 and CD81 on the cell surfaces may be very low but their 
intracellular levels are comparatively higher as CD63 and CD81 are highly enriched in 
the endosomal compartments (Kobayashi et al. 2000; Das and Pellett 2011; Piper and 
Luzio 2001). To date, the intracellular expression levels of CD63 or CD81 in Tregs 
(compared to other T cells) is unclear and thus remains to be further clarified.   
It has been previously reported that T cells (Blanchard et al. 2002) and Tregs (Okoye et 
al. 2014; Lesley Ann Smyth et al. 2013) at steady state release very low numbers of EVs, 
but their activation increases the numbers of EVs released. Most research groups 
activate T cells and Tregs via their TCR and subsequently collect the EVs from their 
culture supernatant (Tung et al. 2018; Lesley Ann Smyth et al. 2013; Okoye et al. 2014; 
Torri et al. 2017). However, at the time that I started the analysis of Treg EVs, a time-
course of EVs collection ranging from 24 to 48 hours post cell activation had not been 
done with human Tregs. Given that human Tregs release EVs which may be dependent 
on Ca2+ influx, like in mouse Tregs (Okoye et al. 2014), it has not been addressed 
whether these human Tregs continually release EVs until their Ca2+ levels decline back 
to normal levels. Furthermore, a direct comparison of the number of EVs released by 
Tregs and autologous Teffs has also not been reported in literature and remains to be 
determined. Given the human to human variation in cell responses, it would be 
important to monitor the release of EVs from both cell types derived from the same 
individual. Furthermore, although in the mouse Treg setting, Okoye et al. found that 
Tregs released more CD63+ EVs than CD4+ T cells (Okoye et al. 2014), whether this is 





Another important point is to understand how human Treg EVs affect Tresps responses 
and whether they regulate for example cytokine production by Tresps. Given that 
murine Treg EVs significantly decreased the production levels of pro-inflammatory 
cytokines IFNγ and IL-2 (Lesley Ann Smyth et al. 2013; Okoye et al. 2014), it would be 
possible that human Treg EVs may also function similarly and thus warranted further 
investigation.  
 
4.2 Aims and Objectives 
Aim 
The aim of this chapter was to investigate whether human Tregs expanded following a 
protocol used for Treg therapy produced EVs and if the answer was positive to assess 
whether they had the ability to inhibit Tresps proliferation and modulate cytokine 
production. 
Objectives:  
(1) Phenotype Human Tregs and Teffs using common T cell markers and also 
markers commonly used to define EVs such as CD63, CD81 and CD9 
(2) Enumerate EV frequency before cell activation and 24 hours and 48 hours post-
cell activation  
(3) Characterise human Treg EVs by EM, NanoSight analysis, and evaluate CD63 and 
CD81 expression on EVs 
(4) Study the immunomodulatory function of Treg EVs and Teff EVs and investigate 













4.3.1 Phenotypic characterisation of human Tregs and Teffs  
CD4+CD25+ human Tregs or autologous CD4+CD25- Teffs were isolated from the buffy 
coat of healthy donor peripheral blood using an established GMP-compatible protocol 
(Scottà et al. 2013). Using this approach, the percentage of cells expressing CD4+CD25+ 
(Tregs) was 95.1% ± 3.02% (Figures 4.1-A and B) and CD4+CD25- (Teffs) was 93.9% ± 
2.01% (Figures 4.1-C and D). Isolated human Tregs and Teffs were expanded ex vivo, 
polyclonally in the presence of activation beads and IL-2. Tregs received the addition of 
rapamycin, which selectively promotes the expansion of CD4+CD25+FoxP3+ Tregs whilst 
minimising the expansion of any contaminating Teffs population (Fort and Narayanan 
2010; Golovina et al. 2011; Scottà et al. 2013; Battaglia et al. 2006). Following 
expansion, the phenotype of Tregs and Teffs was assessed. Expanded human Tregs 
exhibited a typical phenotype; the percentage of cells expressing the following markers 
was; CD3+ (98.7% ± 0.5%), TCRαβ+ (99.8% ± 0.1%), CD4+ (97.1% ± 0.6%), CD25+ (91.7% ± 
1.2%), CD127low (21.4% ± 5.5%), FoxP3+ (88.2% ± 2.8%), CTLA4+ (79.3 ± 3.6%), CD39+ 
(86.3% ± 3.9%) and CD73+ (47.5% ± 9.4%) (Figures 4.2-A and B).  
In addition, human Tregs expressed common markers used to define EVs, these 
included CD63, CD81 and CD9 (Colombo, Raposo, and Théry 2014; Clotilde Théry, 
Zitvogel, and Amigorena 2002) which its expression were found both on the cell surface 
and intracellularly. The latter was anticipated given that CD63, CD81 and CD9 are found 
on endosomes and endocytic compartments (Piper and Luzio 2001; Das and Pellett 
2011). The percentage of Tregs expressing cell surface CD81 was high (98.7% ± 0.4%) 
and higher than the percentage of cells expressing CD63 or CD9 (27.6% ± 8.4% and 
28.02% ± 5.4%, respectively) (Figures 4.2-C and D). The percentage of cells expressing 
total (cell surface and intracellular) CD63 and CD81 were high (92.8% ± 4.3% and 98.8% 
± 0.2%, respectively) although for CD9, this was comparatively lower (30.8% ± 10.9%) 






Figure 4.1- Human Tregs and Teffs phenotype at isolation 
Tregs and Teffs were freshly isolated from the buffy coat of healthy donor peripheral 
blood and subsequently stained for anti-human CD4 and CD25 antibodies or relevant 
isotype controls. Flow cytometry dot plots show the phenotype of stained (A) Tregs and 
(C) Teffs. Bar graph for (B) Tregs n= 6 and (D) Teffs n=3. Representative flow cytometry 
dot plots are shown. 
 
Teffs were also phenotypically assessed following expansion. As expected, human Teffs 
exhibited a phenotype that was similar to Tregs, but the percentages of cells expressing 
defined markers were different. The percentages of human Teffs which expressed the 
following markers were; CD3+ (94.6% ± 4.1%), TCRαβ+ (99.8% ± 0.1%), CD4+ (93.8% ± 
1.5%) and CD127low (28.3% ± 7.1%) (Figures 4.3-A and B). Although the Teffs were also 
CD39+ (55.6% ± 10.2%) (Figures 4.3-A and B), a lower percentage of cells expressed this 
molecule compared to Tregs. In comparison to the Tregs, the percentage of Teffs were 
noticeably CD25low (23.7% ± 5.4%), FoxP3low (6.1% ± 1.0%), CTLA4low (15.8% ± 3.4%) and 




A high percentage of Teffs expressed cell surface CD81 (96.5 ± 1.4%), however, a 
comparably lower number of cells expressed CD63 and CD9 (6.9% ± 2.6% and 32.3% ± 
14.0%, respectively) (Figures 4.3-C and D). A high percentage of Teffs expressed total 
CD63 and CD81 (87.0% ± 9.8% and 90.0% ± 2.8%, respectively) although the percentage 
of cells expressing CD9 was comparatively lower (15.5% ± 3.2%) (Figures 4.3-C and D).  
Overall, human Tregs and Teffs expressed markers commonly used to define them. The 
cell surface and intracellular expression of endosomal markers CD63 and CD81 was 






Figure 4.2- Phenotype of Human Tregs 
Tregs were expanded with anti-CD3/CD28 beads, rapamycin and IL-2. (A) Tregs were 
assessed for the expression of the following markers by flow cytometry by staining for 
anti-human anti-CD3; TCRαβ; CD4; CD25; CD127; FoxP3; CTLA-4; CD39 and CD73. Data 
shown are representative FACS plots from 3-12 independent experiments. The y-axis 
indicates the percentage of maximum expression. (B) Pooled flow cytometry data 
showing the percentage of positive expression levels of individual markers. Bars show 
the mean + SEM pooled from 3-12 individual experiments. (C) The surface and total 
expression of CD63, CD81 and CD9 were assessed in Tregs. The y-axis indicates the 




percentage pf positive expression of surface or total CD63, CD81 and CD9. Bars show the 
mean + SEM pooled from 3-14 individual experiments.  
 
Figure 4.3- Phenotype of Human Teffs 
Teffs were expanded with anti-CD3/CD28 beads and IL-2. (A) Teffs were assessed for the 
expression of the following markers by flow cytometry by staining with anti-human anti- 
CD3; TCRαβ; CD4; CD25; CD127; FoxP3; CTLA-4; CD39 and CD73. Data shown are 
representative FACS plots from 3-5 independent experiments. The y-axis indicates the 
percentage of maximum expression. (B) Pooled flow cytometry data showing the 




from 3-5 individual experiments. (C) The surface and total expression of CD63, CD81 and 
CD9 were assessed in Teffs. The y-axis indicates the percentage of maximum expression. 
(D) Pooled flow cytometry data showing the expression levels of surface or total CD63, 
CD81 and CD9. Bars show the mean + SEM pooled from 3-5 individual experiments.  
 
4.3.2 Activated Human Tregs and Teffs release extracellular vesicles  
As mentioned in section 1.7.8, murine Tregs (Lesley Ann Smyth et al. 2013; Tung et al. 
2018; Okoye et al. 2014; Aiello et al. 2017; X. Yu et al. 2013) and human T cells 
(Blanchard et al. 2002) release EVs upon TCR engagement. During my PhD studies 
another group published in 2017, the first evidence that freshly isolated human Tregs 
produce EVs (Torri et al. 2017), strengthening our preliminary findings, which are 
described below.  
To validate the release of EVs, Tregs or Teffs were stimulated with plate bound anti-
CD3/CD28 antibodies for 24 hours, and activation was assessed and confirmed by 
measuring the upregulation of the T cell activation marker CD69 (Figures 4.4-A and B). 
In order to confirm the presence of EVs released from the activated Tregs, EVs isolated 
from the supernatant of Tregs were examined under EM. Figure 4.4-C shows a 
representative heterogeneous population of Treg EVs with a cup-shape morphology 
that was observed, and previously described by others (Colombo, Raposo, and Théry 
2014). The presence of EVs was further analysed by NanoSight analysis which 
demonstrated that Treg EVs had a mode of 126nm ± 5.9nm and a mean size of 160nm ± 
7.1nm (Figure 4.4-D). Similar analysis with Teff EVs revealed that they had a mode of 
128nm ± 6.9nm and a mean size of 180nm ± 12.8nm (Figure 4.4-E).  A representative 
image of the NTA multi-parameter output of intensity, diameter and concentration of 
particle measurement is shown in Figure 4.4-F.  Due to restricted access to the Centre 
for Ultrastructural Imaging, King’s College London, it was not possible to analyse the 
Teff EVs using EM.  
In order to confirm that TCR activation increased the numbers of released EVs, EVs 
derived from unstimulated cells and activated cells were compared on NanoSight. The 
number of released EVs increased significantly after cell activation compared to 




released per activated Treg cell (Figure 4.4-G). However, Teffs released considerably 
more EVs than Tregs, which on average was 2514 EVs (range of 1884 – 3568 EVs) 
released per activated Teff cell (Figure 4.4-H and I).  
To investigate whether cells activated for an extended period of time released higher 
numbers of EVs, the EV numbers were enumerated by NanoSight after 0, 24 or 48 hours 
post-cell activation. Tregs released significantly higher numbers of EVs after 48 hours 
compared to 0 or 24 hours post-cell activation (p= 0.0336 and p= 0.0310, respectively) 
(Figure 4.4-J). In a similar manner, Teffs also released higher numbers of EVs after 48 
hours compared to 0 or 24 hours of post-cell activation (Figure 4.4-K), however, only 2 
samples were used for the NanoSight readings and thus no statistical test was 
performed.   
It has been suggested that cell culture conditions can influence the types of EVs 
produced (Gudbergsson et al. 2016). It is well documented that Tregs require IL-2 for 
survival (Scottà et al. 2013), however IL-2 was not added to the culture medium when 
Tregs were activated for 24 hours and 48 hours. The reason for not adding IL-2 to the 
culture medium was to avoid the presence of IL-2 in the EV preparations as this could 
have induced the proliferation of Tresps and masked any effect of the EVs in 
downstream applications. However, to avoid Treg death, due to the absence of IL-2, and 
the subsequent release of apoptotic bodies which can be of a similar size range and 
express CD63 (Crescitelli et al. 2013), therefore making it difficult to separate non-
apoptotic EVs from apoptotic bodies, it was decided that 24 hours derived EVs should 
be used instead of 48 hours derived EVs for all the subsequent assays.  
Given that Okoye et al. showed in the mouse setting, Tregs released more CD63+ 
exosomes than CD4+ T cells (Okoye et al. 2014), the EVs released by human Treg and 
Teffs were evaluated by NanoSight. However, NanoSight does not discriminate between 
CD63+ and non-CD63+ EVs but rather measures total EV numbers, thus a CD63 
ExoELISA™ Ultra kit was used to enumerate CD63+ particles. Indeed, human Tregs had a 
trend to release more CD63+ EVs compared to Teffs (Figure 4.4-L). However, because 
only 2 donor samples were used for the CD63 ExoELISA™ Ultra kit, a statistical test was 
not performed. Therefore, despite Teffs releasing more total EV numbers than Tregs, 




To further address how many EVs were CD63 positive and how many were negative for 
CD63, ImageStream® analysis of Treg EVs was employed (Headland et al. 2015). Treg 
EVs were double stained with CFDA-CFSE and CD63. It was clear from the results that 
not all Treg EVs were CD63+ (46% of EVs were CD63+) (Figure 4.4-M), given the 
heterogeneity of EVs (Willms et al. 2018; Ferguson and Nguyen 2016; Willms et al. 
2016), it is therefore appreciable that EVs may instead express CD81 or CD9 (Clotilde 
Théry, Zitvogel, and Amigorena 2002; Colombo, Raposo, and Théry 2014; Graça Raposo 
and Stoorvogel 2013). Indeed, another report demonstrated CD81 and CD9 presence on 
exosomes but not CD63 (Saunderson et al. 2008), further confirming the heterogeneity 
of EVs.  
Exosomes and small EVs are too small in size (50-150nm) to be detected directly on a 
conventional flow cytometer, although for larger EVs this is possible. However, by 
adhering small EVs to 4µm aldehyde/sulphate latex beads their surface area is increased 
thus enabling phenotyping via flow cytometry (Lesley Ann Smyth et al. 2013). To 
investigate whether EVs expressed other Treg-related markers, these particles were 
bound onto latex beads and stained for the EV markers CD63 and CD81 along with 
other markers found on Tregs. The particles displayed typical EV markers CD63 and 
CD81, as expected (Figure 4.4-N). Additionally, Treg-associated markers, namely CD25 
and CD39 molecules were also found expressed by some of the EVs. However, EVs were 
negative for the expression of CD4, CD73 and CTLA4 (Figure 4.4-N). Due to time limits 
on the PhD project and as the main focus of this project was Treg EVs, rather than Teff 
EVs, the latter were not phenotyped. 
Overall, activated human Tregs and Teffs released vesicles that are approximately 
126nm in size, with significantly more EVs released 24 and 48 hours post-cell activation, 
although I cannot exclude that some were apoptotic bodies at the latest time-point 
tested. These Treg EVs expressed EV markers CD63 and CD81, although not all EVs 
expressed these. Furthermore, Treg EVs contained Treg cell-associated proteins CD25 










Figure 4.4- Activated Human Tregs and Teffs release EVs  
Flow cytometry histogram plots showing the expression of CD69 in (A) resting human 
Tregs (dashed line) and activated human Tregs (solid line) compared to isotype control 
(filled gray) or (B) Teffs. Values indicate mean fluorescence intensity (MFI) of isotype 
control (gray), resting cells (black) and activated cells (bold black) within each histogram 
plot. Data representative of 5 independent experiments. The y-axis indicates the 
percentage of maximum expression. (C) Transmission electron microscopy image of EVs 
released by activated human Tregs. Scale bar indicates 100nm. Representative of 3 
independent experiments. (D and E) Representative NanoSight Nanoparticle Tracking 
Analysis (NTA) histogram showing the mean with red error bars indicating +/- 1 SEM. 
Bar graph shows pooled data for mode and mean particle size measurements of (D) Treg 




Representative multiparameter graph showing particle intensity, diameter and 
concentration. Data representative of at least 21 individual experiments. Graphs 
showing the number of EVs released per cell from resting versus activated (G) Tregs or 
(H) Teffs. (I) The numbers of EVs released per activated Treg and activated Teff cell were 
compared. (J) Tregs or (K) Teffs were activated for 0, 24 or 48 hours before enumerating 
the number of released EVs. (L) CD63+ EVs detected and derived from equal numbers of 
Tregs or Teffs. (M) Image stream analysis plots showing the gating of EVs by positive 
CFSE staining and size of EVs. CFSE+ EVs were further gated for CD63+ expression. 
Representative of 2 independent experiments. (N) Flow cytometry histogram plots of 
Treg EVs bound onto latex beads showing the expression of CD63, CD81, CD25, CD39, 
CD4, CD73 and CTLA4 (black lines) compared to the control of stained latex beads alone 
(gray lines). Values indicate mean fluorescence intensity (MFI) of control stained latex 
beads (gray) and human Treg EVs bound onto latex beads (black). The y-axis indicates 
the percentage of maximum expression. Representative of 3 independent experiments.  
 
4.3.3 Human Tregs and Teffs suppress Tresps proliferation in vitro  
Previous studies have shown that both Tregs and Teffs inhibit T cell proliferation 
(Trinchieri 2007; Lang, Wang, and Chen 2017; Putnam et al. 2013; Scottà et al. 2013). To 
confirm this with my expanded cells, CellTrace Violet™ (CTV)-labelled CD4+CD25- Tresps 
were stimulated with anti-CD3/CD28 beads in the presence or absence of Tregs or Teffs 
at varying ratios of 1:1, 1:2, 1:4, 1:8, 1:16 and 1:32 of Tregs:Tresps or Teffs:Tresps. 
As expected, Tresps stimulated with beads alone proliferated compared to Tresps 
cultured alone (Figure 4.5-A). At a 1:1 ratio of Tregs:Tresps, Tregs significantly 
suppressed Tresps proliferation, which on average was 88% inhibition compared to 
Tresps stimulated with beads alone (p<0.0001; Figure 4.5-F). The suppression was dose-
dependent; the presence of Tregs at ratios of 1:2, 1:4, 1:8, 1:16 and 1:32 of 
Tregs:Tresps suppressed Tresps proliferation, an average at 84% (p<0.0001), 78% 
(p<0.0001), 68% (p<0.0001), 54% (p=0.0003) and 35% (p=0.0005) of suppression, 
respectively, compared to Tresps stimulated with beads alone (Figures 4.5-B and F).  
At a 1:1 ratio of Teffs:Tresps, Teffs significantly suppressed Tresps proliferation, which 




(p<0.0001; Figure 4.5-G). The suppression from Teffs was dose-dependent as well 
(Figures 4.5-C and G). The presence of Teffs at ratios of 1:2, 1:4, 1:8, 1:16 and 1:32 of 
Teffs:Tresps suppressed Tresps proliferation, an average at 71% (p<0.0001), 62% 
(p=0.0004), 49% (p=0.0034), 38% (p=0.0062) and 26% (p=0.0045) suppression, 
respectively, compared to Tresps stimulated with beads alone (Figures 4.5-C and G).  
Overall, both Tregs and Teffs significantly inhibited Tresps proliferation which was in a 
dose dependent manner. Additionally, Tregs had a trend to inhibit Tresps proliferation 
at a higher level than Teffs.  
 
4.3.4 Human Treg EVs and Teff EVs suppress Tresps proliferation in vitro  
Next, I investigated the efficiency of EVs derived from human Tregs to inhibit Tresps 
proliferation compared to EVs derived from human Teffs. To this end, CTV-labelled 
Tresps were stimulated with anti-CD3/CD28 beads in the absence or presence of Treg 
EVs or Teff EVs at varying quantities; 50, 35, 10 and 5 x106 Tregs derived EVs or Teffs 
derived EVs. In the presence of EVs derived from 50x106 Tregs significant suppression of 
Tresps proliferation compared to Tresps stimulated with beads alone was observed (p= 
0.0384; Figures 4.5-A, D and H) which on average was approximately 35% suppression, 
with the highest suppression observed at 69%. This suppression from Treg EVs was 
dose-dependent (Figures 4.5-D and H), as the decreased amount of Treg EVs present, a 
reduced suppression was observed; the presence of 35, 10 and 5 x106 Tregs derived EVs 
suppressed Tresps proliferation by an average of 23%, 9% and 5% respectively.  
The presence of Teff EVs derived from 50x106 Teffs also significantly suppressed Tresps 
proliferation compared to Tresps stimulated with beads alone (p= 0.0024; Figures 4.5-A, 
E and H) which on average was 22% suppression, with the highest suppression observed 
at 37%. This suppression from Teff EVs was also dose-dependent (Figures 4.5-E and H), 
the presence of 35, 10 and 5 x106 Teff derived EVs suppressed Tresps proliferation by an 
average of 18%, 10% and 8% respectively.  
To test whether anything pelleted from the media using ExoQuick-TC™ was responsible 
for causing the suppression observed, the pellet resulting from the media alone was 
added to the Tresps stimulated with beads alone. No inhibition on the Tresps 




Teff EVs had immunomodulatory effects leading to significantly lower Tresps 
proliferation in vitro. However, no significant difference was observed between the 







Figure 4.5- Human Treg EVs inhibit the proliferation of Tresps 
Suppression assays results showing flow cytometry histogram plots of Tresps stained 
with CellTrace Violet™ to measure proliferation. (A) Tresps were rested (unstimulated) or 
activated with anti-CD3/28 beads for 5 days, with the addition of media alone pellet. The 
addition of (B) Tregs or (C) Teffs were added to Tresps+ beads at the indicated ratios. 
The addition of (D) Treg EVs or (E) Teff EVs derived from the indicated number of cells 
were added to Tresps+ beads. (A-E) The y-axis indicates the percentage of maximum 
expression. (F to I) Graphs showing the pooled data of the dose-dependent suppression 
of Tresps proliferation (Tresps+ beads) by (F) Tregs (G) Teffs (H) Treg EVs and Teff EVs 
and (I) media pellet. Data are expressed as percentage of suppression of Tresps 
proliferation relative to Tresps cultured with anti-CD3/28 beads alone. Graphs represent 
pooled data from at least 7-9 independent experiments, except media pellet data show 
n=4. Bars show mean + SD. Statistical significance was tested using one-way ANOVA 




4.3.5 Human Treg EVs are acquired by Tresps 
I have shown in section 3.3.6 that mouse Treg EVs are acquired by BM-DCs. Torri et al. 
have previously shown that human Treg EVs are taken up by HuH-7 cancer cells (Torri et 
al. 2017). However, they did not assess whether human Treg EVs are acquired by T cells 
like their mouse counterparts (Okoye et al. 2014). In order to investigate whether 
human Treg EVs are acquired by Tresps, Tregs were labelled with CFDA-CFSE and 
activated; the secreted CFSE+ EVs were isolated and co-cultured with Tresps for 24 
hours before washing extensively. Tresps were acquired on the flow cytometer to 
assess their CFSE status. CFSE+ Treg EVs had acquired the CFSE+ dye. The FACS plot 
indicated that Tresps that were co-cultured with CFSE+ Treg EVs had a higher CFSE MFI 
compared to Tresps cultured alone (MFI of 599 versus 350, respectively; Figure 4.6), 
indicating that CFSE+ Treg EVs had been acquired by Tresps. Due to time limits on the 
PhD project, the co-culture of CFSE+ Teffs EVs with Tresps was not performed. The 
results presented here indicated that in vitro Tresps acquire Treg EVs.  
 
 
Figure 4.6- Human Treg EVs are acquired by Tresps 
Flow cytometry histogram plot showing Tresps alone (gray filled) or Tresps co-cultured 
with CFSE+ Treg EVs for 24 hours. After 24 hours, Tresps were washed twice prior to 
acquisition on the flow cytometry. Values indicate mean fluorescence intensity (MFI) of 







4.3.6 Human Tregs and Teffs modulate Tresps cytokine production profiles  
Previous reports have shown that human Tregs can modulate cytokine production of T 
cells by inhibiting the production of pro-inflammatory cytokines such as IL-2 and IFNγ 
(Sojka, Huang, and Fowell 2008; Hoeppli et al. 2015; S. Sakaguchi et al. 2009). Teffs also 
modulate the cytokine production of T cells (W. G. H. Han et al. 2010; Pawelec et al. 
1996; Fagiolo and Toriani-Terenzi 2002). To confirm these findings with my cells, the 
supernatants taken from the suppression assays were tested using Cytometric Bead 
Array (CBA) kits. 
Tresps stimulated with anti-CD3/CD28 beads produced high levels of IFNγ, however the 
presence of Tregs at 1:1, 1:2, 1:4, 1:8, 1:16 and 1:32 ratios significantly decreased IFNγ 
production levels in a dose dependent manner (all p<0.0001) (Figure 4.7-A). Pro-
inflammatory cytokine IL-2, which is produced by Tresps were also significantly reduced 
in the presence of Tregs at 1:1, 1:2, 1:4, 1:8, 1:16 and 1:32 ratios (all p<0.0001; Figure 
4.7-B). IL-6 and TNF, were also produced by Tresps. Like the aforementioned cytokines, 
the levels of IL-6 and TNF released by Tresps was also significantly reduced in the 
presence of Tregs at 1:1, 1:2, 1:4, 1:8 and 1:16 ratios (IL-6; p<0.0001, p=0.0002, 
p=0.0006, p=0.0012 and p=0.0194, respectively; and TNF; p<0.0001, p<0.0001, 
p<0.0001, p=0.0002, p=0.0006 and for 1:32 ratio p=0.0028; Figure 4.7-C and F).  
IL-10 was significantly decreased in the presence of Tregs at the ratios of 1:1 and 1:2 
(p=0.0053 and p=0.0237, respectively) but had a trend to increase IL-10 production 
levels at the other cell ratios tested; 1:4, 1:8, 1:16 and 1:32 (Figure 4.7-D). IL-4 
production was significantly increased in the presence of Tregs at a 1:4, 1:8, 1:16 and 
1:32 ratios (p=0.0473, p=0.0497, p=0.0495, p=0.0444, respectively) (Figure 4.7-E).  
Despite Teffs having the capacity to inhibit Tresps proliferation (Figures 4.5-C and G), 
they functioned differently to Tregs, in regard to affecting cytokine production by 
Tresps. Namely, unlike Tregs, Teffs had a trend to increase the production levels of IFNγ, 
although this did not reach statistical significance (Figure 4.7-G). Nonetheless, as 
expected the IL-2 production levels were decreased by the addition of Teffs at the 1:1, 
1:2, 1:4, 1:8, 1:16 and 1:32 ratios  (p<0.0001, p<0.0001, p<0.0001, p<0.0001, p<0.0001 
and p=0.0001, respectively) (Figure 4.7-H). In the presence of Teffs, there was an 




respectively) and an increase of IL-10 prolduction levels, at 1:4, 1:8, 1:16 and 1:32 ratios 
(p=0.0337, p=0.0306, p=0.0269 and p=0.0304, respectively) was observed (Figure 4.7-I 
and J). Lastly, Teffs did not significantly alter the production levels of IL-4 (Figure 4.7-K) 
or TNF (Figure 4.7-L) by Tresps. 
Taken together, this demonstrated that human Tregs have the capacity to significantly 
inhibit pro-inflammatory IFNγ, IL-2, IL-6 and TNF cytokine production levels by Tresps 
whilst increasing their IL-4 and IL-10 cytokine production levels.  
Notably, human Teffs acted differently to Tregs, as Teffs promoted rather than inhibited 
the production levels of IFNγ and significantly increased IL-6 production levels by 
Tresps. However, human Teffs inhibited IL-2 cytokine production levels whilst also 
increasing IL-10 production levels. Furthermore, IL-4 and TNF production levels by 









Figure 4.7- Human Tregs, Treg EVs, Teffs and Teff EVs modulate cytokine production 
profiles of Tresps 
Graphs show the relative fold change of cytokine levels detected in the supernatant of 




or (G-L) Teff EVs or Teffs. Cytokines of IFNγ, IL-2, IL-6, IL-10, IL-4 and TNF were assessed. 
Treg EV no. or Teff EV no. represents no. x 106 Treg-derived EVs or Teff-derived EVs. Bars 
show mean ± SD. Data represents pooled data from at least 5 independent experiments. 
Each assay was performed in technical triplicates. The value from each assay of Tresps+ 
beads was set at a value of 10 fold and the relative quantities from each condition is 
expressed relative to Tresps+ beads. Statistical significance was tested using one-way 
ANOVA where *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 and ns= non-significant. 
  
4.3.7 Human Treg EVs and Teff EVs modulate Tresps cytokine production profiles  
Having confirmed that human Tregs and Teffs modulate cytokine production by 
activated Tresps, I analysed whether EVs released by these cells affected cytokine 
production in a similar way. Previous reports have shown that mouse Treg EVs can 
affect cytokine production of the T cells (Lesley Ann Smyth et al. 2013; Okoye et al. 
2014) and BM-DCs (Chapter 3), suggesting that human Treg EVs may alter the cytokine 
production by Tresps. In order to test this, supernatant of the co-cultures from the 
suppression assays (Figure 4.5) were tested for the presence of the various cytokines 
outlined above. 
As expected, Tresps stimulated with anti-CD3/CD28 beads produced high levels of IFNγ, 
but the presence of 50, 35, 10 and 5 x106 Treg derived EVs significantly reduced IFNγ 
production levels (p=0.0076, p=0.0056, p=0.006 and p=0.0124, respectively) (Figure 
4.7-A) and responded according to a dose dependent manner (Figure 4.7-A).  
Similarly, IL-2 was also significantly reduced in the presence of 50x106 Treg derived EVs 
(p=0.034) (Figure 4.7-B). IL-6 was also significantly reduced in the presence of 50, 35, 10 
and 5 x106 Treg derived EVs (p=0.0311, p=0.0114, p=0.0147 and p=0.0106, respectively) 
(Figure 4.7-C). Interestingly, not only does 50x106 Treg derived EVs inhibit cytokine 
release but simultaneously they appeared to significantly increase the production levels 
of IL-10 by Tresps (p=0.0449) (Figure 4.7-D). The pleiotropic cytokine IL-4 was 
significantly increased by 50 and 35 x106 Treg derived EVs (p=0.0268 and p=0.0215, 
respectively) (Figure 4.7-E). 50x106 Treg derived EVs increased the TNF production by 




On the contrary, Teff EVs functioned differently to Treg EVs in regard to affecting 
cytokine production by Tresps. Namely unlike Treg EVs, Teff EVs derived from 50 and 35 
x106 Teffs significantly increased the production levels of IFNγ (p= 0.0028 and p=0.0250, 
respectively) (Figure 4.7-G). The IL-2 production levels were decreased by 50 and 35 
x106 Teff derived EVs (p= 0.0111 and p=0.0248, respectively) (Figure 4.7-H). IL-6 was 
significantly increased by the presence of 50x106 Teff derived EVs (p= 0.029) (Figure 4.7-
I). Interesting, 50x106 Teff derived EVs significantly increased the production levels of IL-
10 (p= 0.0274) (Figure 4.7-J) and IL-4 (p= 0.0478) (Figure 4.7-K). TNF production levels 
were increased by 50, 10 and 5 x106 Teff derived EVs (p= 0.0341, p=0.0306 and 
p=0.0143, respectively) (Figure 4.7-L).  
Overall, these results demonstrate that human Treg EVs have the capacity to 
significantly inhibit pro-inflammatory IFNγ, IL-2 and IL-6 cytokine production by Tresps 
whilst increasing their IL-10 and IL-4 cytokine production levels, perhaps towards 
creating an anti-inflammatory microenvironment. Furthermore, Treg EVs also increased 
TNF production by Tresps. Human Teff EVs acted differently to Treg EVs, as Teff EVs 
promoted rather than inhibited the production levels of IFNγ and IL-6 by Tresps. 
However, human Teff EVs also inhibited IL-2 cytokine production levels whilst also 
increasing IL-10, IL-4 and TNF production levels by Tresps, which is in a similar manner 
to Treg EVs.    
 
4.4 Discussion 
4.4.1 Phenotype of Tregs and Teffs 
The phenotype profile of human Tregs and Teffs were similar but Tregs had a distinct 
higher percentage of cells expressing CD25, FoxP3 and CTLA4 compared to Teffs, in line 
with previous studies (Kmieciak et al. 2009; Jago et al. 2004; Jun Wang et al. 2007; 
Mason et al. 2015; Finney, Riley, and Walther 2009). Despite their overlapping 
phenotype expression profiles, human Tregs and Teffs are functionally divergent. 
However, currently, there is not a single exclusive marker to distinguish between human 
Tregs from Teffs, but rather a combination of cell surface and intracellular markers and 
their differing expression levels are required to discriminate them. As explained in 




are CD25- and FoxP3low/- but as demonstrated by Kmieciak et al., human Teffs 
transiently upregulate CD25 and FoxP3 post-activation (Kmieciak et al. 2009). Due to 
this, challenges exist to separate the two cell populations. Hence, the observation that 
Teffs expressed CD25 and FoxP3, albeit to a lower level than Tregs is therefore not 
surprising.  
Previous reports demonstrate that Tregs express surface CD63 (J. Zheng et al. 2013) 
whilst T cells express surface and intracellular CD63 (Pfistershammer et al. 2004), 
however CD63 cell surface expression of resting T cells are low but increase upon 
activation (Pfistershammer et al. 2004). Pfisterhammer et al. demonstrated that CD63 is 
an activation linked T cell costimulatory element which induced their proliferation and 
their production levels of IL-2 (Pfistershammer et al. 2004). The role of cellular CD63 
was not tested in this project but may have contributed to the cellular functions of 
Tregs and Teffs.  
 
4.4.2 Suppressive ability and cytokine modulation of Tregs and Teffs towards Tresps  
I demonstrated that human Tregs and Teffs inhibit Tresps proliferation; their 
suppressive ability was in a dose dependent manner. As described in section 1.6.3, 
Tregs can use a number of different molecular mechanisms to suppress their target cell 
functions. 
Human Tregs and Teffs modulate the cytokine production by Tresps. Namely, Tregs are 
known to suppress IFNγ and IL-2 whilst increasing IL-10 production levels by T cells to 
create an anti-inflammatory microenvironment. I have shown that both human Tregs 
and Teffs modify Tresps cytokine production profile. Notably, human Teffs responded 
differently to Tregs, as Teffs had a trend to promote rather than inhibit the production 
of IFNγ and also significantly increase IL-6 production by Tresps. However, human Teffs 
inhibited IL-2 cytokine production whilst simultaneously increasing IL-10. In addition, 







4.4.3 Release of EV numbers from activated Tregs and Teffs 
Both human Tregs and Teffs released EVs upon TCR activation, in line with published 
data (Torri et al. 2017). Noteworthy, human Teffs released significantly more EVs than 
Tregs, although Tregs released more CD63+ EVs than Teffs. This is in agreement with the 
mouse setting, whereby Okoye et al. demonstrated that mouse Tregs released more 
CD63+ EVs in comparison to CD4+ naïve T cells, CD8+ naïve T cells, B cells, Th1 or Th17 
cells (Okoye et al. 2014). Although, cell activation induced a significant increase of 
secreted EVs from human Tregs, the secretion of EV numbers continued to elevate from 
24 to 48 hours post-activation. Despite the depletion of activation beads 2 days prior to 
isolating EVs, it cannot be ascertained that these cells were truly ‘rested’ which may 
explain the numbers of EVs detected at their ‘resting Treg’ status. Nevertheless, these 
human Treg EVs were collected 24 hours post-activation, which is in contrast to Torri et 
al. who collected human Treg EVs at 72 hours post-activation (Torri et al. 2017). As 
explained above, to avoid collection of apoptotic bodies, EVs released at 24 hours were 
used instead of 48 hours derived EVs.  
 
4.4.4 Treg EVs are acquired by Tresps 
I have shown that human Treg EVs were acquired by Tresps directly. How EVs interact 
with target cells is not completely understood but has been suggested to involve 
various clathrin-dependent and independent endocytosis, phagocytosis, 
micropinocytosis, receptor-ligand mediated pathways, cell surface membrane fusion 
and protein interactions (Mulcahy, Pink, and Carter 2014; Maas, Breakefield, and 
Weaver 2017; Costa Verdera et al. 2017). This interaction was demonstrated to 
functionally affect Tresps by modulating their proliferation and cytokine production 
profiles. Whether EVs use receptor mediated uptake by target cells has been explored 
(Mulcahy, Pink, and Carter 2014; Maas, Breakefield, and Weaver 2017; Costa Verdera et 
al. 2017). Proteomics and mass spectrometry has been used by various other groups to 
reveal the contents of EVs (Haraszti et al. 2016; Pietrowska et al. 2017; C. Yang et al. 
2017; Pocsfalvi et al. 2016; Joy et al. 2018). As such, for this study, a similar approach 





4.4.5 Suppressive ability of Treg EVs and Teff EVs 
APC derived EVs can be 10-20 times less efficient at stimulating T cell responses 
compared to the parent APC (Zitvogel et al. 1998; Vincent-Schneider et al. 2002). 
However, the response can depend on other factors such as how many EVs were added 
to the target cells and therefore how many active molecules were transferred into the 
target cells to observe a detectable response. Hence, due to these factors, I used 
multiple doses of Treg EVs and Teff EVs to observe a dose dependent response. I 
showed that Treg EVs and Teff EVs suppress Tresps proliferation which the suppressive 
response was at the most potent at 50x106 Treg derived EVs or Teff derived EVs. 
However, of note the suppression observed could be due to EVs actively suppressing 
Tresps or these EVs could be binding to CD3/CD28 beads and thus interfere or block 
Tresps activation leading to their reduced proliferation. 
Despite that EVs were derived from the same number of starting parent cells and given 
that Teffs released approximately 2.4 fold more EVs than Tregs, if based on these EV 
numbers, the Treg EVs suppressed Tresps proliferation more efficiently than Teff EVs. 
However, Torri et al. also further stated that Treg EVs but not Th1 EVs nor Th17 EVs 
inhibited CD4+ T cell proliferation (Torri et al. 2017). This is in contrast with my findings 
that human Teff EVs are immunosuppressive. As described in section 1.7.7, Teff EVs can 
be both anti-inflammatory and pro-inflammatory. Torri et al. used EVs derived from 72 
hours post-cell activation (Torri et al. 2017), whether these EVs contained apoptotic 
bodies is not clear but given the heterogeneity in EVs and thus the active biological 
components in EVs could be different and especially as the methods used to isolate EVs 
could result in the differences between Torri et al.’s finding that  neither Th1 EVs nor 
Th17 EVs inhibited T cell proliferation (Torri et al. 2017), whereas, herein I observed 
that Teff EVs inhibited Tresps proliferation. Torri et al. used ExoMir™ Mini kit, Exo-spin™ 
kit and ultracentrifugation methods of EV isolation (Torri et al. 2017), whereas I used 
ExoQuick-TC™, thus, it is likely that different EV populations may have been isolated and 






4.4.6 Th1 and Th17 EVs- Torri et al.’s publication 
On closer inspection of Torri et al.’s publication, the data to demonstrate Th1 EVs ability 
to inhibit CD4+ T cell proliferation was missing (Torri et al. 2017). Furthermore, Treg EVs 
and Th17 EVs were compared for immunosuppression ability via three different 
approaches: (1) Percentage of cell division (2) Division Index and (3) Proliferation Index. 
Although the authors do state that the percentage of cell division was clearly not 
different with Treg EVs or Th17 EVs treatment, they focused on the division and 
proliferation index values. The division index is an algorithm that calculates the average 
number of cell divisions that a cell from the original population has undergone which 
also takes into account the undivided cells (Division index= Total number of divisions ÷ 
Total number of cells at start of culture). Whereas, the proliferation index is an 
algorithm that calculates only the cells that have undergone at least one division and 
thus does not take into account the undivided cells (Proliferation index= Total number 
of divisions ÷ Number of cells that underwent division). Torri et al. showed that Th17 
EVs decreased the T cell division index, which can be interpreted as Th17 EVs are, in 
fact, immunosuppressive. However, on the other hand, because the proliferation index 
was increased above the control, it was interpreted as non-immunosuppressive. This 
discrepancy in the interpretation of the results was not clearly stated by the authors 
(Torri et al. 2017) and questions whether Th17 EVs are in fact immunosuppressive.  
 
4.4.7 Phenotype of Treg EVs 
The Treg CD63+ CD81+ EVs while they contained Treg cell-associated markers such as 
CD25 and CD39, very low or negligible levels of CD4 was observed on their vesicular 
surfaces. Given that the percentage of parent Tregs exhibits over 97% and 91% of 
expression levels of both CD4 and CD25, respectively, but only CD25 was found on EVs 
further supports the concept that EVs are not a mere smaller version of their parent cell 
but rather an EV that has cargo selected and packaged in a specific manner (Clotilde 
Théry, Zitvogel, and Amigorena 2002).  
Molecules on the surface of EVs are functionally used by EVs to conduct their 
immunomodulation. For example, a study by Clayton et al. in 2011 showed that cancer 




cells activity by converting the pro-inflammatory ATP into anti-inflammatory adenosine 
(A. Clayton et al. 2011). Similarly, my host laboratory has also previously shown the 
presence of CD73 on EVs derived from mouse Tregs which contributed to their 
immunosuppressive ability towards proliferating T cells. Furthermore, these murine 
Tregs EVs caused a reduction of IL-2 and IFNy production by target cells in vitro, leading 
to an immunosuppressed microenvironment (Lesley Ann Smyth et al. 2013). Given that 
both CD25 and CD39 are immunosuppressive molecules used by the Treg cell 
themselves (Vignali, Collison, and Workman 2008; Borsellino et al. 2007; Shimon 
Sakaguchi, Wing, and Miyara 2007), it is tempting to suggest that these molecules 
found on our Treg EVs could also be involved in inhibiting the immune response.  
Given that the host laboratory demonstrated that mouse Treg EVs express CD73 which 
directly contributed to their suppressive function (Lesley Ann Smyth et al. 2013), it 
highlighted a similar possibility with human Treg EVs.  I did not find CD73 enriched in 
human Treg EVs but the presence of CD39 molecules on human Treg EVs was observed. 
Previous studies by others have shown that T cells express A2A adenosine receptors 
(Ohta et al. 2009; Koshiba et al. 1999; Linden and Cekic 2012), suggesting that this CD39 
ectoenzyme on Treg EVs could potentially explain in part their mode of immune 
suppression observed in our co-cultures with Tresps. In the mouse Treg setting, CD39 is 
co-expressed with CD73 (Deaglio et al. 2007; Lesley Ann Smyth et al. 2013). On the 
contrary, human Tregs can independently express CD39 and CD73 (Dwyer et al. 2010; 
Mason et al. 2015). Furthermore, the human CD39hi Treg subset is more stable and 
functionally more suppressive that the CD39low Treg counterparts (Gu et al. 2017). The 
human Tregs used in this chapter had a higher expression level of CD39 compared to 
CD73 and given that human CD39hi Tregs are more suppressive than human CD39low 
Tregs (Gu et al. 2017), the expression of CD39 on human Treg EVs may be a possible 
mechanism used by Treg cells to increase their suppressive ability. CD25 is a high 
affinity receptor for IL-2; Tregs express high levels of this molecule which has been 
shown to deplete IL-2 survival cytokine from the microenvironment, thus preventing 
Teffs proliferation (S. Sakaguchi et al. 2009; Corthay 2009). Nolte-‘t Hoen et al. 
published that MHC-II/peptide complexes-bearing vesicles derived from murine anergic 
T cells can be taken up by APCs and endow them with immune-suppressive properties. 




a role in their immunosuppressive ability (Nolte-'t Hoen et al. 2004).  Thus, the CD25+ 
exosomes bound to the cell surface of APCs, providing the APCs with the ability to 
deplete IL-2 from the microenvironment leading to apoptosis of Teffs (Nolte-'t Hoen et 
al. 2004).  
I have shown that human Tregs express high levels of both CD4 and CD25 but only CD25 
and negligible levels of CD4 were found on their EVs. Whether CD25 was a mechanism 
used by human Treg EVs to deplete IL-2 from the microenvironment was not tested but 
given that Tresps cultured with Treg EVs had reduced IL-2 levels, points to this 
possibility. Why CD4 was not packaged into EVs remains to be determined but other 
previous reports also described that EVs did not contain markers that are highly 
expressed by their parent cells. For example, T cell derived exosomes did not display the 
abundant parent cell-surface CD45 and CD28 but did however contain TCR/CD3ζ 
complexes (Blanchard et al. 2002). Moreover, Thery et al. demonstrated that DCs which 
express high levels of Fc receptors produced exosomes which lacked these cell surface 
molecules (C Théry et al. 1999), further supporting a regulated packaging mechanism of 
EVs. 
 
4.4.8 Cytokine modulation of Treg EVs and Teff EVs 
Although the treatment of Tresps with Treg EVs did inhibit IL-2 production, they only 
significantly reduced this at the highest Treg EV dose used (50x106 Treg derived EVs). 
Although Teff EVs were immunosuppressive as well, their mechanisms of suppression 
may be different to that of Treg EVs given their differential effects in modulating 
cytokine production by Tresps, thus these EVs were different in function and highlights 
the heterogeneity in EVs. The human Treg EVs significantly inhibited pro-inflammatory 
IFNγ and IL-6 cytokine production levels by Tresps, whereas Teff EVs promoted rather 
than inhibited their production levels of IFNγ and IL-6 cytokines. In addition, the Treg 
EVs also increased TNF production levels by Tresps. However, for other cytokines 
human Teff EVs acted similar to Treg EVs in that they also inhibited IL-2 cytokine 
production whilst also increasing IL-10, IL-4 and TNF production levels by Tresps. This 
modulation of cytokine milieu by Treg EVs may be a mechanism to create an anti-




Teff EVs could be due to their miRNA content, as suggested for mouse Treg EVs 
(Chapter 3) and this will be addressed in the next chapter (Chapter 5). 
 
4.4.9 Tregs and Treg EVs differences and similarities 
I have demonstrated that Tregs and their EVs have some similar roles but also EVs acted 
differently in vitro. I demonstrated that human Treg EVs, akin to their parent cells, 
although not as potently can inhibit Tresps production levels of pro-inflammatory IFNγ, 
IL-2 and IL-6 cytokines (Tiemessen et al. 2007; Sojka, Huang, and Fowell 2008; Hoeppli 
et al. 2015; S. Sakaguchi et al. 2009). Concurrently, Treg EVs treatment in vitro 
increased Tresps production levels of immunosuppressive cytokines; IL-10 and IL-4. 
Parent Tregs increased IL-4 production by Tresps in line with previous studies 
(Tiemessen et al. 2007), however, for some Treg donors it promoted IL-10 production 
whereas other Treg donors inhibited IL-10 release by Tresps, this may be due to human 
variability. However, TNF production by Tresps was inhibited by Tregs, in contrast, Treg 
EVs notably increased TNF release. But as shown in the next chapter (Chapter 5) Treg 
EVs have exclusive miRNAs not found in the parent Tregs which may explain their 
differential role in modulating TNF cytokine production.  
 
4.4.10 Teffs and Teff EVs differences and similarities 
Compared to Treg EVs, Teff EVs did not suppress the production of IFNγ by Tresps, but 
instead significantly increased their production levels, in a manner that reflected the 
trend of parent Teffs towards Tresps, although this did not reach statistical significance. 
Teffs EVs akin to their parent Teffs and akin to Tregs and Treg EVs inhibited the 
production levels of IL-2. Teff EVs and their parent Teffs responded differently 
compared to Treg EVs and Tregs by increasing the production levels of IL-6 by Tresps. 
This finding highlighted that Treg EVs and Teff EVs although both are 
immunosuppressive; they have different effects pertaining to cytokine release.  Teff EVs 





4.4.11 Cytokine modulation by Tregs, Teffs, Treg EVs, and Teff EVs in relation to 
literature findings 
The differentiation of precursor Th cells into Th1 or Th2 subsets is highly influenced by 
the presence and levels of IL-4 or IFNγ within the microenvironment during 
differentiation (Paludan 1998). Whilst IL-4 polarises Th2 differentiation and inhibits Th1 
differentiation, IFNγ polarises Th1 differentiation and inhibits Th2 differentiation. Th2 
immune deviation have previously been linked to transplant tolerance (Walsh, Strom, 
and Turka 2004), however this is a complex mechanism. Whilst some groups report that 
skewing of alloimmunity towards a Th2 phenotype by anatagonising IL-12 signalling or 
by in vivo injection of Th2 cytokines still exacerbated rejection of MHC mismatched 
grafts (X. C. Li et al. 1998; Piccotti et al. 1996; X. X. Zheng et al. 1995), but polarising a 
Th1 response towards a Th2 response is adequate to promote transplant survival across 
selected minor histocompatibility barriers (X. C. Li et al. 1998)  
IL-4 cytokine is a critical factor involved in the suppression of the pro-inflammatory 
cytokine response (Tiemessen et al. 2007). Silverman et al. demonstrated that 
Leishmania exosomes-treated mice had a higher number of IL-4 producing CD4+ T cells 
whilst reducing the number of IFNγ producing CD4+ T cells (Silverman et al. 2010), 
highlighting that exosomes/EVs can modify CD4+ T cells cytokine production levels in 
vivo.  In the co-cultures, the Treg EVs decreased IFNγ production levels whilst increased 
the IL-4 production levels, taken with the above publications this finding suggests that 
Treg EVs may be promoting a polarisation towards a Th2 differentiation profile.  
Given that EVs are carriers of cytokines (A. Clayton et al. 2007; Tokarz et al. 2015; 
Hasegawa et al. 2011; Szabó et al. 2014; Konadu et al. 2015) and EVs can offload their 
contents into target cells, it is conceivable that Treg EVs may have directly transferred 
IL-4 along with other cytokines into target cells rather than being directly upregulated in 
CD4+ T cells, as human Tregs can produce IL-4 cytokine (Tiemessen et al. 2007). 
However, I have not tested the direct transfer of cytokines via EVs due to time limits on 
the PhD project.  
Tregs can use a combination of suppressive mechanisms, but in some in vitro assays, it 
appeared to be independent of IL-10 and TGF-b (M K Levings, Sangregorio, and 




report a major role of IL-10 (Chaudhry et al. 2011; Collison et al. 2009). I observed a 
significant increase in IL-10 with Treg EVs treatment but only at the highest dose of Treg 
EVs. This suggests that Treg EVs rather than inducing a general cytokine modulation of 
production in Tresps; it affects specific cytokines, perhaps shifting the balance from a 
pro-inflammatory towards an anti-inflammatory cytokine microenvironment.  
Tregs can suppress IL-6 production (Tiemessen et al. 2007), I have shown that human 
Treg EVs akin to their parent Tregs can also significantly inhibit IL-6 cytokine production. 
IL-6 has been shown by various groups to drive pro-inflammatory microenvironments 
and transplant rejection (Luqiu Chen et al. 2009; Zhao et al. 2012; Shen and Goldstein 
2009) and is suggested to be involved in the Th1/Th2 balance (Zhao et al. 2012). Zhao et 
al. demonstrated that wild-type C57BL/6 mice which received CTLA4-blocking antibody 
rejected fully mismatched BALB/c cardiac grafts, whilst administration of CTLA4-
blocking antibody in IL-6-deficient mice resulted in allograft acceptance. The authors 
suggested that blocking IL-6 production and IL-6 signalling with combined blockage of 
costimulatory molecules could inhibit Th1 responses, and promote transplant tolerance 
(Zhao et al. 2012). Therefore, given my findings that Treg EVs suppressed the 
production of IL-6 it could be a means to prevent transplant rejection and warrants 
further investigation.  
Furthermore, there is a delicate balance between Th17 and Tregs. A signature 
transcription factor, RORγT for Th17 is also induced by TGF-β1. In the absence of IL-6, 
FoxP3 can inhibit RORγT function and drive Treg differentiation. However, when the 
cells also receive a signal from IL-6, FoxP3 function is inhibited and the Th17 
differentiation pathway is induced (Z. Cai et al. 2012; Ziegler and Buckner 2009). Thus, 
the observation that Treg EVs but not Teff EVs significantly inhibited the production of 
IL-6 by Tresps highlights a possibility that Treg EVs are favouring FoxP3 function and 
thus possibly inducing T cell differentiation into induced Tregs, although this has not 








In summary, in this chapter, I demonstrated that both human Tregs and Teffs release 
EVs that inhibit Tresps proliferation. Treg EVs and Teff EVs act differently in regard to 
affecting cytokine release by Tresps. In particular, Treg EVs significantly inhibited IFNγ 
and IL-6 production levels by Tresps, whereas Teff EVs promoted their release. 
However, both Treg EVs and Teff EVs inhibited the production levels of IL-2, whilst 
increasing the production levels of IL-10, IL-4 and TNF by Tresps. In conclusion, human 
Tregs and Teffs release immunomodulatory EVs capable of inhibiting Tresps 









Investigation of miRNAs 





Chapter 5 - Investigation of miRNAs contained in Human Treg 
EVs 
5.1 Introduction 
miRNA are small single stranded RNA molecules approximately 22 nucleotides in length, 
which bind to target mRNA to direct post-transcriptional repression to inhibit their 
translation into protein (Y. Cai et al. 2009). 3’ UTR is the section of mRNA which 
comprises the regulatory regions that post-transcriptionally affect gene expression and 
is the location where miRNA binds to repress or degrade them. Approximately half of all 
protein-coding genes are regulated by miRNA (Friedman et al. 2008) equating to more 
than 8000 genes (Asirvatham, Magner, and Tomasi 2009), thus miRNA plays important 
roles in regulating gene expression.  
One miRNA can target one or more mRNAs and one mRNA can be targeted by one or 
more miRNAs (Y. Cai et al. 2009; Gebert and MacRae 2018). This level of interaction 
between miRNA and target mRNA can control the production of various proteins. 
Therefore, miRNAs are key bioactive molecules that can affect various immune cells; 
the absence or altered levels of miRNAs have resulted in immune system modification 
and dysfunction (Tsitsiou and Lindsay 2009; L.-F. Lu and Liston 2009). miRNAs not only 
have inhibitory effects on mRNA, which could be of therapeutic potential and they can 
be useful biomarkers to monitor health conditions or aid diagnosis and prognosis in 
patients (Jin Wang, Chen, and Sen 2016; K. W. Witwer 2015; Kreth, Hübner, and Hinske 
2018; Hamam et al. 2017). It is therefore not surprising that miRNA is currently being 
considered for use in clinical trials (Chakraborty et al. 2017; Rupaimoole and Slack 
2017).  
 
5.1.1 miRNA and the immune system   
In the immune system, miRNA have been linked to many aspects of T cell 
differentiation, Treg stability, and APC functions (Mehta and Baltimore 2016; Tsitsiou 
and Lindsay 2009; L.-F. Lu and Liston 2009; C. Xiao and Rajewsky 2009). Thus, the 
miRNA pool within the microenvironment can regulate the skewing of T cell lineages. 




2013) describes that miRNA expression in T cells including Tregs, can be downregulated 
after TCR activation. Therefore, given that EVs are produced after Treg activation and 
that miRNAs are shuttled into the Treg EVs, as shown in Chapter 3 with mouse Tregs, it 
would be reasonable to anticipate that human Tregs do the same as a mode of 
communication to other cell types. 
Mittlebrunn et al. demonstrated that MVBs in jurkat T cells migrate toward the 
immunological synapse formed following recognition of antigen presented by APCs. 
These EVs harboured miRNAs, which were transferred in a unidirectional manner into 
APCs during an immunological synapsis; these miRNAs were functional and affected the 
target cell gene expression (Mittelbrunn et al. 2011).  
It has been shown by various groups that miRNA expression can be induced by 
cytokines and cytokines can be influenced by miRNA. For example, IL-2 induces miR-182 
expression and promotes IL-2-driven clonal Th expansion (Stittrich et al. 2010). In 
addition, IFNγ induces miR-29ab-1 expression in a regulatory feedback loop as miR-
29ab-1  regulates T-bet and IFNγ directly, thus miR-29ab-1  regulates Th1 differentiation 
(Smith et al. 2012). Cytokines can be influenced by the presence of inhibitory miRNA as 
well. As demonstrated by Okoye et al., miRNA Let-7d contained in mouse Treg 
exosomes contributed to their suppression. Namely, this exosome-associated miRNA 
was able to function both in vitro to suppress Teffs proliferation and their cytokine 
production of IL-2 and IFNγ and in vivo to prevent inflammatory colitis in mouse models 
(Okoye et al. 2014).  
 
5.1.2 miRNA and Tregs 
EV-associated miRNAs not only affect Teffs but can also influence Tregs. For example, 
Kimura et al. investigated why patients with multiple sclerosis have a decreased 
frequency of Tregs. These authors found that circulating EVs from these patients 
contained high expression levels of Let-7i, and this miRNA targeted the IGF1R and 
TGFBR1 pathways which subsequently blocked the induction of Tregs, thus exacerbating 
the pathogenesis of multiple sclerosis disease (Kimura et al. 2018). 
During my PhD project, the human Treg EVs miRNA contents had not been identified 




human Treg EVs was published (Torri et al. 2017). In this report by Torri et al., the EVs 
derived from Th1, Th17 and Treg cells were assessed for their miRNA content. miR-
146a-5p, miR-150-5p and miR-21-5p were identified as being enriched in Treg EVs. miR-
146a-5p was noted by these authors to be the most probable miRNA contained in Treg 
EVs that drove immunosuppression of proliferating T cells. Two targets of miR-146a-5p; 
Stat1 and Irak2, were found at lower expression levels in T cells when the T cells were 
treated with Treg EVs. Given that Stat1 and Irak2 are two genes that are up-regulated 
upon stimulation of naïve T cells, Torri et al. suggested that the suppressed expression 
of these genes may have prevented their maturation (Torri et al. 2017). Taken together, 
miRNAs can modulate target cell biology. However, how the miRNA repertoire functions 
within human Treg EVs remain to be fully understood. 
 
5.2 Aims and Objectives 
Aim 
As shown in Chapter 3, mouse Treg EVs contained miRNAs and these miRNAs may have 
contributed to their suppressive function. The original aim of this PhD thesis chapter 
was to investigate whether human Treg EVs also contained miRNAs and which of these 
miRNAs were likely to be involved in modulating the cytokine production by Tresps as 
shown in section 4.3.7.  
Objectives: 
(1) Define whether Treg EVs contain miRNAs  
(2) Compare the miRNA repertoire of:  
- Tregs with Teffs 
- Tregs with Treg EVs 
- Teffs with Teff EVs 
- Treg EVs with Teff EVs 
(3) Perform bioinformatic analysis to investigate whether miRNAs that are enriched 
in Treg EVs bind to and target 3’ UTR of IFNγ, IL-2 and IL-6 mRNA  
(4) Perform bioinformatic analysis to investigate which miRNAs are in silico 





5.3.1 Human Tregs, Teffs, Treg EVs and Teff EVs contain different miRNA repertoires 
In section 3.3.8, I have shown that mouse Treg EVs and FoxP3low T cell EVs express 
different miRNA repertoires. As abovementioned, my original aim of this PhD thesis 
chapter was to investigate whether human Treg EVs contained miRNAs. Given that in 
Chapter 3, I demonstrated that murine Treg EVs affect the cytokine production by BM-
DCs and given that EV-associated miRNA can mediate alteration in target cell 
production of cytokines (Okoye et al. 2014), it led to the question of whether the 
suppressive ability of human Treg EVs was possibly due to their miRNA content.  
Thus, to investigate this, the miRNA repertoire in human Tregs, Treg EVs, autologous 
Teffs and Teff EVs were derived from 3 healthy donors and their total RNA isolated and 
the miRNA content assessed.  
Due to this PhD project’s main interest in Treg EVs over the other sample types (Tregs, 
Teffs and Teff EVs); Treg EVs were used as the main comparison for the subsequent 
analysis. Noteworthy, due to human to human variation, not all 3 donors would express 
miRNA-x but if at least one donor had a positive detection of miRNA-x in the RNA 
sample, it was recorded as present within that sample and this rule was applied to 
generate the following results.   
The miRNA content in each of the sample type was different; some miRNAs were found 
exclusively in cells or EVs. The Venn diagrams illustrated in Figure 5.1-A-D show the 
scaled proportion of the commonly and exclusively expressed miRNAs between two 
sample types. When comparing Tregs with Teffs, 347 miRNAs were commonly 
expressed between the two cell types, whereas 39 miRNAs were found exclusively in 
Tregs or Teffs (Figure 5.1-A).  
212 miRNAs were found to be commonly expressed by Tregs and Treg EVs; whilst 175 
miRNAs were found exclusively in parent Tregs and 36 miRNAs were found exclusively 
in Treg EVs (Figure 5.1-B). Teffs and Teff EVs had 253 miRNAs that were commonly 
expressed, moreover, 148 miRNAs were specific to Teffs and 27 miRNAs were specific 




miRNAs were common whilst there were 64 miRNAs found exclusively in Treg EVs and 
65 miRNAs found exclusively in Teff EVs (Figure 5.1-D).  
With the top 50 miRNAs that had the largest variation amongst the sample types, a 
principal component analysis (PCA) plot was used to assess their biological grouping 
based on their clustering profile. From the PCA plot, it was observed that in all 3 donor 
samples of Tregs, Teffs, Treg EVs and Teff EVs, the dot plots clustered together and in 
distinct regions of the PCA plot which indicates that their miRNA differences are likely 
due to their biological content rather than other technical factors such as poor-quality 
RNA input (Figure 5.1-E). For example, if Donor ‘2’ Treg EVs had poor quality RNA used 
in the assays, then Donor ‘2’ Treg EVs will not cluster according to their biology and 
would be separated notably further from Donor ‘3’ or ‘4’ Treg EVs. 
Within the sample types of Tregs, Teffs, Treg EVs and Teff EVs there were commonly 
expressed miRNAs. The top 50 miRNAs that are commonly expressed in all the sample 
types (the sample set) and with the highest standard deviation are showed in the heat 
map in Figure 5.1-F. The heat map shows the two-way hierarchical clustering of miRNA 
and sample types, with the miRNA clustering tree on the left. When comparing the 
sample types together, cells and their EVs have diverse expression levels of particular 
miRNAs. Some miRNAs are found higher expressed in EVs than their parent cells and 
vice versa (Figure 5.1-F). However, to understand these differences better, a 










Figure 5.1- The miRNA repertoire in Tregs, Teffs, Treg EVs and Teff EVs 
Venn diagrams drawn to scale to show the number of miRNAs that are commonly or 
exclusively expressed in (A) Tregs and Teffs (B) Tregs and Treg EVs (C) Teffs and Teff EVs 
and (D) Treg EVs and Teff EVs. (E) Principal component analysis (PCA) plot showing the 
biological variation and clustering profile analysis performed on the top 50 miRNAs with 
the highest standard deviation in the sample set of Tregs (blue), Treg EVs (purple), Teffs 
(pink) and Teff EVs (green). The normalised (dCq) values have been used for the analysis. 
(F) Heatmap diagram and unsupervised hierarchical clustering of the top 50 miRNAs 
with the highest standard deviation in the sample set of Tregs, Teffs, Treg EVs and Teff 
EVs. The heatmap shows the result of the two-way hierarchical clustering of miRNAs and 
samples. Each row represents one miRNA whilst each column is one sample. The miRNA 
clustering tree is depicted on the left of the heatmap. In the colour scale, red represents 
a relative high expression of miRNA compared to green which is a lower expression level 
of miRNA than the mean in all the samples. Normalisation tool used was the global 




5.3.2 Differential expression of miRNAs between Tregs and Teffs 
Tregs and Teffs function differently, which may be due to their different miRNA content 
(Smigielska-Czepiel et al. 2014; Ha 2011). Since human samples used for experimental 
assays can vary considerably due to the genetic variation, it was important to identify 
the various miRNAs which were contained in the parent cells or their EVs. Thus, to first 
understand which miRNAs are present in Tregs and Teffs and to compare their 
expression levels, a heat-map diagram is displayed in Figure 5.2-A. The associated 
volcano plot is showed in Figure 5.2-B. To visualise this in a text format, Table 5.1 lists 
the miRNAs that are most differentially expressed between Tregs and Teffs, ranked 
according their t-test p-value. For example, miR-146a-5p, miR-21-3p, miR-21-5p and 
miR-155-5p are higher expressed in Tregs than Teffs. Although there was a trend of 
increase of miR-142-3p expression levels in Teffs compared to Tregs, this was not 
significant (Figure 5.2-C). Nonetheless, individual qPCR assays validated the miRNOME 
finding that Teffs expressed higher levels of miR-150-5p than in Tregs (Figure 5.2-D).  
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Figure 5.2- Tregs and Teffs contain different miRNA repertoires 
(A) The heatmap diagram shows the two-way unsupervised hierarchical clustering of 
miRNAs and Tregs (first three columns) and Teffs (last three columns). (B) Volcano plot 
displaying the numbers of miRNAs differentially expressed between Tregs and Teffs. 
Validation individual qPCR assays showing the expression levels of Tregs compared to 
Teffs for (C) miR-142-3p and (D) miR-150-5p. Student t-test was used to test 






















Table 5.1- Table of top 50 miRNAs that are most differentially expressed by Tregs and 
Teffs. 
The list is ranked according to the t-test p-value. FDR means false discovery rate. 
miRNA
Fold change           
Tregs to Teffs
t-test p-value Benjamini-Hochberg FDR
hsa-miR-19a-3p 1.413314518 0.000301854 0.077274515
hsa-miR-155-5p 1.905238923 0.001149001 0.147072105
hsa-miR-20a-5p 1.462564833 0.001817306 0.155076779
hsa-miR-92a-3p 1.785910049 0.002553739 0.163439286
hsa-miR-424-5p -1.805132894 0.004601595 0.164762871
hsa-miR-221-3p 2.633130914 0.004962544 0.164762871
hsa-miR-542-5p -8.390895915 0.006068729 0.164762871
hsa-miR-423-5p -1.552357627 0.006155939 0.164762871
hsa-miR-7-5p -2.101132926 0.006168189 0.164762871
hsa-miR-328-3p -1.664885016 0.006766171 0.164762871
hsa-miR-181b-5p -3.135749713 0.007079655 0.164762871
hsa-miR-148a-3p 2.131021135 0.008406853 0.17297185
hsa-miR-29a-3p 2.126556832 0.009060746 0.17297185
hsa-miR-941 -2.089111512 0.010256588 0.17297185
hsa-miR-34c-5p 8.482797531 0.010700425 0.17297185
hsa-miR-29c-3p 1.855371348 0.010810741 0.17297185
hsa-miR-181a-5p -2.417170179 0.011664638 0.173114274
hsa-miR-151a-5p 5.20863425 0.012172097 0.173114274
hsa-miR-21-3p 1.803172249 0.014201982 0.176528635
hsa-miR-1260a -2.751355064 0.014585201 0.176528635
hsa-miR-21-5p 1.711399188 0.015571575 0.176528635
hsa-miR-450a-5p -2.851651819 0.015735626 0.176528635
hsa-miR-425-5p -1.541045019 0.015859995 0.176528635
hsa-miR-181a-3p -2.352371568 0.018564098 0.198017041
hsa-miR-148b-5p -1.649967715 0.01960649 0.200770456
hsa-miR-423-3p -1.394682293 0.02060202 0.202850655
hsa-miR-19b-3p 1.311636024 0.022744983 0.209084659
hsa-miR-17-5p 1.618043183 0.022907207 0.209084659
hsa-miR-185-5p -1.657828564 0.023685371 0.209084659
hsa-miR-454-5p -3.408183968 0.025824942 0.220372839
hsa-miR-940 -2.15230609 0.027740112 0.225514625
hsa-miR-107 1.238502263 0.028189328 0.225514625
hsa-miR-152-3p -1.525654637 0.031154225 0.241681259
hsa-miR-29a-5p 1.422665256 0.034529352 0.259985712
hsa-miR-222-3p 1.60854774 0.036249999 0.264905931
hsa-miR-497-5p 1.493174205 0.037252396 0.264905931
hsa-miR-590-5p -1.313776388 0.039608748 0.274049715
hsa-miR-34a-3p -1.287687634 0.043795863 0.294274834
hsa-miR-29c-5p -1.50541515 0.045572658 0.294274834
hsa-miR-324-5p -1.435935751 0.045980443 0.294274834
hsa-miR-576-3p -2.881794163 0.050844646 0.305987775
hsa-miR-664a-3p -1.950920662 0.053210566 0.305987775
hsa-miR-486-5p 2.011640775 0.054410352 0.305987775
hsa-miR-1972 -4.575921741 0.055801129 0.305987775
hsa-miR-29b-2-5p -2.175839558 0.057503488 0.305987775
hsa-miR-148b-3p -1.409568053 0.057717384 0.305987775
hsa-miR-744-5p -1.707481537 0.057790176 0.305987775
hsa-miR-27b-3p 1.776789392 0.058593065 0.305987775
hsa-miR-629-5p -2.022625837 0.059755157 0.305987775





Table 5.2- Table of miRNAs found exclusively in Treg EVs and not in Tregs.  
The associated information as to whether these miRNAs are reported in ExoCarta is also 
included. 
miRNA name
Treg EVs                 
Ct value




Species Tissue/Sample type PubMed ID
miR-602 >30<40 ND No N/A N/A N/A
miR-376a-3p >30<40 ND Yes Homo Sapiens Plasma 23663360
miR-187-5p >30<40 ND Yes Homo Sapiens Plasma 23663360
miR-133b >30<40 ND Yes Homo Sapiens Colorectal cancer cells N/A
miR-369-3p >30<40 ND Yes Homo Sapiens Melanoma cells              




18589210      
miR-143-3p >30<40 ND Yes Homo Sapiens Colorectal cancer cells 
Melanoma cells                
Plasma  
 25330373   
26176991   
23663360  
miR-122-5p >30<40 ND Yes Homo Sapiens Colorectal cancer cells  
Plasma
N/A            
23663360
miR-760 >30<40 ND No N/A N/A N/A




miR-608 >30<40 ND No N/A N/A N/A
miR-596 >30<40 ND No N/A N/A N/A
miR-382-5p >30<40 ND Yes Homo Sapiens Colorectal cancer cells  
Plasma
N/A                  
23663360




miR-346 >30<40 ND No N/A N/A N/A
miR-934 >30<40 ND No N/A N/A N/A
miR-885-5p >30<40 ND Yes Homo Sapiens B cells                           
Colorectal cancer cells 
Colorectal cancer cells 
Plasma
21505438                 
N/A                         
N/A               
23663360 
miR-885-3p >30<40 ND Yes Homo Sapiens Plasma 23663360
miR-765 >30<40 ND No N/A N/A N/A
miR-675-3p >30<40 ND Yes Homo Sapiens Colorectal cancer cells 
Colorectal cancer cells 
Colorectal cancer cells
N/A                           
N/A           
25330373
miR-638 >30<40 ND No N/A N/A N/A
miR-609 >30<40 ND No N/A N/A N/A
miR-604 >30<40 ND No N/A N/A N/A
miR-584-5p >30<40 ND Yes Homo Sapiens Colorectal cancer cells 
Colorectal cancer cells 
Colorectal cancer cells 
Plasma
N/A                             
N/A                    
25330373   
23663360 
miR-517-5p >30<40 ND No N/A N/A N/A
miR-502-5p >30<40 ND Yes Homo Sapiens Colorectal cancer cells 
Dendritic Cells                            
T cells
N/A                
21505438  
21505438
miR-376b-3p >30<40 ND Yes Homo Sapiens Plasma 23663360  
miR-34c-3p >30<40 ND Yes Homo Sapiens Colorectal cancer cells 
Colorectal cancer cells 
Plasma
N/A                         
N/A                 
23663360 
miR-329-3p >30<40 ND No N/A N/A N/A
miR-218-1-3p >30<40 ND No N/A N/A N/A
miR-206 >30<40 ND No N/A N/A N/A
miR-205-5p >30<40 ND Yes Homo Sapiens Colorectal cancer cells 
Colorectal cancer cells 
Plasma
N/A                     
N/A                 
23663360
miR-200b-5p >30<40 ND Yes Homo Sapiens Colorectal cancer cells 
Colorectal cancer cells 
Plasma
N/A                  
25330373   
23663360 
miR-195-3p >30<40 ND Yes Homo Sapiens Plasma 23663360
miR-133a-3p >30<40 ND Yes Homo Sapiens Colorectal cancer cells N/A
miR-1269a >30<40 ND No N/A N/A N/A
miR-10a-3p >30<40 ND Yes Homo Sapiens Colorectal cancer cells 
Plasma





5.3.3 Human Treg EVs contain exclusive miRNAs that are not found in their parent 
cells  
To investigate which specific miRNAs contained in Treg EVs may be contributing to their 
suppressive function that is not otherwise found in their parent Tregs, the miRNA 
content of Treg EVs was compared to their parent Tregs.  
As displayed in Figure 5.1-B, 36 miRNAs were found exclusively in Treg EVs but not 
Tregs, which are detailed in Table 5.2, along with the associated information of whether 
these miRNAs have previously been reported in ExoCarta (a database of exosomes-
related miRNAs) and the biological sample type from which that miRNA had been 
detected. For example, mir-369-3p, miR-376c-3p, miR-195-3p, miR-885-5p and miR-
125b-5p are all found only in Treg EVs but not their parent Treg cells. 
The heatmap diagram shows the two-way unsupervised hierarchical clustering of 
miRNAs of Treg EVs and their parent Tregs (Figure 5.3-A). The volcano plot displays the 
annotated top 20 miRNAs with the most significantly differentially expressed miRNAs 
between Treg EV and their parent Tregs (Figure 5.3-B), with the miRNAs appearing on 
the left side of the volcano plot being higher expressed in Treg EVs compared to Tregs 
and vice versa.  
In Table 5.3, the top 22 miRNAs (ranked according to the p-value) that were higher 
expressed in Treg EVs compared to their parent Tregs (e.g. miR-1972, miR-126-3p and 
miR-451 were all >300 folds higher expressed in Treg EVs than Tregs) are listed and in 
Table 5.4 the miRNAs that were the most differentially expressed between Treg EVs and 
their parent Tregs and ranked according their t-test p-value are listed.  
The miRNOME screen showed that Tregs expressed higher levels of miR-142-3p than in 
Treg EVs, whereas the expression levels of miR-150-5p may be similar, to validate this 
observation, individual qPCR assays were performed. As shown by individual qPCR 
assays, Tregs expressed higher levels of miR-142-3p than Treg EVs (Figure 5.3-C), 
although no statistical difference was observed for miR-150-5p expression levels (Figure 
5.3-D).   
Overall, this data demonstrated that Treg EVs contain exclusive miRNAs and also 









Figure 5.3- Tregs and Treg EVs contain different miRNA repertoires 
(A) The heatmap diagram shows the two-way unsupervised hierarchical clustering of 
miRNAs and Treg EVs (last three columns) and their parent Tregs (first three columns), 
where each row represents one miRNA and each column represents the indicated 
sample type. The miRNA clustering tree is also indicated with numerical values. Green 
indicates low expression levels whereas red indicates high expression levels. (B) Volcano 
plot displaying the annotated top 20 miRNAs with the most significant differentially 
expressed miRNAs between Treg EVs and their parent Tregs. The miRNAs appearing on 
the left side of the volcano plot are miRNAs higher expressed in Treg EVs compared to 
right side of the volcano plot, Tregs. The miRNA appearing at the right side of the 
volcano plot are higher expressed in parent Tregs compared to Treg EVs. Validation 
individual qPCR assays showing the expression levels of Tregs compared to Treg EVs for 
(C) miR-142-3p and (D) miR-150-5p. Student t-test was used to test significance. *p<0.05 







Table 5.3- Table of the top 22 miRNAs that were higher expressed in Treg EVs compared 
to their parent Tregs. 
 
















Species Tissue/Sample type PubMed ID
miR-320b 5.36 0.000240837 0.004294927 Yes Homo Sapiens                                    
-                                         
Equus caballus   
Colorectal cancer cells                      
Plasma                         
Follicular Fluid
25330373    
23663360           
22116803
miR-1972 536.20 0.000469308 0.006017836 No N/A N/A N/A
miR-451a 311.50 0.000471634 0.006017836 Yes Homo Sapiens Colorectal cancer cells                 
Melanoma cells     Plasma 
25330373  
26176991     
23663360 
miR-548c-5p 40.25 0.001086231 0.010566065 No N/A N/A N/A
miR-99a-5p 21.24 0.002121807 0.0174641 Yes Homo Sapiens Plasma 23663360  
miR-25-3p 1.47 0.002915005 0.02227897 Yes Homo Sapiens Colorectal cancer cells                 
Colorectal cancer cells    
Colorectal cancer cells 
Plasma 
N/A                           
N/A                      
25330373    
23663360 
miR-126-3p 327.89 0.003646443 0.026011293 Yes Homo Sapiens Colorectal cancer cells                 
Colorectal cancer cells    
Colorectal cancer cells 
Plasma 
N/A                                 
N/A                     
25330373    
23663360 
miR-320c 4.70 0.006006923 0.032438531 Yes Homo Sapiens                                    
-                                         
Equus caballus   
Colorectal cancer cells                      
Plasma                         
Follicular Fluid
25330373    
23663360           
22116803
miR-484 1.91 0.006063277 0.032438531 No N/A N/A N/A
miR-320d 8.36 0.007672477 0.037526202 Yes Homo Sapiens Colorectal cancer cells   
Plasma
25330373   
23663360  
miR-34a-3p 27.47 0.007715668 0.037526202 Yes Homo Sapiens Plasma 23663360  
miR-22-3p 4.34 0.008699645 0.04047226 Yes Homo Sapiens Colorectal cancer cells   
Plasma
25330373   
23663360  
miR-34a-5p 5.71 0.009225087 0.041128514 Yes Homo Sapiens Colorectal cancer cells   
Plasma
25330373   
23663360  
miR-423-5p 6.00 0.011356665 0.046400252 Yes Homo Sapiens Colorectal cancer cells                 
Colorectal cancer cells    
Colorectal cancer cells 
N/A                           
N/A                   
25330373    
miR-548a-3p 21.03 0.011708475 0.046400252 No N/A N/A N/A
miR-598-3p 4.48 0.01392848 0.053226693 No N/A N/A N/A
miR-128-3p 2.24 0.017673941 0.061800563 Yes Homo Sapiens Colorectal cancer cells                 
Colorectal cancer cells     
N/A                   
25330373    
miR-24-3p 1.77 0.018645449 0.062230157 Yes Homo Sapiens Colorectal cancer cells                 
Colorectal cancer cells    
Colorectal cancer cells 
Plasma 
N/A                               
N/A                    
25330373    
23663360 
miR-30e-5p 1.40 0.020718435 0.065202134 Yes Homo Sapiens Colorectal cancer cells   
Plasma
25330373   
23663360  
miR-130b-3p 1.76 0.021562289 0.065918999 Yes Homo Sapiens Colorectal cancer cells                 
Colorectal cancer cells    
Colorectal cancer cells 
Plasma 
N/A                               
N/A                      
25330373    
23663360 
miR-125b-5p 16.97 0.030237375 0.076271055 Yes Homo Sapiens Plasma 23663360  
miR-378a-3p 2.88 0.036250096 0.084320876 Yes Homo Sapiens Colorectal cancer cells   
Plasma






Table 5.4- Table of the top 50 miRNAs that are differentially expressed by Treg EVs and 
their parent Tregs. 
The list is ranked according to the t-test p-value. FDR means false discovery rate. 
miRNA
Fold change           
Treg EVs to Tregs
t-test p-value Benjamini-Hochberg FDR
hsa-miR-142-3p -6.24555013402685 2.15E-06 0.000230023
hsa-miR-107 -4.97547678934907 3.07E-05 0.001644362
hsa-miR-26a-5p -5.1510374153722 6.35E-05 0.001914099
hsa-miR-320a 5.043312413 7.16E-05 0.001914099
hsa-let-7f-5p -22.923254886939 0.000115825 0.002478651
hsa-miR-320b 5.363786824 0.000240837 0.004294927
hsa-miR-1972 536.2041719 0.000469308 0.006017836
hsa-miR-451a 311.4972689 0.000471634 0.006017836
hsa-let-7d-5p -11.2194570813883 0.000506173 0.006017836
hsa-miR-142-5p -4.40773694494717 0.000633278 0.006776074
hsa-miR-548c-5p 40.25065003 0.001086231 0.010566065
hsa-miR-30e-3p -1.89824631739953 0.001387203 0.012369229
hsa-miR-99a-5p 21.23968459 0.002121807 0.0174641
hsa-miR-25-3p 1.472822713 0.002915005 0.02227897
hsa-miR-126-3p 327.8891306 0.003646443 0.026011293
hsa-let-7c-5p -10.3309359791692 0.004654476 0.029518582
hsa-miR-181a-5p -4.04018210771861 0.004689868 0.029518582
hsa-let-7a-5p -17.3949853161932 0.005588373 0.032438531
hsa-miR-320c 4.702991269 0.006006923 0.032438531
hsa-miR-484 1.91167977 0.006063277 0.032438531
hsa-miR-320d 8.364473158 0.007672477 0.037526202
hsa-miR-34a-3p 27.47355118 0.007715668 0.037526202
hsa-miR-22-3p 4.343208976 0.008699645 0.04047226
hsa-miR-34a-5p 5.712868943 0.009225087 0.041128514
hsa-miR-103a-3p -9.43036446528997 0.010096539 0.043213186
hsa-miR-423-5p 5.998635445 0.011356665 0.046400252
hsa-miR-548a-3p 21.03119299 0.011708475 0.046400252
hsa-miR-598-3p 4.478958495 0.01392848 0.053226693
hsa-let-7b-5p -3.03111398571247 0.015571422 0.057453178
hsa-miR-128-3p 2.244604168 0.017673941 0.061800563
hsa-miR-15b-5p -4.65842979945997 0.017904836 0.061800563
hsa-miR-24-3p 1.766166674 0.018645449 0.062230157
hsa-let-7g-5p -2.99916007580199 0.019192478 0.062230157
hsa-miR-30e-5p 1.39552414 0.020718435 0.065202134
hsa-miR-130b-3p 1.757368168 0.021562289 0.065918999
hsa-miR-18b-5p -2.47395136005875 0.023486155 0.069806073
hsa-miR-18a-5p -2.1938387140088 0.026525218 0.07583157
hsa-miR-374a-5p -6.40883382522899 0.027762419 0.07583157
hsa-let-7i-5p -2.565579360302 0.028231502 0.07583157
hsa-miR-155-5p -2.13498130365522 0.02834825 0.07583157
hsa-miR-125b-5p 16.97062439 0.030237375 0.076271055
hsa-miR-33a-5p -1.88979675900161 0.030517775 0.076271055
hsa-miR-30c-5p -3.92569104494944 0.030650985 0.076271055
hsa-miR-26b-5p -2.52730102463857 0.031988111 0.07778927
hsa-miR-194-5p -1.71778042500384 0.036103184 0.084320876
mmu-miR-378a-3p 2.880611732 0.036250096 0.084320876
hsa-miR-425-5p -2.40180767105328 0.038162708 0.08688106
hsa-miR-140-5p -3.10013547597412 0.042842556 0.095503199
hsa-miR-21-3p -2.31100253020276 0.047063213 0.102770689




5.3.4 Differential expression of miRNA between Teffs and Teff EVs 
The same analysis performed with Tregs and Treg EVs was extended to Teffs and their 
EVs, as it has previously been reported that Teffs and their EVs differ in their miRNA 
content (Torri et al. 2017). To further confirm these findings, a comparison of the 
relative miRNA expression levels between Teffs and Teffs EVs was performed. A 
heatmap of the different miRNA expression levels is illustrated in Figure 5.4-A, with the 
associated volcano plot (Figure 5.4-B). Table 5.5 lists the top 50 miRNAs that are most 
differentially expressed between Teffs and Teff EVs, ranked according their t-test p-
value. Individual qPCR assays validated the miRNOME finding that Teffs expressed 









Figure 5.4- Teffs and Teff EVs contain different miRNA repertoires 
(A) The heatmap diagram shows the two-way unsupervised hierarchical clustering of 
miRNAs and Teffs (first three columns) and Teff EVs (last three columns). (B) Volcano 
plot displaying the annotated top 20 miRNAs with the most significant differentially 
expressed miRNAs between Teffs and Teff EVs. The miRNAs appearing on the left side of 
the volcano plot are miRNAs higher expressed in Teff EVs compared to right side of the 
volcano plot Teffs. The miRNA appearing at the right side of the volcano plot are higher 
expressed in parent Teffs compared to Teff EVs. Validation individual qPCR assays 
showing the expression levels of Teffs compared to Teff EVs for (C) miR-142-3p and (D) 






Table 5.5- Table of top 50 miRNAs that are most differentially expressed by Teffs and 
Teff EVs.  
The list is ranked according to the t-test p-value. FDR means false discovery rate. 
miRNA
Fold change           
Teffs to Teff EVs
t-test p-value Benjamini-Hochberg FDR
hsa-let-7g-5p 5.764031076 1.23E-05 0.001373622
hsa-miR-34a-3p -7.34352082 2.45E-05 0.001373622
hsa-miR-1972 -120.0202952 0.000135844 0.005071492
hsa-miR-186-5p -2.519385516 0.000342693 0.009359513
hsa-miR-30e-5p -1.777590194 0.000427832 0.009359513
hsa-miR-142-3p 19.04546843 0.000501402 0.009359513
hsa-miR-142-5p 8.51758465 0.000892726 0.014283608
hsa-miR-548c-5p -26.2396222 0.001132572 0.015713425
hsa-let-7i-5p 3.138371234 0.001262686 0.015713425
hsa-miR-320a -2.841826892 0.001584167 0.017742675
hsa-let-7c-5p 12.62541968 0.002763304 0.028135462
hsa-miR-221-3p -4.592014518 0.004256473 0.036558722
hsa-miR-27b-3p -1.690249761 0.004837301 0.036558722
hsa-miR-19b-3p -2.030213385 0.005047221 0.036558722
hsa-miR-92a-3p -1.551939879 0.005098216 0.036558722
hsa-miR-103a-3p 9.274290113 0.005401903 0.036558722
hsa-miR-223-3p 2.223171246 0.005549092 0.036558722
hsa-miR-30c-5p 3.430465047 0.0059801 0.037209512
hsa-miR-181a-5p 3.993922422 0.00638573 0.037642196
hsa-miR-15b-5p 1.959495152 0.00694302 0.038880913
hsa-miR-363-3p 1.640646079 0.007933275 0.042310798
hsa-let-7a-5p 107.7227419 0.008442815 0.042981606
hsa-miR-22-3p -3.521391585 0.008909441 0.043385105
hsa-miR-26a-5p 7.519493218 0.009668981 0.044932536
hsa-miR-222-3p -2.429999915 0.010029584 0.044932536
hsa-miR-19a-3p -2.143328202 0.010615359 0.045173163
hsa-miR-125a-5p 8.91059566 0.010889959 0.045173163
hsa-miR-150-5p 3.788734252 0.01329641 0.052730784
hsa-miR-130b-3p -1.767752096 0.013653507 0.052730784
hsa-miR-148b-3p -2.696903219 0.014525074 0.054226942
hsa-miR-106b-5p 2.097612106 0.015579112 0.056285825
hsa-miR-34a-5p -2.758634718 0.020321518 0.071125315
hsa-miR-424-5p -2.226504699 0.024524114 0.083233356
hsa-miR-24-3p -2.453421622 0.027556118 0.090773093
hsa-miR-486-5p -4.092953755 0.028451752 0.091045605
hsa-miR-140-3p -1.950901866 0.031378371 0.0976216
hsa-miR-374a-5p 10.74398326 0.034299583 0.099337044
hsa-miR-20a-5p -1.418540227 0.034452477 0.099337044
hsa-miR-425-5p 2.276642216 0.035103458 0.099337044
hsa-miR-27a-3p -1.84189176 0.035477516 0.099337044
hsa-miR-342-3p -1.610196945 0.039027444 0.104164345
hsa-miR-29a-3p -1.772772557 0.039061629 0.104164345
hsa-miR-30b-5p 2.075313258 0.04040438 0.105239317
hsa-miR-484 -2.067109609 0.043004837 0.109466857
hsa-miR-497-5p -3.746255049 0.045305328 0.112759928
hsa-miR-191-5p 1.881203385 0.04843244 0.117922463
hsa-miR-107 2.807810051 0.057381917 0.136332086
hsa-miR-29c-3p -1.601380481 0.058428037 0.136332086
hsa-miR-148a-3p -1.845234775 0.062674659 0.143256362




5.3.5 Treg EVs contain specific miRNAs that are not found in Teff EVs 
As shown in section 4.3.7, human Treg EVs and Teff EVs function differently to affect 
certain cytokine production, namely Treg EVs inhibited the production levels of IFNγ 
and IL-6 whereas Teff EVs promoted their production. To understand if these different 
effects on cytokine production could be due to differences in their miRNA repertoire, 
the miRNA content between Treg EVs and Teff EVs was compared.  
As illustrated in Figure 5.1-D, Treg EVs contain 64 specific miRNAs that are not found in 
Teff EVs, these miRNAs are listed in Table 5.6 (e.g. miR-146b-3p, miR-125b-5p, miR-369-
3p, miR-376b-3p and miR-126-5p). To compare the relative miRNA expression levels 
between Treg EVs and Teff EVs, a heatmap diagram is displayed (Figure 5.5-A), with the 
associated volcano plot (Figure 5.5-B). Table 5.7 lists the top 20 miRNAs (e.g. miR-142-
3p, miR-150-5p, miR-146a-5p, miR-142-5p and miR-146b-5p) that are expressed higher 
in Treg EVs compared to Teff EVs whereas Table 5.8 lists the miRNAs that are most 
differentially expressed between Treg EVs and Teff EVs, ranked according their t-test p-
value. To validate the miRNOME finding that Treg EVs expressed higher levels of miR-
142-3p and miR-150-5p than in Teff EVs, individual qPCR assays were performed. Treg 
EVs expressed significantly higher levels of miR-142-3p and miR-150-5p than Teff EVs 
(Figures 5.5-C and 5.5-D, respectively).  
Overall, this data demonstrated that Treg EVs contain exclusive miRNAs and also 















Figure 5.5- Treg EVs and Teff EVs contain different miRNA repertoires 
(A) The heatmap diagram shows the two-way unsupervised hierarchical clustering of 
miRNAs and Treg EVs (first three columns) and Teff EVs (last three columns). (B) Volcano 
plot displaying the numbers of miRNAs differentially expressed between Treg EVs and 
Teff EVs. Validation individual qPCR assays showing the expression levels of Treg EVs 
compared to Teff EVs for (C) miR-142-3p and (D) miR-150-5p. Student t-test was used to 





Table 5.7- Table of top 20 miRNAs found higher in Treg EVs compared to Teff EVs.  
The list is ranked according to the t-test p-value. FDR means false discovery rate. 
  
miRNA name
Fold change                                  
Treg EVs/Teff EVs
t-test p-value Benjamini-Hochberg FDR
hsa-miR-363-3p 1.87841804 0.006489773 0.30523537
hsa-miR-142-3p 3.28324672 0.007269691 0.30523537
hsa-miR-21-5p 1.603604501 0.016675467 0.30523537
hsa-miR-320a 1.655418014 0.019115478 0.30523537
hsa-miR-142-5p 1.464628332 0.020374887 0.30523537
hsa-miR-92a-3p 1.68683633 0.032835366 0.30523537
hsa-let-7a-5p 6.463770322 0.041200915 0.30523537
hsa-miR-150-5p 2.280412933 0.049357387 0.30523537
hsa-miR-146a-5p 3.965772648 0.073967097 0.321090789
hsa-miR-34a-3p 2.905359936 0.075148908 0.321090789
hsa-let-7g-5p 2.027647471 0.081325904 0.332375435
hsa-let-7c-5p 2.125588792 0.101028546 0.351186397
hsa-miR-29a-3p 1.39700209 0.107213845 0.351186397
hsa-let-7i-5p 1.236812457 0.1103023 0.351186397
hsa-miR-320b 2.037393577 0.11581679 0.351186397
hsa-miR-26b-5p 3.887693478 0.135003942 0.388893403
hsa-miR-130b-3p 1.25331183 0.178597111 0.472975136
hsa-miR-320c 2.675779675 0.209262118 0.491765978
hsa-miR-598-3p 4.039348977 0.220140665 0.504712743





Table 5.8- Table of top 50 miRNAs that are most differentially expressed by Treg EVs and 
Teff EVs. 
The list is ranked according to the t-test p-value. FDR means false discovery rate. 
miRNA
Fold change           
Treg EVs to Teff EVs
t-test p-value Benjamini-Hochberg FDR
hsa-miR-363-3p 1.87841804 0.006489773 0.30523537
hsa-miR-142-3p 3.28324672 0.007269691 0.30523537
hsa-miR-21-5p 1.603604501 0.016675467 0.30523537
hsa-miR-320a 1.655418014 0.019115478 0.30523537
hsa-miR-142-5p 1.464628332 0.020374887 0.30523537
hsa-miR-181a-5p -2.445167101 0.026634717 0.30523537
hsa-miR-30e-5p -1.287984211 0.030457804 0.30523537
hsa-miR-92a-3p 1.68683633 0.032835366 0.30523537
hsa-let-7a-5p 6.463770322 0.041200915 0.30523537
hsa-miR-484 -1.358099651 0.041390939 0.30523537
hsa-miR-19b-3p -1.382175592 0.043076496 0.30523537
hsa-miR-23a-3p -1.434745966 0.044690849 0.30523537
hsa-miR-27b-3p -1.591065514 0.048961515 0.30523537
hsa-miR-150-5p 2.280412933 0.049357387 0.30523537
hsa-miR-424-5p -2.387755718 0.050746447 0.30523537
hsa-miR-124-3p -7.273862887 0.05664018 0.30523537
hsa-miR-33a-5p -1.635344187 0.057155836 0.30523537
hsa-miR-32-5p -1.715729053 0.058449326 0.30523537
hsa-miR-15a-5p -1.467263618 0.066367973 0.321090789
hsa-miR-140-5p -2.419327909 0.069782396 0.321090789
hsa-miR-146a-5p 3.965772648 0.073967097 0.321090789
hsa-miR-34a-3p 2.905359936 0.075148908 0.321090789
hsa-let-7g-5p 2.027647471 0.081325904 0.332375435
hsa-miR-210-3p -3.181580065 0.094327373 0.351186397
hsa-miR-24-3p -1.563670237 0.100266279 0.351186397
hsa-let-7c-5p 2.125588792 0.101028546 0.351186397
hsa-miR-29a-3p 1.39700209 0.107213845 0.351186397
hsa-let-7i-5p 1.236812457 0.1103023 0.351186397
hsa-miR-590-5p -2.084429447 0.111381082 0.351186397
hsa-miR-18a-5p -2.064673363 0.115443142 0.351186397
hsa-miR-320b 2.037393577 0.11581679 0.351186397
hsa-miR-26b-5p 3.887693478 0.135003942 0.388893403
hsa-miR-425-5p -1.625768741 0.136526408 0.388893403
hsa-miR-19a-3p -1.240593093 0.165433357 0.457374574
hsa-miR-130b-3p 1.25331183 0.178597111 0.472975136
hsa-miR-22-3p -1.536678445 0.188156857 0.472975136
hsa-miR-148b-3p -1.633670417 0.189487212 0.472975136
hsa-miR-15b-5p -1.731960688 0.195510919 0.472975136
hsa-miR-27a-3p -1.47426479 0.196234365 0.472975136
hsa-miR-320c 2.675779675 0.209262118 0.491765978
hsa-miR-598-3p 4.039348977 0.220140665 0.504712743
hsa-miR-146b-5p 1.563936878 0.233687797 0.523015547
hsa-miR-548a-3p 2.968504504 0.240874768 0.526563447
hsa-miR-140-3p 1.273473703 0.253640261 0.537991301
hsa-miR-23b-3p -1.265608471 0.268195204 0.537991301
hsa-miR-21-3p 1.515030522 0.268947837 0.537991301
hsa-miR-144-3p 2.818905059 0.26899565 0.537991301
hsa-miR-125a-5p 2.365443703 0.289481864 0.562523738
hsa-miR-107 -1.430771155 0.30220773 0.562523738




5.3.6 Target prediction and pathway analysis of miRNAs enriched in human Treg EVs 
reveal they are linked to targeting of pro-inflammatory cytokine genes 
To understand if miRNAs found exclusively in Treg EVs or found expressed at higher 
levels in Treg EVs compared their parent Tregs (collectively ‘miRNAs enriched in Treg 
EVs’) play a role in modifying target cell functions such as modulating cytokine 
production as shown in section 4.3.7, a bioinformatics analysis was performed. This 
bioinformatics tool was available at microRNA.org and was used to predict the miRNA 
to mRNA interactions in the 3’ UTR of IFNγ, IL-2 and IL-6 mRNAs (binding sites with 
matching seed regions) and to obtain the associated algorithms of mirSVR and 
PhastCons scores. Figures 5.6-A, B and C, respectively, indicate the full length of the 3’ 
UTR of IFNγ, IL-2 and IL-6 mRNAs showing the binding target locations/sequences of 
miRNAs enriched in Treg EV. The specific alignment of sequences with seeding 
sequences and associated mirSVR and PhastCons scores are shown in Appendices 3, 4 
and 5, respectively. The mirSVR score measures the miRNA effect on the mRNA 
expression level with values starting at <0, in other words, the more negative the value 
the greater the effect (Riffo-Campos, Riquelme, and Brebi-Mieville 2016). The 
PhastCons scores indicates the conservation of nucleotide sequences between species, 
the values range from 0 to 1, with a value of 1 being highly conserved (Riffo-Campos, 
Riquelme, and Brebi-Mieville 2016). As presented in Figures 5.6-A- C, several miRNAs 
enriched in Treg EVs have one or more targets within each of these pro-inflammatory 
cytokines 3’ UTR of IFNγ, IL-2 and IL-6 mRNAs and notably, multiple miRNAs can target a 
single cytokine 3’ UTR of mRNA. The results of this analysis suggested that miRNAs 
enriched in Treg EVs could potentially modulate cytokine production in target cells such 
as Tresps, given that Tresps produce these pro-inflammatory cytokines as shown in 
Figure 4.7. A summary of the miRNAs that are predicted to target these cytokine mRNAs 
are shown in Figure 5.6-D, with some miRNAs (miR-369-3p, miR-376c-3p and miR-195-
3p) having targets in all cytokine 3’ UTR of IFNγ, IL-2 and IL-6 mRNAs analysed.   
Given that the miRNOME screen showed that human Treg EVs contained miR-1972, 
miR-451 and miR-126 at very high levels and 536.20, 311.50 and 327.89 folds higher 
than in Tregs (Figures 5.3-A and B and Table 5.3), it warranted further investigation. 
However, this further investigation was limited to bioinformatics analysis and not 




predicted in silico binding of miR-1972 to target multiple genes (mRNA) in KEGG 
pathways related to allograft rejection, graft versus host disease and antigen processing 
and presentation (Figures 5.7-A-C, respectively), which targeted HLA-A molecules, 
CD80, CD28 and TNF. KEGG pathways are maps of biological signalling pathways, 
illustrating genes or molecules involved in particular diseases and conditions (Du et al. 
2016).  
In silico analysis revealed that miR-451 and miR-126 targets genes involved in the T cell 
receptor signalling pathways (Figures 5.7-D and E, respectively).  As illustrated in Figure 
5.7-D, miR-451 targets NFATC1; this is upstream of various cytokine productions 
pathway, and, miR-126 targets PIK3R2 (Figure 5.7- E), which is immediately downstream 
of the T cell costimulatory molecules CD28 and ICOS pathways. 
Taken together, the prediction targeting of miRNAs enriched in Treg EVs to their target 
mRNAs suggest that they can inhibit pro-inflammatory cytokines of IFNγ, IL-2 and IL-6 
mRNAs from their translation into protein. Furthermore, these miRNAs can possibly 
inhibit gene expression (mRNAs) associated in KEGG pathways of allograft rejection, 
graft versus host disease, antigen processing and presentation and T cell receptor 









Figure 5.6- Target prediction of miRNAs enriched in human Treg EVs reveals they are 
linked to targeting of pro-inflammatory cytokine genes 
3’ UTR mRNA sections are displayed with the predicted targeting sites of various miRNAs 
found enriched in Treg EVs (A) IFNγ (B) IL-2 and (C) IL-6. (D) Summary of miRNAs that are 















































Figure 5.7- Bioinformatics analysis of miR-1972, miR-451 and miR-126. 
Pathway analysis of miRNAs that are highly enriched in Treg EVs predicted to target 
various genes involved in the immune system pathway. miR-1972, miR-451 and miR-
126, which are highly enriched in human Treg EVs, reveal they are linked to allograft 
rejection and T cell receptor signalling KEGG pathways. Pathway analysis of miR-1972 
predicted that it targets multiple genes involved in (A) Allograft rejection, (B) GvHD (C) 
Antigen processing and presentation. Pathway analysis of (D) miR-451 and (E) miR-126 






As above explained, during my PhD studies, another group had already published that 
human Tregs release EVs that contain miRNAs (Torri et al. 2017), but what is unknown is 
whether human Treg EV-associated miRNAs can modulate cytokine production by 
target cells such as Tresps. As shown in section 4.3.7, human Treg EVs inhibited the 
production levels of IFNγ, IL-2 and IL-6 by Tresps. In this chapter, I have shown that Treg 
EVs contain a collection of miRNAs that are exclusive or found at higher expression 
levels compared to their parent Tregs or compared to Teff EVs, which indicates that 
these miRNAs may be specifically packaged into Treg EVs. The bioinformatics analysis 
revealed that some of the miRNAs found enriched in Treg EVs, namely miR-369-3p, miR-
376c-3p and miR-195-3p were amongst other miRNAs that directly target the 3’ UTR of 
IFNγ, IL-2 and IL-6 mRNA, therefore these miRNAs have the potential to inhibit the 
production of these cytokines, which may in part explain the observations shown in 
section 4.3.7. Treg EVs harboured over 300 folds higher expression levels of miR-1972, 
miR-451 and miR-126 that in their parent Tregs; bioinformatics analysis unravelled that 
these miRNAs target signalling pathways related to allograft rejection, graft versus host 
disease, antigen processing and presentation and T cell receptor signalling.  
However, it is noteworthy that Treg EVs contain other miRNAs that are common to their 
parent Tregs, but even at lower expression levels than Tregs, it may still contribute to 
modulating target cell functions. The analysis performed herein were on miRNAs that 
were enriched in Treg EVs (either found exclusively or found higher expressed than 
Tregs), but other miRNAs found at lower expression levels than the Tregs cannot be 
ruled out for not affecting cytokine production or other target cell function modulation.  
When the cells were compared against EV-associated miRNAs, of the top 50 miRNAs, 
the EVs were more similar to each other than to their parent cells, in agreement with a 
previous report suggesting that EVs derived from various cells are more similar to each 
other than their parent cells (Mittelbrunn et al. 2011). Given that EVs package their 
miRNA in a specific manner, it is therefore reasonable to observe that these Treg EVs 
and Teff EVs may have some commonly expressed miRNAs. The packaging of miRNA 
cargo into EVs is a regulated process with a sorting mechanism in place to select specific 




(Villarroya-Beltri, Gutiérrez-Vázquez, Sánchez-Cabo, et al. 2013). The authors showed 
that sumoylated hnRNPA2B1 controls which miRNAs are packaged into exosomes 
through its interaction with specific motifs (Villarroya-Beltri, Gutiérrez-Vázquez, 
Sánchez-Cabo, et al. 2013). Other mechanisms of miRNA sorting into EVs may also exist. 
Of note, parental T cells and their EVs-contained mRNA and miRNA repertoire differ, 
indicating a possible regulated specific sorting of RNA molecules into EVs for targeted 
roles (Gutiérrez-Vázquez et al. 2013). 
 
5.4.1 miR-142-3p, miR-150-5p, Let-7d 
As shown in section 3.3.8, mouse Treg EVs contain higher expression levels of miR-142-
3p and miR-150-5p compared to FoxP3low T cell EVs. Interestingly, human Teffs had 
higher expression levels of miR-142-3p and miR-150-5p than in Tregs, although Treg EVs 
contained higher expression levels of miR-142-3p and miR-150-5p than in Teff EVs. This 
indicates that Tregs may have specifically packaged a higher amount of miR-142-3p and 
miR-150-5p molecules as these miRNAs have inhibitory roles and thus when delivered 
to target cells can suppress their cellular functions. As I had already discussed in section 
3.4, miR-142-3p and miR-150-5p have been shown by previous studies to be involved in 
inhibiting the immune response, and thus the roles of these miRNAs will not be 
discussed again in this thesis chapter, but I would refer the reader to section 3.4. I also 
found the expression of Let-7d in human Treg EVs, in line with Okoye et al. Okoye et al. 
described that mouse Treg EVs contained Let-7d, which played a role in the reduction of 
IL-2 and IFNγ production by target cells (Okoye et al. 2014). Similarly, these human 
counterparts could be utilising Let-7d in a similar manner. 
 
5.4.2 miRNAs that target IFNγ, IL-2 and IL-6 
Bioinformatics analysis in silico predicted miRNAs enriched in Treg EVs to target pro-
inflammatory IFNγ, IL-2 and IL-6 cytokines mRNAs within the 3’ UTR from translating 
into protein. As demonstrated in section 4.3.7, Treg EVs can significantly inhibit the 
production levels of IFNγ, IL-2 and IL-6 by Tresps. Indeed, this has been shown in the 
mouse Treg setting as mouse Treg exosomes can induce alterations in target cell 




Smyth et al. 2013; Okoye et al. 2014), owing to miRNA carried by exosomes (Okoye et 
al. 2014). Torri et al. found that human T helper cell subsets, Th1, Th17 and Treg cells 
released EVs which had a different miRNA repertoire. These authors showed that Treg 
EVs but not Th1 EVs nor Th17 EVs inhibited CD4+ T cell proliferation. Furthermore, these 
Treg EVs were highly enriched in miR-146a-5p, which suppressed Stat1 and Irak2 in 
target cells (Torri et al. 2017). In agreement to this PhD thesis chapter, human Treg EVs 
used in this project also contained miR-146a-5p which was 3.96 folds higher in 
expression levels than in Teff EVs. This was also the trend for the expression levels of 
miR-146a-5p in Tregs at 3.17 folds higher than in Teffs. This suggests that miR-146a-5p 
may possibly play an important role of regulating the function of target cells. However, 
even though similar miRNAs were found in both Torri et al.’s paper (Torri et al. 2017) 
and in this thesis chapter, there are discrepancies which may be due to different EV 
populations isolated and thus different miRNA repertoires.  
Human Treg EVs held a collection of miRNAs which were found exclusive or higher 
expressed than in their parent Tregs. Of note, certain miRNAs enriched in Treg EVs; miR-
369-3p, miR-376c-3p (also named as miR-368 in literature) and miR-195-3p all had 
bioinformatics predicted targets in 3’ UTR for IFNγ, IL-2 and IL-6 cytokine mRNAs. These 
miRNAs have been reported in literature to affect various cell types. For example, miR-
195 has been shown to inhibit macrophage pro-inflammatory profile and polarising 
their phenotype, in particular IL-6 was significantly decreased by miR-195 (Bras et al. 
2017), thus experimentally validating this miRNA target of IL-6 protein output. Indeed, 
the host laboratory have recently published that Tregs inhibit macrophage production 
of IL-6 (Romano et al. 2018). Although speculative, this could have been mediated by 
Treg EVs transporting this miRNA into the macrophages leading to reduced production 
of IL-6 and warrants further investigation.  
As shown in section 4.3.7, human Treg EVs and Teff EVs affect cytokine production by 
Tresps differently. Treg EVs suppressed the production levels of IL-6, whereas Teff EVs 
increased this. Both miR-142-3p and Let-7g-5p were found at higher expression levels in 
Treg EVs compared to Teff EVs. These miRNAs were experimentally demonstrated by 
Huang et al. to both negatively regulate IL-6 production in leukocytes (Huang et al. 
2017), this finding further supports the notion that Treg EVs cargo are packaged with 




miR-142-3p and Let-7g-5p to target IL-6, this might due to the sensitivity and settings 
used in the bioinformatics program. miR-125-5p is a miRNA that was commonly 
expressed by all the samples tested but were found at higher levels in Treg EVs 
compared to Teff EVs. GATA3 stabilises FoxP3 expression to prevent Tregs 
differentiating into inflammatory cells. Furthermore, GATA3 induces miR-125a-5p 
expression to target IL-6R and STAT3 mRNA. By using miR-125a-5p it dampens the 
sensitivity of Tregs toward IL-6 mediated conversion (Huang et al. 2017). This adds to 
the notion that Treg EVs may be skewing the T cells towards increasing their FoxP3 
expression to differentiate them into induced Tregs. The over-expression of miR-376c-
3p on human adenocarcinoma cell line promoted cell apoptosis and suppressed tumour 
growth in vivo (Tu et al. 2016). Whether Treg EVs promoted target cell apoptosis was 
not tested but given that Tregs use perforin/granzyme as a means of 
immunosuppression (section 1.6.3.3), it is therefore plausible that EVs derived from 
Tregs may also harbour this ability.  
 
5.4.3 miR-1972, miR-126-3p and miR-451 
miR-1972, miR-126-3p and miR-451 that were found >300 folds higher in Treg EVs 
compared to their parent Tregs have also been reported in literature to affect various 
cell types. For example, Agatheeswaran et al. demonstrated that miR-1972 induces G2-
M cell cycle arrest in KCL22 cancer cells (Agatheeswaran, Pattnayak, and Chakraborty 
2016), suggesting that this miRNA may also affect Tresps in a similar manner, although 
cell cycle arrest was not directly tested in this PhD project, I did however test Tresps 
proliferation and observed that Treg EVs have the ability to significantly suppress their 
proliferation which relates to cell cycle arrest. Whether in this project, the suppression 
of Tresps proliferation was due to the actions of miR-1972 initiating cell cycle arrest as 
shown by Agatheeswaran et al. (Agatheeswaran, Pattnayak, and Chakraborty 2016) was 
not tested experimentally, but in silico prediction analysis revealed that miR-1972 can 
target HLA-A molecules, CD28, CD80 and TNF. As demonstrated by Appleman et al., 
CD28 costimulation directly regulates T cell cycle entry and the progression into the G1 
phase of cell cycle (Appleman et al. 2000). Hence, miR-1972 found contained in Treg 




cycle arrest and thus provide an explanation for Treg EVs’ ability to inhibit Tresps 
proliferation.  
Wu et al. demonstrated that miR-126-3p targets PIK3R2 resulting in suppressed cell 
proliferation, arrested cell cycle progression and cell apoptosis in sarcoma cells (X.-J. Wu 
et al. 2016). Similarly, Xiao et al. found that overexpression of miR-126 in bladder 
cancer cells inhibits proliferation, migration, promoted cell apoptosis and induced S cell 
cycle phase arrest which was due to regulation of the PI3K/Akt signalling pathway (J. 
Xiao et al. 2016). As shown in Figure 5.7-E, miR-126-3p targets PIK3R2 within the TCR 
signalling pathway. PIK3R2 is immediately downstream of CD28 signalling. Furthermore, 
the PIK3R2, which is also known as P85β, is a subunit of PI3K and thus regulates PI3K 
enzyme activity. PI3K/AKT/mTOR pathway is essential for T cell development and 
activation. Various studies have shown that blocking the PI3K/AKT/mTOR pathway 
inhibits T cell activation (Herrero-Sánchez et al. 2016; Xue et al. 2008). Chu et al. 
recently published that miR-126 deficiency enhanced the activation and function of 
CD4+ T cells (Chu et al. 2018). Although, not shown directly, it is probable that the 
reverse of increasing miR-126 expression decreases CD4+ T cell activation and function 
which further supports the above findings. Furthermore, miR-126 was shown to be 
important for the suppressive ability of Tregs and silencing miR-126 results in reduced 
FoxP3 expression by targeting of PIK3R2 (Qin et al. 2013). Therefore, it is tempting to 
speculate that Treg EVs specifically packaged over 300 folds higher expression levels 
than their Tregs of miR-1972 and miR-126-3p in an intended way to suppress Tresps 
activation and proliferation given their targeting of CD28 and PIK3R2. 
In 2017, Chapman et al. demonstrated that miR-451 limited CD4+ T cell proliferation in 
response to infection in mice. These authors showed that Myc that has a role in cell 
cycle progression and cell proliferation was a target of miR-451 (Chapman et al. 2017). 
Additionally, Zeng et al. demonstrated that T cells transfected with a miR-451a mimic 
inhibited their activation and proliferation by targeting Myc (Zeng et al. 2017). Taken 
together, miR-451 may also play an important role in suppressing T activation and 
proliferation. Furthermore, miR-451 is linked to DC cytokine regulation of IL-6 
(Rosenberger et al. 2012), which supports the bioinformatics analysis finding that miR-





5.4.4 miRNAs found in human Treg EVs that are linked to inducing or promoting Tregs 
From the human miRNOME results, miR-10a-3p was found in Treg EVs. Bluestone’s 
group published a paper demonstrating how miR-10a marks Tregs due to miR-10a’s 
contribution to stabilise mouse Tregs via FoxP3 expression (Jeker et al. 2012). Whether 
in the human setting, miR-10a is essential for FoxP3 expression in human Tregs is 
unclear. However, given that in the human miRNOME, I found miR-10a-3p in human 
Treg EVs but not in human Tregs might suggest that other miRNAs may be in place to 
stabilise FoxP3 in human Tregs. One of these other miRNAs could be miR-21. miR-21-5p 
expression levels was higher in human Treg EVs compared to Teff EVs. As demonstrated 
by Rouas et al., miR-21 in an indirect manner positively regulates FoxP3 expression, 
whereas, on the other hand, miR-31 negatively regulates FoxP3 expression in human 
Tregs (Rouas et al. 2009). 
In 2014, Dong et al. found that in rheumatoid patients’ Tregs had a significant decrease 
of miR-21 and FoxP3 mRNA expressions compared to healthy controls, which was 
associated with increased STAT3 and decreased STAT5 protein expression and a 
skewing towards Th17 cells (Dong et al. 2014). Due to these findings, it was suggested 
that miR-21 may be part of a negative feedback loop dysregulated in rheumatoid 
arthritis patients which might explain the imbalance between Th17 cells and Tregs. 
Indeed, the study by Rouas et al. supports this hypothesis (Rouas et al. 2009). IL-2 
signalling is crucial for Treg differentiation and can be more efficient by miRNA-driven 
downregulation of the IL-2R signalling inhibitors of SOCS1 and STAT3. These inhibitors 
keep STAT5 transcription factor inactive, however STAT5 is involved in many aspects of 
Treg activity and important for their FoxP3 expression (Passerini et al. 2008). miR-155 
have been demonstrated to target SOCS1 (Ye et al. 2016; Pathak et al. 2015; D. Wang et 
al. 2018) and miR-21 to target STAT3 (Hippen et al. 2018; Haider et al. 2010). Together, 
this suggest that miR-21 found in Treg EVs could be targeting STAT3 and thus promoting 
STAT5 signalling and promoting FoxP3 expression, possibly to convert Tresps into 
induced Tregs. For instance, from the human miRNOME, miR-155 was commonly 
expressed in all the sample types of Tregs, Teffs, Treg EVs and Teffs EVs. Increased 
expression levels of miR-155 enhances the inhibitory function of CD39+ Tregs (J. Liu et 
al. 2015). Additionally, FoxP3 directly induces miR-155 and promotes the survival of 




It is important to note that the mentioned publications reflects the miRNAs that are 
found exclusively or higher expressed in Treg EVs compared to Tregs or Teff EVs, but as 
Treg EVs will contain other common miRNAs to Tregs and Teff EVs (but at the same or 
lower expression levels), these common miRNAs may still contribute to 
immunosuppression given that Tregs and Teff EVs (and Teffs) were all 
immunosuppressive (sections 4.3.3 and 4.3.4). However, as a step towards unravelling 
the complex miRNA repertoire, the miRNAs found exclusively or higher expressed in 
Treg EVs compared to Tregs or Teff EVs was used. 
 
5.5 Summary 
Taken together, the miRNAs found in Treg EVs are likely to play a role in modifying the 
in vitro immune responses observed in Chapter 4 and warrants further validation. 
Specifically, human Treg EVs significantly inhibited the production levels of IFNγ, IL-2 
and IL-6 by Tresps which may be driven by a collection of miRNAs found exclusively or 
highly enriched in Treg EVs. Bioinformatics analysis predicted these miRNAs to target 
the 3’ UTR the pro-inflammatory cytokines; IFNγ, IL-2 and IL-6 mRNA, hence inhibiting 
their translating into protein and to play a role in suppressing genes within the allograft 









Assessing Human Treg EV 




Chapter 6 - Assessing Human Treg EV functions in vivo 
6.1 Introduction 
In this thesis chapter I will present data that assesses the function of Treg EVs in vivo. To 
address this aim, humanised mouse models were used. To understand whether Treg 
EVs have the potential to reach the transplanted human skin allograft, the expression of 
homing receptors and the trafficking of EVs to the allograft were tested.  
 
6.1.1 Humanised mouse models of transplantation 
The results obtained by manipulating the immune system of rodents have not been 
translated into the clinical setting and this is due in part to the fundamental differences 
that exist between animal and human cells and their immune responses (Mestas and 
Hughes 2004; Kenney et al. 2016). An example of this is when mouse tissues/organs 
have been depleted of CD45+ cells before transplantation; it significantly promotes the 
longevity of the graft and in some cases induces immune tolerance. On the contrary, 
the removal of CD45+ cells in human tissues provides no advantage as the graft still 
rapidly rejects (Mestas and Hughes 2004; Wood 2003). Another key example is the non-
obese diabetes (NOD) mice which spontaneously develop diabetes (Makino et al. 1980), 
but when treated with rapamycin and IL-2 prevented spontaneous and recurrent 
autoimmune diabetes following islet transplantation (Rabinovitch et al. 2002). However, 
when this approach was used in a clinical trial, rapamycin and IL-2 treatment caused a 
detrimental outcome in humans as this treatment impaired β-cell function (Long et al. 
2012). 
Thus, the development of immunodeficient mice for engrafting and therefore 
reconstituting the mice with a functional human immune system have been extensively 
researched (Kenney et al. 2016; Safinia et al. 2016). To achieve engraftment in mice, it is 
vital to use immunocompromised mice as the transfer of human cells would otherwise 
be targeted for destruction by xeno-immune responses mediated by the existing mouse 
T cells (Kenney et al. 2016). To date, there are various strains of immunodeficient mice 
that can be used for the engraftment of human haematopoietic cells, the common 




NOD.Cg-Rag1tm1MoMIl2rgtm1Wjl (NRG) and C.Cg-Rag2tm1FwaIl2rgtm1Sug (BRG). NSG, NOG 
and NRG are all NOD strains of mice and lack T, B and NK cells with additional defects in 
innate immune cells (Kenney et al. 2016). Whereas, BRG mice has a mixed genetic 
background mainly derived from the BALB/c strain, nonetheless BRG mice also lack T, B 
and NK cells but the remaining mouse innate immune cells are functional (Kenney et al. 
2016).  
The NSG and NRG mice have mutations in IL-2Rγ which means there are no expressions 
of these genes and thus without IL-2Rγ, it will not bind cytokines. NOG mice lack the 
intracytoplasmic domain of IL-2Rγ which means these cells will recognise cytokines but 
will not transduce downstream signalling. BRG mice lack the intracytoplasmic domain of 
IL-2Rγ also (Kenney et al. 2016). This receptor binds to cytokines but cannot signal and 
thus these mice are unresponsive to IL-2, IL-4, IL-9, IL-15, IL-17 and IL-21. Blocking these 
cytokines signalling pathways effectively inhibits innate and adaptive immunity (Kenney 
et al. 2016). These mice lack RAG2 and consequently, the rearrangement of TCR/BCR 
loci is inhibited and thus BRG mice lack functional T and B cells and NK cells. However, 
as described above, the remaining mouse innate immune cells are functional (Kenney et 
al. 2016), these functional granulocytes can significantly damage transplanted human 
tissues hence to achieve high levels of human cell engraftment, continual depletion of 
these granulocytes are required and can be performed through twice weekly injections 
of mouse anti-granulocyte receptor 1 (anti-Gr1) antibody (Racki et al. 2010). 
The use of humanised mouse models as pre-clinical models for transplantation 
research, in particular with transplant rejection have undoubtedly been instrumental in 
advancing the understanding of the human immune system (Issa et al. 2010; Safinia et 
al. 2016; Kenney et al. 2016). Various human tissues can be transplanted into mice; the 
most frequently used human tissue for transplantation onto mice is human skin as it is 
readily available from surgical procedures and due to the less invasive procedure of 
transplantation onto mice with this tissue type.  
The host laboratory has already established a humanised mouse model of 
transplantation using BRG mice and using human skin (P. Sagoo et al. 2011), whereby 
the transfer of allogeneic PBMCs causes alloimmune mediated graft damage. This 
damage was measured by inflammation of the epidermal layers and destruction of 




Sagoo et al. 2011). However, this level of alloimmune mediated damage was prevented 
with the additional adoptive transfer of alloantigen specific Tregs, which were more 
potent at inhibiting the inflammatory response compared to polyclonal Tregs (P. Sagoo 
et al. 2011; Putnam et al. 2013). The BRG strain of mice were selected as the humanised 
mouse models of human skin transplantation to test the in vivo function of Treg EVs in 
this PhD thesis.  
 
6.1.2 Homing receptors and tracking EVs in vivo 
An important in vivo feature of Tregs is their ability to migrate to specific locations to 
mediate efficient immune responses (Issa et al. 2012). Trafficking of Tregs is principally 
driven by homing receptors, chemokine to chemokine receptors and integrin to integrin 
ligands interactions (Lim, Broxmeyer, and Kim 2006; S. Wei, Kryczek, and Zou 2006).   
CD62L is an important homing receptor found on Tregs (Lim, Broxmeyer, and Kim 2006; 
S. Wei, Kryczek, and Zou 2006). In previous studies, murine CD62L+ Tregs and CD62L- 
Tregs were both able to suppress T cell activation (Szanya et al. 2002; A M Thornton and 
Shevach 2000), however the CD62L+ Tregs rather than the CD62L- Tregs were more 
efficient in protecting against lethal acute GvHD (Ermann et al. 2005; Taylor et al. 2004) 
and delayed diabetes onset in NOD mice (Szanya et al. 2002). Furthermore, blocking 
CD62L activity with neutralising antibodies blocked Treg expansion in draining lymph 
nodes and led to rapid cardiac allograft rejection (Ochando et al. 2005). Thus, entry into 
the secondary lymphoid organs is important and made efficient by the expression of 
CD62L on Tregs. 
CCR4 is a skin homing receptor found on Tregs (Issa et al. 2012). CCR4 expression on 
Tregs allows for their migration toward its ligands CCL17 and CCL22, which are 
produced by mature dendritic cells, thus mediating migration of Tregs into lymphoid 
tissues (Halim et al. 2017). 
Tracking of EVs in vivo and understanding their migratory patterns and how they are 
distributed in vivo can aid their development as potential delivery vehicles. Takahashi et 
al. provided some insights into the trafficking of exosomes in vivo, these authors 




protein and visualised using whole body imaging was possible and tracking can be 
performed for hours (Y. Takahashi et al. 2013).  
Labelling of exosomes can also be performed by transfecting the parent cells with 
CD63-eGFP (Mittelbrunn et al. 2011) and visualised in vivo (Lai et al. 2015) and using 
whole body optical imaging (M. Yang et al. 2000). Tracking EVs in the context of a 
humanised mouse model of transplantation will provide invaluable insights into the 
spatiotemporal dynamics which may aid the understanding of their specific 
immunomodulatory functions. However, the migratory route of Treg EVs post-injection 
into an animal host remains elusive, but important to understand if used as a potential 
immunotherapeutic agent.  
 
6.2 Aims and objectives 
Aim 
The aim of this thesis chapter was to assess whether Treg EVs function in vivo by 
assessing their ability to suppress alloimmune mediated skin allograft damage.  
Objectives: 
(1) Test for the presence of homing receptors on Tregs and their EVs to provide an 
understanding of their potential migratory ability.  
(2) Assess the suppressive function of Treg EVs and Teff EVs in vivo using humanised 
mouse models of human skin transplantation.  




6.3.1 Human Tregs, Teffs and Treg EVs express homing receptors  
As previously described, homing of Tregs to specific locations is important for their 
efficient function (Issa et al. 2012). To test that the Tregs and Teffs express homing 
markers, Tregs and Teffs were immunostained with antibodies and acquired on a flow 




(78.5% ± 11.4%) (Figures 6.1-A, C and D) while a lower percentage of Teffs were CD62L+ 
(56.7% ± 12.6%) and CCR4+ (62.7% ± 1.6%) (Figures 6.1-B- D). To test whether Treg EVs 
also expressed CCR4, Treg EVs were attached to latex beads and immunostained and 
acquired on a flow cytometer. Treg EVs displayed a low expression level of CCR4 on 
their surfaces (Figure 6.1-E), suggesting that they have the potential bind to its ligands; 
CCL17 and CCL22, which are present in human skin (K. Fukuda et al. 2003; Tapia et al. 
2007). Due to time constraints on this project the presence of CCR4 on Teff EVs and the 
expression of CD62L were not assessed on Treg EVs or Teff EVs.  
 
Figure 6.1- Human Tregs, Teffs and Treg EVs express homing receptors 
(A) Human Tregs and (B) Teffs were expanded in vitro and at the end of culture were 
immunostained to test for the expression of CD62L and CCR4. The y-axis indicates the 
percentage of maximum expression. (C and D) The pooled data of percentage of cells 
that had positive expression levels on Tregs or Teffs for (C) CD62L and (D) CCR4. n= 3-4 
per group. (E) Human Tregs were activated using plate-bound anti-CD3/CD28 antibodies 
and after 24 hours, the supernatant was collected and EVs purified using 




presence of CCR4 expression. The y-axis indicates the percentage of maximum 
expression. Representative FACS plot from 4 independent experiments.   
 
6.3.2 Human Treg EVs and Teff EVs function in vivo to prevent human skin allograft 
morphological damage 
To investigate whether human Treg EVs elicited a similar protective role in vivo as 
observed in vitro in section 4.3.4 and section 4.3.7, we utilised a well-established 
humanised mouse model of skin transplantation (P. Sagoo et al. 2011; Putnam et al. 
2013). In this model, recipient-derived T cells are the major driver of human skin 
transplant rejection.  
Using this model, two preparations of Treg EVs were used due to previous reports 
describing the differences of EVs functionality depending on the EV isolation method 
used (Y.-T. Tang et al. 2017; Rekker et al. 2014). Therefore, it was important to 
determine whether the in vivo function of Treg EVs isolated by ExoQuick-TC™ (EQ) were 
similar to Treg EVs isolated by ultracentrifuge (ultra).  
To test whether anything pelleted from the media using ExoQuick-TC™ was responsible 
for causing the response observed in vivo, the pellet resulting from the media alone was 
injected into the mice. This was arranged by preparing a pellet of media alone (no cells 
or EVs) mixed with ExoQuick-TC™. Using the above mentioned humanised mouse model 
of skin transplantation approach, human skin grafts were transplanted onto BRG 
immunodeficient mice and after 35 days, 5x106 allogeneic human CD25- peripheral 
blood mononuclear cells (PBMCs) were adoptively transferred alone or in combination 
with 1x106 autologous Tregs, 50x106 Tregs-derived EVs isolated by ExoQuick-TC™ (EQ), 
50x106 Tregs-derived EVs isolated by ultracentrifugation (ultra), 50x106 Teffs-derived 
EVs (EQ) or the equivalent amount of media alone used to isolate the EVs (media pellet 





Figure 6.2- Humanised mouse model of skin transplantation 
Diagram outlining the experimental set up and time-line of the human skin xenograft 
transplant and adoptive transfer of cells and EVs. BRG immunodeficient mice were 
transplanted with a section of human skin which was derived from healthy donors with 
written consent. After 35 days, the mice received allogeneic CD25- PBMCs, in the 
absence or presence of autologous 1x106 Tregs, 50x106 Tregs-derived EVs isolated by 
ExoQuick-TC™ (EQ), 50x106 Tregs-derived EVs isolated by ultracentrifuge (ultra), 50x106 
Teffs-derived EVs isolated by EQ or the pellet resulting from media alone mixed with EQ 
(media pellet EQ). Cells and EVs were injected via the tail vein intravenous route. From 
that point onwards until day 70 post-transplant, the mice received 100µg of anti-mouse 
anti-Gr1 injection twice weekly via the intraperitoneal route.  
 
As explained in section 6.1.1, the innate mouse cells are functional in these mouse 
models therefore to prevent the mouse cells from damaging the injected human cells; 
the transplanted mice received twice weekly injections of anti-mouse anti-Gr1 antibody 
from the time of injection of the human cells (day 30) until the end point of study; day 
70 post-transplantation. Throughout the study, the mice did not exhibit symptomatic 




after the injection of the human cells and the skin allografts were assessed 
macroscopically for visible signs of skin damage (Appendix 6-A). The mice treated with 
PBMCs alone appeared to display visible signs of inflammatory damage compared to 
saline controls, however with the additional treatment of Tregs, Treg EVs (EQ), Treg EVs 
(ultra) and Teffs EVs (EQ), the visual appearance of inflammatory damage was reduced 
(Appendix 6-A). The parameters used to assess visual macroscopic inflammatory 
damage were the changes in skin colour; whereby skin that had darkened indicated 
higher levels of damage due to vessel ruptures caused by alloimmune mediated 
responses.  
The ventral side of the human skin allograft were checked for visible vascular networks 
providing the allograft with blood supply which otherwise the allograft may deteriorate 
due to lack of bloody supply which could subsequently be mistaken for transplant 
rejection (Appendix 6-B). 
 
 
Figure 6.3- Mice body weight throughout study 
The body weight of each mouse was recorded throughout the study. The initial weight of 
each mouse was recorded as 100%, and every week their weight was taken and 
presented as relative to the initial 100% weight. Bars show mean+ SEM. n= 3-9 per 
group. 
 
Human skin allografts were analysed using various histological immunostaining 




the various treatments, haematoxylin & eosin (H&E) staining was performed on cross-
sections of the grafted human skin. The PBMCs-treated mice displayed an irregular 
stratum corneum, disrupted epidermis and dense cellular infiltration compared to 
saline-treated control mice (Figures 6.4-B and A, respectively). Additional treatment 
with Tregs, Treg EVs (EQ), Treg EVs (ultra) and Teff EVs (EQ) resulted in a uniform 
stratum corneum and the epidermis appeared regular with less cellular infiltration 
compared with PBMCs treated mice (Figures 6.4-D-G, respectively). Having confirmed 
that the EVs isolated from media alone did not contribute to inhibition of T cell 
proliferation in vitro (Figure 4.5-I), I next tested whether the media alone pellet affected 
the outcome in vivo. Mice treated with Media pellet (EQ) showed thickening of the 
epidermis layer akin to the PBMCs-treated controls (Figures 6.4-C and B, respectively) 
suggesting that the media pellet does not contribute to morphological changes seen 
with the EV preparations.  
Morphometric measurements and statistical analysis of the epidermis architecture was 
performed using two assessment criteria; the epidermal thickness (without the rete 
ridges) and the height of the rete ridges from the base (Figure 6.4-H), similar to the 
histological assessment criteria employed by other groups (Giangreco et al. 2010; 
Chanadanwale et al. 2015). 
The epidermal thickness was significantly increased by the treatment of PBMCs alone or 
PBMCs+ Media pellet (EQ) as compared to saline controls (p<0.0001 and p=0.0197, 
respectively; Figure 6.4-I), indicating an alloimmune mediated inflammatory response. 
When PBMCs were co-injected with the addition of Tregs, Treg EVs (EQ), Treg EVs 
(ultra) or Teff EVs (EQ) this significantly decreased the epidermal thickness (all 
p<0.0001; Figure 6.4-I). When PBMCs+ Media pellet (EQ) was injected or PBMCs with 
Treg EVs (EQ) or Treg EVs (ultra), a significantly decreased epidermal thickness was 
observed (p=0.0414 and p=0.0437, respectively; Figure 6.4-I), indicating that Treg EVs 
function in vivo. However, the comparison PBMCs+ Media pellet (EQ) with PBMCs+ Teff 
EVs (EQ) resulted in no statistically significant difference (p=ns; Figure 6.4-I). 
The rete ridges elongate from the epidermal to dermal regions to enhance the surface 
area of the capillary-epidermal junction, but irregular elongation of rete ridges are signs 
of inflammatory skin lesions (Lawlor and Kaur 2015). To test whether rete ridge heights 




ridge height was significantly increased by the treatment of PBMCs alone or PBMCs+ 
Media pellet (EQ) compared to saline (both p<0.0001; Figure 6.4-J), providing another 
indication of an alloimmune mediated inflammatory response. When PBMCs were co-
injected with the addition of Tregs, Treg EVs (EQ), Treg EVs (ultra) or Teff EVs (EQ), the 
rete ridge heights were significantly decreased (all p<0.0001; Figure 6.4-J).  
When PBMCs+ Media pellet (EQ) was injected or PBMCs with Treg EVs (EQ) or Treg EVs 
(ultra), a significantly decreased rete ridge height was also noted (p=0.0291 and 
p=0.0037, respectively; Figure 6.4-J), providing yet another indication that Treg EVs 
function in vivo. However, the comparison PBMCs+ Media pellet (EQ) with PBMCs+ Teff 
EVs (EQ) resulted in no statistically significant difference (Figure 6.4-J). 
Overall, the data suggests that human Treg EVs and Teff EVs may protect against 










Figure 6.4- Human Treg EVs prevented alloimmune mediated morphological damage of 
human skin  
Transplanted human skin allografts were harvested 35 days post- cells/EVs injection and 
stained with haematoxylin and eosin (H&E) and acquired using a high definition 
scanning light microscope. Representative images are shown. The left panel indicates a 
5X objective with a scale bar of 500μm, the dotted box is enlarged and displayed in the 
middle panel which indicates a 10X objective with a scale bar of 250μm. The lined box is 
enlarged and displayed in the right panel which indicates a 20X objective with a scale 
bar of 100μm. The H&E images show mice treated with (A) Saline (B) PBMCs (C) PBMCs+ 
Media pellet (EQ) (D) PBMCs+ Tregs (E) PBMCs+ Treg EVs (EQ) (F) PBMCs+ Treg EV 




histological assessment of epidermis was performed. The blue arrow indicates the start 
and end point for measuring epidermal thickness and the red arrow indicates the start 
and end point for measuring rete ridge height. Graphs show (I) the epidermal thickness 
and (J) rete ridge height of the various treated mice. Bars show mean ± SEM. For each 
condition, the number of mice used were; Saline n=7, PBMCs n=9, PBMCs+ Media pellet 
n=3, PBMCs+ Tregs n=8, PBMCs+ Treg EVs (EQ) n=5, PBMCs+ Teff EVs (EQ) n=4 and 
PBMCs+ Treg EVs (Ultra) n=3. Statistical significance was tested using one-way ANOVA 
where *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 and ns= non-significant.  
 
6.3.3 Human Treg EVs and Teff EVs protect against alloimmune mediated human skin 
allograft damage by reducing immune cell infiltration 
To further investigate how human Treg EVs inhibited alloimmune mediated human skin 
allograft damage I used a panel of immunofluorescence staining parameters to test 
various markers previously used to assess skin graft condition (P. Sagoo et al. 2011; 
Putnam et al. 2013). These staining panels included: CD45, a common leukocyte antigen 
marker; CD3, a T cell marker; Ki67, a cell proliferation marker (proliferating 
keratinocytes); CD31, an endothelial marker indicating the integrity of blood vessels and 
involucrin, a human skin protein marker present in the epidermis.  
A significant increase of CD45+ immune cells and CD3+ T cells was observed in the 
PBMCs-treated mice compared to saline-treated control mice (CD45+ cells p<0.0001 
and CD3+ cells p<0.0001; Figures 6.5-A, B, H and I). In addition, the Ki67+ proliferating 
keratinocytes were also significantly increased in the PBMCs-treated mice compared to 
saline-treated control mice (p<0.0001; Figures 6.5-A, B and J). Together, this 
demonstrated that the transfer of allogeneic PBMCs induced a high level of infiltration 
of cells, linking to the inflammatory damage observed macroscopically and 
morphologically (Appendix 6-A and Figures 6.4-A and B).   
The mice which received PBMCs with the addition of Tregs, Treg EVs (EQ), Treg EVs 
(ultra) or Teff EVs (EQ) had significantly decreased numbers of infiltrating CD45+ cells 
compared to PBMCs alone (Tregs p=0.0026; Treg EVs (EQ) p<0.0001; Treg EVs (ultra) 
p=0.0016; Teff EVs (EQ) p=0.0003; Figure 6.5-H), which correlated with significantly 




p=0.0001; Teff EVs (EQ) p<0.0001; Figure 6.5-I). Notably, when Tregs were adoptively 
transferred into the hosts, the reduction of infiltrating CD45+ and CD3+ cells were not as 
pronounced as expected (P. Sagoo et al. 2011; Putnam et al. 2013; Boardman et al. 
2017) as the adoptive transfer of Treg EVs (EQ) (For CD45+; Tregs p=0.0026 and Treg 
EVs (EQ) p<0.0001; For CD3+; Tregs p=0.0058 and Treg EVs (EQ) p<0.0001), which may 
be due to the Tregs inducing a population of adaptive Tregs within the transplanted 
allograft, as previously demonstrated by the host laboratory (P. Sagoo et al. 2011; 
Putnam et al. 2013; Boardman et al. 2017).     
Furthermore, I also observed a significantly decreased frequency of Ki67+ proliferating 
keratinocytes with the addition of Tregs, Treg EVs (EQ), Treg EVs (ultra) or Teff EVs (EQ) 
compared to PBMCs alone (Tregs p<0.0001; Treg EVs (EQ) p<0.0001; Treg EVs (ultra) 
p=0.0006; Teff EVs (EQ) p=0.0001; Figure 6.5-J). The involucrin-expressing epidermal 
layer was intact in the saline treated mice but was partially lost or defected in PBMCs 
treated mice, indicating signs of damage. This level of damage (as observed by 
involucrin) was not observed in the presence of Tregs, Treg EVs (EQ), Treg EVs (ultra) or 
Teff EVs (EQ) (Figures 6.5-B, D-G). The CD31 endothelial marker indicating the integrity 
of blood vessels in the saline treated mice were intact and had a uniform vascular 
structure but this was clustered in the PBMCs treated mice, indicating alloimmune 
damage. These vessels were protected from damage by the presence of Tregs, Treg EVs 
(EQ), Treg EVs (ultra) or Teff EVs (EQ) (Figures 6.5-B, D-G).   
Additional treatment with the Media pellet (EQ) had no significant effect on the 
infiltration of cells compared to PBMCs alone as measured by the frequency of CD45+ 
cells, Ki67+ cells and CD3+ cells (Figures 6.5-H-J). Hence the background control of Media 
pellet (EQ) does not contribute to the effects observed by Treg EVs (EQ) nor Teff EVs 
(EQ). However, when statistical testing was performed for CD45+ frequencies for 
PBMCs+ Media pellet (EQ) and PBMCs+ Treg EVs (EQ) or PBMCs+ Teff EVs (EQ) it 
resulted in p=0.0036 and p=ns, respectively (Figure 6.5-H). Similarly, for CD3+ 
frequencies, PBMCs+ Media pellet (EQ) and PBMCs+ Treg EVs (EQ) or PBMCs+ Teff EVs 
(EQ) it resulted in p=0.0016 and p=0.0172, respectively (Figure 6.5-I). Whereas, for 
Ki67+ frequencies, PBMCs+ Media pellet (EQ) and PBMCs+ Treg EVs (EQ) or PBMCs+ Teff 
EVs (EQ) it resulted in p<0.0001 and p=0.0027, respectively (Figure 6.5-J). Taken 




alone with each of the treatment groups, the p-values from PBMCs alone were more 
statistically significant compared to the p-values obtained when comparing PBMCs+ 
Media pellet (EQ) with each treatment group, which might indeed be due to some 
minimal effects from the Media pellet (EQ). 
Nonetheless, there was no significant difference between Treg EVs (EQ) and Treg EVs 
(ultra) when injected in vivo and assessed for the frequency of CD45+ cells, Ki67+ cells 
and CD3+ cells (Figures 6.5-H-J). Furthermore, there was no significant difference 
between Treg EVs (EQ) and Teff EVs (EQ) treatment when assessed for the frequency of 
CD45+ cells, Ki67+ cells and CD3+ cells (Figures 6.5-H-J), thus Treg EVs (EQ) and Teff EVs 
(EQ) have similar effects in vivo. 
Overall, the adoptive transfer of human Treg EVs, isolated by ExoQuick-TC™ or 
ultracentrifuge, and Teff EVs protected against human skin damage mediated by 
alloreactive CD3+ T cells. Human Treg EVs reduced the numbers of CD45+ immune cells, 
CD3+ immune cells and Ki67+ keratinocytes within the allograft, suggesting that human 
Treg EVs may have a role in promoting transplant tolerance by inhibiting intra-graft cell 
infiltration.   
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Figure 6.5- Human Treg EVs protect against alloimmune mediated human skin allograft 
damage by reducing the infiltration of immune cells and inhibiting the proliferation of 
keratinocytes 
(A-G) Representative confocal immunofluorescence images of human skin graft sections 
fixed and stained for (first column) human CD45 (green), Ki67 (red) and DAPI (blue); 
(second column) CD31 (green), involucrin (red) and DAPI (blue); (third column) human 
CD3 (red) and DAPI (blue) with the various indicated treatments. Mice were treated with 
(A) saline (B) PBMCs (C) PBMCs+ Media pellet (EQ) (D) PBMCs+ Tregs (E) PBMCs+ Treg 
EVs (EQ) (F) PBMCs+ Treg EVs (ultra) and (G) PBMCs+ Teff EVs (EQ). Quantification of 
the numbers of (H) human CD45+ cells (I) CD3+ cells and (J) Ki67+ cells per field of view 




per group where two to three fields of view were quantified per section and data are 
representative of 5 individual experiments. For each condition, the number of mice used 
were; Saline n=7, PBMCs n=9, PBMCs+ Media pellet n=3, PBMCs+ Tregs n=8, PBMCs+ 
Treg EVs (EQ) n=5, PBMCs+ Teff EVs (EQ) n=4 and PBMCs+ Treg EVs (Ultra) n=3. 
Statistical significance was tested using one-way ANOVA where *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 and ns= non-significant. 
 
6.3.4 Human Tregs can be labelled with eGFP-CD63 and mCherry-CD63 
Given the above findings it could be envisaged that Treg EVs may have migrated to the 
site of transplanted tissue to exert their suppressive function. Thus, to determine 
whether Treg EVs migrated to the transplanted human skin tissue or whether these 
migrated to secondary lymphoid organs such as the spleen or lymph nodes, Treg EVs 
were labelled with eGFP-CD63 or mCherry-CD63 to initially assess which construct 
provided the best transduction efficiency. To this end, Tregs were transduced with 
eGFP-CD63 or mCherry-CD63 lentiviral particles with the aim to track their migration 
and uptake by target T cells. Given that Tregs and Teffs are difficult to distinguish, I 
aimed to transduce Tregs with eGFP-CD63 (or mCherry-CD63 if this provided a higher 
transduction efficiency) and T cells with the other construct to discriminate the two EV 
populations and to visualise the transfer of EVs (Figure 6.6). Furthermore, the process 
of Treg release of EVs and their uptake by target T cells has not previously been imaged. 
As shown in Figures 4.2 and 4.3, human Tregs and Teffs express CD63 both on the 









Figure 6.6- Diagram of labelled Treg EVs 
Diagram showing the aim to visualise the interaction of pre-labelled Treg EVs (eGFP-
CD63+) and target cells (e.g. T cells). To discriminate between the different EVs (in case 
of EV cross-talk between the two cells), target cells will be labelled with mCherry-CD63+ 
to obtain mCherry-CD63+ EVs. 
 
The eGFP-CD63 and mCherry-CD63 vector constructs were a kind gift from Professor 
Tony Ng, King’s College London. A vector map of eGFP-CD63 and mCherry-CD63 are 
included in Appendix 1 and 2, respectively. To prepare plasmid DNA, maxipreps were 
processed and restriction analysis using EcoRI-HF® and AgeI-HF® enzymes performed on 
the selected clones to confirm the correct DNA was purified (Appendix 7). HEK293Ts are 
highly transfectable cells derived from HEK293 cells (Russell et al. 1977) which have 
been modified to stably express the Simian Vacoulating Virus 40 (SV40) large T-antigen. 
The presence of the SV40 T-antigen allows this cell line to replicate vectors carrying the 
SV40 region of replication (DuBridge et al. 1987; Pear et al. 1993) and able to support 
high titre lentivirus and retrovirus production. Thus, HEK293Ts were used as the viral 
particle producer cell line due to their efficiency in high titre viral particle production. 
HEK293Ts were transfected with a 3rd generation lentiviral system using 4 plasmids. 
These 4 plasmids consisted of pVSV-g (envelope vector), pRRE and pREV (packaging 
vectors) (a kind gift from Dr Gilbert Fruhwirth, King’s College London) and eGFP-CD63 or 
mCherry-CD63 (gene of interest vectors). 48 hours post transfection, HEK293Ts 
expressed either eGFP or mCherry, demonstrating that they were successfully 




of eGFP and mCherry expression, the supernatant containing eGFP-CD63+ or mCherry-
CD63+ viral particles were harvested and concentrated.  
 
Figure 6.7- Transfection of HEK293Ts with eGFP-CD63 and mCherry-CD63 
HEK293Ts were transfected with pVSV-g (envelope vector), pRRE and pREV (packaging 
vectors) and (A) eGFP-CD63 or (B) mCherry-CD63 vectors. Top panels show 10X 
objectives with a scale bar of 400µm and bottom panels show 40X objectives with a 
scale bar of 100µm. Left panels show the respective fluorescence detected using GFP or 
RFP filters and right panels show the corresponding differential interference contrast 




Three days post human Treg isolation; Tregs were transduced with various volumes of 
viral particles at 30µl, 50µl and 80µl to test the effect of increasing viral particle titre 
and the corresponding transduction efficiency. Seven days later, the transduction 
efficiency was assessed by flow cytometry. The transduction efficiency correlated with 
the volumes of eGFP-CD63 viral particles, namely 30µl of viral particles achieved 41.4% 
transduction efficiency, whereas 50µl achieved 46.8% and 80µl achieved 55.3% (Figure 
6.8-A). The positive expression of eGFP was further confirmed by fluorescence 
microscopy (Figure 6.8-B). Similarly, the trend of higher viral particle titre with higher 
transduction efficiency was also observed for Tregs transduced with mCherry-CD63 viral 
particles (30µl of viral particles achieved 21.1%, whereas 50µl achieved 26.7% and 80µl 
achieved 30.3%) (Figure 6.8-C). This result was also confirmed by fluorescence 
microscopy (Figure 6.8-D). Ten days post-transduction, the cells were assessed by flow 
cytometry to check the percentage of cells positive for eGFP and mCherry expression 
(Figures 6.9-A and B, respectively). As observed, the percentage of cells positive for 
eGFP and mCherry had notably decreased from day seven to day ten post-transduction 
(Figures 6.8 and 6.9), possibly due to the untransduced cells having a survival, growth or 
expansion advantage over transduced cells as cells that have been transduced may slow 
their metabolism or general cell functions. To expand a pure population of eGFP-CD63+ 
and mCherry-CD63+ Tregs, transduced cells were FACS-sorted on day eleven, post 






Figure 6.8- Transduction efficiency of human Tregs with CD63-eGFP and CD63-mCherry 
viral particles 7 days post-transduction 
Human Tregs were transduced with various volumes of viral particles of 0µl, 30µl, 50µl 
or 80µl of eGFP-CD63 or mCherry-CD63 and 7 days post-transduction, the transduction 
efficiency was assessed by gating on eGFP or mCherry expressing cells and the values of 
transduction efficiency are indicated. eGFP-CD63 was assessed by (A) flow cytometry 
and (B) fluorescence microscopy. mCherry-CD63 was assessed by (C) flow cytometry and 





Figure 6.9- Transduction efficiency of human Tregs with CD63-eGFP and CD63-mCherry 
viral particles 10 days post transduction 
Various volumes of viral particles of 0µl, 30µl, 50µl or 80µl of eGFP-CD63 or mCherry-
CD63 were used to transduce human Tregs. Human Tregs were assessed for 
transduction efficiency before FACS-sorting, 10 days post transduction by gating on 
eGFP or mCherry expressing cells and the values of transduction efficiency are indicated 
for (A) eGFP-CD63 and (B) mCherry-CD63.  
 
The eGFP+ and mCherry+ Tregs showed >98% purity (Figure 6.10). Tregs were expanded 
further using anti-CD3/CD28 beads, rapamycin and IL-2 for an additional 10 days, as 
described in section 2.13. At the end of culture, 21 days post-transduction, Tregs were 
assessed for their eGFP and mCherry positive expression before Tregs were activated to 
release EVs. Figure 6.11 shows that the percentage of eGFP and mCherry positive cells 
had reduced from >98% to 58.2% and 31.4%, respectively. Nonetheless, Tregs were 
activated and isolated EVs were attached to latex beads and assessed for endogenous 
CD63 eGFP+ or CD63 mCherry+ expression or were stained with anti-CD63 antibodies in 
the case of EVs derived from untransduced Tregs. As expected EVs derived from 
untransduced Tregs were CD63+, but EVs derived from eGFP+ or from mCherry+ Tregs 
were neither eGFP nor mCherry positive (Figure 6.12-A). To confirm that the EVs were 
successfully adhered to the latex beads, the EVs were immunostained for the presence 
of CD81. The EVs derived from untransduced Tregs were CD81+ but the CD81 
expression on EVs derived from eGFP+ Tregs or mCherry+ Tregs was minimal (Figure 




release or alternatively only EVs derived from transduced Tregs had adhered to the 
latex beads with all labelled EVs not efficiently attached. However, this experiment was 
derived from 1 donor, and therefore to draw conclusions, more donors and repeat 
experiments would be required.  
 
Figure 6.10- eGFP and mCherry expression levels in Tregs before and after FACS-sorting 
Transduced human Tregs were assessed for transduction efficiency by eGFP or mCherry 
expression levels before and after FACS-sorting.   
 
Figure 6.11- eGFP and mCherry expression levels in Tregs before cell activation for EV 
release 
Transduced human Tregs were assessed for eGFP or mCherry expression levels before 





Figure 6.12- Transduced Treg EVs expression of endogenous CD63  
Untransduced and transduced Tregs were activated with anti-CD3/CD28 antibodies and 
EVs were harvested and adhered to latex beads before immunostaining. (A) 
Untransduced Treg EVs were tested for the presence of CD63 by antibody staining, 
whereas transduced Tregs were tested by the presence of endogenous eGFP or mCherry 
expression. (B) All EVs were tested for the presence of CD81 via antibody staining. Black 
lines indicate beads alone, grey line indicates beads stained with CD81 antibodies and 
coloured lines indicate EVs adhered to beads. 
 
6.4 Discussion 
In this PhD thesis chapter, I focused on the question that has not been published so far, 
namely whether human Treg EVs function in vivo and whether human Treg EVs can 
suppress the pro-inflammatory microenvironment to promote allograft survival. In this 
chapter, I have demonstrated that human Treg EVs express the skin homing receptor 
CCR4. Importantly, I have shown that the adoptive transfer of human Treg EVs (but also 
Teff EVs) protected against alloimmune mediated human skin damage, indicating that 
human Treg EVs can suppress the pro-inflammatory microenvironment and thus 
increase the longevity of transplanted allografts. The Treg EVs and Teff EVs inhibited 
cellular infiltration within the transplanted human skin graft by preventing the presence 
and/or expansion of CD45+ leukocytes, CD3+ T cells and Ki67 proliferating keratinocytes. 




4.4.7, namely that human Treg EVs were immunosuppressive in vitro. It also confirmed 
that Teff EVs also function in vivo. Furthermore, I showed that human Tregs can be 
labelled with eGFP-CD63 and mCherry-CD63 lentiviral particles and could provide a tool 
for labelling their EVs, although more experimental optimisation was required.  
The humanised mouse model used in this study only addressed the effect of the direct 
alloresponse. Although, as discussed in section 1.3, the direct allorecognition pathway is 
involved mainly in the acute rejection, whereas, in chronic rejection involves mainly the 
indirect allorecognition pathway. Further advancements in the humanised mouse 
models are required to address the function of EVs in regulating the indirect 
allorecognition pathway.  
 
6.4.1 Homing receptors 
For EVs to function efficiently, the EVs may have to migrate to the site of interest. For 
Tregs EVs this could be achieved by the expression of homing receptors, as has been 
shown in Tregs (Scottà et al. 2013). Homing receptors have previously been discovered 
in DC EVs by Wei et al. Wei et al. demonstrated that CCR7 expression on DC EVs allowed 
their migration into the spleen and induced inflammation at the site (G. Wei et al. 
2017). T cells secrete exosomes containing CXCR4 (Blanchard et al. 2002), possibly to 
enhance T cell exosomes’ ability to home to specific locations where chemokines are 
secreted. However, the specific destination of Treg EVs after adoptive transfer into mice 
is unknown. Although the expression of homing receptors has been described in T cell 
EVs (Guillaume van Niel, D’Angelo, and Raposo 2018), the literature so far to date has 
not unravelled the presence of homing receptors in Treg derived EVs. I found low 
expression levels of CCR4 on Treg EVs, given that the parent Tregs have high expression 
of this chemokine receptor that allows their homing to lymphoid organs and to skin it is 
a possibility that CCR4 facilitated their uptake into lymphoid organs whereby they can 
action their suppressive functions, although this was not tested. Importantly, when Treg 
EVs were adoptively transferred into the mice a level of protection within the allograft 
was mediated suggesting that Treg EVs exert their suppressive function towards the 





6.4.2 Suppressive ability of Treg EVs 
The microscopic analysis of the transplanted mice skins showed that the addition of 
Treg EVs (EQ) and Treg EVs (ultra) had protected against inflammatory damage 
compared to PBMCs alone control. As there was no difference between Treg EVs 
purified via ExoQuick-TC™ or ultracentrifuge in vivo, it could be concluded that these 
two EV isolation methods are comparable at least for in vivo assessments. Other studies 
have used ExoQuick-TC™ and ultracentrifuge isolated EVs to assess their different 
responses in vitro (Okoye et al. 2014), however, very few studies have used direct 
comparison of ExoQuick-TC™ versus ultracentrifuge in the in vivo setting.  
Both Treg EVs and Teff EVs protected against alloreactivity in vivo by preventing the 
infiltration of CD45+ and CD3+ cells within the allograft. Furthermore, Ki67+ proliferating 
keratinocytes were also significantly reduced in the presence of Treg EVs and Teff EVs, 
suggesting that Treg EVs and Teff EVs may exert their inhibitory effects in non-immune 
cells as well as immune cells. Given that in section 4.3.7, I showed that Treg EVs and 
Teff EVs functioned differently in terms of affecting the cytokine production by Tresps, 
in this chapter both Treg EVs and Teff EVs functioned similarly in vivo. 
Given that other studies have shown that Teff EVs can be both pro-inflammatory or 
anti-inflammatory (see section 1.7.7), it suggests that parent Teffs are somewhat 
‘plastic’ and thus can produce EVs that function according to their parent cell status and 
thus Teff EVs can promote or suppress the immune response. On the contrary, all 7 
publications to date regarding mouse, rat and human Treg EVs have collectively 
demonstrated that Treg EVs are immunosuppressive and not pro-inflammatory (Tung et 
al. 2018; Lesley Ann Smyth et al. 2013; Okoye et al. 2014; X. Yu et al. 2013; Aiello et al. 
2017; Torri et al. 2017; Azimi et al. 2018). Therefore, whether this favours Treg EVs over 
Teff EVs as an immunotherapy for promoting transplantation tolerance is plausible.   
Despite very similar behaviour in vivo, human Treg EVs and Teff EVs have different 
mechanisms of action as the Teff EVs promoted rather than suppressed the production 
levels of IFNγ and IL-6 (see section 4.3.7). Furthermore, in Chapter 5, it was shown that 
Teff EVs contain different miRNA repertoires compared to Treg EVs. Furthermore, and 
as displayed in Figure 5.7, bioinformatics analysis predicted that miRNAs enriched in 




and T cell receptor signalling pathways. As listed in Table 5.5, Teff EVs also contained 
high expression levels of miR-1972 compared to parent Teffs; miR-1972 was in silico 
predicted to target genes associated with the allograft rejection pathway which may 
provide an explanation of how Teff EVs functioned in vivo to protect allograft 
inflammatory damage. Collectively, these findings could potentially link to the in vivo 
protection provided by Treg EVs and Teff EVs against alloimmune mediated allograft 
damage and rejection observed in this PhD thesis chapter. As listed in Table 5.4, miR-
126 is enriched in Treg EVs, and Wang et al. demonstrated that miR-126 governs 
vascular integrity and angiogenesis (S. Wang et al. 2008). The presence of miR-126 in 
Treg EVs might explain how these EVs were able to inhibit allogeneic PBMCs from 
damaging CD31+ vessels as observed.  
Whether Treg EVs can replace Tregs as a therapy is uncertain but given that Tregs may 
be unstable and that Treg EVs function in vivo to prevent allograft inflammatory 
damage, it has the potential to be used as a combinatory therapy with Tregs to maintain 
their suppressive potency. Whether Treg EVs can be used as a standalone therapy is 
uncertain due to Tregs being more potent at suppressing Tresps proliferation but 
nonetheless, Treg EVs are immunosuppressive both in vitro and in vivo. This could 
potentially be thought of as a cell-free maintenance therapy whereby Treg EVs can be 
injected in vivo to maintain the longevity of an allograft.  
 
6.4.3 Labelling of EVs 
To further clarify the mechanisms of action of EVs and to track their migration and 
destination in transplanted mice, Treg EVs were labelled with eGFP-CD63 and mCherry-
CD63 with the aim to apply whole body optical imaging of GFP+ or RFP+ EVs (M. Yang et 
al. 2000). Although as presented in Figure 6.12, EVs derived from the transduced Tregs 
did not display eGFP or mCherry positive expression. Whether this was due to technical 
reasons or the biology of the transduced Tregs is not clear as only 1 donor sample was 
used, further donors will be required to enhance the isolation of eGFP or mCherry 
positive EVs. Nonetheless, the data acquired suggested that Tregs can be successfully 
labelled with CD63-eGFP or CD63-mCherry viral particles and thus has potential to be 




EVs derived from other cell types have been tracked in vivo. Takahashi et al. showed 
that following the intravenous injection of cancer exosomes, these vesicles migrated 
firstly towards the liver and then to the lungs (Y. Takahashi et al. 2013). Exosomes 
derived from MSC have also been imaged and these EVs migrated to the kidney and 
spleens of mice undergoing acute kidney injury (GRANGE et al. 2014). Whether Tregs 
and their EVs migrate to the same location is unknown. But others have demonstrated 
that directional cell movement, mobility, motility and chemotaxis, are enhanced by 
exosomes released by their parent cells; cancer cells, neutrophils and endothelial cells 
(Sung et al. 2015; Majumdar, Tavakoli Tameh, and Parent 2016; Sung and Weaver 2017; 
Brown et al. 2018) 
Imaging of Tregs has been performed by the host laboratory by Sharif-Paghaleh et al. 
(Sharif-Paghaleh et al. 2011). Sharif-Paghaleh et al. showed that mouse Tregs can be 
transduced with a sodium/iodide symporter and thus enabled the radiolabelling of 
these Tregs with Technetium-99m pertechnetate (a radioactive substance) and 
subsequently visualised in vivo with a Single Photon Emission Computed Tomography 
(SPECT)/ Computerised Tomography (CT) imaging modality. After 24 hours post-
injection into mice, these radiolabelled mouse Tregs were observed in the spleen 
(Sharif-Paghaleh et al. 2011). Human Tregs have also been radiolabelled in a similar 
manner to track their migratory pattern in vivo and is currently still under investigation 
within the host laboratory and unpublished work shows that human Tregs migrate to 
the transplanted human skin whereby the Tregs are likely to function to suppress the 
proliferation of Tresps (Jacinta Jacob, unpublished work). Whether, Treg EVs follow the 
same route as their parent Treg cells is unknown, hence, I aimed to label Treg EVs with 
eGFP-CD63 with the aim to track them in vivo, but due to time restrictions, I was not 
able to complete this part of the study. Nevertheless, given the CCR4 expression on 
these human Treg EVs, it does provide them with a potential property of homing to the 
human skin, similar to how their parent Tregs use CCR4 to home to the skin (Issa et al. 








In summary, human Treg EVs and Teff EVs were able to protect against alloimmune 
mediated inflammatory skin allograft damage by preventing CD3+ T cells and CD45+ 
immune cells infiltration and reducing proliferating keratinocytes as well as maintaining 
involucrin protein expression within the skin allograft. Labelling of Tregs with eGFP-
CD63 or mCherry-CD63 viral particles are possible; however experimental optimisation 
is required to isolate eGFP+ or mCherry+ Treg EVs.  If eGFP+ or mCherry+ Treg EVs can be 
isolated it can enable the researcher to track their migration in vivo and to understand 









General Discussion  




Chapter 7 - General Discussion and Future Work 
My data supports the idea that the release of EVs plays a key role in the functions of 
Treg cells. Given my findings it could be suggested that EVs released by Tregs used in 
clinical trials are influencing the clinical outcome, although this is highly speculative and 
requires further investigation. In clinical trials, Tregs are administered with drugs such 
as rapamycin, ATRA and IL-2 complex; whether these affect Treg release of EVs in vivo is 
not known. Interestingly, rapamycin regulates exosomes release. For example, 
Abdulrahman et al. showed that autophagy stimulation in neuronal cells in the presence 
of rapamycin inhibited exosomal prion release (Abdulrahman, Abdelaziz, and Schatzl 
2018). Another study by Aung et al. demonstrated that 1μM, 5μM and 10μM 
concentrations of rapamycin inhibited exosomes release from B cell lymphoma cells, 
with 10μM concentration of rapamycin providing the most potent inhibition of 
exosomes release (Aung et al. 2011). It was suggested that rapamycin regulates MVB 
biogenesis and this might thus affect exosomes release (Aung et al. 2011). What is 
important to note from this study by Aung et al., is that these authors tested 1μM, 5μM 
and 10μM concentrations of rapamycin in affecting exosomes release. From their 
results it can be observed at 0μM to 10μM, the 1μM had a minimal effect on exosomes 
release compared to the 10μM concentrations of rapamycin used (Aung et al. 2011). 
However, the human Tregs used in this thesis were cultured with 100nM concentration 
of rapamycin (1/10th of the lowest concentration used by Aung et al. (Aung et al. 2011)). 
Whether 100nM concentration of rapamycin affects human Treg release of EVs is 
unknown, but human Tregs were cultured in the absence of rapamycin 48 hours prior 
to their activation for EVs release in case that rapamycin affected EV release from 
human Tregs.  
ATRA, IL-2 and IL-2 complex (IL-2 in complexed with anti-IL-2) was demonstrated by 
Okoye et al. to regulate EV release from mouse Tregs. The presence of IL-2 complex on 
mouse Tregs resulted in a significant increase of exosomes whereas; the presence of 
ATRA resulted in a modest increase of exosomes release (Okoye et al. 2014).  
The translation of Tregs therapy in the clinical setting was delayed for many years, 
which were exacerbated by concerns that Tregs were unstable (Zhou et al. 2009; 




Kleinewietfeld and Hafler 2013). Various studies have shown that under certain pro-
inflammatory environments Tregs can convert into Th-17 like cells whereby they 
produce high levels of IL-17 (H. J. P. M. Koenen et al. 2008; X. O. Yang et al. 2008), thus 
Tregs can change from a regulatory cell to one that is immune stimulating. Therefore, 
further measures are required to increase and maintain the suppressive potency of 
these cells or to find an alternative or additional cell-free immunotherapy to ensure 
their stability for therapeutic use. Given our and other group’s findings (Tung et al. 
2018; Lesley Ann Smyth et al. 2013; Okoye et al. 2014; X. Yu et al. 2013; Aiello et al. 
2017; Torri et al. 2017; Azimi et al. 2018), and the current interest in cell-free therapies, 
Treg EVs as a potential candidate for a novel cell-free therapy, alternative or 
combinatory therapy to whole Treg cell therapy is appealing. This thesis explored 
whether the use of these vesicles was possible in this setting. The results generated in 
this thesis demonstrated that human Treg EVs are functionally immunosuppressive 
perhaps due to their miRNA content, and can protect against transplant rejection, 
suggesting that Treg EVs may indeed have a future as a clinically applicable cell-free 
therapy for transplant patients.  
Interestingly, the data exhibited herein showed that human Teff EVs, like the Treg EVs, 
were also immunosuppressive. Teff EVs can be both pro-inflammatory and 
immunosuppressive as described in section 1.7.7, highlighting the contrasting roles of 
Teff EVs. On the other hand, all 7 publications to date presenting Treg EVs have 
consistently and agreeably shown that Treg EVs are immunosuppressive (Tung et al. 
2018; Lesley Ann Smyth et al. 2013; Okoye et al. 2014; X. Yu et al. 2013; Aiello et al. 
2017; Torri et al. 2017; Azimi et al. 2018). Given this body of evidence, it favours Treg 
EVs over Teff EVs as an immunosuppressive agent for treatment of immune conditions 
such as diabetes and transplant rejection.   
 
7.1 EVs treatment in clinical trials and future of Treg EVs for clinical use 
Due to the complexity and complications of using whole cells for therapy, increasingly 
more research groups are pursuing the search for a cell-free vaccine or therapy. EVs are 
naturally-occurring biological particles which offer functions that may mirror certain 




combinatory therapy with whole cells for patients. My research mirrors these 
assumptions. EVs are more stable than cells and do not change according to their 
microenvironment, they can be stored in -80°C for 2 years without losing their potency 
(Ribeiro et al. 2013), and also for clinical trials, exosomes were stored at -80°C until use 
(Morse et al. 2005; Escudier et al. 2005; Dai et al. 2008; Besse et al. 2016). Furthermore, 
EVs are metabolically-inactive components and therefore do not require further 
expansion. In another report, EVs can be stored at -20°C for 6 months provided they are 
resuspended in non-toxic chemicals and EVs maintained their functions with minimal 
loss of efficiency (Barile et al. 2012). These reports together suggest that EVs can be 
stored as an ‘off-the-shelf’ product. Due to these collective attributes of EVs; cell-free 
product; GMP grade EVs/large scale manufacture possible; ‘off-the-shelf’ product; and 
ease of manipulation of EVs it promotes EVs as a potential therapy that circumvents 
many of the limitations of viable cells for therapeutic applications in healthcare 
medicine. However, the following question still needs addressing: can Treg derived EVs 
be isolated and used for clinical use as an ‘off-the-shelf’ product? 
Large scale production of clinical grade GMP EVs is possible (Lamparski et al. 2002; 
Mendt et al. 2018). Although EVs research is generally in its infancy, exosomes has 
already reached phase I clinical trials (Morse et al. 2005; Escudier et al. 2005; Dai et al. 
2008) and a phase II clinical trial (Besse et al. 2016).  In all four of the clinical trials using 
exosomes described below (Morse et al. 2005; Escudier et al. 2005; Dai et al. 2008; 
Besse et al. 2016), exosomes were isolated using ultracentrifuge and sucrose gradient 
methods.  
Morse et al. performed a phase I clinical trial testing the safety, feasibility and efficacy 
of using the cancer patients’ own dendritic cells-derived exosomes (dexosomes) to treat 
non-small cell lung cancer (Morse et al. 2005). The dexosomes were loaded with MAGE 
tumour antigens with the aim to prime MAGE-specific T cell responses. How the authors 
decided on the dose of dexosomes to use was based upon how many MHC class II 
molecules were present on the dexosomes. The patients received 4 doses of exosomes 
vaccinations, which were given at 1 week intervals. The results showed that some of 
these non-small cell lung cancer patients that were immunised with the dexosomes 
vaccine had activation of immune effectors; MAGE-specific T cell responses and NK lytic 




dexosomes therapy was generally well tolerated by the patients with no signs of serious 
toxicity observed (Morse et al. 2005).  
Similar to Morse et al. (Morse et al. 2005), Escudier et al. also used patient-derived 
dexosomes to treat cancer patients, which also their doses depended upon the number 
of MHC class II molecules present on dexosomes (Escudier et al. 2005).  The patients 
received 4 doses of exosomes vaccinations, which were given at 1 week intervals. These 
patients had stage III/IV metastatic melanoma and were treated with dexosomes loaded 
with MAGE 3 peptides. The results showed that one patient (from 15 patients) exhibited 
a partial response where there was depigmentation in the melanoma lesion. 
Additionally, two stable, one minor and one mixed response was also observed in some 
patients in the skin and lymph nodes regions. However, MAGE-3 specific CD4+ and CD8+ 
T cell responses was not observed in the peripheral of treated patients (Escudier et al. 
2005).  
In the two clinical trials in 2005 testing dexosomes by Morse et al. (Morse et al. 2005) 
and Escudier et al. (Escudier et al. 2005), the same authors had advanced their studies 
and recently published another clinical trial using dexosomes but this time in a phase II 
clinical trial (Besse et al. 2016). Besse et al. (Besse et al. 2016) used a more advanced 
dexosomes preparation treatment in comparison their first phase I clinical trials (Morse 
et al. 2005; Escudier et al. 2005). This dexosomes preparation, were also isolated using 
ultracentrifugation and sucrose gradient methods, but these dexosomes aimed to boost 
NK and T cell immune responses, by priming these dexosomes with IFNγ and loading 
them with MHC class I and II-restricted cancer antigens (IFNγ dexosomes). These IFNγ 
dexosomes were tested for the clinical benefit as a maintenance immunotherapy for 
non-small lung cell cancer patients (whom do not have tumour progression) after their 
induction chemotherapy treatment. In this study, 22 patients received IFNγ dexosomes 
injections; these patients received on median 7 IFNγ dexosomes injections with a range 
of 1-27 injections. These results indicated that IFNγ dexosomes did not induce cancer-
specific T cell immune responses but it did boost NK cells activity against the tumour in 
these patients (Besse et al. 2016).   
Patients’ own ascites-derived exosomes have been tested for the clinical treatment of 
colorectal cancer. This phase I clinical trial by Dai et al. enrolled 40 patients, and the two 




exosomes plus GM-CSF (Dai et al. 2008). Both treatment groups tolerated the 
therapeutic treatment and patients received 4 doses of exosomes vaccinations, which 
were given at 1 week intervals. Moreover, the patients whom received ascites-derived 
exosomes plus GM-CSF had elicited a more efficient and beneficial tumour-specific anti-
tumour cytotoxic T lymphocyte response compared to the ascites-derived exosomes 
alone treatment group. Thus, the use of GM-CSF as an adjuvant significantly promoted 
the efficiency of ascites-derived exosomes therapy. These ascites-derived exosomes 
contained tumour-associated carcinoembryonic antigen and MHC molecules which the 
authors suggested that these may be recognised by epidermic APCs and thus indirectly 
stimulate T cell activation.  
Furthermore, there are multiple ongoing clinical trials registered on 
http://clinicaltrials.gov which are using exosomes either as a therapy or as a biomarker 
discovery source. For example, ClinicalTrials.gov Identifier: NCT02138331 aimed to test 
MSC-derived microvesicles and exosomes therapy on islet β-cells of the pancreas, in the 
aim to reduce inflammation and treat or manage type I diabetes mellitus. In another 
clinical trial: NCT03384433, it aims to administer allogeneic MSC exosomes, enriched in 
miR-124 to treat patients with acute ischemic stroke-associated disability. Clinical trials: 
NCT03102268; NCT01344109; NCT02702856 and NCT03562715 aims to detect 
exosome-associated miRNA, ncRNA or other RNA molecules signatures that may be 
used as diagnostic or prognostic markers in cancers and various other health conditions. 
Clinical trial: NCT02327403 aims to test urine extracellular vesicles from kidney 
transplant patients to assess B7-1 (CD80) derived from APCs.  
Taking the above together; this thesis findings; GMP isolation of EVs; the published and 
the ongoing clinical trials that used or uses EVs, highly supports that Treg EVs have the 
potential to reach clinical trials and thus likely to be a favourable agent to use in the 
setting of autoimmune diseases such as diabetes to suppress the immune responses. 
Current commercial biotechnology-based companies are developing EVs for use in 
clinical trials and GMP-grade isolation of EVs is commonplace. GMP-grade ExoQuick™ 
(ExoQuick-CG™) is available for isolating EVs in a GMP manner for clinical use. 
Therefore, the likelihood of EVs use in the clinic setting is highly feasible. As described 




properties, whereas Treg EVs would be immune suppressing and thus likely unsuitable 
to treat cancer patients.  
 
7.2 Improving the use of Treg EVs for clinical use 
Theoretically, GMP-grade isolation of human Treg EVs should be possible. But, should 
Treg EVs be used alone or together with Tregs? This is a question that remains open. 
Given that Treg EVs are not as potent as parent Tregs, it could be suggested to initially 
be used as a combination therapy after which immunological tolerance of the 
transplant can be maintained by the treatment of cell-free Treg EVs. In addition, 
extensive research is currently ongoing to manipulate EVs to carry certain drugs, miRNA 
or other biological components within them and these vesicles may be engineered to 
target specific cells to deliver drugs and other biological material.  
I have shown in this thesis that Treg EVs alone modulates cytokine production by BM-
DCs (Chapter 3) and by Tresps (Chapter 4), whether Treg EVs together with other agents 
such as rapamycin, ATRA, IL-2 or IL-2 complex or with whole Treg cells can further 
modulate cytokine profile production by Tresps is worth further investigations. Given 
that cytokines potently affect immune cells, it can be envisaged that Treg EVs used 
alone or in combination with other agents can be used in favour to suppress pro-
inflammatory cytokines whilst concurrently promoting anti-inflammatory cytokine 
production. Hence, with this aim it can potentially benefit the clinical outcome of 
transplant patients. In the next subsections I will discuss the aforementioned. 
 
7.2.1 EVs combined with rapamycin or other agents treatment 
The use of immunosuppressive drugs together with EVs has been shown to promote 
transplant tolerance in vivo. A study by Li et al. showed that immature DC exosomes 
together with rapamycin promoted heart allograft tolerance in mice (X. Li et al. 2012). 
Moreover, in another study by Peche et al., these authors demonstrated that donor 
exosomes together with short-term immunosuppression induced cardiac transplant 
tolerance in fully MHC-mismatched rats (Peche et al. 2006). These studies are further 




Therefore, taken the above, engineering EVs to carry specific drugs to the allograft may 
clinically benefit transplant recipients. Furthermore, the use of rapamycin or other 
immunosuppressive drugs in culturing Tregs for EV release or using Treg EVs in 
combination with immunosuppressive drugs may favour the clinical outcome for 
transplant patients and warrants further investigation. 
 
7.2.2 EVs combined with IL-2 modulate cytokine production 
Various miRNAs can induce Tregs (section 5.4.4); similarly, EVs have also been reported 
to regulate Tregs. EVs have been described by various groups to promote the induction 
of Tregs (Song et al. 2016; G.-J. Wang et al. 2008; Wieckowski et al. 2009), or 
conversely, can reduce the frequency of Tregs (Rao et al. 2016; Kimura et al. 2018). 
Whether Treg EVs induce Tregs is unknown. However, a study in 2012 by Wahlgren et 
al. had shed some light into human CD3+ T cell derived exosomes and their ability to 
modulate autologous cells (Wahlgren et al. 2012). Wahlgren et al. isolated exosomes 
from activated CD3+ T cells, and together with IL-2 treated resting CD3+ T cells and 
observed their responses. The exosomes plus IL-2 treatment was able to stimulate 
proliferation in autologous resting CD3+ T cells, more efficiently than exosomes or IL-2 
treatment alone. Importantly, the use of IL-2 alone, exosomes alone or exosomes plus 
IL-2 results in different cytokine production profiles from the target CD3+ T cells. 
Namely, when the CD3+ T cells were treated with IL-2 alone or exosomes alone, IL-4 was 
downregulated whilst treatment with exosomes plus IL-2 upregulated IL-4 production. 
With IL-2 alone treatment, IL-6 was downregulated whereas with exosomes alone 
treatment, it was upregulated by 0.4 folds and with exosomes plus IL-2 treatment, IL-6 
was upregulated by 4 folds. Furthermore, IL-10 was also affected. IL-2 alone and 
exosomes plus IL-2 treatments both upregulated IL-10 production by 0.5 folds, whereas 
exosomes alone treatment, IL-10 was downregulated by 2 folds (Wahlgren et al. 2012). 








7.2.3 EVs combined with Tregs in transplantation 
Ma et al. showed that the combined therapy of immature DC exosomes with donor 
antigen-specific Tregs induces liver transplant tolerance in rats (Ma et al. 2016). In these 
treated rats, the infiltrating cells in the allograft were reduced and the recipient 
immune responses were inhibited in a donor-specific manner. These authors suggested 
that immature DC exosomes may have promoted the proliferation of Tregs within the 
allograft, which as a result may overall enhance the regulatory effects of the treatment 
(Ma et al. 2016). Noteworthy, immature DC exosomes together with donor antigen-
specific Tregs induced transplant tolerance without the need for immunosuppressive 
drugs (Ma et al. 2016). Whether a similar approach can be used with human Treg EVs 
together with donor-antigen specific Tregs to induce transplant tolerance in patients 
would be interesting to investigate.  
 
7.3 Modifying Treg EVs for therapy 
What is also achievable is the engineering of EVs to package specific miRNAs (Luan et al. 
2017). miRNAs have been linked to inducing or promoting the expansion of Tregs 
(section 5.4.4), and in the context of transplantation, tipping the balance in favour of a 
higher frequency of Tregs than Teffs leads to a better outcome in transplant patients. 
Indeed, the clinical trial: NCT03384433, uses exosomes loaded with miRNA to treat 
patients with acute ischemic stroke-associated disability. As reviewed by Jeker and 
Bluestone, miRNAs are key biological molecules that regulate T cell differentiation and 
function and more is being discovered about how miRNA shapes the immune system 
(Jeker and Bluestone 2013). Many miRNA functions are still being fully elucidated and 
many of the miRNAs found in the Treg EVs have been linked to various aspects of 
inhibiting T cell activation and their proliferation or inducing Treg expansion. This 
further supports my finding that Treg EVs not only are immunosuppressive, but their 
miRNA cargo is suggested to be selective possibly to enhance a regulatory effect in the 
target cells. Collectively, taking the above publications together with Chapter 5 
Discussion (section 5.4), it provides support that designing and engineering Treg EVs to 
carry specific miRNAs that inhibit pro-inflammatory cytokine production and/or 




with rapamycin, ATRA, IL-2, IL-2 complex or other agents may have potential in the 
clinic for transplant patients.  
Which miRNAs could be targeting to Treg EVs? I found that mouse Treg EVs transferred 
miR-142-3p and miR-150-5p into BM-DCs. These miRNAs have previously been reported 
to modulate DC cytokine profiles (section 3.4.4). Indeed, mouse Treg EVs reduced IL-6 
whilst increased IL-10 production levels by BM-DCs, perhaps to prevent a pro-
inflammatory microenvironment and instead promote an anti-inflammatory milieu. 
Exclusive miRNAs which were absent in Tregs but enriched in human Treg EVs included; 
miR-369-3p, miR-376c-3p and miR-195-3p, which were predicted to target the 3’ UTR 
regions of IFNγ, IL-2 and IL-6 mRNA. I also found that in the human miRNOME, miR-99a-
5p were found higher expression levels in Treg EVs than Tregs and not present in Teff 
EVs; and miR-150 were found in higher expression levels in Treg EVs than Teff EVs. A 
study by Warth et al. demonstrated that miR-99a and miR-150 work in unison to inhibit 
the Th17-promoting mTOR activity to promote Treg differentiation (Warth et al. 2015). 
Furthermore, miR-100 which was found in the human Treg EVs and not Teff EVs, was 
also described by Warth et al. to promote Tregs and inhibit Th17 differentiation (Warth 
et al. 2015)  
More recently, there is growing interest in the use of chimeric antigen receptor (CAR) T 
cell exosomes for immunotherapy against cancers instead of CAR T cells due to the cell 
treatment-related toxicities (X.-J. Tang et al. 2015). CARs are engineered recombinant 
receptors that implement a specificity of a monoclonal antibody onto a cell with the aim 
of the CAR cell to bind specific markers found on target cells to modulate them. 
Whether CAR Tregs release CAR EVs has so far not been demonstrated. However, in 
theory if CAR Treg EVs are possible it can be anticipated that these CAR EVs will be 
designed and engineered to be allospecific to the transplant graft and thus CAR EVs and 
their cargo may be more efficiently delivered to the allograft to suppress immune cells 
and thus inhibit transplant rejection. 
Nonetheless, CAR exosomes have been assessed as a drug delivery mechanism to treat 
mantle cell lymphoma (Bao et al. 2017). This study by Bao et al. used CAR engineered 
exosomes that exhibited a membrane fused anti-CD19 single chain variable fragment 
(scFv) which were designed to package and carry doxorubicin drug to be delivered to 




demonstrated that treatment of mantle cell lymphoma cells with CAR exosomes 
carrying doxorubicin increased toxicity more efficiently than free doxorubicin alone. 
Thus, EVs derived from Tregs may also have the capacity to package and deliver 
immunosuppressive drugs to targeted cells, namely, T cells and DCs, the main culprit 
cells in driving transplant rejection. 
 
In conclusion, the scope of designing and engineering Treg EVs for their application in 
the clinical setting to treat transplant rejection is undeniably promising given the 
collective data presented in this thesis and all the mentioned publications that provide 
support that Treg EVs immunotherapy may one day, in the future, benefit transplant 
patients. Future studies are however still required to investigate where EVs migrate to 
once it is administered into a patient as well as their safety. For example, would they 
induce wide spread immunosuppression; something that could be addressed by 
creating antigen-specific EVs. Although I have shown in humanised mouse models of 
transplantation that human Treg EVs function in vivo to protect against allograft 
damage, whether the same occurs in humans remains to be elucidated. Given that 
exosomes are being used in clinical trials, the next step in my research would be to 
define protocols to isolate GMP compatible Treg EVs and to move these exciting 
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Appendix 3- IFNγ mirSVR and PhastCons scores 
Specific alignments of each miRNA to IFNγ 3’ UTR of mRNA and associated miSVR and 








Appendix 4- IL-2 mirSVR and PhastCons scores 
Specific alignments of each miRNA to IL-2 3’ UTR of mRNA and associated miSVR and 






Appendix 5- IL-6 mirSVR and PhastCons scores 
Specific alignments of each miRNA to IL-6 3’ UTR of mRNA and associated miSVR and 











Appendix 6- Macroscopic analysis of human skin transplanted mice with various 
treatments 
BRG immunodeficient mice were transplanted with a section of human skin which was 
derived from healthy donors with written consent. After 35 days, the mice received 
saline or allogeneic CD25- PBMCs, in the absence or presence of autologous 1x106 Tregs, 
50x106 Tregs-derived EVs isolated by ExoQuick-TC™ (EQ), 50x106 Tregs-derived EVs 
isolated by ultracentrifugation (ultra), 50x106 Teffs-derived EVs isolated by EQ or the 
pellet resulting from media alone mixed with EQ (media pellet EQ). At the end point of 
study, human skin allografts were assessed (A) macroscopically and (B) on the 
underside; displayed is a representative image of the human skin allograft on the ventral 









Appendix 7- Maxiprep restriction analysis results 
To prepare plasmid DNA of eGFP-CD63 and mCherry-CD63, maxipreps were processed 
and restriction analysis using EcoRI-HF® and AgeI-HF® enzymes performed on the 
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